WO2009135842A1 - Azetidines and cyclobutanes as histamine h3 receptor antagonists - Google Patents

Azetidines and cyclobutanes as histamine h3 receptor antagonists Download PDF

Info

Publication number
WO2009135842A1
WO2009135842A1 PCT/EP2009/055418 EP2009055418W WO2009135842A1 WO 2009135842 A1 WO2009135842 A1 WO 2009135842A1 EP 2009055418 W EP2009055418 W EP 2009055418W WO 2009135842 A1 WO2009135842 A1 WO 2009135842A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbonyl
azetidin
cyclobutyl
oxy
diazepan
Prior art date
Application number
PCT/EP2009/055418
Other languages
French (fr)
Inventor
Adam James Davenport
David James Hallett
Massimo Corsi
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Priority to US12/991,225 priority Critical patent/US8691804B2/en
Priority to EP09742060.8A priority patent/EP2300422B1/en
Priority to CN200980117615.XA priority patent/CN102015636B/en
Priority to BRPI0913057A priority patent/BRPI0913057A2/en
Priority to JP2011507892A priority patent/JP5780954B2/en
Priority to CA2721303A priority patent/CA2721303C/en
Publication of WO2009135842A1 publication Critical patent/WO2009135842A1/en
Priority to IL208613A priority patent/IL208613A/en
Priority to HK11110177.1A priority patent/HK1155749A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to Histamine H3 receptor antagonists, pharmaceutical compositions thereof, the preparation of such compounds as well as the production and use as medicament.
  • the histamine H3 receptor is a G protein-coupled receptor (GPCR) and one out of four receptors of the histamine receptor family. Histamine receptors have long been attractive drug targets, mirrored in the development of antihistamines, which were directed at the histamine Hl receptor for the treatment of allergic reactions or at the histamine H2 receptor to ameliorate gastric ulcers by inhibiting gastric acid secretion.
  • the H3 receptor has been identified as a presynaptic autoreceptor, regulating the release of histamine (Arrang et al.
  • H3 receptor antagonists / inverse agonists have been developed and shown to comprise activity in a variety of cognition tests in mice and rat (e.g. Esbenshade et al. (2006) MoI Interventions: 6 (2); 77 - 88) as well as in models for sleeping disorders and energy balance.
  • Such antagonists comprise a potential treatment for a variety of disorders affecting cognition (e.g., Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, Schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome and others), as well as sleep (e.g., hypersomnia and narcolepsy), and energy homeostasis (e.g. obesity)
  • cognition e.g., Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, Schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome and others
  • sleep e.g., hypersomnia and narcolepsy
  • energy homeostasis e.g. obesity
  • Histamine H3 receptor antagonists are described in the art for the treatment of the above mentioned diseases and disorders.
  • WO-A 2007/080140 cyclylhexyl piperazinyl methanone derivatives are disclosed, which are useful as H3 receptor modulators.
  • WO-A 2006/136924 cyclo butyl derivatives are disclosed as Histamine-3 receptor antagonists.
  • US-A 4956359 describes anticonvulsants and antiepileptics having similar chemical structures without referring to H3 receptor antagonism.
  • an object of the present invention is to provide a new class of compounds as Histamine H3 receptor antagonists which may be effective in the treatment of H3 receptor related diseases and may show improved pharmaceutically relevant properties including activity, ADMET properties and/or reduced side effects.
  • R 1 is Ci_5 alkyl; C2-5 alkenyl; C2-5 alkynyl; or T 0 , wherein Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH 3 ; OCH 2 F; OCHF 2 ; OCF 3 ; CN; and T 0 ;
  • T 0 is C3_5 cycloalkyl; or 4 to 5 membered saturated heterocyclyl, wherein T 0 is optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl; OH; O-Ci_ 5 alkyl; O-C2-5 alkenyl; O-C2-5 alkynyl; and CN, wherein Ci_ 5 alkyl; C 2 -5 alkenyl; C 2 -5 alkynyl; O-Ci_5 alkyl; O-C 2 -5 alkenyl; and O-C 2 -5 alkynyl are optionally substituted with one or more halogen, which are the same or different;
  • n 1 or 2;
  • X 1 is N; or CH;
  • X 2 is O; S; N-CN; N-OH; or N-OC1.4 alkyl;
  • X 3 is N; CH; or CF;
  • X 4 is H; F; or (CH 2 ) n iX 5 (CH 2 ) n 2R 2 ;
  • R 0 is F
  • n 0, 1, 2, 3, or 4;
  • R is H; or F;
  • nl; n2 are independently selected from the group consisting of 0; 1; and 2;
  • X 5 is C(O); C(O)O; OC(O); O; C(0)N(R la ); N(R la )C(0); S(O) 2 N(R la ); N(R la )S(O) 2 ; S(O)N(R la ); N(R la )S(O); S(O) 2 ; S(O); N(R la )S(0) 2 N(R lb ); S; N(R la );
  • R la , R lb are independently selected from the group consisting of H; Ci_4 alkyl; C2-4 alkenyl; and C2-4 alkynyl, wherein Ci_4 alkyl; C2-4 alkenyl; and C2-4 alkynyl are optionally substituted with one or more halogen, which are the same or different;
  • R 2 is H; T; Ci_6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R , which are the same or different;
  • R 3 is halogen; CN; C(O)R 4 ; C(O)OR 4 ; OR 4 ; C(O)N(R 4 R 4a ); S(O) 2 N(R 4 R 4a ); S(O)N(R 4 R 4a ); S(O) 2 R 4 ; S(O)R 4 ; N(R 4 )S(O) 2 N(R 4a R 4b ); SR 4 ; N(R 4 R 4a ); NO 2 ; OC(O)R 4 ; N(R 4 )C(O)R 4a ; N(R 4 )SO 2 R 4a ; N(R 4 )S(O)R 4
  • R 4 , R 4a , R 4b are independently selected from the group consisting of H; T; Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl, wherein Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl are optionally substituted with one or more R 5 , which are the same or different;
  • R 5 is halogen; CN; C(O)R 6 ; C(O)OR 6 ; OR 6 ; C(O)N(R 6 R 6a ); S(O) 2 N(R 6 R 6a );
  • R 6 , R 6a , R 6b are independently selected from the group consisting of H; T; Ci_6 alkyl;
  • Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl wherein Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
  • T is phenyl; naphthyl; azulenyl; indenyl; indanyl; C 3 - 7 cycloalkyl; 3 to 7 membered heterocyclyl; or 7 to 11 membered heterobicyclyl, wherein T is optionally substituted with one or more R 7 , which are the same or different;
  • R 7 is halogen; CN; C(O)OR 8 ; OR 8 ; C(O)R 8 ; C(O)N(R 8 R 8a ); S(O) 2 N(R 8 R 8a );
  • R 8 , R 8a , R 8b are independently selected from the group consisting of H; T 1 ; Ci_6 alkyl;
  • R 11 , R l la , R l lb are independently selected from the group consisting of H; T 1 ; Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl, wherein Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
  • T 1 is phenyl; C3-7 cycloalkyl; or 3 to 7 membered heterocyclyl, wherein T 1 is optionally substituted with one or more R 12 , which are the same or different;
  • R 12 is halogen; CN; C(O)OR 13 ; OR 13 ; C(O)R 13 ; C(O)N(R 13 R 13a ); S(O) 2 N(R 13 R 13a ); S(O)N(R 13 R 13a ); S(O) 2 R 13 ; S(O)R 13 ; N(R 13 )S(O) 2 N(R 13a R 13b ); SR 13 ; N(R 13 R 13a ); NO 2 ;
  • R 13 , R 13a , R 13b are independently selected from the group consisting of H; Ci_ 6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl, wherein Ci_6 alkyl; C 2 _6 alkenyl; and C 2 _6 alkynyl are optionally substituted with one or more halogen, which are the same or different,
  • the 4 compounds are not excluded as far as pharmaceutical compositions, compounds or pharmaceutical acceptable salts thereof for use as medicament or in a method of treating or preventing disorders, methods of treating or preventing diseases or disorders of the present invention are addressed.
  • the 5 compounds are not excluded as far as pharmaceutical compositions, compounds or pharmaceutical acceptable salts thereof for use as medicament or in a method of treating or preventing disorders, methods of treating or preventing diseases or disorders of the present invention are addressed.
  • variable or substituent in formula (I) as defined above can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
  • Alkyl means a straight-chain or branched saturated hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent as further specified.
  • Alkenyl means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon double bond. Each hydrogen of an alkenyl carbon may be replaced by a substituent as further specified.
  • Alkynyl means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon triple bond. Each hydrogen of an alkynyl carbon may be replaced by a substituent as further specified.
  • Ci_ 4 alkyl means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g. - CH 2 -, -CH 2 -CH 2 -, -CH(CH 3 )-, -CH 2 -CH 2 -CH 2 -, -CH(C 2 H 5 )-, -C(CHs) 2 -, when two moieties of a molecule are linked by the alkyl group.
  • Each hydrogen of a Ci_4 alkyl carbon may be replaced by a substituent as further specified.
  • Ci_6 alkyl means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: Ci_ 4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, or e.g.
  • Ci_ 6 alkyl when two moieties of a molecule are linked by the alkyl group.
  • Each hydrogen of a Ci_6 alkyl carbon may be replaced by a substituent as further specified.
  • the term "Ci_ 5 alkyl" is defined accordingly.
  • Each hydrogen of a C2-6 alkenyl carbon may be replaced by a substituent as further specified.
  • the terms "C2-4 alkenyl” and "C2-5 alkenyl” are defined accordingly.
  • C2-6 alkynyl means an alkynyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: -C ⁇ CH, -CH 2 -C ⁇ CH, CH 2 -CH 2 -C ⁇ CH, CH 2 -C ⁇ C-CH 3 , or e.g. -C ⁇ C- when two moieties of a molecule are linked by the alkynyl group.
  • Each hydrogen of a C2-6 alkynyl carbon may be replaced by a substituent as further specified.
  • the terms "C2-4 alkynyl” and "C2-5 alkynyl” are defined accordingly.
  • C 3 _ 7 cycloalkyl or "C 3 _ 7 cycloalkyl ring” means a cyclic alkyl chain having 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent as further specified.
  • the term “C 3 - S cycloalkyl” is defined accordingly.
  • Halogen means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
  • Examples for 3 to 7 membered heterocycles are azeridine, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydro furan, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridine -N-oxide, pyri
  • “4 to 5 membered saturated heterocyclyl” or “4 to 5 membered saturated heterocycle” means a “4 to 5 membered heterocyclyl” or “4 to 5 membered heterocycle” without double bonds in the ring.
  • Examples for 7 to 11 membered heterobicycles are imidazo[l,5-a]pyridine, imidazo[2,l-b][l,3]oxazole, imidazo[2,l-b][l,3]thiazole, 5,6,7,8-tetrahydro-l,6-naphthyridine, indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydro isoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine.
  • 7 to 11 membered heterobicycle also includes spiro structures of two rings like l,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
  • the term “8 to 11 membered heterobicyclyl” or “8 to 11 membered heterobicycle” is defined accordingly.
  • heterocycles examples include furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, pyranium, pyridine, pyridine-N-oxide, pyridazine, pyrimidine, triazole, tetrazole.
  • Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given below, with all combinations of preferred substituent definitions being a subject of the present invention.
  • the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts as well as their isotopic derivatives.
  • the substituents R, R 0 , R 1 , m, n and X 1 to X 4 of formula (I) independently have the following meaning.
  • one or more of the substituents R, R 0 , R 1 , m, n and X 1 to X 4 can have the preferred or more preferred meanings given below.
  • R 1 is Ci_5 alkyl; C2-5 alkenyl; C2-5 alkynyl; C3-5 cycloalkyl; CH 2 -cyclopropyl; CHF-cyclopropyl; CF 2 -cyclopropyl; CH 2 -cyclobutyl; CHF-cyclobutyl; CF 2 -cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH 3 ; OCH 2 F; OCHF 2 ; OCF 3 ; and CN, and wherein C 3 _5 cycloalkyl; CH 2 -cyclopropyl; CHF-cyclopropyl; CF 2 -cyclopropyl; CH 2 - eye Io butyl; CH
  • R 1 is Ci_5 alkyl; C 3 _5 cycloalkyl; CH 2 -cyclopropyl; CHF-cyclopropyl; CF 2 - cyclopropyl; CH 2 -cyclobutyl; CHF-cyclobutyl; CF 2 -cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein Ci_5 alkyl; C 3 _5 cycloalkyl; CH 2 -cyclopropyl; CHF-cyclopropyl; CF 2 - cyclopropyl; CH 2 -cyclobutyl; CHF-cyclobutyl; CF 2 -cyclobutyl; and 4 to 5 membered saturated heterocyclyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH 3 ; OCH 2 F; OCHF 2 ; OCF 3 ; CN; CH 3
  • R 1 is C 3 _5 cycloalkyl; CH 2 -cyclopropyl; CHF-cyclopropyl; CF 2 -cyclopropyl; CH 2 -cyclobutyl; CHF-cyclobutyl; CF 2 -cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein C 3 _5 cycloalkyl; CH 2 -cyclopropyl; CHF-cyclopropyl; CF 2 -cyclopropyl; CH 2 - cyclobutyl; CHF-cyclobutyl; CF 2 -cyclobutyl; and 4 to 5 membered saturated heterocyclyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH 3 ; OCH 2 F; OCHF 2 ; OCF 3 ; CN; CH 3 ; CH 2 F; CHF 2 ; and CF 3
  • R 1 is substituted or unsubstituted Ci .5 alkyl; substituted or unsubstituted C 3 _5 cycloalkyl; substituted or unsubstituted CH 2 -cyclopropyl; or substituted or unsubstituted CH 2 -cyclobutyl.
  • R 1 is substituted or unsubstituted C 3 _5 cycloalkyl; substituted or unsubstituted CH 2 -cyclopropyl; or substituted or unsubstituted CH 2 -cyclo butyl.
  • R 1 is isopropyl; cyclobutyl; ethyl; cyclopentyl; cyclopropyl; CH 2 -cyclopropyl; or CH 2 -cyclobutyl. In yet another even more preferred embodiment R 1 is isopropyl; cyclobutyl; cyclopentyl; cyclopropyl; CH 2 -cyclopropyl; or CH 2 -cyclobutyl.
  • R 1 is cyclobutyl; ethyl; isopropyl; or cyclopentyl.
  • R 1 is cyclobutyl; or cyclopentyl.
  • n is 2.
  • X 1 is N. In another preferred embodiment X 1 is CH.
  • X 2 is S; or O. In a more preferred embodiment X 2 is O.
  • At least one of X 7-1 , X - ⁇ ⁇ -3 is N.
  • X is CH.
  • X is N.
  • X 1 , X 3 are N.
  • m is 0.
  • nl; n2 are independently selected from the group consisting of 0; and 1.
  • nl is 0 or 1 and n2 is 0.
  • nl and n2 are 0.
  • X 4 is (CH 2 ) nl X 5 (CH 2 ) n2 R 2 .
  • X 5 is C(O); O; C(O)N(R la ); N(R la )C(O); S(O) 2 N(R la ); N(R la )S(O) 2 ; N(R la ); or N(R la )C(O)N(R lb ).
  • X 5 is C(O); C(O)N(R la ); N(R la )C(O); S(O) 2 N(R la ); N(R la )S(O) 2 ; N(R la ); or N(R la )C(O)N(R lb ).
  • X 5 is C(O); O; C(O)N(R la ); N(R la )C(O); N(R la )S(O) 2 ; N(R la ); or N(R la )C(O)N(R lb ). In a further more preferred embodiment X 5 is C(O); C(O)N(R la ); N(R la )C(O); N(R la )S(O) 2 ; N(R la ); or N(R la )C(O)N(R lb ). In an even more preferred embodiment X 5 is C(O); O; C(O)N(R la ); N(R la )C(O); or N(R la ). In a further even more preferred embodiment X 5 is C(O); C(O)N(R la ); N(R la )C(O); or N(R la ).
  • R 2 is H; or T.
  • R 2 is T, especially when T is aromatic.
  • T is a 6 membered heterocyclyl, especially when T is aromatic.
  • T is phenyl; or pyridine.
  • T is a phenyl.
  • T is pyridine.
  • T may be unsubstituted or substituted.
  • T is unsubstituted or substituted with one, two or three (more preferably, with one or two) R 7 , which are the same or different.
  • R 7 is preferably selected from the group consisting of halogen; CN; C(O)R 8 ; N(R 8 R 8a ); OR 8 ; C(O)N(R 8 R 8a ); S(O) 2 R 8 ; Ci_ 6 alkyl optionally substituted with one or more R 9 (even more preferably substituted or unsubstituted CH 2 -T 1 ), which are the same or different; or substituted or unsubstituted T ! .
  • Preferred individual compounds of the present invention are selected from the group consisting of
  • Prodrugs of the compounds of the invention are also within the scope of the present invention.
  • “Prodrug” means a derivative that is converted into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically.
  • Examples of a prodrug are compounds, wherein the amino group in a compound of the present invention is acylated, alkylated or phosphorylated to form, e.g., eicosanoylamino, alanylamino, pivaloyloxymethylamino or wherein the hydroxyl group is acylated, alkylated, phosphorylated or converted into the borate, e.g. acetyloxy, palmitoyloxy, pivaloyloxy, succinyloxy, fumaryloxy, alanyloxy or wherein the carboxyl group is esterif ⁇ ed or amidated.
  • These compounds can be produced from compounds of the present invention according to well-known methods.
  • Metabolites of compounds of formula (I) are also within the scope of the present invention.
  • tautomerism like e.g. keto-enol tautomerism
  • the individual forms like e.g. the keto and enol form, are comprised separately and together as mixtures in any ratio.
  • stereoisomers like e.g. enantiomers, cis/trans isomers, conformers and the like.
  • each pure form separately and any mixture of at least two of the pure forms in any ratio is comprised by formula (I) and is a subject of the present invention.
  • Iso topic labeled compounds of formula (I) are also within the scope of the present invention.
  • Methods for isotope labeling are known in the art.
  • Preferred isotopes are those of the elements H, C, N, O and S.
  • isomers can be separated by methods well known in the art, e.g. by liquid chromatography. Same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials, reagents and/or catalysts.
  • the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
  • the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • Compounds of the formula (I) which contain one or more basic groups i.e.
  • acids which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
  • suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
  • the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
  • the respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
  • the present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • the present invention provides compounds of general formula (I) as Histamine H3 receptor antagonists.
  • the histamine H3 receptor is a G protein-coupled receptor (GPCR) and one out of four receptors of the histamine receptor family. Histamine receptors have long been attractive drug targets, mirrored in the development of antihistamines, which were directed at the histamine Hl receptor for the treatment of allergic reactions or at the histamine H2 receptor to ameliorate gastric ulcers by inhibiting gastric acid secretion.
  • the H3 receptor has been identified as a presynaptic autoreceptor, regulating the release of histamine (Arrang et al.
  • H3 receptor antagonists / inverse agonists have been developed and shown to comprise activity in a variety of cognition tests in mice and rat (e.g. Esbenshade et al. (2006) MoI Interventions: 6 (2); 77 - 88) as well as in models for sleeping disorders and energy balance.
  • Such antagonists comprise a potential treatment for a variety of disorders affecting cognition (e.g., Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, Schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome and others), as well as sleep (e.g., hypersomnia and narcolepsy), and energy homeostasis (e.g. obesity)
  • cognition e.g., Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, Schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome and others
  • sleep e.g., hypersomnia and narcolepsy
  • energy homeostasis e.g. obesity
  • the pharmacology of the H3 receptor seems not only to be determined by its localization but appears also to be regulated by differential splicing.
  • the H3 receptor is localized primarily to the central nervous system (CNS), with highest expression, in rodents, in the cerebral cortex, hippocampal formations, striatum, and hypothalamus (Drutel et al. (2001) MoI Pharmacol: 59; 1 - 8).
  • H3 receptor expression is prominent in the basal ganglia, globus pallidus, hippocampus, and cortex (Martinez-Mir et al. (1990) Brain Res: 526; 322 327). Notably, many of these brain regions are critical for cognition (cortex and hippocampus) and sleep and homeostatic regulation (hypothalamus).
  • the H3 receptor has been shown also to localize to regions which might be involved in pain sensation or transmission and therefore might offer treatment opportunities for different pain states (Cannon et al. (2007) Pain: 129; 76 - 92).
  • the H3 receptor is constitutively active and capable of signaling independently of agonist both in vitro and in vivo (Morisset et al. (2000) Nature: 408, 860 - 864). All these considerations suggest that novel H3 receptor antagonists like the series in this application could be useful in the treatment of cognitive dysfunctions as well as sleeping and energy homeostasis disorders.
  • the term "antagonist” also includes inverse agonists.
  • Neurological disorders include - behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease,
  • seizure disorders e.g. Alzheimer's disease, Parkinson's disease, Multiple obstructive obstructive pulmonary disease, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, and others.
  • neurodegenerative disorders e.g. Alzheimer's disease, Parkinson's disease, Multiple obstructive fibros, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders,
  • sleep disorders e.g. hypersomnia and narcolepsy, excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns
  • neurological disorders also includes psychiatrical disorders within the meaning of the present invention.
  • neurodegenerative disorders also includes neuro- inflammatory disorders within the meaning of the present invention.
  • disorders affecting energy homeostasis as well as complications associated therewith e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus.
  • Pain e.g. neuropathic pain, inflammatory pain, nociception.
  • Pain includes acute and chronic pain within the meaning of the present invention.
  • Cardiovascular disorders e.g. acute myocardial infarction
  • other disorders i.e. gastrointestinal disorders
  • vestibular dysfunction e.g. Morbus Meniere, motion sickness, drug abuse
  • nasal congestion e.g. allergic rhinitis (hay fever), asthma.
  • convulsion and epilepsy are excluded.
  • Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease- related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere), motion sickness, drug abuse, nasal congestion, allergic rhinitis (hay fever), asthma.
  • schizophrenia Foetal Alcohol Syndrome
  • Mild Cognitive Impairment Mild Cognitive Impairment
  • Age-related Memory Dysfunction disease-related cognitive dysfunctions
  • Lewy body dementia vascular dementia
  • Down Syndrome epilepsy
  • convulsion depression
  • More preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma.
  • Alzheimer's disease Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
  • one aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use as a medicament.
  • Yet another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing diseases and disorders associated with the H3 receptor.
  • Yet another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing neurological disorders, e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis), sleep disorders (e.g.
  • behavioral/cognitive syndromes e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders
  • seizure disorders e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis
  • sleep disorders e.g.
  • hypersomnia and narcolepsy excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns), Migraine, Stroke, tremor; disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus; Pain, e.g. neuropathic pain, inflammatory pain, nociception; cardiovascular disorders, e.g. acute myocardial infarction; gastrointestinal disorders; vestibular dysfunction (e.g. Morbus Meniere, motion sickness, drug abuse); nasal congestion; allergic rhinitis (hay fever); or asthma.
  • disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus
  • Pain e.g. neuropathic pain, inflammatory pain, nociception
  • Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease- related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere), motion sickness, drug abuse, nasal congestion, allergic rhinitis (hay fever), asthma.
  • schizophrenia Foetal Alcohol Syndrome
  • Mild Cognitive Impairment Mild Cognitive Impairment
  • Age-related Memory Dysfunction disease-related cognitive dysfunctions
  • Lewy body dementia vascular dementia
  • Down Syndrome epilepsy
  • convulsion depression
  • Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma.
  • Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
  • Yet another aspect of the present invention is the use of a compound or a pharmaceutically acceptable salt thereof of the present invention for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with the H3 receptor.
  • Yet another aspect of the present invention is the use of a compound or a pharmaceutically acceptable salt thereof of the present invention for the manufacture of a medicament for the treatment or prophylaxis of neurological disorders, e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g.
  • Alzheimer's disease, Parkinson's disease, Multiple Sclerosis sleep disorders (e.g. hypersomnia and narcolepsy, excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns), Migraine, Stroke, tremor; disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus; Pain, e.g. neuropathic pain, inflammatory pain, nociception; cardiovascular disorders, e.g. acute myocardial infarction; gastrointestinal disorders; vestibular dysfunction (e.g.
  • Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease-related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g.
  • Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma.
  • Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
  • Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of diseases and disorders associated with the H3 receptor, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of neurological disorders, e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis), sleep disorders (e.g.
  • neurological disorders e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g. Alzheimer'
  • hypersomnia and narcolepsy excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns), Migraine, Stroke, tremor; disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus; Pain, e.g. neuropathic pain, inflammatory pain, nociception; cardiovascular disorders, e.g. acute myocardial infarction; gastrointestinal disorders; vestibular dysfunction (e.g.
  • Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease-related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g.
  • Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma.
  • Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
  • the mammalian patient is a human patient.
  • Yet another aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof of the present invention together with a pharmaceutically acceptable carrier, optionally in combination with one or more other bioactive compounds or pharmaceutical compositions.
  • the one or more bioactive compounds are lipase inhibitors, anorectic agents, selective serotonin uptake inhibitors, neurotransmitter reuptake blocker, agents that stimulate metabolism of body fat, anti-diabetic agents, lipid lowering agents, or histamine Hl receptor antagonists.
  • a combination of one or more histamine H3 receptor antagonists of the present invention and histamine Hl receptor antagonists is preferred, especially for the treatment of allergic rhinitis, allergic congestion or nasal congestion.
  • “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like one or more compounds of formula (I) not being the first compound in the composition or other Histamine H3 receptor antagonists.
  • the active ingredients may be comprised in one or more different pharmaceutical compositions (combination of pharmaceutical compositions).
  • the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • oral liquid preparations such as, for example, suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
  • the active compounds can also be administered intranasally, for example, as liquid drops or spray.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compounds of formula (I) are administered orally.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • One method for the preparation of a compound of the present invention comprises the steps of (a) reacting the amino group of a compound of formula (II) with a suitable chloroformate
  • n and R 1 have the meaning as indicated above;
  • step (b) reacting the resulting carbamate compound from step (a) with a compound of formula (III)
  • n has the meaning as indicated above and R 1 is R 1 as indicated above or as suitable N-atom protecting group
  • step (b) reacting the resulting carbamate compound from step (a) with a compound of formula (Ilia)
  • the method may comprise the further step when X 4 is OH
  • the alcohol is deprotonated with a strong base (such as NaH or 1 BuOK) and the resulting alkoxide reacted with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0 C) to yield a compound of formula (I), wherein X 4 is X 5 (CH 2 ) n2 R 2 .
  • a strong base such as NaH or 1 BuOK
  • R 1 of formula (I) is a suitable N-atom protecting group (such as Boc or cbz)
  • the resulting compound represented by formula (Ii) requires the following additional steps to synthesise a compound of formula (I);
  • a reducing agent such as STAB
  • compounds of formula (I) wherein X 1 and X 3 are N and X 2 is S may be prepared by a method comprising the steps of
  • compounds of formula (I) wherein X 1 and X 3 are N and X 2 is N-CN may be prepared by a method comprising the steps of
  • compounds of general formula (I) wherein X 2 is N-OCi_4 alkyl and X 4 is H or OH may be prepared from a compound of formula (Ia) by a method comprising the steps of
  • compounds of general formula (I) wherein X 1 is CH and n is 1, may be prepared from a compound of formula (Ib) by a method comprising the steps of
  • compounds of general formula (I) wherein X 1 is CH and n is 2 may be prepared from a compound of formula (Ic) by a method comprising the steps of
  • compounds of general formula (I) wherein X 1 is CH and n is 2 may be prepared from a compound of formula (Ih) where PG is a protecting group (usually a carbonate protecting group such as cbz) by a method comprising the steps of
  • the method may comprise the further steps where compounds of formula (If), wherein the meanings are as indicated above, are further modified as follows;
  • the method may comprise the further step
  • the alcohol is deprotonated with a strong base (such as NaH or 1 BuOK) and the resulting alkoxide reacted with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0 C) to yield a compound of formula (I), wherein X 4 is X 5 (CH 2 ) n2 R 2 .
  • a strong base such as NaH or 1 BuOK
  • R 1 , R, n, X 1 , X 2 , X 3 have the meaning as indicated above.
  • the alcohol may be deprotonated with a strong base (such as NaH or 1 BuOK, optionally in the presence of CsF) and the resulting alkoxide reacted with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0 C) to yield a compound of formula (I), wherein X 4 is X 5 (CH 2 ) n2 R 2 .
  • a strong base such as NaH or 1 BuOK, optionally in the presence of CsF
  • compounds of formula (I) wherein X 5 is O can be prepared in a two step process starting from a compound of formula (V), wherein the method comprises the steps of
  • compounds of formula (I) wherein X 5 is O can be prepared in a one step Ullmann reaction starting from a compound of formula (V) above, wherein the method comprises the steps of;
  • compounds of formula (I) wherein X 5 is O can be prepared in a one step process starting from a compound of formula (V) above, wherein the method comprises the steps of; the alcohol is deprotonated with a strong base (such as NaH or 1 BuOK) and the resulting alkoxide reacted (usually between room temperature and 18O 0 C) with a suitable (hetero)aryl fluoride preformed in situ by the reaction of a (hetero)aryl chloride or bromide with KF and a suitable fluorinating agent (such as Kryptof ⁇ x-222) usually between room temperature and 18O 0 C, to yield a compound of formula (I) wherein X 5 is O.
  • a strong base such as NaH or 1 BuOK
  • a suitable (hetero)aryl fluoride preformed in situ by the reaction of a (hetero)aryl chloride or bromide with KF and a suitable fluorinating agent (such as Kryptof ⁇ x-22
  • nl of formula (I) 1, the compounds can be prepared in a two step process starting from a compound of formula (VI) above by;
  • the method may comprise further steps where compounds of formula (VII), wherein the meanings are as indicated above, are further modified as follows;
  • step (ff) reacting the resulting secondary amine from step (ee) with a suitable alkyl halide or activated alcohol (such as OMs or OTs) in the presence of an organic base (such as TEA) at room temperature or elevated temperature (up to 200 0 C) to yield a compound of formula (I), wherein X 4 is
  • compounds of formula (I), wherein X 4 is N(R la )(CH 2 ) n2 R 2 can be prepared in a one step process as follows;
  • step (ee) by reacting the secondary amine from step (ee) with a suitable alkyl aldehyde in the presence of an organic acid (such as AcOH) and reducing agent (such as NaBH 3 CN) at room temperature or elevated temperature (up to 100 0 C), to yield a compound of formula (I), wherein X 4 is N(R la )(CH 2 ) n2 R 2 .
  • an organic acid such as AcOH
  • reducing agent such as NaBH 3 CN
  • step (ee) above may be replaced with step (gg) below, to yield compounds formula (I), wherein X 4 is NHR 2 ;
  • the method may comprise the further step where compounds of formula (VIII), wherein the meanings are as indicated above, are further modified as follows;
  • the method may comprise the further steps where compounds of formula (I), wherein the meanings are as indicated above and R 2 has a potentially chemically reactive group, are further modified as follows:
  • the method may comprise the further steps where compounds of formula (I) represented by formula (X), wherein the meanings are as indicated above, are further modified as follows;
  • the method may comprise the further step where compounds of formula (I) represented by formula (XI), wherein the meanings are as indicated above, are further modified as follows;
  • the method may comprise the further step where compounds of formula (I) represented by formula (XII), wherein the meanings are as indicated above, are further modified as follows;
  • CHO-Kl cell line expressing human H3 receptors were purchased from Euroscreen (Gosselies, Belgium, Cat. no.: ES-392-C)
  • Human H3 receptor-expressing cell-lines were grown in Ham's F12 [Sigma, Cat. no. N6658], supplemented with 10% FBS [Sigma, Cat. no. F9665], 400 ⁇ g/ml G418 [Sigma, Cat. no. Nl 876] and 250 ⁇ g/ml Zeocin [Invitrogen, Cat. no. 46-0509]) according to the protocol provided by Euroscreen.
  • the assay measures the ability of test compounds to inhibit Histamine receptor agonist- induced decrease of intracellular free cAMP (receptor is G 1 coupled).
  • cAMP quantification assay system from Disco veRx (cAMP XS+; Cat. no. 90- 0075) was used.
  • cAMP assay confluent cells were detached from the culture vessels with Ix trypsin- EDTA solution (Sigma), and seeded into 384-well Costar plates (white, clear bottom, Cat. no. 3707) at a density of 10,000 cells per well. Cells were seeded in a volume of 50 ⁇ l in medium without antibiotics and incubated overnight in a humidified atmosphere with 5% CO 2 at 37°C. The cAMP assay was performed according to the protocol provided by DiscoveRx.
  • the cell culture medium was removed and the cells washed once with PBS (50 ⁇ l per well).
  • the plates were emptied by inversion and 7.5 ⁇ l/well of compound in PBS (containing ImM IBMX and 0.03% BSA) were added and incubated for 30min at 37°C. Subsequent 7.5 ⁇ l/well specific agonist solution was added and the plates for another 30min incubated at 37°C.
  • hH3 100 nM histamine, 10 ⁇ M forskolin in PBS (containing ImM IBMX and 0.03% BSA)
  • Test compounds were assayed at 8 concentrations in triplicate. Serial 10-fold dilutions in 100% DMSO were made at a 100-times higher concentration than the final concentration and then diluted with a 2 step protocol in assay buffer to reach the required assay concentrations and 1% DMSO.
  • A ⁇ 100 nM
  • B > 100 nM to 500 nM
  • C > 500 nM to 5000 nM.
  • the Caco-2 Permeability assay uses an established method for predicting the in vivo absorption of drugs across the gut wall by measuring the rate of transport of a compound across the Caco-2 cell line.
  • the Caco-2 cell line is derived from a human colon carcinoma. These cells have characteristics that resemble intestinal epithelial cells such as the formation of a polarised monolayer, well-defined brush border on the apical surface and intercellular junctions. Assessing transport in both directions (apical to basolateral (A-B) and baso lateral to apical (B-A)) across the cell monolayer enables an efflux ratio to be determined which provides an indicator as to whether a compound undergoes active efflux.
  • Preferred compounds of Formula (I) have Caco-2 efflux ratios of ⁇ 3.0.
  • Example compounds and their intermediates were analysed by HPLC-MS using a combination of the following instrumentation: Shimadzu, Waters or Micromass ZMD, ZQ or LCT mass spectrometers with an Agilent, Waters or Polymer Labs UV and ELS detector.
  • the HPLC conditions are tabulated below.
  • Micromass MassLynxTM Operating Software with OpenLynxTM Browser were used for data acquisition, processing and reporting.
  • Example compounds and their intermediates were purified by one of or any combination of the following methods.
  • Acetic acid (0.6 ml, 10.5 mmol) was added dropwise to a solution of 2-amino-4- chloropyridine (384 mg, 3.0 mmol), formaldehyde (2.4 ml of a 37% aqueous solution, 29.6 mmol) and NaBH 3 CN (581 mg, 9.0 mmol) in MeCN (10 ml) and water (2 ml) at 0 0 C. After 10 minutes the reaction was warmed to room temperature and stirred for 3 days. The reaction was basif ⁇ ed to pH4 with IM aq. NaOH and then extracted with diethyl ether (3 x 30 ml), dried (MgSO 4 ), filtered and concentrated at reduced pressure. The residue was purified by
  • n-BuLi (8.5 ml of a 1.2 M soln in hexanes, 10.2 mmol) was added dropwise to a solution of 2,2,6,6-tetramethylpiperidine (1.73 ml, 10.2 mmol) in THF (30 ml) at 0 0 C. The mixture was then cooled to -78 0 C and 4-chloro-3-fluoropyridine (1.0 ml, 10.2 mmol) was added dropwise over 15 minutes and then stirred for 25 minutes. MeI (0.64 ml, 10.2 mmol) was added dropwise at -78 0 C and the resulting solution was left to warm to room temperature over several hours and quenched with saturated NaHCO 3 (5 ml).
  • Azetidin-3-ol hydrochloride (1.3 g, 11.86 mmol) and DIPEA (3.37 g, 26.1 mmol) were added and the resulting mixture was heated to reflux ( ⁇ 90 0 C) overnight. After cooling to RT, the solvent was evaporated and the residue partitioned between DCM (40 ml) and 2M K2CO3 aq (20 ml). The organic layer was separated and the aq. phase re- extracted with DCM (20 ml). The combined organic phases were dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure. Purification by silica flash column chromatography (eluting with DCM/MeOH/NH 3 90:10:1) provided the title compound as yellow solid (1.16g, 39%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Description

Evotec Neurosciences GmbH May 5, 2009
EVO65427PC IB/EBU/ust
Azetidines and cyclobutanes as Histamine H3 receptor antagonists
The present invention relates to Histamine H3 receptor antagonists, pharmaceutical compositions thereof, the preparation of such compounds as well as the production and use as medicament.
The histamine H3 receptor is a G protein-coupled receptor (GPCR) and one out of four receptors of the histamine receptor family. Histamine receptors have long been attractive drug targets, mirrored in the development of antihistamines, which were directed at the histamine Hl receptor for the treatment of allergic reactions or at the histamine H2 receptor to ameliorate gastric ulcers by inhibiting gastric acid secretion. The H3 receptor has been identified as a presynaptic autoreceptor, regulating the release of histamine (Arrang et al. (1983) Nature: 302; 832 - 837), as well as a heteroreceptor that regulates the release of many other important neurotransmitters (acetylcholine, norepinephrine, dopamine, and serotonin). Structurally divergent H3 receptor antagonists / inverse agonists have been developed and shown to comprise activity in a variety of cognition tests in mice and rat (e.g. Esbenshade et al. (2006) MoI Interventions: 6 (2); 77 - 88) as well as in models for sleeping disorders and energy balance. From these studies it is concluded that such antagonists comprise a potential treatment for a variety of disorders affecting cognition (e.g., Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, Schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome and others), as well as sleep (e.g., hypersomnia and narcolepsy), and energy homeostasis (e.g. obesity) (Witkin & Nelson (2004) JPET: 103; 1 - 20; Hancock & Brune (2005) Exp Opin Inves Drugs: 14 (3), 223 - 241).
Accordingly, Histamine H3 receptor antagonists are described in the art for the treatment of the above mentioned diseases and disorders.
In WO-A 2007/080140 cyclylhexyl piperazinyl methanone derivatives are disclosed, which are useful as H3 receptor modulators. In WO-A 2006/136924 cyclo butyl derivatives are disclosed as Histamine-3 receptor antagonists.
US-A 4956359 describes anticonvulsants and antiepileptics having similar chemical structures without referring to H3 receptor antagonism.
However there is a continuing need for new compounds useful as Histamine H3 receptor antagonists.
Thus, an object of the present invention is to provide a new class of compounds as Histamine H3 receptor antagonists which may be effective in the treatment of H3 receptor related diseases and may show improved pharmaceutically relevant properties including activity, ADMET properties and/or reduced side effects.
Accordingly, the present invention provides compounds of formula (I)
Figure imgf000003_0001
or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein
R1 is Ci_5 alkyl; C2-5 alkenyl; C2-5 alkynyl; or T0, wherein Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; CN; and T0;
T0 is C3_5 cycloalkyl; or 4 to 5 membered saturated heterocyclyl, wherein T0 is optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl; OH; O-Ci_5 alkyl; O-C2-5 alkenyl; O-C2-5 alkynyl; and CN, wherein Ci_5 alkyl; C2-5 alkenyl; C2-5 alkynyl; O-Ci_5 alkyl; O-C2-5 alkenyl; and O-C2-5 alkynyl are optionally substituted with one or more halogen, which are the same or different;
n is 1 or 2;
X1 is N; or CH;
X2 is O; S; N-CN; N-OH; or N-OC1.4 alkyl;
X3 is N; CH; or CF;
X4 is H; F; or (CH2)niX5(CH2)n2R2;
R0 is F;
m is 0, 1, 2, 3, or 4;
R is H; or F;
Optionally, R, X4 are joined to form oxo (=0);
nl; n2 are independently selected from the group consisting of 0; 1; and 2;
X5 is C(O); C(O)O; OC(O); O; C(0)N(Rla); N(Rla)C(0); S(O)2N(Rla); N(Rla)S(O)2; S(O)N(Rla); N(Rla)S(O); S(O)2; S(O); N(Rla)S(0)2N(Rlb); S; N(Rla);
N(Rla)C(0)N(Rlb); N(Rla)C(0)0; or 0C(0)N(Rla);
Rla, Rlb are independently selected from the group consisting of H; Ci_4 alkyl; C2-4 alkenyl; and C2-4 alkynyl, wherein Ci_4 alkyl; C2-4 alkenyl; and C2-4 alkynyl are optionally substituted with one or more halogen, which are the same or different;
R2 is H; T; Ci_6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R , which are the same or different; R3 is halogen; CN; C(O)R4; C(O)OR4; OR4; C(O)N(R4R4a); S(O)2N(R4R4a); S(O)N(R4R4a); S(O)2R4; S(O)R4; N(R4)S(O)2N(R4aR4b); SR4; N(R4R4a); NO2; OC(O)R4; N(R4)C(O)R4a; N(R4)SO2R4a; N(R4)S(O)R4a; N(R4)C(O)N(R4aR4b); N(R4)C(O)OR4a; OC(O)N(R4R4a); or T;
R4, R4a, R4b are independently selected from the group consisting of H; T; Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more R5, which are the same or different;
R5 is halogen; CN; C(O)R6; C(O)OR6; OR6; C(O)N(R6R6a); S(O)2N(R6R6a);
S(O)N(R6R6a); S(O)2R6; S(O)R6; N(R6)S(O)2N(R6aR6b); SR6; N(R6R6a); NO2; OC(O)R6; N(R6)C(O)R6a; N(R6)SO2R6a; N(R6)S(O)R6a; N(R6)C(O)N(R6aR6b); N(R6)C(O)OR6a; OC(O)N(R6R6a); or T;
R6, R6a, R6b are independently selected from the group consisting of H; T; Ci_6 alkyl;
C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
T is phenyl; naphthyl; azulenyl; indenyl; indanyl; C3-7 cycloalkyl; 3 to 7 membered heterocyclyl; or 7 to 11 membered heterobicyclyl, wherein T is optionally substituted with one or more R7, which are the same or different;
R7 is halogen; CN; C(O)OR8; OR8; C(O)R8; C(O)N(R8R8a); S(O)2N(R8R8a);
S(O)N(R8R8a); S(O)2R8; S(O)R8; N(R8)S(O)2N(R8aR8b); SR8; N(R8R8a); NO2; OC(O)R8; N(R8)C(O)R8a; N(R8)S(O)2R8a; N(R8)S(O)R8a; N(R8)C(O)OR8a;
N(R8)C(O)N(R8aR8b); OC(O)N(R8R8a); oxo (=0), where the ring is at least partially saturated; T1; Ci_6 alkyl; C2_6 alkenyl; or C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more R9, which are the same or different;
R8, R8a, R8b are independently selected from the group consisting of H; T1; Ci_6 alkyl;
C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more R10, which are the same or different; R9, R10 are independently selected from the group consisting of halogen; CN; C(O)R11; C(O)OR11; OR11; C(O)N(R11R1 la); S(O)2N(R11R1 la); S(O)N(R11R1 la); S(O)2R11; S(O)R11; N(R1 ^S(O)2N(R1 laRl lb); SR11; N(RπRl la); NO2; OC(O)R11; N(R1 ^C(O)R1 la; N(R1 ^SO2R1 la; N(R1 ^S(O)R1 la; N(R1 ^C(O)N(R1 laRl lb); N(R1 ^C(O)OR11"; OC(O)N(R11R1 la); and T1;
R11, Rl la, Rl lb are independently selected from the group consisting of H; T1; Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
T1 is phenyl; C3-7 cycloalkyl; or 3 to 7 membered heterocyclyl, wherein T1 is optionally substituted with one or more R12, which are the same or different;
R12 is halogen; CN; C(O)OR13; OR13; C(O)R13; C(O)N(R13R13a); S(O)2N(R13R13a); S(O)N(R13R13a); S(O)2R13; S(O)R13; N(R13)S(O)2N(R13aR13b); SR13; N(R13R13a); NO2;
OC(O)R13; N(R13)C(O)R13a; N(R13)S(O)2R13a; N(R13)S(O)R13a; N(R13)C(O)OR13a; N(R13)C(O)N(R13aR13b); OC(O)N(R13R13a); oxo (=0), where the ring is at least partially saturated; Ci_6 alkyl; C2_6 alkenyl; or C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
R13, R13a, R13b are independently selected from the group consisting of H; Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more halogen, which are the same or different,
provided that the following compound salts are excluded:
1 -Propyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyljpiperazine fumarate
[1 :1]; 1 -Methyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyljpiperazine oxalate
[1 :1.5];
1 -Methyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyljpiperazine fumarate
[1 :1];
1 - [3 -(4-Bromophenoxy)- 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1]; l-[3-(3-Bromophenoxy)-l-azetidinylcarbonyl]-4-methylpiperazine fumarate [1 :1]; 1 - [3 -(4-Fluorophenoxy)- 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1]; 1 - [3 -(3 ,4-Dichlorophenoxy)- 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1]; 1 - [3 - [(4-Chlorophenyl)thio] - 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1]; Hexahydro- 1 -methyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyl] - IH-
1 ,4-diazepine fumarate [1:1].
The individual salts excluded from formula (I) are described in US-A 4956359. Preferably, the underlying compounds as such and pharmaceutical salts thereof are also excluded.
Preferably, the following 4 compounds are excluded from compounds according to formula (I) as far as compounds as such are addressed by the present invention.
Figure imgf000007_0001
Preferably, the 4 compounds are not excluded as far as pharmaceutical compositions, compounds or pharmaceutical acceptable salts thereof for use as medicament or in a method of treating or preventing disorders, methods of treating or preventing diseases or disorders of the present invention are addressed.
Furthermore it is preferred that the following 5 compounds are also excluded from compounds according to formula (I) as far as compounds as such are addressed by the present invention.
Figure imgf000007_0002
Preferably, the 5 compounds are not excluded as far as pharmaceutical compositions, compounds or pharmaceutical acceptable salts thereof for use as medicament or in a method of treating or preventing disorders, methods of treating or preventing diseases or disorders of the present invention are addressed.
In case a variable or substituent in formula (I) as defined above can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
Within the meaning of the present invention the terms are used as follows:
"Alkyl" means a straight-chain or branched saturated hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent as further specified.
"Alkenyl" means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon double bond. Each hydrogen of an alkenyl carbon may be replaced by a substituent as further specified.
"Alkynyl" means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon triple bond. Each hydrogen of an alkynyl carbon may be replaced by a substituent as further specified.
"Ci_4 alkyl" means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g. - CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CHs)2-, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a Ci_4 alkyl carbon may be replaced by a substituent as further specified.
"Ci_6 alkyl" means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: Ci_4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, or e.g. -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, - C(CH3)2-, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a Ci_6 alkyl carbon may be replaced by a substituent as further specified. The term "Ci_5 alkyl" is defined accordingly.
"C2_6 alkenyl" means an alkenyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: -CH=CH2, -CH=CH-CH3, -CH2-CH=CH2, -CH=CH-CH2-CH3, -CH=CH- CH=CH2, or e.g. -CH=CH-, when two moieties of a molecule are linked by the alkenyl group. Each hydrogen of a C2-6 alkenyl carbon may be replaced by a substituent as further specified. The terms "C2-4 alkenyl" and "C2-5 alkenyl" are defined accordingly.
"C2-6 alkynyl" means an alkynyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: -C≡CH, -CH2-C≡CH, CH2-CH2-C≡CH, CH2-C≡C-CH3, or e.g. -C≡C- when two moieties of a molecule are linked by the alkynyl group. Each hydrogen of a C2-6 alkynyl carbon may be replaced by a substituent as further specified. The terms "C2-4 alkynyl" and "C2-5 alkynyl" are defined accordingly.
"C3_7 cycloalkyl" or "C3_7 cycloalkyl ring" means a cyclic alkyl chain having 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent as further specified. The term "C3-S cycloalkyl" is defined accordingly.
"Halogen" means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
"3 to 7 membered heterocyclyl" or "3 to 7 membered heterocycle" means a ring with 3, 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen and nitrogen (including N-oxide: =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for 3 to 7 membered heterocycles are azeridine, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydro furan, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridine -N-oxide, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine. The term "4 to 5 membered heterocyclyl" or "4 to 5 membered heterocycle" is defined accordingly. The term "5 to 6 membered heterocyclyl" or "5 to 6 membered heterocycle" is defined accordingly.
"4 to 5 membered saturated heterocyclyl" or "4 to 5 membered saturated heterocycle" means a "4 to 5 membered heterocyclyl" or "4 to 5 membered heterocycle" without double bonds in the ring. "7 to 11 membered heterobicyclyl" or "7 to 11 membered heterobicycle" means a heterocyclic system of two rings with 7 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen and nitrogen (including N-oxide: =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for 7 to 11 membered heterobicycles are imidazo[l,5-a]pyridine, imidazo[2,l-b][l,3]oxazole, imidazo[2,l-b][l,3]thiazole, 5,6,7,8-tetrahydro-l,6-naphthyridine, indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydro isoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The term 7 to 11 membered heterobicycle also includes spiro structures of two rings like l,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane. The term "8 to 11 membered heterobicyclyl" or "8 to 11 membered heterobicycle" is defined accordingly.
"5 to 6 membered aromatic heterocyclyl" or "5 to 6 membered aromatic heterocycle" means a heterocycle derived from cyclopentadienyl or benzene, where at least one carbon atom is replaced by a heteoatom selected from the group consisting of sulfur (including -S(O)-, - S(O)2-), oxygen and nitrogen (including N-oxide: =N(O)-). Examples for such heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, pyranium, pyridine, pyridine-N-oxide, pyridazine, pyrimidine, triazole, tetrazole.
Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given below, with all combinations of preferred substituent definitions being a subject of the present invention. With respect to all preferred compounds of the formula (I) the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts as well as their isotopic derivatives.
In preferred embodiments of the present invention, the substituents R, R0, R1, m, n and X1 to X4 of formula (I) independently have the following meaning. Hence, one or more of the substituents R, R0, R1, m, n and X1 to X4 can have the preferred or more preferred meanings given below.
Preferably, R1 is Ci_5 alkyl; C2-5 alkenyl; C2-5 alkynyl; C3-5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2-cyclopropyl; CH2-cyclobutyl; CHF-cyclobutyl; CF2-cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; and CN, and wherein C3_5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2-cyclopropyl; CH2- eye Io butyl; CHF-cyclobutyl; CF2-Cy clo butyl; and 4 to 5 membered saturated heterocyclyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; CN; CH3; CH2F; CHF2; and CF3.
More preferably, R1 is Ci_5 alkyl; C3_5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2- cyclopropyl; CH2-cyclobutyl; CHF-cyclobutyl; CF2-cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein Ci_5 alkyl; C3_5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2- cyclopropyl; CH2-cyclobutyl; CHF-cyclobutyl; CF2-cyclobutyl; and 4 to 5 membered saturated heterocyclyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; CN; CH3; CH2F; CHF2; and CF3.
More preferably, R1 is C3_5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2-cyclopropyl; CH2-cyclobutyl; CHF-cyclobutyl; CF2-cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein C3_5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2-cyclopropyl; CH2- cyclobutyl; CHF-cyclobutyl; CF2-cyclobutyl; and 4 to 5 membered saturated heterocyclyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; CN; CH3; CH2F; CHF2; and CF3.
In a more preferred embodiment R1 is substituted or unsubstituted Ci .5 alkyl; substituted or unsubstituted C3_5 cycloalkyl; substituted or unsubstituted CH2-cyclopropyl; or substituted or unsubstituted CH2-cyclobutyl.
In yet another more preferred embodiment R1 is substituted or unsubstituted C3_5 cycloalkyl; substituted or unsubstituted CH2-cyclopropyl; or substituted or unsubstituted CH2-cyclo butyl.
In an even more preferred embodiment R1 is isopropyl; cyclobutyl; ethyl; cyclopentyl; cyclopropyl; CH2-cyclopropyl; or CH2-cyclobutyl. In yet another even more preferred embodiment R1 is isopropyl; cyclobutyl; cyclopentyl; cyclopropyl; CH2-cyclopropyl; or CH2-cyclobutyl.
In an even more preferred embodiment R1 is cyclobutyl; ethyl; isopropyl; or cyclopentyl.
In yet another even more preferred embodiment R1 is cyclobutyl; or cyclopentyl.
Preferably, n is 2.
Preferably, X1 is N. In another preferred embodiment X1 is CH.
Preferably, X2 is S; or O. In a more preferred embodiment X2 is O.
Preferably, at least one of X 7-1 , X -τ τ-3 is N. Preferably, X is CH. Preferably, X is N. Preferably, X1, X3 are N.
Preferably, m is 0.
Preferably, nl; n2 are independently selected from the group consisting of 0; and 1. In a preferred embodiment nl is 0 or 1 and n2 is 0. In a more preferred embodiment nl and n2 are 0. In another preferred embodiment is at least one of nl, n2 other than 0.
Preferably, X4 is (CH2)nlX5(CH2)n2R2.
Preferably, X5 is C(O); O; C(O)N(Rla); N(Rla)C(O); S(O)2N(Rla); N(Rla)S(O)2; N(Rla); or N(Rla)C(O)N(Rlb). Also preferably, X5 is C(O); C(O)N(Rla); N(Rla)C(O); S(O)2N(Rla); N(Rla)S(O)2; N(Rla); or N(Rla)C(O)N(Rlb). In a more preferred embodiment X5 is C(O); O; C(O)N(Rla); N(Rla)C(O); N(Rla)S(O)2; N(Rla); or N(Rla)C(O)N(Rlb). In a further more preferred embodiment X5 is C(O); C(O)N(Rla); N(Rla)C(O); N(Rla)S(O)2; N(Rla); or N(Rla)C(O)N(Rlb). In an even more preferred embodiment X5 is C(O); O; C(O)N(Rla); N(Rla)C(O); or N(Rla). In a further even more preferred embodiment X5 is C(O); C(O)N(Rla); N(Rla)C(O); or N(Rla).
Preferably, R2 is H; or T. In a more preferred embodiment R2 is T, especially when T is aromatic. In an even more preferred embodiment T is a 6 membered heterocyclyl, especially when T is aromatic. In a further even more preferred embodiment T is phenyl; or pyridine. In a further even more preferred embodiment T is a phenyl. In a further even more preferred embodiment T is pyridine. T may be unsubstituted or substituted. Preferably, T is unsubstituted or substituted with one, two or three (more preferably, with one or two) R7, which are the same or different.
R7 is preferably selected from the group consisting of halogen; CN; C(O)R8; N(R8R8a); OR8; C(O)N(R8R8a); S(O)2R8; Ci_6 alkyl optionally substituted with one or more R9 (even more preferably substituted or unsubstituted CH2-T1), which are the same or different; or substituted or unsubstituted T ! .
Compounds of the formula (I) in which some or all of the above-mentioned groups have the preferred or more preferred meanings are also an object of the present invention.
Preferred individual compounds of the present invention are selected from the group consisting of
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-ol;
1 -[(4-cyclo butylpiperazin- 1 -yl)carbonyl]azetidin-3 -ol;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylpyridine-3- carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridine-2-carboxamide.;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylpyridine-2- carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N-dimethylpyridine-2- carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N-diethylpyridine-2- carboxamide; 4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylbenzamide;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N-dimethylbenzamide;
1 -cyclobutyl-4-( {3-[4-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3 - { [5 -(trifluoromethyl)pyridin-2-yl]oxy } azetidin- 1 -yl)carbonyl] - 1 ,4- diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)benzonitrile;
1 -cyclobutyl-4- { [3-(4-fluorophenoxy)azetidin- 1 -yl]carbonyl} - 1 ,4-diazepane;
1 - { [3-(4-chlorophenoxy)azetidin- 1 -yljcarbonyl} -4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3 -phenoxyazetidin- 1 -yl)carbonyl]- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3 - [4-( 1 H-pyrazo 1- 1 -ylmethyl)phenoxy] azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4- [(3- {[5 -(I H-pyrazo 1- 1 -ylmethyl)pyridin-2-yl]oxy} azetidin- 1 -yl)carbonyl]- 1 ,4- diazepane;
1 -[4-( { l-[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)phenyl]pyrrolidin-2- one;
1 -cyclobutyl-4-( {3-[4-(piperidin- 1 -ylmethyl)phenoxy] azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3- {4- [(4-methylpiperazin- 1 -yl)methyl]phenoxy} azetidin- 1 -yl)carbonyl]- 1 ,A- diazepane;
1 -cyclobutyl-4- [(3- {4-[(4,4-difluoropiperidin- 1 -yl)methyl]phenoxy} azetidin- 1 -yl)carbonyl]- 1 ,4-diazepane; 1 -( {3-[(5-bromopyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(3 ,4-dichlorophenoxy)azetidin- 1 -yl]carbonyl} - 1 ,4-diazepane;
1 -( {3-[(6-bromopyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 - { [3-(4-chloro-2-methylphenoxy)azetidin- 1 -yljcarbonyl} -4-cyc Io butyl- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-(lH-imidazol- 1 -yl)phenoxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(2-methylpyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[3-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[2-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
3-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)benzonitrile;
2-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)benzonitrile;
1 - { [3-(3-chlorophenoxy)azetidin- 1 -yl]carbonyl} -4-cyc Io butyl- 1 ,4-diazepane;
1 - { [3-(2-chlorophenoxy)azetidin- 1 -yljcarbonyl} -4-cyc Io butyl- 1 ,4-diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,3-dimethylbenzamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- (cyclopropylmethyl)pyridine-2-carboxamide;
1 -cyclobutyl-4- [(3 - { [5 -(trifluoromethyl)pyridin-3 -yl]oxy } azetidin- 1 -yl)carbonyl] - 1 ,4- diazepane;
5 -( { 1 - [(4-cyclo butylpiperazin- 1 -yl)carbonyl] azetidin-3 -yl} oxy)-N-methylpyridine-2- carboxamide; 1 -cyclobutyl-4-[(3-phenoxyazetidin- 1 -yl)carbonyl]piperazine;
1 -cyclobutyl-4-( {3-[4-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)piperazine;
4-( { 1 - [(4-cyclobutylpiperazin- 1 -yl)carbonyl] azetidin-3 -yl} oxy)benzonitrile;
1 -cyclobutyl-4- { [3 -(4-fluorophenoxy)azetidin- 1 -yl] carbonyl} piperazine;
6-cyclobutyl-2-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-5, 6,7,8- tetrahydro-l,6-naphthyridine;
4-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-3-fluoro-N- methylbenzamide;
1 -cyclobutyl-4- { [3-(4-iodophenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(5-fluoropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -( {3-[(6-chloropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
4-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-2-fluoro-N- methylbenzamide;
1 -( {3-[(4-chloropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(3-fluoropyridin-4-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -( {3-[(4-chloro-2-methylpyridin-3-yl)oxy]azetidin- 1 -yl}carbonyl)-4-cyc Io butyl- 1 ,4- diazepane;
5-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)imidazo[l ,5-a]pyridine;
1 -cyclobutyl-4-( {3-[(2-methoxypyrimidin-4-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane; 2-[4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan-2- ol;
1 -cyclobutyl-4-( {3-[(2-ethylpyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3 -{ [2-( 1 -methylethyl)pyridin-4-yl]oxy } azetidin- 1 -yl)carbonyl] - 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[(2-methoxypyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-amine;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N-dimethylpyridin-2- amine;
1 -cyclobutyl-4-( {3-[(6-methylpyridazin-3-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
2-[4-( { l-[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-2- fluorophenyl]propan-2-ol;
1 -cyclobutyl-4-( {3-[(3,5-dimethylpyrazin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(2-methoxypyrimidin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(6-methylpyrazin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(3,6-dimethylpyrazin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(2-methylpyrimidin-4-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(6-methoxypyrazin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -( {3-[(3-chloropyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane; 4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)quinoline;
1 -cyclobutyl-4-( {3-[(2,6-dimethylpyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
8-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)imidazo[l ,2-a]pyridine;
7-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)imidazo[l ,2-a]pyridine;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridine-2-carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- (cyclopropylmethyl)pyridine-2-carboxamide;
1 -cyclobutyl-4-[(3- {[6-(piperidin- 1 -ylcarbonyl)pyridin-3-yl]oxy} azetidin- 1 -yl)carbonyl]- 1 ,4- diazepane;
3-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylbenzamide;
1 -( {3-[(5-chloropyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -( {3-[(5-chloropyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(3,5-dimethylpyrazin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -( {3-[(3-chloropyridin-4-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -( {3-[(5-chloropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(pyridin-4-yloxy)azetidin- 1 -yl] carbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(5-methoxypyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
2-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-6-(cyclopropylcarbonyl)- 5,6,7,8 -tetrahydro - 1 , 6-naphthyridine ; 2-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-6-(cyclopropylacetyl)- 5,6,7,8-tetrahydro-l,6-naphthyridine;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylpyridine-3- carboxamide;
1 -cyclobutyl-4- {[3-(4-methoxyphenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-( 1 H-pyrazol- 1 -yl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-(trifluoromethoxy)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-(difluoromethoxy)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 - { [3-(4-chloro-2-fluorophenoxy)azetidin- 1 -yljcarbonyl} -4-cyclobutyl- 1 ,4-diazepane;
1 -cyclobutyl-4- {[3 -(3 -methoxyphenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(2-methoxyphenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
6-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-2-methylquinoline;
1 -cyclobutyl-4- [(3 - {[6-(trifluoromethyl)pyridin-3-yl]oxy} azetidin- 1 -yl)carbonylj- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[(4-fluorobenzyl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3 -methoxyazetidin- 1 -yl)carbonyl]- 1 ,4-diazepane;
1 -( {3-[(4-chlorobenzyl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
4-[( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)methyl]benzonitrile;
1 -cyclobutyl-4- { [3-(prop-2-yn- 1 -yloxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane; 3-[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutanone;
cώ-3- [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutanol;
6-( {cώ-3-[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)-N-methylpyridine-3- carboxamide;
4-( {cώ-3-[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)benzonitrile;
1 -cyclobutyl-4-[(cώ-3- {[5-(trifluoromethyl)pyridin-2-yl]oxy} cyclobutyl)carbonyl]- 1 ,A- diazepane;
trans-3 - [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] cyclobutano 1;
4-( {trans-3-[(A-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)benzonitrile;
1 -cyck>butyi-A-[(trans-3- {[5-(trifluoromethyl)pyridin-2-yl]oxy} cyclobutyl)carbonyl]- 1 ,A- diazepane;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-one;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3 -amine;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} amino)-N-methylpyridine-2- carboxamide;
5-[ { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} (methyl)amino]-N- methylpyridine-2-carboxamide;
4-[( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} amino)methyl]benzonitrile;
5 -( { 1 - [(4-methyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -yl} oxy)-N-methylpyridine-2- carboxamide; 5-({l-[(4-(l -methylethyl)- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -yl} oxy)-N-methylpyridine- 2-carboxamide;
5-( { 1 -[(4-cyclopentyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylpyridine-2- carboxamide;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-3,4-dihydroisoquinolin- l(2H)-one;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} oxy)-2-methyl-3 ,A- dihydroisoquino lin- 1 (2H)-one;
2-[5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan-2- ol;
1 -[5-( { l-[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]ethanone;
1 -cyclobutyl-4-( {3-[(5-methoxypyrimidin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(6-methylpyridin-3-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
methyl 1 - [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidine-3 -carboxylate;
N-(4-chlorophenyl)- 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidine-3 -carboxamide;
1 -cyclobutyl-4- { [3-(piperidin- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(morpholin-4-ylcarbonyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 - {[3-(azetidin- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} -4-cyclobutyl- 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(pyrrolidin- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 - { [3-(azepan- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} -4-cyclobutyl- 1 ,4-diazepane; 1 -cyclobutyl-4-( {3-[(4-fluoropiperidin- 1 -yl)carbonyl]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(4,4-difluoropiperidin- 1 -yl)carbonyl]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-cyclohexylazetidine-3-carboxamide;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-(6-methylpyridin-3-yl)azetidine-3- carboxamide;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-methylazetidine-3-carboxamide;
{ 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methanol;
1 -( {3-[(4-chlorophenoxy)methyl]azetidin- 1 -yl}carbonyl)-4-cyc Io butyl- 1 ,4-diazepane;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methoxy)-3,4- dihydroisoquino lin- 1 (2H)-one;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methoxy)-2-methyl-3,4- dihydroisoquino lin- 1 (2H)-one;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methoxy)-N-methylpyridine- 2-carboxamide;
N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -6-methylpyridine-3- carboxamide;
4-chloro-N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}benzamide;
N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} cyclohexanecarboxamide;
4-chloro-N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -N-methylbenzamide; N- { 1 -[(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -N,6-dimethylpyridine-3- carboxamide;
N- { 1 -[(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -N- methylcyclohexanecarboxamide;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-methyl-N-(6-methylpyridin-3-yl)azetidine-3- carboxamide;
N-(4-chlorophenyl)- 1 -[(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-methylazetidine-3- carboxamide;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-methylpyridine-2- carboxamide;
1 -cyclobutyl-4- { [3 -(methoxymethyl)azetidin- 1 -yl] carbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-( 1 -methyl- 1 H-pyrazol-4-yl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
l-cyclobutyl-4-({3-[4-(l,3,5-trimethyl-lH-pyrazol-4-yl)phenoxy]azetidin-l-yl}carbonyl)-l,4- diazepane;
1 -cyclobutyl-4-( {3-[(3-fluoro-2-methylpyridin-4-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4- {[3-(naphthalen-2-yloxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-( { [6-(trifluoromethyl)pyridin-3 -yl]oxy }methyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)- lH-indole;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)- 1 -methyl- lH-indo Ie; 2-[5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]-2- methylpropan- 1 -ol;
2-[5-({l-[(4-ethyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan-2-ol;
2-{5-[(l-{[4-(l -methylethyl)- 1 ,4-diazepan- 1 -yl] carbonyl} azetidin-3 -yl)oxy]pyridin-2- yl}propan-2-ol;
2-[5-({l-[(4-cyclopentyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan- 2-ol;
1 -cyclobutyl-4-( {3-[(5-fluoropyrimidin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(5-methoxypyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(5-ethylpyrimidin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-(methylsulfonyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(6-methylpyridin-3-yl)methoxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
2-[5-( {cώ-3-[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)pyridin-2-yl]propan- 2-ol;
1 -cyclobutyl-4-( {3-[(6-methylpyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)azepane;
1 -[(4-ethyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -ol;
1 - { [4-( 1 -methylethyl)- 1 ,4-diazepan- 1 -yl]carbonyl} azetidin-3 -ol;
1 -[(4-cyclopentyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -ol;
ethyl 5-( { 1 -[(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridine-2- carboxylate; 1 -cyclobutyl-4- {[3-(3-methyl-4-nitrophenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
trans-3 - [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] eye Io butyl acetate; and
methyl 2-[5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]-2- methylpropanoate.
Prodrugs of the compounds of the invention are also within the scope of the present invention. "Prodrug" means a derivative that is converted into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically. Examples of a prodrug are compounds, wherein the amino group in a compound of the present invention is acylated, alkylated or phosphorylated to form, e.g., eicosanoylamino, alanylamino, pivaloyloxymethylamino or wherein the hydroxyl group is acylated, alkylated, phosphorylated or converted into the borate, e.g. acetyloxy, palmitoyloxy, pivaloyloxy, succinyloxy, fumaryloxy, alanyloxy or wherein the carboxyl group is esterifϊed or amidated. These compounds can be produced from compounds of the present invention according to well-known methods.
Metabolites of compounds of formula (I) are also within the scope of the present invention.
Where tautomerism, like e.g. keto-enol tautomerism, of compounds of formula (I) may occur, the individual forms, like e.g. the keto and enol form, are comprised separately and together as mixtures in any ratio. Same applies for stereoisomers, like e.g. enantiomers, cis/trans isomers, conformers and the like.
Especially, when enantiomeric or diastereomeric forms are given in a compound according to formula (I) each pure form separately and any mixture of at least two of the pure forms in any ratio is comprised by formula (I) and is a subject of the present invention.
Iso topic labeled compounds of formula (I) are also within the scope of the present invention. Methods for isotope labeling are known in the art. Preferred isotopes are those of the elements H, C, N, O and S.
If desired, isomers can be separated by methods well known in the art, e.g. by liquid chromatography. Same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials, reagents and/or catalysts.
In case the compounds according to formula (I) contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formula (I) which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the formula (I) simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
The present invention provides compounds of general formula (I) as Histamine H3 receptor antagonists.
As described before, the histamine H3 receptor is a G protein-coupled receptor (GPCR) and one out of four receptors of the histamine receptor family. Histamine receptors have long been attractive drug targets, mirrored in the development of antihistamines, which were directed at the histamine Hl receptor for the treatment of allergic reactions or at the histamine H2 receptor to ameliorate gastric ulcers by inhibiting gastric acid secretion. The H3 receptor has been identified as a presynaptic autoreceptor, regulating the release of histamine (Arrang et al. (1983) Nature: 302; 832 - 837), as well as a heteroreceptor that regulates the release of many other important neurotransmitters (acetylcholine, norepinephrine, dopamine, and serotonin). Structurally divergent H3 receptor antagonists / inverse agonists have been developed and shown to comprise activity in a variety of cognition tests in mice and rat (e.g. Esbenshade et al. (2006) MoI Interventions: 6 (2); 77 - 88) as well as in models for sleeping disorders and energy balance. From these studies it is concluded that such antagonists comprise a potential treatment for a variety of disorders affecting cognition (e.g., Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, Schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome and others), as well as sleep (e.g., hypersomnia and narcolepsy), and energy homeostasis (e.g. obesity) (Witkin & Nelson (2004) JPET: 103; 1 - 20; Hancock & Brune (2005) Exp Opin Inves Drugs: 14 (3), 223 - 241).
The pharmacology of the H3 receptor seems not only to be determined by its localization but appears also to be regulated by differential splicing. Today more than 20 splice variants (isoforms) have been described but their functions have yet to be elucidated completely (Bongers et al. (2007) Biochem Pharm: 73; 1195 - 1204). The H3 receptor is localized primarily to the central nervous system (CNS), with highest expression, in rodents, in the cerebral cortex, hippocampal formations, striatum, and hypothalamus (Drutel et al. (2001) MoI Pharmacol: 59; 1 - 8). Similarly in human, H3 receptor expression is prominent in the basal ganglia, globus pallidus, hippocampus, and cortex (Martinez-Mir et al. (1990) Brain Res: 526; 322 327). Notably, many of these brain regions are critical for cognition (cortex and hippocampus) and sleep and homeostatic regulation (hypothalamus). The H3 receptor has been shown also to localize to regions which might be involved in pain sensation or transmission and therefore might offer treatment opportunities for different pain states (Cannon et al. (2007) Pain: 129; 76 - 92).
In addition to agonist-induced signaling, the H3 receptor is constitutively active and capable of signaling independently of agonist both in vitro and in vivo (Morisset et al. (2000) Nature: 408, 860 - 864). All these considerations suggest that novel H3 receptor antagonists like the series in this application could be useful in the treatment of cognitive dysfunctions as well as sleeping and energy homeostasis disorders. The term "antagonist" also includes inverse agonists.
Based on the information above and further literature, like WO-A 2007/080140 and WO-A 2006/136924 the following diseases and disorders are preferably affected.
Neurological disorders: Major conditions include - behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease,
Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol
Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down
Syndrome, epilepsy, convulsion, depression, anxiety disorders) seizure disorders - neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Multiple
Sclerosis) sleep disorders (e.g. hypersomnia and narcolepsy, excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns)
Migraine - Stroke tremor.
The term "neurological disorders" also includes psychiatrical disorders within the meaning of the present invention. The term "neurodegenerative disorders" also includes neuro- inflammatory disorders within the meaning of the present invention.
Disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus.
Pain, e.g. neuropathic pain, inflammatory pain, nociception. The term "pain" includes acute and chronic pain within the meaning of the present invention.
Cardiovascular disorders, e.g. acute myocardial infarction, and other disorders, i.e. gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere, motion sickness, drug abuse), nasal congestion, allergic rhinitis (hay fever), asthma.
Preferably, convulsion and epilepsy are excluded.
Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease- related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere), motion sickness, drug abuse, nasal congestion, allergic rhinitis (hay fever), asthma.
More preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma.
Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
Accordingly, one aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use as a medicament.
Yet another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing diseases and disorders associated with the H3 receptor.
Yet another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing neurological disorders, e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis), sleep disorders (e.g. hypersomnia and narcolepsy, excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns), Migraine, Stroke, tremor; disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus; Pain, e.g. neuropathic pain, inflammatory pain, nociception; cardiovascular disorders, e.g. acute myocardial infarction; gastrointestinal disorders; vestibular dysfunction (e.g. Morbus Meniere, motion sickness, drug abuse); nasal congestion; allergic rhinitis (hay fever); or asthma. Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease- related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere), motion sickness, drug abuse, nasal congestion, allergic rhinitis (hay fever), asthma. More preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma. Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
Yet another aspect of the present invention is the use of a compound or a pharmaceutically acceptable salt thereof of the present invention for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with the H3 receptor. Yet another aspect of the present invention is the use of a compound or a pharmaceutically acceptable salt thereof of the present invention for the manufacture of a medicament for the treatment or prophylaxis of neurological disorders, e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis), sleep disorders (e.g. hypersomnia and narcolepsy, excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns), Migraine, Stroke, tremor; disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus; Pain, e.g. neuropathic pain, inflammatory pain, nociception; cardiovascular disorders, e.g. acute myocardial infarction; gastrointestinal disorders; vestibular dysfunction (e.g. Morbus Meniere, motion sickness, drug abuse); nasal congestion; allergic rhinitis (hay fever); or asthma. Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease-related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere), motion sickness, drug abuse, nasal congestion, allergic rhinitis (hay fever), asthma. More preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma. Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of diseases and disorders associated with the H3 receptor, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of neurological disorders, e.g. behavioral/cognitive syndromes (e.g. Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders), seizure disorders, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis), sleep disorders (e.g. hypersomnia and narcolepsy, excessive daytime sleepiness, diurnal and seasonal variations in sleep patterns), Migraine, Stroke, tremor; disorders affecting energy homeostasis as well as complications associated therewith, e.g. obesity, eating disorders associated with excessive food intake, bulima, binge eating, complications associated therewith e.g. diabetes mellitus; Pain, e.g. neuropathic pain, inflammatory pain, nociception; cardiovascular disorders, e.g. acute myocardial infarction; gastrointestinal disorders; vestibular dysfunction (e.g. Morbus Meniere, motion sickness, drug abuse); nasal congestion; allergic rhinitis (hay fever); and asthma, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof. Preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Foetal Alcohol Syndrome, Mild Cognitive Impairment, Age-related Memory Dysfunction, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, Down Syndrome, epilepsy, convulsion, depression, anxiety disorders, idiopathic hypersomnia, narcolepsy, shift-work sleep disorder, disease-related fatigue, chronic fatigue syndrome, Migraine, Stroke, tremor, obesity, eating disorders, diabetes mellitus, neuropathic pain, inflammatory pain, acute myocardial infarction, gastrointestinal disorders, vestibular dysfunction (e.g. Morbus Meniere), motion sickness, drug abuse, nasal congestion, allergic rhinitis (hay fever), asthma. More preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, Mild Cognitive Impairment, disease-related cognitive dysfunctions, Lewy body dementia, vascular dementia, idiopathic hypersomnia, narcolepsy, obesity, diabetes mellitus, neuropathic pain, nasal congestion, allergic rhinitis (hay fever), asthma. Even more preferred disorders are Alzheimer's disease, Parkinson's disease, Attention Deficit and Hyperactivity Disorder, schizophrenia, idiopathic hypersomnia, narcolepsy, obesity, neuropathic pain.
Preferably, the mammalian patient is a human patient.
Yet another aspect of the present invention is a pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof of the present invention together with a pharmaceutically acceptable carrier, optionally in combination with one or more other bioactive compounds or pharmaceutical compositions.
Preferably, the one or more bioactive compounds are lipase inhibitors, anorectic agents, selective serotonin uptake inhibitors, neurotransmitter reuptake blocker, agents that stimulate metabolism of body fat, anti-diabetic agents, lipid lowering agents, or histamine Hl receptor antagonists. A combination of one or more histamine H3 receptor antagonists of the present invention and histamine Hl receptor antagonists is preferred, especially for the treatment of allergic rhinitis, allergic congestion or nasal congestion.
"Pharmaceutical composition" means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
A pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like one or more compounds of formula (I) not being the first compound in the composition or other Histamine H3 receptor antagonists.
The active ingredients may be comprised in one or more different pharmaceutical compositions (combination of pharmaceutical compositions).
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids. The compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
In practical use, the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally, for example, as liquid drops or spray.
The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor. Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of formula (I) are administered orally.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
Starting materials for the synthesis of preferred embodiments of the invention may be purchased from commercially available sources such as Array, Sigma Aldrich, Acros, Fisher, Fluka, ABCR or can be synthesized using known methods by one skilled in the art.
In general, several methods are applicable to prepare compounds of the present invention. In some cases various strategies can be combined. Sequential or convergent routes may be used.
One method for the preparation of a compound of the present invention, wherein in formula (I) X1 and X3 are N; X2 is O; nl and n2 are 0 in the definition of X4 and R2 is an aromatic cycle T, comprises the steps of (a) reacting the amino group of a compound of formula (II) with a suitable chloroformate
Figure imgf000036_0001
wherein n and R1 have the meaning as indicated above;
(b) reacting the resulting carbamate compound from step (a) with a compound of formula (III)
Figure imgf000036_0002
wherein X rV is OH and R has the meaning as indicated above; and
(c) reacting the resulting compound with a compound of formula Cl-T or F-T to yield a compound of formula (I), wherein X1 and X3 are N; X2 is O; nl and n2 are 0 in the definition of X4 and R2 is an aromatic cycle T.
In general, compounds of formula (I), wherein X1 and X3 are N and X2 is O, can be prepared by a method comprising the steps of
(a) reacting the amino group of compound of formula (Ha) with a suitable chloroformate such as 4-nitrophenylchloroformate
Figure imgf000036_0003
wherein n has the meaning as indicated above and R1 is R1 as indicated above or as suitable N-atom protecting group
(b) reacting the resulting carbamate compound from step (a) with a compound of formula (Ilia)
Figure imgf000037_0001
wherein X4 is H; OH; or C(0)2(alkyl), R has the meaning as indicated above, to yield a compound of formula (I) when R1 is R1 as indicated above and X4 is defined as above.
The method may comprise the further step when X4 is OH
(cl) the alcohol is deprotonated with a strong base (such as NaH or 1BuOK) and the resulting alkoxide reacted with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula (I), wherein X4 is X5(CH2)n2R2.
In the case when R1 of formula (I) is a suitable N-atom protecting group (such as Boc or cbz), the resulting compound represented by formula (Ii) requires the following additional steps to synthesise a compound of formula (I);
Figure imgf000037_0002
(dl) deprotecting compound of formula (Ii) at the nitrogen atom; and (el) reacting the resulting compound from step (dl) with R^=O) in the presence of a reducing agent such as STAB to yield a compound of formula (I); or alternatively, reacting the resulting compound from step (dl) with a compound of formula R'-halide (optionally in the presence of base) to yield a compound of formula (I).
Alternatively, compounds of formula (I) wherein X1 and X3 are N and X2 is S, may be prepared by a method comprising the steps of
(c) reacting the amino group of compound of formula (III) with thio-CDI
(usually between O0C and room temperature) and reacting the resulting intermediate with a compound of formula (II) at elevated temperature (up to
1000C), to yield a compound of formula (I) when X2 = S and X4 are defined as above.
Alternatively, compounds of formula (I) wherein X1 and X3 are N and X2 is N-CN, may be prepared by a method comprising the steps of
(d) reacting cyanamide with carbon disulfide and then treating the resulting intermediate with dimethyl sulphate to form a compound of formula (IV)
Figure imgf000038_0001
(e) reacting the amino group of compound of formula (II) with compound of formula (IV) (usually between room temperature and 8O0C);
(f) reacting the compound from step (e) with a compound of formula (III) at elevated temperature (up to 1000C), to yield a compound of formula (I) when X2 = N-CN and X4' are defined as above. Alternatively, compounds of general formula (I) wherein X2 is N-OCi_4 alkyl and X4 is H or OH, may be prepared from a compound of formula (Ia) by a method comprising the steps of
Figure imgf000039_0001
(g) reaction with oxalyl chloride followed by reaction with a compound of formula NH2-OCi-4 alkyl, to yield a compound of formula (I), wherein X2 is N-OCi-4 alkyl and X4' is H or OH.
Alternatively, compounds of general formula (I) wherein X1 is CH and n is 1, may be prepared from a compound of formula (Ib) by a method comprising the steps of
Figure imgf000039_0002
(i) reacting the amino group with a compound of formula R1=0, wherein the oxo group is attached to a carbon atom of R1, followed by reduction of the resulting imine;
(J) saponification of the ester group with base such as LiOH; (k) activation of the resulting intermediate with amide coupling reagents (such as HOBt and HBTU) and reacting the resulting activated ester with a compound of formula (III), to yield a compound of formula (I) wherein X4 is defined as above.
Alternatively, compounds of general formula (I) wherein X1 is CH and n is 2, may be prepared from a compound of formula (Ic) by a method comprising the steps of
Figure imgf000039_0003
(1) reacting the ketone group with sodium azide and MeSO3H at between RT and
8O0C, followed by reduction of the resulting lactam and ester with LAH
(usually between RT and 8O0C)
(m) reacting the amino group with a compound of formula R1=O, wherein the oxo group is attached to a carbon atom of R1, followed by reduction of the resulting imine (n) oxidation of the primary alcohol to the carboxylic acid with an oxidising agent (such as chromic acid / Jones oxidation)
(o) activation of the resulting carboxylic acid with amide coupling reagents (such as HOBt and HBTU) and reacting the resulting activated ester with a compound of formula (III), to yield a compound of formula (I) wherein X4 is defined as above.
Alternatively, compounds of general formula (I) wherein X1 is CH and n is 2, may be prepared from a compound of formula (Ih) where PG is a protecting group (usually a carbonate protecting group such as cbz) by a method comprising the steps of
Figure imgf000040_0001
(pp) reacting the ketone group with an alkyl diazoacetate (such as ethyl diazoacetate) in the presence of a Lewis acid (such as boron trifluoride diethyl etherate) usually between -80 0C and RT;
(qq) eliminating the resulting alcohol to give an α,β-unsaturated ester by acid catalysed elimination (Alternatively the alcohol can be converted into a halide (such as bromide using a reagent such as PBr3) or sulfonate (such as a mesylate via reaction with MsCl and TEA) and eliminated in the presence of a base (such as DBU) usually between RT and 100 0C); (rr) removal of the alkene via hydrogenation (usually using hydrogen gas or ammonium formatate in the presence of a source of palladium such as Pd/C) (ss) hydrolysis of the ester to give the carboxylic acid using aqueous base such as LiOH or acid such as HCl;
(tt) activation of the resulting intermediate with amide coupling reagents (such as HOBt and HBTU) and reacting the resulting activated ester with a compound of formula (III), to yield a compound of formula (I) wherein X4 is defined as above;
(uu) Removal of the protecting group (using H2/Pd/C for a cbz protecting group) and reacting the amino group with a compound of formula R1=O, wherein the oxo group is attached to a carbon atom of R1, followed by reduction of the resulting imine.
In general, compounds of formula (I), wherein X1 is N and X3 is CH can be prepared by a method comprising the following four steps;
(p) reacting a malonate ester (such as diisopropylmalonate) with a strong base (such as NaH) and reacting the resulting di-anion with a l,3-dihalo-2,2- dialkoxypropane (such as l,3-dibromo-2,2-dimethoxypropane) to form a compound of formula (Id)
Figure imgf000041_0001
(q) treating the compound of formula (Id) with strong acid (such as 5M HCl) at elevated temperature (up to 100 0C) to form a compound represented by formula (Ie)
Figure imgf000041_0002
(r) reacting a compound of formula (Ie) with amide coupling reagents (such as CDI) and treating the resulting intermediate with a compound of formula (II); (s) reducing the ketone group of step (r) product with a reducing agent (such as NaBH4) to give a predominantly (>95:5) cis alcohol of formula (If), wherein X5 is O
Figure imgf000042_0001
The method may comprise the further steps where compounds of formula (If), wherein the meanings are as indicated above, are further modified as follows;
(t) converting the alcohol to a suitable leaving group (such as OMs or OTs) by reaction with the appropriate sulfonyl chloride in the presence of base (such as
TEA) (u) reacting the resulting sulfonate ester with an acetate salt (such as potassium acetate) at high temperature (usually up to 12O0C) (v) hydrolysis of the acetate group with base (such as LiOH) to give a predominantly (>9.5:1) trans alcohol of formula (Ig), wherein X5 is O
Figure imgf000042_0002
The method may comprise the further step
(w) the alcohol is deprotonated with a strong base (such as NaH or 1BuOK) and the resulting alkoxide reacted with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula (I), wherein X4 is X5(CH2)n2R2. Similarly, a further method route is given by a method for the preparation of a compound of the present invention, wherein in formula (I) X1 is N and X3 is CH; X2 is O; m is 0; R is H, comprising the steps of
(x) reacting a malonate ester with a strong base and reacting the resulting di- anion with a l,3-dihalo-2,2-dialkoxypropane to form a compound of formula (Id)
Figure imgf000043_0001
(y) treating the compound of formula (Id) with strong acid at elevated temperature to form a compound represented by formula (Ie)
Figure imgf000043_0002
(z) reacting a compound of formula (Ie) with amide coupling reagents and treating the resulting intermediate with a compound of formula (II);
Figure imgf000043_0003
(aa) reducing the ketone group of step (z) product with a reducing agent to give a predominantly (>95:5) cis alcohol of formula (If), wherein X5 is O and R1 and n have the meaning as indicated above
Figure imgf000044_0001
optionally comprising the further steps
(bb) converting the alcohol to a suitable leaving group by reaction with the appropriate sulfonyl chloride in the presence of base or acid;
(cc) reacting the resulting sulfonate ester with an acetate salt such as potassium acetate at high temperature;
(dd) hydrolysis of the acetate group with base to give a predominantly (>9.5:1) trans alcohol of formula (Ig)
Figure imgf000044_0002
optionally comprising the further step of
• deprotonating the alcohol with a strong base and reacting the resulting alkoxide with a suitable alkyl halide, benzyl halide, activated alcohol or (hetero)aromatic halide at room temperature or elevated temperature to yield a compound of formula (I), wherein X4 is 0(CH2)D2R2.
The above step may also apply for alcohols of formula (V)
Figure imgf000045_0001
wherein R1, R, n, X1, X2, X3 have the meaning as indicated above.
The alcohol may be deprotonated with a strong base (such as NaH or 1BuOK, optionally in the presence of CsF) and the resulting alkoxide reacted with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula (I), wherein X4 is X5(CH2)n2R2.
Alternatively, compounds of formula (I) wherein X5 is O, can be prepared in a two step process starting from a compound of formula (V), wherein the method comprises the steps of
converting the alcohol to a suitable leaving group (such as OMs or OTs) by reaction with the appropriate sulfonyl chloride in the presence of base (such as TEA) reacting the resulting sulfonate ester with the alkoxide formed by treating a compound of formula HO(CH2)n2R2 with a suitable base such as NaH or K3CO3, to yield a compound of formula (I) wherein X5 is O.
Alternatively, compounds of formula (I) wherein X5 is O, can be prepared in a one step Ullmann reaction starting from a compound of formula (V) above, wherein the method comprises the steps of;
reacting the alcohol with a (hetero)aryl halide in the presence of a phenanthroline derivative, copper salt (usually CuI or Cu2O) and base (such as CS2CO3) at elevated temperature (usually circa 10O0C), to yield a compound of formula (I) wherein X5 is O.
Alternatively, compounds of formula (I) wherein X5 is O, can be prepared in a one step process starting from a compound of formula (V) above, wherein the method comprises the steps of; the alcohol is deprotonated with a strong base (such as NaH or 1BuOK) and the resulting alkoxide reacted (usually between room temperature and 18O0C) with a suitable (hetero)aryl fluoride preformed in situ by the reaction of a (hetero)aryl chloride or bromide with KF and a suitable fluorinating agent (such as Kryptofϊx-222) usually between room temperature and 18O0C, to yield a compound of formula (I) wherein X5 is O.
In the case when X5 of formula (I) is C(O), the compounds can be prepared in a two step process starting from a compound of formula (VI) by;
Figure imgf000046_0001
saponification of the ester group of formula (VI) with base (such as aqueous LiOH) or acid followed by activation of the resulting intermediate with amide coupling reagents (such as HOBt and HBTU) and reacting the resulting activated ester with either a primary or secondary amine compound, as defined for R2, to yield a compound of formula (I), wherein X4 is X5(CH2)n2R2.
In the case when nl of formula (I) is 1, the compounds can be prepared in a two step process starting from a compound of formula (VI) above by;
reduction of the ester group of formula (VI) with sodium boro hydride - followed by deprotonation at the resulting alcohol with strong base (such as NaH or
1BuOK) and reacting the resulting alkoxide with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula
(I), wherein X4 is (CH2)niX5(CH2)n2R2. In the case when X5 of formula (I) is N(Rla), the compounds represented by formula (VII) can be prepared starting from compound of formula (V) above, in the following three step process;
Figure imgf000047_0001
- deprotonation at the alcohol with strong base (such as NaH or 1BuOK) and reacting the resulting alkoxide with MsCl
- displacement of the mesylate by an azide (such as sodium azide) with heating at elevated temperatures (usually up to 100 0C)
- reduction of the azide with PPh3 in the presence of water at room temperature, to yield a compound of formula (I), wherein X5 is NH.
The method may comprise further steps where compounds of formula (VII), wherein the meanings are as indicated above, are further modified as follows;
(ee) reacting primary amine with a suitable alkyl halide, benzyl halide, activated alcohol (such as OMs or OTs) or (hetero)aromatic halide in the presence of an organic base (such as TEA) at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula (I), wherein X4 is
NH(CH2)n2R2
(ff) reacting the resulting secondary amine from step (ee) with a suitable alkyl halide or activated alcohol (such as OMs or OTs) in the presence of an organic base (such as TEA) at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula (I), wherein X4 is
N(Rla)(CH2)n2R2,
Alternatively, compounds of formula (I), wherein X4 is N(Rla)(CH2)n2R2, can be prepared in a one step process as follows;
by reacting the secondary amine from step (ee) with a suitable alkyl aldehyde in the presence of an organic acid (such as AcOH) and reducing agent (such as NaBH3CN) at room temperature or elevated temperature (up to 100 0C), to yield a compound of formula (I), wherein X4 is N(Rla)(CH2)n2R2.
Alternatively step (ee) above may be replaced with step (gg) below, to yield compounds formula (I), wherein X4 is NHR2;
(gg) reacting the primary amine of a compound of formula (VII) with a (hetero)aromatic halide at elevated temperature (up to 120 0C) in the presence of palladium catalysed coupling reagents (such as Pd2(dba)3, BINAP and 1BuOK) to yield compounds of formula (I), wherein X4 is NHR2.
In the case when X5 of formula (I) is NHC(O), the compounds represented by formula (VIII) can be prepared by a method comprising of;
Figure imgf000048_0001
(hh) reacting the amine group of a compound of formula (VII) either with a compound of formula R > 2 (CH2)n2COCl in the presence of an organic base (such as TEA), or, with a compound of formula R2(CH2)n2C(O)OH in the presence of amide coupling reagents (such as DCC/DMAP) to yield compounds of formula (I), wherein X4 is NHC(O)(CH2)n2R2
The method may comprise the further step where compounds of formula (VIII), wherein the meanings are as indicated above, are further modified as follows;
(ii) reacting the primary amide group of a compound of formula (VIII) with a strong base (such as NaH) followed by addition of a compound of formula
Rla-halide or activated alcohol (such as Rla-OMs or Rla-OTs) at room temperature or elevated temperature (up to 200 0C) to yield a compound of formula (I), wherein X4 is N(Rla)C(O)(CH2)n2R2. The same reaction types may apply for compounds of the present invention, where in formula (I) m is other than 0.
In the case when X5 of formula (I) is NHS(O)2, the compounds represented by formula (IX) can be prepared by a method comprising of;
Figure imgf000049_0001
(jj) reacting the amine group of a compound of formula (VII) with a compound of formula R2(CH2)n2S(O)2Cl in the presence of an organic base (such as TEA or pyridine) to yield compounds of formula (I), wherein X4 is NHS(O)2(CH2)n2R2
The method may comprise the further steps where compounds of formula (I), wherein the meanings are as indicated above and R2 has a potentially chemically reactive group, are further modified as follows:
(kk) reacting a suitable alcohol or (hetero)aryl alcohol with a strong base (such as NaH or 1BuOK) and the resulting alkoxide or (hetero)aryloxide reacted
(usually between room temperature and 18O0C) with the halide or activated alcohol (sulfonate ester) substituent of R2, to yield a compound of formula (I); or
(11) reacting a halide or acticated alcohol (sulfonate ester) substituent of R2 in a Suzuki reaction using a palladium phosphine catalyst (such as that formed from Pd2(dba)3 and tricyclohexylphosphine) and suitable boronate ester or boronic acid (usually at room temperature to 15O0C) in the presence of a base (such as K3PO4 or K2COs), to yield a compound of formula (I).
The method may comprise the further steps where compounds of formula (I) represented by formula (X), wherein the meanings are as indicated above, are further modified as follows;
Figure imgf000050_0001
(mm) reacting the nitro group with DMF. DM A and pyrrolidine at elevated temperature (usually > 5O0C) and reacting the resulting intermediate with Raney Nickel and hydrazine (usually at room temperature), to yield a compound of formula (I).
The method may comprise the further step where compounds of formula (I) represented by formula (XI), wherein the meanings are as indicated above, are further modified as follows;
Figure imgf000050_0002
(nn) reacting the ester group with a Grignard reagent (such as MeMgBr), optionally in the presence of lithium chloride, at a temperature usually between -780C and 15O0C, to yield a compound of formula (I).
The method may comprise the further step where compounds of formula (I) represented by formula (XII), wherein the meanings are as indicated above, are further modified as follows;
Figure imgf000050_0003
(oo) reducing the ester group (usually with LiAlH4) at temperatures ranging from ■
50 to 1000C, to yield a compound of formula (I). The same reaction types may apply for compounds of the present invention, where in formula (I) m is other than 0.
It is clear for a practitioner in the art that the preparation routes mentioned herein can be combined and varied optionally by using activation and protection/deprotection techniques.
Examples
Biological evaluation:
Cell-lines used to characterize invented compounds in vitro
CHO-Kl cell line expressing human H3 receptors were purchased from Euroscreen (Gosselies, Belgium, Cat. no.: ES-392-C)
Human H3 receptor-expressing cell-lines were grown in Ham's F12 [Sigma, Cat. no. N6658], supplemented with 10% FBS [Sigma, Cat. no. F9665], 400μg/ml G418 [Sigma, Cat. no. Nl 876] and 250μg/ml Zeocin [Invitrogen, Cat. no. 46-0509]) according to the protocol provided by Euroscreen.
cAMP quantification protocol for human H3 receptor testing
The assay measures the ability of test compounds to inhibit Histamine receptor agonist- induced decrease of intracellular free cAMP (receptor is G1 coupled).
Specifically, a cAMP quantification assay system from Disco veRx (cAMP XS+; Cat. no. 90- 0075) was used.
For the cAMP assay, confluent cells were detached from the culture vessels with Ix trypsin- EDTA solution (Sigma), and seeded into 384-well Costar plates (white, clear bottom, Cat. no. 3707) at a density of 10,000 cells per well. Cells were seeded in a volume of 50μl in medium without antibiotics and incubated overnight in a humidified atmosphere with 5% CO2 at 37°C. The cAMP assay was performed according to the protocol provided by DiscoveRx.
The cell culture medium was removed and the cells washed once with PBS (50 μl per well). The plates were emptied by inversion and 7.5μl/well of compound in PBS (containing ImM IBMX and 0.03% BSA) were added and incubated for 30min at 37°C. Subsequent 7.5μl/well specific agonist solution was added and the plates for another 30min incubated at 37°C.
The following agonist solution is used for the individual cell- lines: hH3: 100 nM histamine, 10 μM forskolin in PBS (containing ImM IBMX and 0.03% BSA)
After the incubation with the agonist, 5μl/well cAMP XS antibody solution was added followed by 20μl/well Gal/EII/Lysis(l :5:19) +ED (1 :1). The plates were incubated for one hour at room temperature and afterwards 20μl/well EA reagent was added. The luminescence was developed for approximately three hours at room temperature and the plates were read out using a 'BMG Novostar' plate reader.
Assaying of compounds
Test compounds were assayed at 8 concentrations in triplicate. Serial 10-fold dilutions in 100% DMSO were made at a 100-times higher concentration than the final concentration and then diluted with a 2 step protocol in assay buffer to reach the required assay concentrations and 1% DMSO.
The specific compounds exemplified below were categorized by the following potency ranges (IC50 values):
A: < 100 nM; B: > 100 nM to 500 nM; C: > 500 nM to 5000 nM.
Caco-2 permeability assay
The Caco-2 Permeability assay uses an established method for predicting the in vivo absorption of drugs across the gut wall by measuring the rate of transport of a compound across the Caco-2 cell line.
The Caco-2 cell line is derived from a human colon carcinoma. These cells have characteristics that resemble intestinal epithelial cells such as the formation of a polarised monolayer, well-defined brush border on the apical surface and intercellular junctions. Assessing transport in both directions (apical to basolateral (A-B) and baso lateral to apical (B-A)) across the cell monolayer enables an efflux ratio to be determined which provides an indicator as to whether a compound undergoes active efflux.
Studying the permeability of compounds across a Caco-2 cell monolayer is widely accepted as an established in vitro model to screen for oral absorption and to evaluate the mechanism of transport. Using LC-MS/MS for the analysis of samples derived from Caco-2 cell studies allows the rapid and accurate determination of drug transport across the Caco-2 cell monolayer. (Wang Z, Hop C.E., Leung K.H. and Pang J. (2000) J Mass Spectrom 35 (1); 71- 6).
Preferred compounds of Formula (I) have Caco-2 efflux ratios of < 3.0.
Synthesis of compounds :
ANALYTICAL METHODS
NMR Spectrometers Used: Bruker DRX 500 MHz NMR
Bruker AVANCE 400 MHz NMR Bruker DPX 250 MHz NMR Bruker DPX 360 MHz NMR
Configuration of the Bruker DRX 500 MHz NMR
High performance digital NMR spectrometer, 2-channel microbay console and Windows XP host workstation running Topspin version 1.3.
Equipped with:
• Oxford instruments magnet 11.74 Tesla (500 MHz proton resonance frequency)
• B-VT 3000 temperature controller
• GRASP II gradient spectroscopy accessory for fast acquisition of 2D pulse sequences • Deuterium lock switch for gradient shimming • 5mm Broad Band Inverse geometry double resonance probe with automated tuning and matching (BBI ATMA). Allows 1H observation with pulsing/decoupling of nuclei in the frequency range 15N and 31P with 2H lock and shielded z-gradient coils.
Configuration of the Bruker DPX 250MHz NMR
High performance one bay Bruker 250 MHz digital two channel NMR spectrometer console and Windows XP host workstation running XwinNMR version 3.5. Equipped with:
• Oxford instruments magnet 5.87 Tesla (250 MHz proton resonance frequency) • B-VT 3300 variable temperature controller unit
• Four nucleus (QNP) switchable probe for observation of 1H, 13C, 19F and 31P with 2H lock
Configuration of the Bruker AVANCE 400MHz NMR High performance one bay Bruker AVANCE 400 MHz digital two channel NMR spectrometer console Equipped with:
• Bruker magnet 9.40 Tesla (400MHz proton resonance frequency)
• B-VT 3200 variable temperature controller unit • GRASP II gradient spectroscopy accessory for the generation of one field gradient of up to 50 Gauss cm"1
• Four nucleus (QNP) switchable probe for observation of 1H, 13C, 19F and 31P with 2H lock with z-gradient coils for gradient spectroscopy.
LCMS methods used
Example compounds and their intermediates were analysed by HPLC-MS using a combination of the following instrumentation: Shimadzu, Waters or Micromass ZMD, ZQ or LCT mass spectrometers with an Agilent, Waters or Polymer Labs UV and ELS detector. The HPLC conditions are tabulated below. Micromass MassLynx™ Operating Software with OpenLynx™ Browser were used for data acquisition, processing and reporting.
LCMS Method A (2 min method)
Figure imgf000054_0001
Figure imgf000055_0001
LCMS Method B (3.5 min method)
Figure imgf000055_0002
LCMS Method C (7 min method)
Figure imgf000056_0001
LCMS Method D (10 min method)
Figure imgf000057_0001
LCMS Method E (15 min method)
Figure imgf000058_0001
Preparative HPLC Methods Used:
Where indicated, Example compounds and their intermediates were purified by one of or any combination of the following methods.
Prep Method 1 (Low pH)
Figure imgf000058_0002
Prep Method 2
Figure imgf000059_0001
Prep Method 3 (Low pH)
Figure imgf000059_0002
Prep method 4
Figure imgf000059_0003
Prep method 5 (Neutral)
Figure imgf000059_0004
Compound Naming
All compounds are named using ACD Labs 10.0 naming software which conforms to IUPAC naming protocols. Some compounds are isolated as TFA salts, which is not reflected by the chemical name. Within the meaning of the present invention the chemical name represents the compound in neutral form as well as its TFA salt or any other salt, especially pharmaceutically acceptable salt, if applicable.
List of Abbreviations
AcOH acetic acid
Ag2CO3 silver carbonate br s broad singlet
Boc te/t-butoxycarbonyl
BINAP 2,2'-δώ(diphenylphosphino)-l,rbinaphthyl
'BuOK potassium tert-butoxidc nBuLi n-butyl lithium secBuLi secondary-butyl lithium cat catalytic cbz benzyloxycarbonyl
CDI 1 , 1 '-carbonyldiimidazole
Chloroform-ύf deuterated chloroform
DCC dicyclohexylcarbodiimide
DCE 1 ,2-dichloroethane
DCM dichloromethane
DIPEA JV,jV-diisopropylethylamine
DMAP N,Λ/-4-dimethylaminopyridine
EDCI 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride eq equivalent
Ether diethyl ether
Et2O diethyl ether
EtOAc ethyl acetate
EtOH ethanol
FCC flash column chromatography h hours hrs hours
HCl hydrochloric acid
H2SO4 sulfuric acid
HDA diisopropylamine
HOBt 1 -hydroxybenzotriazo Ie
HBTU o-benzotriazol-l-yl-N,N,N\N"-tetramethyluronium tetrafluoroborate
IBX 1 -hydroxy- 1 ,2-benziodoxol-3(lh)-one 1 -oxide
IPA isopropyl alcohol
Kryptofϊx-2224,7,13,16,21,24-hexaoxa-l,10-diazabicyclo[8.8.8]-hexacosane
LAH lithium aluminium hydride
LiAlH4 lithium aluminium hydride
LiTMP 2,2,6, 6-tetramethylpiperidine
LCMS liquid chromatography and mass spectrometry
MeCN acetonitrile
MeOH methanol
MeOD dueterated methanol
MsCl methanesulfonyl chloride
MeI methyl iodide m multiplet min(s) minute(s) mL millilitre ml millilitre mol/M mole/molar
MW molecular weight
NMR nuclear magnetic resonance
NaBH3CN sodium cyanoborohydride
NaBH4 sodium borohydride
NEt3 triethylamine
OMs methanesulfonate
OTs /?αra-toluenesulfonate
Pd2(dba)3 έώ(dibenzylideneacetone)palladium(0)
PBr3 tribromophospine
PMA phosphomolibdic acid
PPh3 triphenylphosphine PS-DIPEA polymer-supported N, N-diisopropylethylamine
Rt retention time
RT room temperature
SOCl2 thionyl chloride
STAB sodium triacetoxyborohydride pTSA para-toluene sulfonic acid thio-CDI thio-carbonyl diimidazole
TBAF tetra-n-butylammonium fluoride
TBAI tetra-n-butylammonium iodide
TBDMSCl te/t-butyldimethylsilyl chloride
TEA triethylamine
TFA 2,2,2-trifluoroacetic acid
TFAA 2,2,2-trifluoroacetic acid anhydride
TFE 2,2,2-trifluoroethanol
THF tetrahydrofuran
TLC thin layer chromatography
TMS trimethylsilyl
W watt(s)
Route 1
General Procedure A General Procedure B
Figure imgf000062_0001
General Procedure A:
Preparation of tert-butyl 4-cyclobutyl-l,4-diazepane-l-carboxylate
Figure imgf000062_0002
To a stirred solution of [l,4]diazepane-l-carboxylic acid tert-butyi ester (5 g, 24.97 mmol) in DCE (70 ml) at 20 to 25 0C was added cyclobutanone (1.75 g, 24.97 mmol) followed by acetic acid (1.5 g, 24.97 mmol) dropwise. The resulting mixture was stirred at 20 to 25 0C for ca. 2 h. Sodium triacetoxyborohydride (7.94 g, 37.46 mmol) was added in 9 portions, keeping the temperature in the range of 20 to 25 0C. The resulting suspension was stirred at 20 to 25 0C overnight. Saturated NaHCOs (80 ml) was added in four portions and the biphasic mixture stirred at 20 to 25 0C for ca. 1A h. The organic layer was separated, washed with water (20 ml) and the aqueous phase back extracted at pH 9 with DCM (20 ml). The combined organic phases were dried (Na2SO4), filtered and concentrated in vacuo to provide the title compound as yellow oil (6.1 g, 96%).
LCMS data: Calculated MH+ (255); Found 100% [2(M-Boc)]H+ m/z (307), Rt = 1.4 mins. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 3.38 - 3.52 (4 H, m), 2.86 - 2.98 (1 H, m), 2.40 - 2.54 (4 H, m), 2.02 - 2.12 (2 H, m), 1.77 - 1.92 (4 H, m), 1.61 - 1.75 (2 H, m), 1.46 (9 H, s).
The following intermediates were prepared as described in Route 1, General Procedure A above.
Preparation of tert-butyl 4-(l-methylethyl)-l,4-diazepane-l-carboxylate
Figure imgf000063_0001
In a similar fashion (Rl, GP A), tert-butyl 1,4-diazepane-l-carboxylate (500 mg, 2.45 mmol) and acetone (198 μL, 2.69 mmol), gave the title compound (560 mg, 93 % yield) as colourless oil. The product was taken through to the next step without further purification.
Preparation of tert-butyl 4-cyclopentyl-l,4-diazepane-l-carboxylate
Figure imgf000063_0002
In a similar fashion (Rl, GP A), cyclopentanone (1.36 mL, 15 mmol), gave the title compound (3.68g, 91% yield) as clear pale yellow oil. LCMS data: Calculated MH+ (269); Found 98% [(M-BoC)]H+ m/z (213), Rt = 1.4 mins.
NMR data: 1H NMR (400 MHz, Chloroform-J) δ ppm 1.24 - 1.35 (2 H, m), 1.37 (9 H, s), 1.42 - 1.49 (2 H, m), 1.53 - 1.66 (4 H, m), 1.97 - 2.08 (2 H, m), 1.69 - 1.84 (4 H, m), 2.55 - 2.67 (4 H, m), 2.73 - 2.85 (1 H, m), 3.33- 3.47 (4 H, m).
Preparation of tert-butyl 4-cyclobutylpiperazine-l-carboxylate
Figure imgf000064_0001
In a similar fashion (Rl, GP A), tert-butyl piperazine-1-carboxylate (13.0 g, 69.8 mmol) and cyclobutanone (1.36 rnL, 15 mmol), gave the title compound (12 g, 71.5 % yield) as clear pale yellow oil. This compound showed a single spot by TLC (uv 215 nm) and was taken through to the next step without further purification.
General Procedure B:
Preparation of l-cyclobutyl-l,4-diazepane
Figure imgf000064_0002
To a stirred solution of tert-butyi 4-cyclo butyl- 1,4-diazepane-l-carboxylate (6.1 g, 23.98 mmol) in DCM (70 ml) at 20 to 25 0C was added a solution of 4M HCl in dioxane (30 ml, 120 mmol) dropwise. The resulting mixture was stirred at 20 to 25 0C for ca. 2h. MeOH (6 ml) was added and the resulting mixture stirred at 20 to 25 0C for 1 to 2 days. The solvent was removed in vacuo and the resulting gummy residue slurried in ether (100 ml) for 0.5 h. The solvent was evaporated and the residue slurried in ether/MeOH (10:1, 66 ml). The resulting white solid was collected by filtration, suspended in DCM (150 ml) and treated with 2M NaOH. The aqueous phase was extracted with DCM until complete transfer of product in the organic layer, as monitored by TLC analysis (eluent, DCM/MeOH/conc.NH3 (90:10:1); stain, PMA) was achieved. The combined organic phases were dried (Na2SO4), filtered and concentrated in vacuo to provide the title compound as orange oil (2.67 g, 73%). LCMS data: Calculated MH+ (155); Found 100% (MH+) m/z 155, Rt = 0.44 min. NMR data: 1H NMR (400 MHz, Chloroform-J) δ ppm 2.85 - 2.97 (5 H, m), 2.43 - 2.53 (4 H, m), 1.97 - 2.08 (2 H, m), 1.52 - 1.91 (7 H, m).
The following intermediate was prepared as described in Route 1, General Procedure B above.
Preparation of l-(l-methylethyl)-l,4-diazepane
Hl/ V In a similar fashion (Rl, GP B), tert-butyl 4-(l-methylethyl)-l,4-diazepane-l-carboxylate (560 mg, 2.31 mmol) gave the title compound (633 mg, 133 % yield - 1H NMR analysis shows a significant amount of entrained dioxane) as brown oil. 1H NMR (500 MHz, CDCl3) δ 3.41 - 3.85 (9 H, m), 2.27 - 2.46 (2 H, m), 1.42 (6 H, d).
Preparation of l-cyclopentyl-l,4-diazepane
HN rO
In a similar fashion (Rl, GP B), tert-butyl 4-cyclopentyl-l,4-diazepane-l-carboxylate (3.68g, 13.7 mmol), gave the title compound (1.96 g, 85% yield) as pale yellow semi-solid. LCMS data: Calculated MH+ (169); Found 100% (MH+) m/z 169, Rt = 0.25 min.
NMR data: 1H NMR (400 MHz, Chloroform-J) δ ppm 2.73 - 2.84 (5 H, m), 2.53 - 2.62 (4 H, m), 1.56 - 1.76 (4 H, m), 1.16 - 1.56 (6 H, m).
Preparation of 1-cyclobutylpiperazine
HN N~O^ ^^
In a similar fashion (Rl, GP B), tert-butyl 4-cyclobutylpiperazine-l-carboxylate (12g, 49.9 mmol), gave the title compound (5.23 g, 74.7 % yield) as white semi-crystalline solid. LC data: Rt = 2.74 mins (High pH).
1H NMR (500 MHz, CHLOROFORM-d) δ ppm 5.39 (2 H, br. s.), 3.03 (2 H, t, J=4.8 Hz), 2.63 - 2.82 (1 H, m), 2.10 - 2.62 (6 H, m), 1.96 (2 H, q, J=7.7 Hz), 1.73 - 1.92 (2 H, m), 1.53 - 1.72 (2 H, m).
Route 2
Figure imgf000065_0001
Preparation of ό-chloro-N-methylpyridine-S-carboxamide
To a stirred solution of β-chloropyridine-S-carbonyl chloride (1.5 g, 8.52 mmol) in DCM (10 ml) at O0C was added methylamine hydrochloride (1.73g, 25.5 mmol) followed by drop wise additional of triethylamine (3.55 ml, 25.5 mmol) over 10 mins. The reaction mixture was stirred at RT for 2h then quenched by addition of brine (15 ml) and saturated Na2CO3 (5 ml). The organic layer was collected and the aqueous layer extracted with DCM (2 x 20 ml). The combined organic phase was washed with brine (10 ml), dried (Na2SO4), filtered and evaporated to dryness. Recystallisation from hot DCM (~10 ml) provided the title compound (0.995 g, 5.8 mmol, 68%) as white crystals. LCMS data: Calculated MH+ (171); Found 100% (MH+) m/z 171, Rt = 2.30 min.
IH NMR (400 MHz, CHLOROFORM-d) δ ppm 8.74 (1 H, d, J=2.4 Hz), 8.09 (1 H, dd, J=8.3, 2.4 Hz), 7.42 (1 H, d, J=8.1 Hz), 6.41 (1 H, br. s.), 3.03 (3 H, d, J=4.9 Hz).
Route 3
General
Figure imgf000066_0002
General Procedure C:
Preparation of S-chloro-N-methylpyridine-l-carboxamide
Figure imgf000066_0003
To a stirred solution of 5-chloropyridine-2-carboxylic acid (315 mg, 2.0 mmol) in DCE (2.5 ml) at 20 to 25 0C was added CDI (324 mg, 2.0 mmol) and the mixture was stirred at RT overnight. The reaction mixture was heated to ca. 50 0C and a solution of methylamine in THF (2 M, 5.0 mmol) was added. The resulting mixture was stirred at 50 0C overnight and then cooled to RT and diluted with DCM (20 mL). the reaction mixture was washed with sat. NaHCO3 (10 ml) and the organic layer dried (Na2SO4), filtered and concentrated in vacuo. Purification by silica flash column chromatography (eluting with DCM/MeOH 95:5) provided the title compound as off-white solid (140 mg, 41%).
LCMS data: Calculated MH+ (171); Found 100% (MH+) m/z 171, Rt = 1.32 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 8.58 (1 H, d, J=2.4 Hz), 8.02 - 8.08 (1 H, m), 7.94 - 8.00 (1 H, m), 2.95 (3 H, s).
The following compounds were made as described in Route 3, General Procedure C above.
Preparation of S-chloro-r^N-dimethylpyridine-l-carboxamide
Figure imgf000067_0001
In a similar fashion (Route 3, GP C), 5-chloropyridine-2-carboxylic acid (315 mg, 2.0 mmol) and a solution of dimethyl amine in EtOH (5.6 M, 5.0 mmol) gave the title compound as off white solid (190 mg, 51%).
LCMS data: Calculated MH+ (185); Found 100% (MH+) m/z 185, Rt = 1.16 min. NMR data: (400 MHz, MeOD) δ ppm 8.60 (1 H, d, J=2.2 Hz), 7.99 (1 H, dd, J=8.3, 2.4 Hz), 7.62 (1 H, d, J=8.3 Hz), 3.13 (3 H, s), 3.04 (3 H, s).
Preparation of 5-chloro-pyridine-2-carboxamide
Figure imgf000067_0002
In a similar fashion (Route 3, GP C), 5-chloropyridine-2-carboxylic acid (126 mg, 0.80 mmol) and a solution of ammonia in methanol (7 M, 2.38 mmol) gave the title compound as pale pink solid (40 mg, 32%).
LCMS data: Calculated MH+ (157); Found 99% (MH+) m/z 157, Rt = 1.17 min NMR data: (500 MHz, DMSO) δ ppm 8.68 (1 H, d), 8.09 - 8.17 (2 H, m), 8.04 (1 H, d), 7.73 (1 H, br. s.).
Preparation of 5-chloro-N,N-dimethylpyridine-2-carboxamide
Figure imgf000067_0003
In a similar fashion (Route 3, GP C), S-chloropyridine^-carboxylic acid (126 mg, 0.80 mmol) and diethylammonium chloride (259 mg, 2.38 mmol) and DIPEA (0.55 ml, 3.18 mmol) gave the title compound as pink oil (105 mg, 62%).
LCMS data: Calculated MH+ (213); Found 100% (MH+) m/z 213, Rt = 1.53 min.
NMR data: (500 MHz, CDC13) δ ppm 8.48 (1 H, d, J=2.4 Hz), 7.71 (1 H, dd, J=8.3, 2.5 Hz),
7.54 (1 H, d, J=8.4 Hz), 3.50 (2 H, q, J=7.2 Hz), 3.34 (2 H, q, J=7.0 Hz), 1.21 (3 H, t, J=7.2
Hz), 1.12 (3 H, t, J=7.1 Hz).
Preparation of 4-fluoro-N,3-dimethylbenzamide
Figure imgf000068_0001
In a similar fashion (Route 3, GP C), 4-fluoro-3-methylbenzoic acid (97 mg, 0.63 mmol) and a solution of methylamine in MeOH (2 M, 0.89 mmol) gave the title compound as an off white solid (73 mg, 69%).
LCMS data: Calculated MH+ (168); Found 100% (MH+) m/z 168, Rt = 1.03 min.
NMR data: (250 MHz, CDC13) δ ppm 7.64 (1 H, dd, J=IA, 1.9 Hz), 7.50 - 7.59 (1 H, m),
7.03 (1 H, 7, J=8.8 Hz), 6.07 (1 H, br s), 3.0 (3 H, d, J=4.9 Hz), 2.30 (3 H, d, J=2.0 Hz).
Route 4
General Procedure D
Figure imgf000068_0002
General Procedure D:
Preparation of 4-fluoro-N-methylbenzamide
Figure imgf000068_0003
To a stirred solution of 4-fluorobenzoic acid (200 mg, 1.43 mmol) in DCE (3 ml) at RT, was added a solution of methyl amine in THF (2 M, 1.43mmol) and NEt3 (198 μl, 1.43 mmol) and allowed to stir for ca. 10 mins. HOBt (221 mg, 1.43 mmol) and DCC (295 mg, 1.43 mmol) were added and the reaction mixture heated at 70 0C for 3 h. After cooling to RT, the reaction mixture was washed with sat. NaHCO3 (5 ml) and the aqueous back extracted with DCM. The organics were combined, dried (MgSO4), filtered and concentrated under reduced pressure. Purification by silica flash column chromatography (eluting with DCM/MeOH gradient 100:0 to 80:20) provided the title compound as off-white solid (137 mg, 63%).
LCMS data: Calculated MH+ (154); Found 100% (MH+) m/z 154.2, Rt = 1.11 min.
The following compound was made as described in Route 4, General Procedure D above.
Preparation of 4-fluoro-N,N-dimethylbenzamide
Figure imgf000069_0001
In a similar fashion (Route 4, GP D), 4-fluorobenzoic acid (200 mg, 1.43 mmol) and a solution of dimethyl amine in EtOH (5.6 M, 1.43 mmol) gave the title compound as off white solid (172 mg, 72%). LCMS data: Calculated MH+ (168); Found 89% (MH+) m/z 168, Rt = 1.03 mins.
Route 5
General Procedure E
Figure imgf000069_0002
General Procedure E:
Preparation of l-(4-fluorobenzyl)-lH-pyrazole
Figure imgf000069_0003
To a stirred solution of pyrazole (300 mg, 4.4 mmol) in DMSO (2 ml) at RT was added NaH (176 mg, 4.4 mmol, 60% in mineral oil) portionwise. The mixture was stirred at RT for 1 h and 4-fluorobenzylbromide (1.0 g, 5.3 mmol) added dropwise. The mixture was stirred at 50 0C for 0.5 h, cooled to RT and diluted with DCM (20 ml). The resulting mixture was filtered and the filtrate washed with brine (10 ml). The organic layer was then dried (NaSO), filtered and concentrated at reduced pressure. Purification by silica flash column chromatography (eluting with DCM/MeOH 95:5) provided the title compound as colourless oil (650 mg,
%).
LCMS data: Calculated MH+ (177); Found 100% (MH+) m/z 177, Rt = 1.66 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 7.68 (1 H, d, J=2.2 Hz), 7.51 (1 H, d, J=I.7 Hz), 7.19 - 7.27 (2 H, m), 7.01 - 7.09 (2 H, m), 6.32 (1 H, t, J=2.2 Hz), 5.32 (2 H, s).
The following compounds were made as described in Route 5, General Procedure E above.
Preparation of 2-chloro-5-(lH-pyrazol-l-ylmethyl)pyridine
Figure imgf000070_0001
In a similar fashion (Route 5, GP E), 2-chloro-5-(chloromethyl)pyridine (450 mg, 2.5 mmol, 90% purity) and pyrazole (170 mg, 2.5 mmol) gave the title compound as colourless oil (372 mg, 77%). LCMS data: Calculated MH+ (194); Found 89% (MH+) m/z 194, Rt = 1.39 min.
NMR data: 1H NMR (400 MHz, MeOD) δ ppm 8.25 (1 H, d, J=2.2 Hz), 7.77 (1 H, d, J=2.2 Hz), 7.64 (1 H, dd, J=8.2, 2.3 Hz), 7.55 (1 H, d, J=I.5 Hz), 7.42 (1 H, d, J=8.3 Hz), 6.35 (1 H, t, J=2.1 Hz), 5.40 (2 H, s).
Route 6
Figure imgf000070_0002
. STArB, RT
General Procedure F: Preparation of l-(4-fluorobenzyl)piperidine
Figure imgf000070_0003
To a stirred solution of 4-fluorobenzaldehyde (500 mg, 4.0 mmol) in DCE (3 ml) at RT was added piperidine (309 mg, 3.6 mmol) followed by AcOH (242 mg, 4.0 mmol). The solution was stirred at RT for 2 h, and then STAB (1.3 g, 6.05 mmol) was added in one portion. The resulting mixture was stirred at RT overnight and then quenched with saturated NaHCOs (10 ml). The organic layer was separated, dried (Na2SO4), filtered and concentrated at reduced pressure. Purification by silica flash column chromatography (eluting with DCM/MeOH/NH3 90: 10: 1) provided the title compound as colourless oil (650 mg, 95%).
LCMS data: Calculated MH+ (194); Found 100% (MH+) m/z 194, Rt = 0.62 min. NMR data: 1H NMR (360 MHz, CHLOROFORM-J) δ ppm 7.23 - 7.32 (2 H, m), 6.99 (2 H, t, J=8.6 Hz), 3.43 (2 H, s), 2.36 (4 H, br. s.), 1.57 (4 H, quin, J=5.6 Hz), 1.44 (2 H, d, J=5.4 Hz).
The following compounds were made as described in Route 6, General Procedure F above.
Preparation of l-(4-fluorobenzyl)-4-methylpiperazine
Figure imgf000071_0001
In a similar fashion (Route 6, GP F), 4-fluorobenzaldehyde (500 mg, 4.0 mmol) and N- methylpiperazine (363. mg, 3.63 mmol) gave the title compound as colourless oil (657 mg,
88%).
LCMS data: Calculated MH+ (209); Found 100% (MH+) m/z 209, Rt = 0.48 min.
NMR data: 1H NMR (360 MHz, CHLOROFORM-^) δ ppm 7.28 (2 H, dd, J=8.6, 5.4 Hz), 6.94 - 7.03 (2 H, m), 3.47 (2 H, s), 2.46 (8 H, d, J=5.9 Hz), 2.29 (3 H, s).
Preparation of 4,4-difluoro-l-(4-fluorobenzyl)piperidine
Figure imgf000071_0002
In a similar fashion (Route 6, GP F), 4-fluorobenzaldehyde (250 mg, 2.0 mmol) and 4,4- difluoropiperidine (285. mg, 1.8 mmol) gave the title compound as colourless oil (370 mg,
90%).
LCMS data: Calculated MH+ (230); Found 100% (MH+) m/z 230, Rt = 0.66 min.
NMR data: 1H NMR (250 MHz, CHLOROFORM-^) δ ppm 7.22 - 7.35 (2 H, m), 6.94 - 7.08
(2 H, m), 3.51 (2 H, s), 2.53 (4 H, t, J=5.6 Hz), 1.89 - 2.09 (4 H, m). Route 7
Figure imgf000072_0001
Preparation of 2-(4-chloropyridin-2-yl)propan-2-ol
Figure imgf000072_0002
Ethyl 4-chloropyridine-2-carboxylate (200 mg, 1.08 mmol) was dissolved in diethyl ether (10 ml) and cooled to 0 0C. MeMgBr (1.08 ml of a 3M solution in diethyl ether, 3.24 mmol) was added dropwise and the reaction was warmed to room temperature and stirred for 30 minutes. After quenching with saturated NaHCOs (2 ml) and diluting with diethyl ether (40 ml), the resulting mixture stirred vigorously for 30 minutes to break up the resulting solid. The mixture was washed twice with saturated NaHCOs (20 ml), dried (MgSO4) and concentrated at reduced pressure. The resulting residue was dissolved in diethyl ether (10 ml) and the Grignard reaction repeated giving the title compound as colourless oil (157 mg, 85%). LCMS data: Calculated MH+ (186); Found 92% (MH+) m/z 186, Rt = 1.57 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.43 (1 H, d, J=5.3 Hz), 7.42 (1 H, d, J=I.2 Hz), 7.22 (1 H, dd, J=5.3, 1.8 Hz), 4.56 (1 H, s), 1.55 (6 H, s).
Route 8
Figure imgf000072_0003
Preparation of 2-(2,4-Difluoro-phenyl)-propan-2-ol
Figure imgf000072_0004
MeMgBr (1.83 ml of a 3M solution in diethyl ether, 5.5 mmol) was added dropwise to a solution of 2,4-difluoroacetophenone (782 mg, 5.0 mmol) in diethyl ether (20 ml) at 0 0C. The reaction was warmed to room temperature and after 1 hour was quenched and washed with water (2 x 20 ml), dried (MgSO4) and concentrated under reduced pressure to give the title product as colourless oil (800 mg, 93%). LCMS data: MH+ (173); Found 75% (M-OH)+ m/z 155, Rt = 1.75 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.49 - 7.61 (1 H, m), 6.83 - 6.89 (1 H, m),
6.75 - 6.83 (1 H, m), 2.02 (1 H, s), 1.63 (6 H, s).
Route 9
Figure imgf000073_0001
Preparation of 4-chloro-2-methoxy-pyridine
Figure imgf000073_0002
4-Chloro-2-hydroxy-pyridine (247 mg, 1.91 mmol), Ag2CO3 (1.58 g, 5.74 mmol) and MeI
(0.13 ml, 2.11 mmol) were heated in a sealed tube at 50 0C for 16 hours and then filtered through celite and concentrated at reduced pressure. The residue was purified by FCC (Pentane/Diethyl ether with gradient, 99:1 to 95:5) to provide the title compound as colourless oil (160 mg, 58%).
LCMS data: Calculated MH+ (144); Found 100% (MH+) m/z 144, Rt = 1.71 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.07 (1 H, d, J=5.5 Hz), 6.89 (1 H, dd, J=5.5,
1.5 Hz), 6.77 (1 H, d, J=1.7 Hz), 3.94 (3 H, s).
Route 10
Figure imgf000073_0003
Preparation of 4-chloro-N,N-dimethylpyridin-2-amine
Figure imgf000073_0004
Acetic acid (0.6 ml, 10.5 mmol) was added dropwise to a solution of 2-amino-4- chloropyridine (384 mg, 3.0 mmol), formaldehyde (2.4 ml of a 37% aqueous solution, 29.6 mmol) and NaBH3CN (581 mg, 9.0 mmol) in MeCN (10 ml) and water (2 ml) at 0 0C. After 10 minutes the reaction was warmed to room temperature and stirred for 3 days. The reaction was basifϊed to pH4 with IM aq. NaOH and then extracted with diethyl ether (3 x 30 ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by
FCC (Hexane/Diethyl ether with gradient, 98:2 to 8:2) to provide the title compound as colourless oil (260 mg, 56%).
LCMS data: Calculated MH+ (157); Found 100% (MH+) m/z 157, Rt = 0.63 mins.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.05 (1 H, d, J=5.3 Hz), 6.54 (1 H, d, J=5.5
Hz), 6.49 (1 H, d, J= 1.5 Hz), 3.08 (6 H, s).
Route 11
Figure imgf000074_0001
Preparation of 4-chloro-3-fluoro-2-methylpyridine
Figure imgf000074_0002
n-BuLi (8.5 ml of a 1.2 M soln in hexanes, 10.2 mmol) was added dropwise to a solution of 2,2,6,6-tetramethylpiperidine (1.73 ml, 10.2 mmol) in THF (30 ml) at 0 0C. The mixture was then cooled to -78 0C and 4-chloro-3-fluoropyridine (1.0 ml, 10.2 mmol) was added dropwise over 15 minutes and then stirred for 25 minutes. MeI (0.64 ml, 10.2 mmol) was added dropwise at -78 0C and the resulting solution was left to warm to room temperature over several hours and quenched with saturated NaHCO3 (5 ml). The reaction was concentrated at reduced pressure, diluted with dichloromethane (50 ml), washed twice with saturated NaHCO3 (25 ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (pentane/diethyl ether with gradient, 9:1 to 8:2) to provide the title compound as colourless oil (833 mg, 56%). LCMS data: The product did not ionise, 96% UV at Rt = 3.59 mins observed (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.20 (1 H, d, J=5.2 Hz), 7.17 - 7.25 (1 H, m), 2.56 (3 H, d, J=3.2 Hz).
Route 12
Figure imgf000075_0001
Preparation of 2-ethyl-4-chloropyridine
Figure imgf000075_0002
To a stirred solution of diisopropylamine (0.86 ml, 6.1 mmol) in THF (15 ml) at -2O0C was added dropwise a solution of n-butyllithium in hexanes (1.2M, 5.07 ml, 6.1 mmol). The reaction mixture was stirred at -2O0C for 20 minutes and was then cooled to -7O0C. A solution of 2-methyl-4-chloropyridine (0.74 g, 5.8 mmol) in THF (10 ml) was added dropwise over 20 minutes and the reaction mixture was stirred for 1 hour at -7O0C. Methyl iodide (0.38 ml, 6.1 mmol) was then added dropwise and the reaction was allowed to warm to room temperature with stirring. The solvent was evaporated at reduced pressure and the resulting residue purified by FCC. 1H NMR indicated a -2.2 : 1 mixture of 2-ethyl and 2-(l-methylethyl) compounds. Re-purification by silica FCC [pentane / ether eluting with gradient 9:1 to 1 :1] gave the title compound (209 mg, 24%) as colourless oil. LCMS data: The product did not ionise, 99% UV at Rt = 4.34 mins observed (High pH method).
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.43 (1 H, d, J=5.3 Hz), 7.19 (1 H, d, J=2.0 Hz), 7.13 (1 H, dd, J=5.3, 2.0 Hz), 2.82 (2 H, q, J=7.6 Hz), 1.31 (3 H, t, J=7.6 Hz).
Preparation of 4-chloro-2-(l-methylethyl)pyridine
Figure imgf000075_0003
The title compound (97 mg, 10%) was recovered from Route 12 as colourless oil. LCMS data: The product did not ionise, 91% UV at Rt = 3.93 min observed (High pH method). NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.44 (1 H, d, J=5.3 Hz), 7.19 (1 H, d, J=I.8 Hz), 7.13 (1 H, dd, J=5.3, 2.0 Hz), 2.97 - 3.12 (1 H, sept, J=6.8 Hz), 1.30 (6 H, d, J=6.8 Hz). Route 13
Figure imgf000076_0001
Preparation of 2-chloro-6-(cyclopropylcarbonyl)-5,6,7,8-tetrahydro- 1 ,6-naphthyridine
Figure imgf000076_0002
To a room temperature stirred suspension of 2-chloro-5,6,7,8-tetrahydro-l,6-naphthyridine hydrochloride (50 mg, 0.24 mmol) in dichloromethane (2 ml) under a nitrogen atmosphere was added DIPEA (0.12 ml, 0.73 mmol) followed by cyclopropyl carbonyl chloride (24 μl, 0.27 mmol). The resulting mixture was stirred for 16 hours, diluted with dichloromethane (30 ml) and IM aq. HCl (2 ml). The organic layer was separated and washed with saturated aqueous NaHCCh (15 ml) and brine (15 ml), dried (MgSO4), filtered and concentrated at reduced pressure to provide the title compound (60 mg, 95%) which was used without further purification. LCMS data: Calculated MH+ (237); Found 100% (MH+) m/z 237, Rt = 1.08 mins. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 7.41 (1 H, d, J=7.5Hz), 7.18 (1 H, d, J=7.5Hz), 4.68 - 4.92 (2 H, m), 3.83 - 4.10 (2 H, m), 2.90 - 3.19 (2 H, m), 1.86 - 1.92 (1 H, m), 0.97 - 1.08 (2 H, m), 0.77 - 0.88 (2 H, m).
Route 14 o
Figure imgf000076_0003
Preparation of 2-chloro-6-(cyclopropylacetyl)-5,6,7,8-tetrahydro- 1 ,6-naphthyridine
Figure imgf000076_0004
To a stirred solution of cyclopropylacetic acid (24 mg, 0.24 mmol) in DMF (1 ml) at room temperature was added HBTU (185 mg, 0.49 mmol) and HOBt (72 mg, 0.53 mmol) sequentially and the resulting solution stirred for 15 mins. 2-Chloro-5,6,7,8-tetrahydro-l,6- naphthyridine hydrochloride (50 mg, 0.24 mmol) and DIPEA (89 μl, 0.53 mmol) in DMF (ImI) were then added and the resulting mixture stirred at room temperature for 16 hours. The reaction mixture was evaporated to dryness and the residue was purified by FCC on silica gel (99: 1 : 1 DCM/MeOH/NH3) to provide the title compound (56 mg, 95%).
LCMS data: Calculated MH+ (251); Found 89% (MH+) m/z 251, Rt = 1.14 mins. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 7.44 (1 H, d, J=7.5Hz), 7.20 (1 H, d, J=7.5Hz), 4.76 (2 H, s), 3.78 (2 H, t, J=7.5Hz), 3.00 - 3.06 (2 H, m), 2.40 (2 H , d, J=7.5Hz), 1.03 - 1.16 (1 H, m), 0.56 - 0.64 (2 H, m), 0.16 - 0.25 (2 H, m).
Route 15
Figure imgf000077_0001
Preparation of ethyl S-chloropyridine-l-carboxylate
Figure imgf000077_0002
A mixture of 5-chloro-2-pyridinecarboxylic acid (1.0 g, 6.35 mmol) and cone. H2SO4 (0.1 ml) was heated in EtOH (10 ml) at 80 0C for 16 hours. After cooling and concentrating at reduced pressure, the residue was dissolved in EtOAc (50 ml), washed with saturated NaHCO3 (25 ml) and brine (25 ml), dried (MgSO4), filtered and re-concentrated at reduced pressure giving the title compound (990 mg, 84%).
LCMS data: Calculated MH+ (186); Found 98% (MH+) m/z 186, Rt = 1.13 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.63 - 8.76 (1 H, m), 8.10 (1 H, d, J=8.4 Hz), 7.82 (1 H, dd, J=8.5, 2.4 Hz), 4.49 (2 H, q, J=7.2 Hz), 1.45 (3 H, t, J=7.2 Hz).
Route 16 General
Figure imgf000078_0001
DIPEA, DCM
General Procedure G:
Preparation of 5-bromo-N-methylpyridine-2-carboxamide
Figure imgf000078_0002
S-Bromo-pyridine^-carboxylic acid (2.59 g, 12.8 mmol) and thionylchloride (2.79 ml) were heated at reflux in toluene (25 ml) for 16 hours. Excess reagents were removed in vacuo and the residue was diluted in dichloromethane (50 ml). A mixture of methyl amine hydrochloride (2.60 g, 38.5 mmol) and DIPEA (6.7 ml, 38.5 mmol) in dichloromethane (10 ml) was added dropwise to the stirred solution and the resulting mixture was maintained at room temperature for 5 hours. The solution was washed with saturated aqueous NaHCOs (25 ml), dried (MgSO4), filtered and concentrated in vacuo. The resulting brown solid was recrystallised (Heptane/EtOAc) to provide the title compound as off-white needles (1.74 g, 63%). LCMS data: Calculated MH+ (215/217); Found 100% (MH+) m/z 215/217, Rt = 1.36 min. 1H NMR data: (250MHz, MeOD) δ ppm 8.70 (1 H, d, J=2.3 Hz), 8.06 - 8.19 (1 H, m), 7.99 (1 H, d, J=8.4 Hz), 2.95 (3 H, s).
The following compounds were made as described in Route 16, General Procedure G above.
Preparation of 5-chloro-2-(piperidin-l-ylcarbonyl)pyridine
Figure imgf000078_0003
In a similar fashion (Route 16, GP G), 5-Chloropyridine-2-carboxylic acid (100 mg, 0.64 mmol) and piperidine (189 μl, 1.91 mmol) gave the title compound as light brown oil (122 mg, 86%) after purification by SiO2 plug (Heptane/EtOAc). LCMS data: Calculated MH+ (225); Found 92% (MH+) m/z 225, Rt = 1.17 min.
1H NMR data: (250MHz, Chloroform-^) δ ppm 8.54 (1 H, dd, J=2.4, 0.6 Hz), 7.77 (1 H, dd, J=8.4, 2.4 Hz), 7.58 (1 H, dd, J=8.3, 0.7 Hz), 3.73 (2 H, br.s.), 3.37 - 3.53 (2 H, m), 1.48 - 1.77 (7 H, m). Preparation of 5-chloro-N-(cyclopropylmethyl)pyridine-2-carboxamide
Figure imgf000079_0001
In a similar fashion (Route 16, GP G), 5-Chloropyridine-2-carboxylic acid (100 mg, 0.64 mmol) and cyclopropyl methylamine (166 μl, 1.91 mmol) gave the title compound as light brown oil (86 mg, 64%) after purification by SiO2 plug (Heptane/EtOAc).
LCMS data: Calculated MH+ (211); Found 94% (MH+) m/z 211, Rt = 1.28 min. 1H NMR data: (250MHz, Chloroform-J) δ ppm 8.47 - 8.57 (1 H, m), 8.17 (1 H, d, J=8.4 Hz), 7.90 - 8.09 (1 H, m), 7.83 (1 H, dd, J=8.4, 2.4 Hz), 3.34 (2 H, dd, J=7.0, 5.8 Hz), 1.08 (1 H, s), 0.52 - 0.66 (2 H, m), 0.21 - 0.35 (2 H, m).
Preparation of 2,4-difluoro-N-methylbenzamide
Figure imgf000079_0002
In a similar fashion (Route 16, GP G), 2,4-difluorobenzoic acid (874 mg, 5.5 mmol) and methylamine hydrochloride (1.87 g, 27.6 mmol) gave the title compound as off white solid (393 mg, 42%) after purification by re-crystallising from heptane / EtOAc.
LCMS data: Calculated MH+ (172); Found 100% (MH+) m/z 172, Rt = 1.19 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.09 - 8.21 (1 H, m), 6.95 - 7.06 (1 H, m),
6.81 - 6.91 (1 H, m), 6.52 - 6.77 (1 H, s (broad)), 3.03 (3 H, d, J=4.9 Hz).
Preparation of ethyl 4-chloropyridine-2-carboxylate
Figure imgf000079_0003
In a similar fashion (Route 16, GP G), 4-chloropyridine-2-carboxylic acid (463 mg, 2.94 mmol) and ethanol (2 ml) gave the title product as colourless oil after purification by silica FCC (310 mg, 79%) LCMS data: Calculated MH+ (186); Found 92% (MH+) m/z 186, Rt = 1.57 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.59 (1 H, d, J=5.2 Hz), 8.07 (1 H, d, J=2.1 Hz), 7.42 (1 H, dd, J=5.2, 2.0 Hz), 4.42 (2 H, q, J=7.2 Hz), 1.38 (3 H, t, J=7.2 Hz).
Preparation of 4-chloro-N-(cyclopropylmethyl)pyridine-2-carboxamide
Figure imgf000080_0001
In a similar fashion (Route 16, GP G), 5-chloro-2-pyridinecarboxylic acid (100 mg, 0.63 mmol) and 1-cyclopropylmethanamine (166 μl, 1.91 mmol) gave the title product after purification by recrystallisation (Heptane/EtOAc) as a white solid (86 mg, 65%). LCMS data: Calculated MH+ (211); Found 100% (MH+) m/z 211 , Rt = 1.25 min.
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.52 (1 H, d, J=2.3 Hz), 8.17 (1 H, d, J=8.4 Hz), 8.00 (1 H, br. s.), 7.83 (1 H, dd, J=8.4, 2.4 Hz), 3.34 (2 H, dd, J=7.0, 5.8 Hz), 1.00 - 1.16 (1 H, m), 0.52 - 0.63 (2 H, m), 0.24 - 0.35 (2 H, m).
Preparation of 4-chloro-2-(piperidin-l-ylcarbonyl)pyridine
Figure imgf000080_0002
In a similar fashion (Route 16, GP G), 5-chloro-2-pyridinecarboxylic acid (100 mg, 0.63 mmol) and piperidine (189 μl, 1.91 mmol) gave the title product after purification by recrystallisation (Heptane/EtOAc) as white solid (122 mg, 84%). LCMS data: Calculated MH+ (225); Found 100% (MH+) m/z 225, Rt = 1.55 min.
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.54 (1 H, dd, J=2.4, 0.6 Hz), 7.77 (1 H, dd, J=8.4, 2.4 Hz), 7.58 (1 H, dd, J=8.3, 0.7 Hz), 3.65 - 3.81 (2 H, m), 3.37 - 3.53 (2 H, m), 1.48 - 1.77 (6 H, m).
Preparation of 3-fluoro-N-methyl-benzamide
Figure imgf000080_0003
In a similar fashion (Route 16, GP G), 3-fluorobenzoic acid (300 mg, 2.1 mmol) and methylamine hydrochloride (430 mg, 6.4 mmol) gave the title product after workup as a white solid (235 mg, 72%). LCMS data: Calculated MH+ (154); Found 90% (MH+) m/z 154, Rt = 1.15 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.41 - 7.70 (3 H, m), 7.16 - 7.36 (1 H, m), 2.91 (3 H, s). Route 17
General Procedure X
Cl O Cl
,Cl
H
NH2 NaHCO3 Jk/ H2O / EtOH
General Procedure X: Preparation of 5-chloroimidazo[l,2-a]pyridine
Figure imgf000081_0001
To a solution of pTSA (103 mg, 0.65 mmol) in water (5 ml) and ethanol (20 ml) was added chloroacetaldehyde dimethyl acetal (2.0 g, 16.0 mmol) at room temperature. The reaction was stirred at 65 0C for 30 minutes and then cooled to room temperature and a saturated solution of NaHCOs was added dropwise until pH 7 was reached. 2-Amino-6-chloropyridine (2.1 g, 16 mmol) in 4:1 ethanohwater (20 ml) was then added and the reaction was heated at reflux for 3 hours. After cooling and concentrating at reduced pressure, the residue was purified by FCC (98:2 DCM/MeOH) to give the title compound (850 mg, 36%) as brown oil. LCMS data: Calculated MH+ (153/155); Found 97% (MH+) m/z 153/155, Rt = 3.35 min (High pH method). NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.79 (1 H, s), 7.73 (1 H, s), 7.64 (1 H, d, J=9.2 Hz), 7.19 (1 H, dd, J=8.9, 7.3 Hz), 6.92 (1 H, d, J=7.3 Hz).
The following compounds were made as described in Route 17, General Procedure X above.
Preparation of 8-Chloroimidazo[l,2-a]pyridine
Figure imgf000081_0002
In a similar fashion (Route 17, GP X), 2-amino-3-chloropyridine (2.05 g, 16.0 mmol) gave the title compound (500 mg, 20%) as white solid after purification by recrystallisation from petrolium ether.
LCMS data: Calculated MH+ (153/155); Found 100% (MH+) m/z 153/155, Rt = 2.90 min. (High pH method).
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.08 (1 H, dd, J=6.7, 0.9 Hz), 7.66 (2 H, dd, J=8.5, 1.1 Hz), 7.18 - 7.31 (1 H, m), 6.73 (1 H, t, J=7.1 Hz). Preparation of 7-Chloroimidazo[l,2-a]pyridine
Figure imgf000082_0001
In a similar fashion (Route 17, GP X), 2-amino-4-chloropyridine (2.0 g, 15.5 mmol) gave the title compound (1.0 g, 42%) as orange oil after purification by FCC. LCMS data: Calculated MH+ (153/155); Found 100% (MH+) m/z 153/155, Rt = 3.19 min (High pH method).
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.05 (1 H, dd, J=I 2, 0.7 Hz), 7.62 (2 H, s), 7.56 (1 H, s), 6.78 (1 H, dd, J=I 2, 2.0 Hz).
Route 18
Figure imgf000082_0002
Preparation of 4-Chloro-2,6-dimethylpyridine
Figure imgf000082_0003
To a solution of concentrated HCl (10 ml) at 10 0C was added 2,6-dimethylpyridine N-oxide (3.0 g, 24.3 mmol) and the resulting white slurry was stirred at room temperature for 3 hours. The product was filtered and washed with 1PrOH (2 x 10 ml) and dried at reduced pressure. The resulting solid was dissolved in POCl3 (10 ml) and heated at reflux for 8 hours then cooled to 0 0C. The reaction was quenched carefully with saturated K2CO3 (40 ml) and extracted with dichloromethane (2 x 50 ml), dried (Na2SO4), filtered and concentrated at reduced pressure. The residue was dissolved in ethanol (20 ml) and NEt3 (5 ml) and heated at reflux for 24 hours then cooled to room temperature and concentrated at reduced pressure. Water (5 ml) was added to the residue the aqueous mixture was extracted with chloroform (2 x 10 ml). The organics were combined and washed with brine (10 ml), dried (Na2SO4), filtered and concentrated at reduced pressure to give the title compound as brown solid (1.0 g, 33%).
LCMS data: The product did not ionise, 100% UV at Rt = 3.99 mins observed (High pH method).
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.88 (2 H, s), 2.76 (6 H, s). Route 19a
Figure imgf000083_0001
Preparation of 4-chloropyridine-2-carboxamide
Figure imgf000083_0002
Ammonium hydroxide (2 ml) was added to methyl 4-chloropyridine-2-carboxylate (100 mg, 0.58 mmol) in MeOH (4 ml) in a sealed tube and heated at 50 0C for 4 hours. The reaction was cooled to room temperature and concentrated at reduced pressure. The residue was dissolved in dichloromethane (20 ml), washed with water (2 x 10 ml), dried (Na2SO4), filtered and concentrated at reduced pressure to give the title compound (66 mg, 72%). LCMS data: Calculated MH+ (157/159); Found 100% (MH+) m/z 157/159, Rt = 3.68 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.5 (1 H, dd, J=5, 0.6 Hz), 8.22 (1 H, d, J=I.5 Hz), 7.48 (1 H, dd, J=5, 1.5 Hz).
Preparation of 4-chloropyridine-2-carbonitrile
Figure imgf000083_0003
To a stirred solution of 4-chloropyridine-2-carboxamide (150 mg, 0.96 mmol) in THF (5 ml) at -15 0C was added NEt3 (331 μl, 2.40 mmol) followed by TFAA (150 μl, 1.08 mmol). After stirring for 2 hours at 0 0C the reaction was concentrated then diluted with EtOAc (30 ml) and washed with water (2 x 15 ml), dried (Na2SO4), filtered and concentrated at reduced pressure. The title compound was obtained as white solid (105 mg, 79%) after purification by FCC. LCMS data: The product did not ionise, 100% UV at Rt = 3.47 min observed (High pH method).
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.64 (1 H, d, J=4.9 Hz), 7.72 (1 H, dd, J=2.0, 0.6 Hz), 7.56 (1 H, dd, J=5.3, 2.0 Hz).
Route 19b
Figure imgf000084_0001
Preparation of 2-amino-3-chloropyridine
Figure imgf000084_0002
2,3-Dichloropyridine (5.0 g, 34 mmol) and ammonium hydroxide (125 ml) were placed in a steel bomb and heated at 190 0C for 48 hours. After cooling to room temperature the reaction was diluted with EtOAc (150 ml), washed with water (3 x 50 ml), dried (MgSO4), filtered and concentrated at a reduced pressure. Recrystallisation (EtOAc) gave the title compound (2.0 g, 45%) as pale yellow solid.
LCMS data: Calculated MH+ (129/131); Found 100% (MH+) m/z 129/131, Rt = solvent front. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.0 (1 H, dd, J=2, 0.6 Hz), 7.49 (1 H, d, J=4.9, 0.6 Hz), 6.6 (1 H, dd, J=A.9, 2 Hz).
Route 20
General Procedure H
Figure imgf000084_0003
General Procedure H:
Example 1 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-ol. Potency range A
Figure imgf000085_0001
To a stirred RT solution of 4-nitrophenylchloro formate (2.63 g, 13.05 mmol) in DCM (10 ml) was added drop wise a solution of 1-cyclo butyl- 1 ,4-diazepane (1.83 g, 11.86 mmol) and pyridine (1.03 g, 13.05 mmol) in DCM (2 ml). The resulting mixture was stirred at RT for approximately 3 days. The solvent was evaporated in vacuo and the residue dissolved in MeOH / IPA (1 :3, 40 ml). Azetidin-3-ol hydrochloride (1.3 g, 11.86 mmol) and DIPEA (3.37 g, 26.1 mmol) were added and the resulting mixture was heated to reflux (~90 0C) overnight. After cooling to RT, the solvent was evaporated and the residue partitioned between DCM (40 ml) and 2M K2CO3 aq (20 ml). The organic layer was separated and the aq. phase re- extracted with DCM (20 ml). The combined organic phases were dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by silica flash column chromatography (eluting with DCM/MeOH/NH3 90:10:1) provided the title compound as yellow solid (1.16g, 39%). LCMS data: Calculated MH+ (254); Found 100% (MH+) m/z 254, Rt = 3.00 min. NMR data: 1H NMR (360 MHz, chloroform-J) δ ppm 4.47 - 4.60 (1 H, m), 4.16 (2 H, dd, J=9.5, 6.8 Hz), 3.84 (2 H, dd, J=9.5, 4.5 Hz), 3.33 - 3.46 (4 H, m), 2.76 - 2.89 (1 H, m), 2.36 - 2.55 (4 H, m), 1.95 - 2.09 (2 H, m), 1.74 - 1.91 (4 H, m), 1.52 - 1.73 (2 H, m).
The following compounds were made as described in Route 20, General Procedure H above.
Example 2 - Preparation of l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3-ol.
Potency range C
Figure imgf000085_0002
In a similar fashion (Route 20, GP H), 1-cyclo butylpiperazine (200 mg, 1.42 mmol) gave the title compound as yellow oil (198 mg, 59%).
LCMS data: Calculated MH+ (240); Runs in solvent front.
NMR data: 1H NMR (360 MHz, MeOH) δ ppm 4.38 - 4.57 (1 H, m), 4.15 - 4.24 (2 H, m),
3.69 - 3.84 (2 H, m), 3.34 - 3.38 (3 H, m), 2.71 - 2.83 (2 H, m), 2.27 - 2.37 (4 H, m), 1.99 -
2.11 (2 H, m), 1.85 - 1.93 (2 H, m), 1.70 - 1.78 (2 H, m). Example 2a- Preparation of l-[(4-ethyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-ol.
Figure imgf000086_0001
In a similar fashion (Route 20, GP H), 1 -ethyl- 1 ,4-diazepane (292 mg, 2.23 mmol) gave the title compound as yellow oil (90 mg, 16%). LCMS data: Calculated MH+ (228); Found (MH+) m/z 228. The product eluted in the solvent front.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.52 - 4.61 (1 H, m), 4.14 - 4.21 (2 H, m), 3.80 - 3.87 (2 H, m), 3.43 - 3.49 (2 H, m), 3.36 - 3.43 (2 H, m), 2.64 - 2.72 (2 H, m), 2.57 - 2.64 (2 H, m), 2.53 (2 H, q, J=7.1 Hz), 1.83 - 1.92 (2 H, m), 1.06 (3 H, t, J=7.2 Hz).
Example 2b- Preparation of l-{[4-(l-methylethyl)-l,4-diazepan-l-yl]carbonyl}azetidin-
3-oL
Figure imgf000086_0002
In a similar fashion (Route 20, GP H), l-(l-methylethyl)-l,4-diazepane (662 mg, 3.07 mmol) gave the title compound as yellow oil (335 mg, 45%).
LCMS data: Calculated MH+ (242); Found 100% (MH+) m/z 242, Rt = 1.25 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.50 - 4.61 (1 H, m), 4.11 - 4.22 (2 H, m),
3.79 - 3.90 (2 H, m), 3.32 - 3.45 (4 H, m), 2.82 - 2.95 (1 H, m), 2.62 - 2.71 (2 H, m), 2.53 -
2.62 (2 H, m), 1.73 - 1.87 (2 H, m), 0.99 (6 H, d, J=6.6 Hz).
Example 2c- Preparation of l-[(4-cyclopentyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-ol.
Figure imgf000086_0003
In a similar fashion (Route 20, GP H), l-cyclopentyl-l,4-diazepane (387 mg, 2.23 mmol) gave the title compound as yellow oil (350 mg, 59%). LCMS data: Calculated MH+ (268); Found 100% (MH+) m/z 286, Rt = 1.36 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ 4.47 - 4.61 (1 H, m), 4.08 - 4.21 (2 H, m), 3.76 - 3.90 (2 H, m), 3.32 - 3.52 (4 H, m), 2.76 - 2.87 (1 H, m), 2.69 - 2.76 (2 H, m), 2.59 - 2.68 (2 H, m), 1.74 - 1.92 (4 H, m), 1.59 - 1.73 (2 H, m), 1.45 - 1.59 (2 H, m), 1.30 - 1.43 (2 H, m). General Procedure I:
Example 3 - Preparation of 6-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylpyridine-3-carboxamide. Potency range A
Figure imgf000087_0001
To a stirred solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol ( 40 mg, 0.158 mmol) in DMSO (2 ml) was added NaH (14 mg, 0.316 mmol, 60 in mineral oil) at RT in one portion. The suspension was stirred for 2h at RT then 6-chloro-N-methylpyridine-3- carboxamide (54 mg, 0.316 mmol) was added in one portion. The mixture was heated at 80 - 100 0C in a sealed tube over night. After cooling to RT, the solution was partitioned between brine/water (1 :1 mixture, 15 ml) and DCM (20ml). The organic layer was separated, washed with brine (2 x 20 ml), dried (Na2SO4), filtered and concentrated at reduced pressure. The residue was purified by preparative HPLC to provide the title compound as white solid (83 mg, 56% yield). LCMS data: Calculated MH+ (388); Found 100% (MH+) m/z 388, Rt = 2.31 min. 1H NMR (250 MHz, MeOD) δ ppm 8.58 (1 H, s), 8.09 (1 H, d), 6.91 (1 H, d), 5.33 - 5.45 (1 H, m), 4.34 - 4.48 (2 H, m), 3.95 - 4.06 (2 H, m), 3.41 - 3.54 (4 H, m), 2.85 - 3.06 (4 H, m), 2.44 - 2.65 (4 H, m), 2.03 - 2.18 (2 H, m), 1.87 - 1.94 (4 H, m), 1.65 - 1.78 (2 H, m).
The following compounds were made as described in Route 20, General Procedure I above.
Example 4 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)pyridine-2-carboxamide. Potency range A
Figure imgf000087_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (54 mg, 0.21 mmol) and 5-chloropyridine-2-carboxamide (40 mg, 0.26 mmol) gave the title compound as white solid after purification by FCC (20 mg, 26%).
LCMS data: Calculated MH+ (374); Found 100% (MH+) m/z 374, Rt = 2.24 min.
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.25 (1 H, d, J=2.8 Hz), 8.07 (1 H, d, J=8.8
Hz), 7.35 (1 H, dd, J=8.7, 2.8 Hz), 5.08 - 5.19 (1 H, m), 4.46 (2 H, dd, J=9.4, 6.5 Hz), 4.05 (2 H, dd, J=9.7, 3.7 Hz), 3.39 - 3.52 (4 H, m), 2.85 - 2.98 (1 H, m), 2.52 - 2.61 (2 H, m), 2.42 -
2.52 (2 H, m), 2.01 - 2.13 (2 H, m), 1.79 - 1.95 (4 H, m), 1.57 - 1.76 (2 H, m). Example 5 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000088_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and S-chloro-N-methylpyridine^-carboxamide (44 mg, 0.26 mmol) gave the title compound as colourless oil after purification by preparative HPLC (54 mg,
%).
LCMS data: Calculated MH+ (388); Found 100% (MH+) m/z 388, Rt = 2.34 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 8.22 (1 H, d, J=2.7 Hz), 8.03 (1 H, d, J=8.6 Hz), 7.33 (1 H, dd, J=8.8, 2.7 Hz), 5.09 - 5.17 (1 H, m), 4.34 - 4.65 (2 H, m), 3.82 - 4.19 (3 H, m), 3.72 (1 H, quin, J=8.4 Hz), 3.38 - 3.61 (5 H, m), 2.87 - 3.08 (5 H, m), 2.07 - 2.39 (6 H, m), 1.69 - 1.91 (2 H, m).
Example 6 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N,N-dimethylpyridine-2-carboxamide. Potency range A
Figure imgf000088_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and 5-chloro-N,N-dimethylpyridine-2-carboxamide (47 mg, 0.26 mmol) gave the title compound as colourless oil after purification by preparative HPLC (49 mg, 48%).
LCMS data: Calculated MH+ (402); Found 100% (MH+) m/z 402, Rt = 2.27 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 8.21 (1 H, br. s.), 7.61 (1 H, d, J=8.6 Hz), 7.38 (1 H, dd, J=8.7, 2.8 Hz), 5.10 - 5.19 (1 H, m), 4.34 - 4.64 (2 H, m), 3.83 - 4.21 (3 H, m), 3.72 (1 H, quin, J=8.4 Hz), 3.38 - 3.62 (5 H, m), 2.89 - 3.16 (8 H, m), 2.05 - 2.40 (6 H, m), 1.71 - 1.91 (2 H, m).
Example 7 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N,N-diethylpyridine-2-carboxamide. Potency range A
Figure imgf000089_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (104 mg, 0.41 mmol) and 5-chloro-N,N-diethylpyridine-2-carboxamide (105 mg, 0.49 mmol) gave the title compound as colourless oil after purification by FCC (56 mg, 32%). LCMS data: Calculated MH+ (430); Found 97% (MH+) m/z 430, Rt = 2.63 min.
NMR data: 1H NMR (400 MHz, MeOD) δ ppm 8.20 (1 H, d, J=2.7 Hz), 7.56 (1 H, d, J=8.7 Hz), 7.36 (1 H, dd, J=8.7, 2.9 Hz), 5.04 - 5.19 (1 H, m), 4.45 (2 H, dd, J=9.4, 6.5 Hz), 4.04 (2 H, dd, J=9.5, 4.0 Hz), 3.33 - 3.63 (8 H, m), 2.80 - 3.00 (1 H, m), 2.40 - 2.62 (4 H, m), 1.98 - 2.16 (2 H, m), 1.77 - 1.98 (4 H, m), 1.56 - 1.77 (2 H, m), 1.21 (6 H, dt, J=19.9, 7.0 Hz).
Example 8 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylbenzamide. Potency range A
Figure imgf000089_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and 4-fluoro-N-methylbenzamide (48 mg 0.316 mmol) gave the tittle compound as colourless oil after purification by preparative HPLC (11 mg, 18%).
LCMS data: Calculated MH+ (388); Found 100% (MH+) m/z 388, Rt = 2.32 min.
IH NMR (250 MHz, MeOD) δ ppm 8.55 (1 H, s), 8.08 (1 H, d), 6.91 (1 H, d), 5.31 - 5.47 (1
H, m), 4.35 - 4.49 (2 H, m), 3.94 - 4.09 (2 H, m), 3.37 - 3.54 (4 H, m), 2.94 - 3.08 (4 H, m), 2.49 - 2.67 (4 H, m), 2.03 - 2.18 (2 H, m), 1.85 - 1.96 (4 H, m), 1.65 - 1.77 (2 H, m).
Example 9 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N,N-dimethylbenzamide. Potency range A
Figure imgf000089_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and 4-fluoro-N,N-dimethylbenzamide (52 mg 0.316 mmol) gave the tittle compound as colourless oil after purification by preparative HPLC (7 mg, 11%). LCMS data: Calculated MH+ (401); Found 100% (MH+) m/z 401, Rt = 2.51 min. 1H NMR (360 MHz, MeOH) δ ppm 7.41 (2 H, d, J=9.1 Hz), 6.89 (2 H, d, J=8.6 Hz), 5.01 - 5.09 (1 H, m), 4.54 (1 H, t, J=7.5 Hz), 4.30 - 4.46 (1 H, m), 4.04 - 4.18 (1 H, m), 3.82 - 4.04 (2 H, m), 3.62 - 3.79 (1 H, m), 3.36 - 3.61 (5 H, m), 3.05 (8 H, d, J=17.7 Hz), 2.04 - 2.41 (6 H, m), 1.69 - 1.93 (2 H, m).
Example 10 - Preparation of l-cyclobutyl-4-({3-[4-(trifluoromethyl)phenoxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000090_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-fluoro-4-(trifluoromethyl)benzene (26 mg, 0.24 mmol) gave the title compound as colourless oil after purification by preparative HPLC (35 mg, 34%).
LCMS data: Calculated MH+ (398); Found 100% (MH+) m/z 398, Rt = 3.17 min.
NMR data: 1H NMR (400 MHz, MeOD) δ ppm 7.60 (2 H, d, J=8.6 Hz), 6.97 (2 H, d, J=8.6
Hz), 5.04 - 5.12 (1 H, m), 4.32 - 4.63 (2 H, m), 3.85 - 4.18 (3 H, m), 3.72, (1 H, quin, J=8.4 Hz), 3.38 - 3.61 (5 H, m), 2.88 - 3.08 (2 H, m), 2.03 - 2.40 (6 H, m), 1.71 - 1.92 (2 H, m).
Example 11 - Preparation of l-cyclobutyl-4-[(3-{[5-(trifluoromethyl)pyridin-2- yl]oxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000090_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (57 mg, 0.316mmol) gave the title compound as colourless oil after purification by preparative HPLC (15 mg, 24%). LCMS data: Calculated MH+ (399); Found 98% (MH+) m/z 399, Rt = 2.95 min. 1H NMR (400 MHz, MeOD) δ ppm 8.45 (1 H, s), 7.99 (1 H, d, J=8.8 Hz), 7.02 (1 H, d, J=8.8 Hz), 5.36 - 5.48 (1 H, m), 4.43 (2 H, dd), 4.03 (2 H, dd, J=9.5, 4.2 Hz), 3.38 - 3.52 (4 H, m), 2.94 (1 H, qt), 2.55 - 2.65 (2 H, m), 2.47 - 2.54 (2 H, m), 2.04 - 2.13 (2 H, m), 1.84 - 1.95 (4 H, m), 1.62 - 1.75 (2 H, m).
Example 12 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)benzonitrile. Potency range A
Figure imgf000091_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and 4-fluorobenzonitrile (48 mg, 0.4 mmol) gave the title compound as colourless oil after purification by preparative HPLC (36 mg, 39%). LCMS data: Calculated MH+ (355); Found 100% (MH+) m/z 355, Rt = 2.69 min.
NMR data: 1H NMR (400 MHz, MeOD) δ ppm 7.65 - 7.71 (2 H, m), 6.94 - 7.01 (2 H, m), 5.05 - 5.13 (1 H, m), 4.32 - 4.62 (2 H, m), 3.83 - 4.17 (3 H, m), 3.72 (1 H, quin, J=8.4 Hz), 3.37 - 3.61 (5 H, m), 2.89 - 3.10 (2 H, m), 2.04 - 2.40 (6 H, m), 1.70 - 1.91 (2 H, m).
Example 13 - Preparation of l-cyclobutyl-4-{[3-(4-fluorophenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000091_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and 1 ,4-difluorobenzene (56 mg, 0.49 mmol) gave the title compound as colourless oil after purification by preparative HPLC (19 mg, 21%).
LCMS data: Calculated MH+ (348); Found 100% (MH+) m/z 348, Rt = 2.86 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 6.98 - 7.07 (2 H, m), 6.76 - 6.85 (2 H, m), 4.92 - 4.99 (1 H, m), 4.28 - 4.57 (2 H, m), 3.84 - 4.15 (3 H, m), 3.72 (1 H, quin, J=8.4 Hz), 3.37 - 3.61 (5 H, m), 2.89 - 3.08 (2 H, m), 2.03 - 2.40 (6 H, m), 1.71 - 1.93 (2 H, m).
Example 14 - Preparation of l-{[3-(4-chlorophenoxy)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000091_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and l-chloro-4-fluorobenzene (33.7μl, 41mg, 0.316mmol) gave the title compound as colourless oil after purification by FCC (silica, eluting with Heptane/EtOAc 20:80) (47 mg, 84%). LCMS data: Calculated MH+ (364); Found 94% (MH+) m/z 364, Rt = 2.98 min. 1U NMR (400 MHz, MeOD) δ ppm 7.21 - 7.34 (2 H, m), 6.77 - 6.87 (2 H, m), 4.92 - 5.01 (1 H, m), 4.40 (2 H, dd, J=9.3, 6.4 Hz), 3.98 (2 H, dd), 3.37 - 3.53 (4 H, m), 2.80 - 2.96 (1 H, m), 2.52 - 2.62 (2 H, m), 2.42 - 2.50 (2 H, m), 2.01 - 2.13 (2 H, m), 1.79 - 1.93 (4 H, m), 1.61 - 1.74 (2 H, m).
Example 15 - Preparation of l-cyclobutyl-4-[(3-phenoxyazetidin-l-yl)carbonyl]-l,4- diazepane. Potency range A
Figure imgf000092_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and fluorobenzene (20μl, 30mg, 0.316mmol) gave the title compound as colourless oil after purification by preparative HPLC (13 mg, 25%).
LCMS data: Calculated MH+ (330); Found 100% (MH+) m/z 330, Rt = 2.83 min.
1H NMR (360 MHz, MeOH) δ ppm 7.20 - 7.36 (2 H, m), 6.92 - 7.03 (1 H, m), 6.74 - 6.87 (2
H, m), 4.97 - 5.07 (1 H, m), 4.31 - 4.57 (2 H, m), 3.86 - 4.17 (3 H, m), 3.68 - 3.78 (1 H, m), 3.42 - 3.58 (5 H, m), 2.93 - 3.09 (2 H, m), 2.11 - 2.39 (6 H, m), 1.77 - 1.93 (2 H, m).
Example 16 - Preparation of l-cyclobutyl-4-({3-[4-(lH-pyrazol-l- ylmethyl)phenoxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000092_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-(4-fluorobenzyl)-lH-pyrazole (35 mg, 0.19 mmol) gave the title compound as colourless oil after purification by preparative HPLC (42 mg, 40%). LCMS data: Calculated MH+ (410); Found 100% (MH+) m/z 410, Rt = 2.76 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 7.66 (1 H, d, J=2.2 Hz), 7.51 (1 H, d, J=I.7 Hz), 7.19 (2 H, d, J=8.6 Hz), 6.78 (2 H, d, J=8.6 Hz), 6.31 (1 H, t, J=2.0 Hz), 5.27 (2 H, s), 4.98 (1 H, tt, J=6.4, 3.9 Hz), 4.26 - 4.56 (2 H, m), 3.82 - 4.15 (3 H, m), 3.71 (1 H, quin, J=8.4 Hz), 3.49 (5 H, d, J=I LO Hz), 2.97 (2 H, d, J=9.8 Hz), 2.04 - 2.39 (6 H, m), 1.71 - 1.91 (2 H, m).
Example 17 - Preparation of l-cyclobutyl-4-[(3-{[5-(lH-pyrazol-l-ylmethyl)pyridin-2- yl]oxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000093_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and 2-chloro-5-(lH-pyrazol-l-ylmethyl)pyridine (35 mg, 0.19 mmol) gave the title compound as colourless oil after purification on silica gel (50 mg, 62%). LCMS data: Calculated MH+ (411); Found 100% (MH+) m/z 411, Rt = 2.57 min.
NMR data: 1H NMR (360 MHz, MeOH) δ ppm 8.04 (1 H, d, J=I.8 Hz), 7.71 (1 H, d, J=I.8 Hz), 7.60 (1 H, dd, J=8.6, 2.7 Hz), 7.51 (1 H, s), 6.81 (1 H, d, J=8.6 Hz), 6.32 (1 H, t, J=2.0 Hz), 5.24 - 5.35 (3 H, m), 4.38 (2 H, dd, J=10.0, 6.8 Hz), 3.97 (2 H, dd, J=10.0, 4.5 Hz), 3.36 - 3.47 (4 H, m), 2.82 - 2.95 (1 H, m), 2.50 - 2.57 (2 H, m), 2.41 - 2.48 (2 H, m), 1.99 - 2.11 (2 H, m), 1.77 - 1.93 (4 H, m), 1.57 - 1.75 (2 H, m).
Example 18 - Preparation of l-[4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}oxy)phenyl]pyrrolidin-2-one. Potency range A
Figure imgf000093_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-(4-fluorophenyl)pyrrolidin-2-one (35 mg, 0.19 mmol) gave the title compound as colourless oil after purification on silica gel (50 mg, 62%). LCMS data: Calculated MH+ (413); Found 100% (MH+) m/z 413, Rt = 2.65 min. NMR data: 1H NMR (360 MHz, MeOH) δ ppm 8.04 (1 H, d, J=I.8 Hz), 7.71 (1 H, d, J=I.8 Hz), 7.60 (1 H, dd, J=8.6, 2.7 Hz), 7.51 (1 H, s), 6.81 (1 H, d, J=8.6 Hz), 6.32 (1 H, t, J=2.0 Hz), 5.24 - 5.35 (3 H, m), 4.38 (2 H, dd, J=10.0, 6.8 Hz), 3.97 (2 H, dd, J=10.0, 4.5 Hz), 3.36 - 3.47 (4 H, m), 2.82 - 2.95 (1 H, m), 2.50 - 2.57 (2 H, m), 2.41 - 2.48 (2 H, m), 1.99 - 2.11 (2 H, m), 1.77 - 1.93 (4 H, m), 1.57 - 1.75 (2 H, m).
Example 19 - Preparation of l-cyclobutyl-4-({3-[4-(piperidin-l- ylmethyl)phenoxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000093_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (60 mg, 0.24 mmol) and l-(4-fluorobenzyl)piperidine (55 mg, 0.28 mmol) gave the title compound as colourless oil after purification by preparative HPLC (22 mg, 17%). LCMS data: Calculated MH+ (427); Found 100% (MH+) m/z 427, Rt = 2.17 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.44 (2 H, d, J=8.7 Hz), 6.92 (2 H, d, J=8.8 Hz), 4.98 - 5.10 (1 H, m), 4.31 - 4.62 (2 H, m), 4.22 (2 H, s), 3.32 - 4.16 (11 H, m), 2.80 - 3.13 (4 H, m), 2.08 - 2.44 (6 H, m), 1.36 - 2.01 (8 H, m).
Example 20 - Preparation of l-cyclobutyl-4-[(3-{4-[(4-methylpiperazin-l- yl)methyl]phenoxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000094_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (60 mg, 0.24 mmol) and l-(4-fluorobenzyl)-4-methylpiperazine (59 mg, 0.28 mmol) gave the title compound as colourless oil after purification by preparative HPLC (33 mg, 25%). LCMS data: Calculated MH+ (442); Found 100% (MH+) m/z 442, Rt = 1.91 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.29 - 7.38 (2 H, m), 6.78 - 6.88 (2 H, m), 4.94 - 5.05 (1 H, m), 4.28 - 4.61 (2 H, m), 3.36 - 4.17 (12 H, m), 2.67 - 3.23 (10 H, m), 2.04 - 2.42 (6 H, m), 1.67 - 1.96 (2 H, m).
Example 21 - Preparation of l-cyclobutyl-4-[(3-{4-[(4,4-difluoropiperidin-l- yl)methyl]phenoxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000094_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (60 mg, 0.24 mmol) and 4,4-difluoro-l-(4-fluorobenzyl)piperidine (65 mg, 0.28 mmol) gave the title compound as colourless oil after purification by preparative HPLC (25 mg, 18%).
LCMS data: Calculated MH+ (463); Found 100% (MH+) m/z 463, Rt = 2.17 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.41 - 7.50 (2 H, m), 6.88 - 6.98 (2 H, m), 4.98 - 5.10 (1 H, m), 4.26 - 4.63 (4 H, m), 3.33 - 4.18 (12 H, m), 2.77 - 3.27 (3 H, m), 2.02 - 2.50 (10 H, m), 1.65 - 1.96 (2 H, m). Example 22 - Preparation of l-({3-[(5-bromopyridin-2-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000095_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (100 mg, 0.395 mmol) and 5-bromo-2-fluoropyridine (81μl, 139 mg, 0.79 mmol) gave the title compound (89 mg, 54%) as off white solid after purification by FCC (silica, using a gradient of eluents; EtOAc/MeOH/NH3 100:0:0 to 80:20:1). LCMS data: Calculated MH+ (410); Found 100% (MH+) m/z 410, Rt = 2.83 min. 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 8.14 (1 H, d, J=2.6 Hz), 7.68 (1 H, dd, J=8.7, 2.6 Hz), 6.70 (1 H, d, J=8.7 Hz), 5.22 - 5.33 (1 H, m), 4.34 (2 H, dd, J=9.5, 6.6 Hz), 3.99 (2 H, dd, J=9.9, 4.7 Hz), 2.85 (1 H, t, J=7.6 Hz), 2.34 - 2.60 (4 H, m), 1.51 - 2.11 (12 H, m).
Example 23 - Preparation of l-cyclobutyl-4-{[3-(3,4-dichlorophenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000095_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and l,2-dichloro-4-fluorobenzene (37 μl, 52 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (14 mg, 23%). LCMS data: Calculated MH+ (398); Found 100% (MH+) m/z 398, Rt = 3.06 min. iH NMR (250 MHz, MeOD) δ ppm 7.43 (1 H, d, J=8.8 Hz), 7.01 (1 H, d, J=2.9 Hz), 6.79 (1 H, dd, J=8.8, 2.9 Hz), 4.95 - 5.06 (1 H, m), 4.24 - 4.60 (2 H, m), 3.81 - 4.17 (3 H, m), 3.71 (1 H, t, J=8.3 Hz), 3.37 - 3.62 (5 H, m), 2.81 - 3.20 (2 H, m), 2.00 - 2.46 (6 H, m), 1.65 - 1.97 (2 H, m).
Example 24 - Preparation of l-({3-[(6-bromopyridin-3-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000095_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (100 mg, 0.398 mmol) and 2-bromo-5-fluoropyridine (139 mg, 0.79 mmol) gave the title compound as off white solid after purification by FCC (silica, using a gradient of eluents; EtOAc/MeOH/NHs 100:0:0 to 80:20:1), followed by trituration with diethyl ether (106mg, 65%).
LCMS data: Calculated MH+ (410); Found 100% (MH+) m/z 410, Rt = 2.67 min. 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 7.91 (1 H, d, J=3.2 Hz), 7.40 (1 H, d, J=8.7 Hz), 6.99 (1 H, dd, J=8.7, 3.2 Hz), 4.84 - 4.99 (1 H, m), 4.28 - 4.41 (2 H, m), 4.04 (2 H, dd, J=9.7, 4.1 Hz), 3.33 - 3.52 (4 H, m), 2.77 - 2.90 (1 H, m), 2.37 - 2.58 (4 H, m), 1.95 - 2.12 (2 H, m), 1.75 - 1.94 (4 H, m), 1.65 - 1.72 (2 H, m).
Example 25 - Preparation of l-{[3-(4-chloro-2-methylphenoxy)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000096_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and 4-chloro-l-fluoro-2-methylbenzene (43 mg, 0.29 mmol) gave the title compound as colourless oil after purification by preparative HPLC (59 mg, 60%).
LCMS data: Calculated MH+ (378); Found 100% (MH+) m/z 378, Rt = 3.12 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.00 - 7.21 (2 H, m), 6.48 - 6.66 (1 H, m),
5.00 - 5.05 (1 H, m), 4.26 - 4.60 (2 H, m), 3.35 - 4.18 (9 H, m), 3.00 (2 H, br. s.), 2.03 - 2.42
(9 H, m), 1.82 (2 H, m).
Example 26 - Preparation of l-cyclobutyl-4-({3-[4-(lH-imidazol-l-yl)phenoxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000096_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-(4-fluorophenyl)-lH-imidazole (48 mg, 0.29 mmol) gave the title compound as colourless oil after purification by preparative HPLC (49 mg, 49%). LCMS data: Calculated MH+ (396); Found 100% (MH+) m/z 396, Rt = 1.92 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 9.35 (1 H, t, J=I.4 Hz), 7.98 (1 H, t, J=I.8 Hz), 7.71 - 7.79 (1 H, m), 7.61 - 7.71 (2 H, m), 7.02 - 7.12 (2 H, m), 5.11 (1 H, tt, J=6.4, 4.0 Hz), 4.49 (2 H, br. s.), 3.33 - 4.33 (9 H, m), 2.80 - 3.28 (2 H, m), 2.09 - 2.42 (6 H, m), 1.70 1.95 (2 H, m).
Example 27 - Preparation of l-cyclobutyl-4-({3-[(2-methylpyridin-4-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000097_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and 4-chloro-2-methylpyridine (33 mg, 0.26 mmol) gave the title compound as colourless oil after purification on silica gel (27 mg, 40%). LCMS data: Calculated MH+ (345); Found 100% (MH+) m/z 345, Rt = 0.65 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 8.23 (1 H, d, J=5.9 Hz), 6.77 (1 H, d, J=2.4 Hz), 6.72 (1 H, dd, J=5.8, 2.4 Hz), 5.08 (1 H, tt, J=6.5, 4.0 Hz), 4.37 - 4.50 (2 H, m), 3.95 - 4.06 (2 H, m), 3.37 - 3.51 (4 H, m), 2.82 - 2.97 (1 H, m), 2.51 - 2.60 (2 H, m), 2.41 - 2.51 (5 H, m), 1.98 - 2.15 (2 H, m), 1.77 - 1.96 (4 H, m), 1.57 - 1.76 (2 H, m).
Example 28 - Preparation of l-cyclobutyl-4-({3-[3-(trifluoromethyl)phenoxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000097_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and l-fluoro-3-(trifluoromethyl)benzene (52 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (25 mg, 31%).
LCMS data: Calculated MH+ (398); Found 100% (MH+) m/z 398, Rt = 3.02 min.
1H NMR (360 MHz, MeOH) δ ppm 7.45 - 7.55 (1 H, m), 7.29 (1 H, d, J=7.7 Hz), 7.09 (2 H, br. s.), 5.06 - 5.12 (1 H, m), 4.51 - 4.59 (1 H, m), 4.36 - 4.43 (1 H, m), 4.09 - 4.16 (1 H, m), 3.88 - 4.02 (2 H, m), 3.68 - 3.76 (1 H, m), 3.40 - 3.57 (5 H, m), 2.93 - 3.07 (2 H, m), 2.06 -
2.36 (6 H, m), 1.75 - 1.92 (2 H, m).
Example 29 - Preparation of l-cyclobutyl-4-({3-[2-(trifluoromethyl)phenoxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000098_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and l-fluoro-2-(trifluoromethyl)benzene (52 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (27 mg, 33%). LCMS data: Calculated MH+ (398); Found 100% (MH+) m/z 398, Rt = 2.99 mins.
1H NMR (360 MHz, MeOH) δ ppm 7.50 - 7.65 (2 H, m), 7.12 (1 H, t, J=7.5 Hz), 6.90 (1 H, d, J=8.6 Hz), 5.08 - 5.17 (1 H, m), 4.53 - 4.61 (1 H, m), 4.36 - 4.46 (1 H, m), 4.09 - 4.18 (1 H, m), 3.87 - 4.04 (2 H, m), 3.64 - 3.77 (1 H, m), 3.40 - 3.60 (5 H, m), 2.88 - 3.09 (2 H, m), 2.08 - 2.37 (6 H, m), 1.73 - 1.91 (2 H, m).
Example 30 - Preparation of 3-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)benzonitrile. Potency range A
Figure imgf000098_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and 3-fluorobenzonitrile (38 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (19 mg, 26%).
LCMS data: Calculated MH+ (355); Found 100% (MH+) m/z 355, Rt = 2.66 min.
1H NMR (360 MHz, MeOH) δ ppm 7.42 - 7.54 (1 H, m), 7.36 (1 H, d, J=7.3 Hz), 7.13 - 7.20
(2 H, m), 5.02 - 5.11 (1 H, m), 4.32 - 4.61 (2 H, m), 3.86 - 4.18 (3 H, m), 3.72 (1 H, q), 3.40 - 3.60 (5 H, m), 2.87 - 3.10 (2 H, m), 2.07 - 2.39 (6 H, m), 1.70 - 1.92 (2 H, m).
Example 31 - Preparation of 2-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)benzonitrile. Potency range A
Figure imgf000098_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and 2-fluorobenzonitrile (38 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (21 mg, 26%). LCMS data: Calculated MH+ (355); Found 100% (MH+) m/z 355, Rt = 2.65 min. 1H NMR (360 MHz, MeOH) δ ppm 7.56 - 7.72 (1 H, m), 7.06 - 7.18 (1 H, m), 6.92 (1 H, d, J=8.2 Hz), 5.10 - 5.19 (1 H, m), 4.51 - 4.62 (1 H, m), 4.38 - 4.47 (1 H, m), 4.11 - 4.24 (1 H, m), 4.01 - 4.08 (1 H, m), 3.90 - 3.97 (1 H, m), 3.68 - 3.75 (1 H, m), 3.40 - 3.58 (5 H, m), 2.91 - 3.10 (2 H, m), 2.04 - 2.40 (6 H, m), 1.77 - 1.90 (2 H, m).
Example 32 - Preparation of l-{[3-(3-chlorophenoxy)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000099_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and l-chloro-3-fluorobenzene (48 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (33 mg, 44%). LCMS data: Calculated MH+ (364); Found 100% (MH+) m/z 364, Rt = 2.95 min. 1H NMR (360 MHz, MeOH) δ ppm 7.22 - 7.33 (1 H, m), 6.96 - 7.05 (1 H, m), 6.86 (1 H, s), 6.71 - 6.81 (1 H, m), 4.97 - 5.07 (1 H, m), 4.45 - 4.60 (1 H, m), 4.28 - 4.44 (1 H, m), 4.04 - 4.16 (1 H, m), 3.86 - 4.01 (2 H, m), 3.68 - 3.78 (1 H, m), 3.43 - 3.61 (5 H, m), 2.95 - 3.06 (2 H, m), 2.10 - 2.39 (6 H, m), 1.72 - 1.91 (2 H, m).
Example 33 - Preparation of l-{[3-(2-chlorophenoxy)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000099_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.158 mmol) and l-chloro-2-fluorobenzene (48 mg, 0.316 mmol) gave the title compound as colourless oil after purification by preparative HPLC (5 mg, 7%). LCMS data: Calculated MH+ (364); Found 100% (MH+) m/z 364, Rt = 2.92 min.
1H NMR (360 MHz, MeOH) δ ppm 7.40 (1 H, d, J=7.7 Hz), 7.25 (1 H, t, J=7.9 Hz), 6.97 (1 H, t, J=7.7 Hz), 6.80 (1 H, d, J=8.6 Hz), 5.02 - 5.11 (1 H, m), 4.50 - 4.59 (1 H, m), 4.35 - 4.44 (1 H, m), 4.11 - 4.19 (1 H, m), 3.98 - 4.06 (1 H, m), 3.88 - 3.96 (1 H, m), 3.73 (1 H, q), 3.40 - 3.58 (5 H, m), 2.93 - 3.07 (2 H, m), 2.16 - 2.40 (6 H, m), 1.74 - 1.92 (2 H, m). Example 34 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N,3-dimethylbenzamide. Potency range A
Figure imgf000100_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1 ,4-diazepan- lyl)carbonyl]azetidin-3- ol (40 mg, 0.16 mmol) and 4-fluoro-N,3-dimethylbenzamide (54 mg, 0.32 mmol) gave the title compound as colourless oil after purification on silica gel (24 mg, 38 %). LCMS data: Calculated MH+ (401); Found 100% (MH+) m/z 401, Rt = 2.35 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 7.52 - 7.60 (2 H, m), 6.43-6.49 (1 H, d, J=10.8 Hz), 5.99 - 6.06 (IH, m), 4.88 - 4.98 (1 H, m), 4.35 (2 H, dd,, J=9.4, 6.6 Hz), 4.05 (2 H, dd, J=9.5, 4.3 Hz), 3.37 - 3.51 (5H, m), 3.00 (3H, d, NCH3), 2.76 - 2.92 (IH, m), 2.48 - 2.57 (2H, m), 2.39 - 2.47 (2H, m), 2.63 (3H, s), 1.96 - 2.10 (2H, m), 1.55 - 1.94 (8H, m).
Example 35 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-(cyclopropylmethyl)pyridine-2-carboxamide. Potency range A
Figure imgf000100_0002
In a similar fashion (Route 20, GP I; except using DMF instead of DMSO as solvent), l-[(4- cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.20 mmol) and 5-chloro-N- (cyclopropylmethyl)pyridine-2-carboxamide (84 mg, 0.40 mmol) gave the title compound as colourless oil (25 mg, 0.48 mmol, 0.047 mmol, 23%) after purification by preparative HPLC. LCMS data: Calculated MH+ (428); Found 100 % (MH+) m/z 428, Rt = 2.81 min.
NMR data: 1H NMR (500 MHz, Chloroform-^) δ ppm 11.42 - 11.61 (1 H, m), 7.99 (1 H, d, J=2.7 Hz), 7.87 (1 H, t, J=5.3 Hz), 6.98 (1 H, dd, J=8.7, 2.7 Hz), 5.06 (3 H, br. s.), 4.86 - 4.92 (1 H, m), 4.37 - 4.47 (2 H, m), 4.13 - 4.22 (1 H, m), 4.04 - 4.12 (1 H, m), 3.84 (2 H, br. s.), 3.36 - 3.51 (3 H, m), 3.27 - 3.35 (2 H, m), 3.19 (3 H, t, J=6.4 Hz), 2.74 (1 H, br. s.), 2.28 - 2.55 (4 H, m), 2.11 (3 H, d, J=6.5 Hz), 1.77 (1 H, q, J=10.2 Hz), 1.52 - 1.66 (1 H, m), 0.86 - 1.00 (1 H, m), 0.38 - 0.49 (2 H, m), 0.11 - 0.21 (2 H, m).
Example 36 - Preparation of l-cyclobutyl-4-[(3-{[5-(trifluoromethyl)pyridin-3- yl]oxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000101_0001
In similar fashion (Route 7 GP H), l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.20 mmol) and 5-Bromo-2-trifluoromethylpyridine (59 mg, 0.26 mmol) gave the title compound (16 mg, 0.031 mmol, 16%) as colourless oil after purification by preparative HPLC.
LCMS data: Calculated MH+ (399); Found 100% (MH+) m/z 399, Rt = 2.81 min. NMR data: 1H NMR (500 MHz, MeOD-J) δ ppm 8.32 (1 H, d, J=2.7 Hz), 7.77 (1 H, d, J=8.7 Hz), 7.42 (1 H, dd, J=8.6, 2.6 Hz), 5.14 - 5.21 (1 H, m), 4.54 - 4.61 (1 H, m), 4.38 - 4.47 (1 H, m), 4.11 - 4.20 (1 H, m), 4.00 - 4.08 (1 H, m), 3.88 - 3.97 (1 H, m), 3.72 (1 H, quin, J=8.4 Hz), 3.39 - 3.61 (5 H, m), 3.00 (2 H, m, J=10.9 Hz), 2.30 - 2.40 (2 H, m), 2.18 - 2.30 (3 H, m), 2.05 - 2.18 (1 H, m), 1.73 - 1.93 (2 H, m).
Example 37 - Preparation of 5-({l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000101_0002
In a similar fashion (Route 20, GP I; except using DMF instead of DMSO as solvent), l-[(4- cyclobutylpiperazin-l-yl)carbonyl]azetidin-3-ol (150 mg, 0.63 mmol) and 5-chloro-N- methylpyridine-2-carboxamide (214 mg, 1.26 mmol) gave the title compound (156 mg, 0.42 mmol, 66%) as white solid after purification by FCC [SiO2 eluting with DCM/MeOH/NH3 98:2:0.5).
LCMS data: Calculated MH+ (374); Found 100% (MH+) m/z 374, Rt = 2.35 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.24 (1 H, d, J=2.7 Hz), 8.04 (1 H, d, J=8.7 Hz), 7.34 (1 H, dd, J=8.7, 2.8 Hz), 5.12 - 5.18 (1 H, m), 4.53 - 4.60 (1 H, m), 4.39 - 4.46 (1 H, m), 4.11 - 4.18 (1 H, m), 3.97 - 4.06 (1 H, m), 3.84 - 3.94 (1 H, m), 3.41 - 3.63 (5 H, m), 3.17 - 3.29 (2 H, m), 2.94 (6 H, d, J=5.2 Hz), 1.98 - 2.30 (2 H, m).
Example 38 - Preparation of l-cyclobutyl-4-[(3-phenoxyazetidin-l- yl)carbonyl]piperazine. Potency range A
Figure imgf000102_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3-ol (40 mg, 0.167 mmol) and 4-fluorobenzene (32 mg, 0.334 mmol) gave the title compound (11.1 mg, 15%) as colourless oil after purification by preparative HPLC. LCMS data: Calculated MH+ (316); Found 100% (MH+) m/z 316, Rt = 2.66 min.
1H NMR (360 MHz, MeOD) δ ppm 7.29 (2 H, t, J=7.9 Hz), 6.97 (1 H, t, J=7.3 Hz), 6.80 (2 H, d, J=8.2 Hz), 4.98 - 5.05 (1 H, m), 4.47 (2 H, dd, J=9.5, 6.4 Hz), 4.06 (4 H, dd, J=9.3, 3.9 Hz), 3.64 - 3.76 (1 H, m), 3.43 - 3.53 (2 H, m), 3.13 - 3.22 (2 H, m), 2.81 - 2.93 (2 H, m), 2.30 - 2.39 (2 H, m), 2.19 - 2.28 (2 H, m), 1.84 - 1.95 (2 H, m).
Example 39 - Preparation of l-cyclobutyl-4-({3-[4-(trifluoromethyl)phenoxy]azetidin-l- yl}carbonyl)piperazine. Potency range A
Figure imgf000102_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3-ol (40 mg, 0.167 mmol) and l-fluoro-4-(trifluoromethyl)benzene (55 mg, 0.334 mmol) gave the title compound (14.5 mg, 18%) as colourless oil after purification by preparative HPLC.
LCMS data: Calculated MH+ (384); Found 100% (MH+) m/z 384, Rt = 3.12 min.
1H NMR (360 MHz, MeOD) δ ppm 7.61 (2 H, d, J=8.2 Hz), 6.97 (2 H, d, J=8.6 Hz), 5.06 -
5.14 (1 H, m), 4.50 (2 H, dd, J=9.5, 6.4 Hz), 3.93 - 4.16 (4 H, m), 3.63 - 3.76 (1 H, m), 3.36 - 3.49 (2 H, m), 3.11 - 3.22 (2 H, m), 2.81 - 2.92 (2 H, m), 2.32 - 2.38 (2 H, m), 2.23 - 2.26 (2
H, m), 1.79 - 1.97 (2 H, m).
Example 40 - Preparation of 4-({l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3- yl}oxy)benzonitrile. Potency range A
Figure imgf000102_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3-ol
(40 mg, 0.167 mmol) and 4-fluorobenzonitrile (40 mg, 0.334 mmol) gave the title compound (14.8 mg, 19%) as colourless oil after purification by preparative HPLC. LCMS data: Calculated MH+ (341); Found 100% (MH+) m/z 341, Rt = 2.56 min. 1H NMR (360 MHz, MeOD) δ ppm 7.69 (2 H, d, J=8.2 Hz), 6.98 (2 H, d, J=8.6 Hz), 5.08 - 5.15 (1 H, m), 4.45 - 4.53 (2 H, m), 3.99 - 4.12 (4 H, m), 3.64 - 3.73 (1 H, m), 3.39 - 3.55 (2 H, m), 3.09 - 3.24 (2 H, m), 2.82 - 2.94 (2 H, m), 2.28 - 2.41 (2 H, m), 2.20 - 2.27 (2 H, m), 1.81 - 1.95 (2 H, m).
Example 41 - Preparation of l-cyclobutyl-4-{[3-(4-fluorophenoxy)azetidin-l- yl]carbonyl}piperazine. Potency range A
Figure imgf000103_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclobutylpiperazin-l-yl)carbonyl]azetidin-3-ol (40 mg, 0.167 mmol) and 1 ,4-difluorobenzene (38 mg, 0.334 mmol) gave the title compound (12.9 mg, 18%) as colourless oil after purification by preparative HPLC. LCMS data: Calculated MH+ (334); Found 100% (MH+) m/z 334, Rt = 2.70 min. 1H NMR (360 MHz, MeOD) δ ppm 7.03 (2 H, t, J=8.9 Hz), 6.80 (2 H, dd, J=9.1, 4.5 Hz), 4.95 - 5.01 (1 H, m), 4.46 (2 H, dd, J=9.3, 6.6 Hz), 4.04 (4 H, dd, J=9.3, 3.9 Hz), 3.64 - 3.75 (1 H, m), 3.37 - 3.54 (2 H, m), 3.10 - 3.25 (2 H, m), 2.80 - 2.98 (2 H, m), 2.18 - 2.38 (4 H, m), 1.80 - 1.96 (2 H, m).
Example 42 - Preparation of 6-cyclobutyl-2-({l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)-5,6,7,8-tetrahydro-l,6-naphthyridine. Potency range A
Figure imgf000103_0002
In a similar fashion (Route 20, GP I), (4-cyc Io butyl- 1,4-diazepan-l -yl)(3-hy droxyazetidin-1 - yl)methanone (40 mg, 0.16 mmol) and 2-chloro-6-cyclobutyl-5,6,7,8-tetrahydro-l,6- naphthyridine (39 mg, 0.17 mmol) gave the title compound as colourless oil after purification by FCC on silica (5.6 mg, 8 %).
LCMS data: Calculated MH+ (440); Found 100% (MH+) m/z 440, Rt = 4.87 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.25 (IH, d, J=8.3), 6.54 (IH, d, J=8.3), 5.34- 5.28 (IH, m), 4.34 (2H, dd, J=9.5 and 6.9 Hz), 3.98 (2H, dd, J= 9.7 and 4.5 Hz), 3.51-3.38 (5H, m), 2.65 (2H, t, J=6.1 Hz), 2.57-2.41 (4H, m), 2.19-1.58 (13H, m). Example 43 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-3-fluoro-N-methylbenzamide. Potency range A
Figure imgf000104_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (40 mg, 0.16 mmol) and 3,4-difluoro-iV-methylbenzamide (54 mg, 0.32 mmol) gave the title compound as colourless oil after purification by preparative HPLC (2.2 mg, 3 %). LCMS data: Calculated MH+ (405); Found 100% (MH+) m/z 405, Rt = 2.27 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 7.37 - 7.53 (2 H, m), 6.58 - 6.67 (1 H, m), 6.01 - 6.12 (IH, m), 4.88 - 5.00 (1 H, m), 4.08 - 4.52 (9 H, m), 3.81 - 3.99 (2 H, m), 3.18 - 3.58 (7H, m), 2.92 (3H, d), 2.28 - 2.61 (2H, m), 1.78 - 2.26 (IH, m).
Example 44 - Preparation of l-cyclobutyl-4-{[3-(4-iodophenoxy)azetidin-l-yl]carbonyl}- 1,4-diazepane. Potency range A
Figure imgf000104_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (300 mg, 1.19 mmol) and l-fluoro-4-iodobenzene (184 μl, 1.78 mmol) gave the title compound as an off-white solid after purification by silica FCC (200 mg, 37%). LCMS data: Calculated MH+ (456); Found 94% (MH+) m/z 456, Rt = 3.13 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.56 (2 H, d, J=8.8 Hz), 6.53 (2 H, d, J=8.8 Hz), 4.81 - 4.88 (1 H, m), 4.32 (2 H, m), 4.01 (2 H, m), 3.37 - 3.48 (4 H, m), 2.84 (1 H, m), 2.46 - 2.55 (2 H, m), 2.37 - 2.46 (2 H, m), 1.97 - 2.09 (2 H, m), 1.56 - 1.91 (6 H, m).
Example 45 - Preparation of l-cyclobutyl-4-({3-[(5-fluoropyridin-3-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000104_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (35 mg, 0.14 mmol) and 3,5-difluoropyridine (38 μl, 0.42 mmol) gave the title compound as colourless oil after purification by preparative HPLC as the TFA salt (29 mg, 44%). LCMS data: Calculated MH+ (349); Found 100% (MH+) m/z 349, Rt = 2.33 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.19 (1 H, m), 8.12 (1 H, m), 7.29 (1 H, dt, J=10.3, 2.3 Hz), 5.08 - 5.18 (1 H, m), 4.48 - 4.63 (1 H, m), 4.34 - 4.47 (1 H, m), 4.07 - 4.20 (1 H, m), 3.83 - 4.07 (2 H, m), 3.66 - 3.77 (1 H, m), 3.37 - 3.62 (5 H, m), 2.88 - 3.08 (2 H, m), 2.07 - 2.40 (6 H, m), 1.70 - 1.92 (2 H, m).
Example 46 - l-({3-[(6-chloropyridin-3-yl)oxy]azetidin-l-yl}carbonyl)-4-cyclobutyl-l,4- diazepane. Potency range A
Figure imgf000105_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol and 2-chloro-5-fluoropyridine gave the title compound as the TFA salt (31 mg, 48%). LCMS data: Calculated MH+ (365); Found 100% (MH+) m/z 365, Rt = 2.45 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 7.97 (1 H, d, J=2.9 Hz), 7.36 - 7.41 (1 H, m), 7.30 - 7.36 (1 H, m), 5.04 - 5.11 (1 H, m), 4.46 - 4.59 (1 H, m), 4.32 - 4.46 (1 H, m), 4.06 - 4.17 (1 H, m), 3.84 - 4.05 (2 H, m), 3.67 - 3.77 (1 H, m), 3.37 - 3.61 (5 H, m), 2.98 (2 H, d, J=12.5 Hz), 2.05 - 2.39 (6 H, m), 1.72 - 1.91 (2 H, m).
Example 47 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-2-fluoro-N-methylbenzamide. Potency range A
Figure imgf000105_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (125 mg, 0.20 mmol) and 2,4-difluoro-N-methylbenzamide (171 mg, 0.22 mmol) gave the title compound as colourless oil after purification by preparative HPLC as the TFA salt (46 mg, 44%). LCMS data: Calculated MH+ (405); Found 95% (MH+) m/z 405, Rt = 2.33 min.
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 7.84 (1 H, dd, J=8.5, 6.9 Hz), 6.76 - 6.87 (1 H, m), 6.61 (1 H, dd, J=10.5, 2.0 Hz), 5.08 - 5.15 (1 H, m), 4.48 - 4.62 (1 H, m), 4.34 - 4.47 (1 H, m), 4.13 - 4.25 (1 H, m), 4.01 - 4.12 (1 H, m), 3.86 - 4.00 (1 H, m), 3.65 - 3.77 (1 H, m), 3.38 - 3.61 (5 H, m), 2.86 - 3.07 (5 H, m), 2.08 - 2.39 (6 H, m), 1.70 - 1.90 (2 H, m). Example 48 - Preparation of l-({3-[(4-chloropyridin-3-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000106_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (44 mg, 0.17 mmol) and 4-chloro-3-fluoropyridine (21 μl, 0.20 mmol) gave the title compound as colourless oil after purification by preparative HPLC and SCX (22 mg, 37%). LCMS data: Calculated MH+ (365); Found 95% (MH+) m/z 365, Rt = 3.98 mins (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.13 - 8.21 (1 H, m), 8.05 - 8.13 (1 H, m), 7.54 (1 H, d, J=5.0 Hz), 5.16 - 5.25 (1 H, m), 4.49 (2 H, dd, J=9.5, 6.6 Hz), 4.11 (2 H, dd, J=9.6, 3.8 Hz), 3.42 - 3.65 (4 H, m), 3.30 (1 H, m), 2.70 - 3.02 (4 H, m), 2.13 - 2.27 (2 H, m), 1.94 - 2.12 (4 H, m), 1.67 - 1.85 (2 H, m).
Example 49 - Preparation of l-cyclobutyl-4-({3-[(3-fluoropyridin-4-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000106_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (44 mg, 0.17 mmol) and 4-chloro-3-fluoropyridine (21 μl, 0.20 mmol) gave the title compound as colourless oil after purification by preparative HPLC as the free base (4 mg,
70,
LCMS data: Calculated MH+ (349); Found 99% (MH+) m/z 349, Rt = 3.59 mins (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.32 - 8.41 (1 H, m), 8.19 - 8.29 (1 H, m), 6.93 - 7.03 (1 H, m), 5.14 - 5.25 (1 H, m), 4.43 - 4.54 (2 H, m), 4.04 - 4.15 (2 H, m), 3.42 - 3.68 (5 H, m), 2.65 - 3.07 (4 H, m), 2.15 - 2.29 (2 H, m), 1.93 - 2.14 (4 H, m), 1.66 - 1.87 (2 H, m).
Example 50 - Preparation of l-({3-[(4-chloro-2-methylpyridin-3-yl)oxy]azetidin-l- yl}carbonyl)-4-cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000107_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (45 mg, 0.17 mmol) and 4-chloro-3-fluoro-2-methylpyridine (31 mg, 0.21 mmol) gave the title compound as colourless oil after purification by preparative HPLC (8 mg, 13%). LCMS data: Calculated MH+ (378); Found 100% (MH+) m/z 378, Rt = 2.25 mins (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.24 - 8.33 (1 H, m), 7.64 - 7.74 (1 H, m), 4.93 - 5.02 (1 H, m), 4.43 - 4.56 (1 H, m), 4.28 - 4.42 (2 H, m), 4.15 - 4.29 (1 H, m), 3.87 - 4.00 (1 H, m), 3.66 - 3.79 (1 H, m), 3.38 - 3.61 (5 H, m), 2.98 (2 H, m), 2.62 (3 H, s), 2.04 - 2.41 (6 H, m), 1.74 - 1.92 (2 H, m).
Example 51 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)imidazo[l,5-a]pyridine. Potency range A
Figure imgf000107_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (60 mg, 0.24 mmol) and 5-chloroimidazo[l,2-a]pyridine (43 mg, 0.28 mmol) gave the title compound as a colourless oil after purification by silica FCC (45 mg, 50%). LCMS data: Calculated MH+ (370); Found 100% (MH+) m/z 370, Rt = 3.53 min (High pH method). NMR data: 1H NMR (500 MHz, MeOD) δ ppm 7.68 (1 H, s), 7.61 (1 H, s), 7.26 - 7.35 (1 H, m), 7.14 (1 H, dd, J=8.9, 7.4 Hz), 5.76 (1 H, d, J=7.5 Hz), 5.07 - 5.19 (1 H, m), 4.44 (2 H, dd, J=9.8, 6.6 Hz), 4.18 (2 H, dd, J=9.8, 4.1 Hz), 3.34 - 3.54 (4 H, m), 2.84 (1 H, quin, J=7.9 Hz), 2.48 - 2.58 (2 H, m), 2.23 - 2.39 (2 H, m), 1.97 - 2.11 (2 H, m), 1.75 - 1.94 (4 H, m), 1.54 - 1.74 (2 H, m).
Example 52 - Preparation of l-cyclobutyl-4-({3-[(2-methoxypyrimidin-4-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000107_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (333 mg, 1.31 mmol) and 4-chloro-2-methoxypyrimidine (377 mg, 2.63 mmol) in THF (10 ml) gave the title compound as an orange oil after purification by silica FCC (309 mg, 65%). LCMS data: Calculated MH+ (362); Found 100% (MH+) m/z 362, Rt = 3.69 min (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.23 (1 H, d, J=5.6 Hz), 6.41 (1 H, d, J=5.6 Hz), 5.34 - 5.43 (1 H, m), 4.36 (2 H, dd, J=9.6, 6.7 Hz), 4.02 (2 H, dd, J=9.8, 4.4 Hz), 3.96 (3 H, s), 3.35 - 3.50 (4 H, m), 2.77 - 2.89 (1 H, m), 2.46 - 2.58 (2 H, m), 2.34 - 2.46 (2 H, m), 1.92 - 2.00 (2 H, m), 167-1.83 (4 H, m), 1.54 - 1.71 (2 H, m).
Example 53 - Preparation of 2-[4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3-yl}oxy)pyridin-2-yl]propan-2-ol. Potency range A
Figure imgf000108_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl] azetidin-3- ol (64 mg, 0.25 mmol) and 2-(4-chloropyridin-2-yl)propan-2-ol (52 mg, 0.30 mmol) gave the title compound as an orange oil after purification by silica FCC (35 mg, 36%).
LCMS data: Calculated MH+ (389); Found 100% (MH+) m/z 389, Rt = 3.57 min (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.34 (1 H, d, J=5.8 Hz), 6.76 (1 H, d, J=2.3 Hz), 6.53 (1 H, dd, J=5.8, 2.3 Hz), 4.95 (1 H, m), 4.82 (1 H, br. s.), 4.35 (2 H, dd, J=9.4, 6.6
Hz), 4.03 (2 H, dd, J=9.6, 4.1 Hz), 3.35 - 3.48 (4 H, m), 2.76 - 2.88 (1 H, m), 2.45 - 2.54 (2 H, m), 2.37 - 2.45 (2 H, m), 1.97 - 2.07 (2 H, m), 1.74 - 1.91 (4 H, m), 1.54 - 1.71 (2 H, m), 1.46
- 1.53 (6 H, s).
Example 54 - Preparation of l-cyclobutyl-4-({3-[(2-ethylpyridin-4-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000108_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (60 mg, 0.24 mmol) and 4-chloro-2-ethylpyridine (40 mg, 0.28 mmol) gave the title compound as orange oil after purification by preparative HPLC as the free base (21 mg, 24%).
LCMS data: Calculated MH+ (359); Found 100% (MH+) m/z 359, Rt = 3.84 min (High pH method). NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.26 (1 H, d, J=5.8 Hz), 6.77 (1 H, d, J=2.1 Hz), 6.72 (1 H, dd, J=5.8, 2.3 Hz), 5.05 - 5.14 (1 H, m), 4.44 (2 H, dd, J=9.3, 6.6 Hz), 4.01 (2 H, dd, J=9.5, 3.9 Hz), 3.38 - 3.50 (4 H, m), 2.90 (1 H, m), 2.75 (2 H, q, J=7.5 Hz), 2.51 - 2.62 (2 H, m), 2.40 - 2.51 (2 H, m), 1.99 - 2.12 (2 H, m), 1.78 - 1.93 (4 H, m), 1.59 - 1.74 (2 H, m), 1.27 (3 H, t, J=7.6 Hz).
Example 55 - Preparation of l-cyclobutyl-4-[(3-{[2-(l-methylethyl)pyridin-4- yl]oxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000109_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (60 mg, 0.24 mmol) and 4-chloro-2-(l-methylethyl)pyridine (44 mg, 0.28 mmol) gave the title compound as an colourless oil after purification by silica FCC (70 mg, 78%).
LCMS data: Calculated MH+ (373); Found 95% (MH+) m/z 373, Rt = 4.06 min (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.35 (1 H, d, J=5.6 Hz), 6.54 (1 H, d, J=2.4 Hz), 6.44 (1 H, dd, J=5.8, 2.4 Hz), 4.86 - 4.97 (1 H, m), 4.33 (2 H, dd, J=9.7, 6.6 Hz), 4.01 (2
H, dd, J=9.9, 4.1 Hz), 3.33 - 3.49 (4 H, m), 2.89 - 3.04 (1 H, m), 2.75 - 2.88 (1 H, m), 2.30 -
2.54 (4 H, m), 1.94 - 2.08 (2 H, m), 1.72 - 1.91 (4 H, m), 1.53 - 1.72 (2 H, m), 1.26 (6 H, d,
J=6.9 Hz).
Example 56 - Preparation of l-cyclobutyl-4-({3-[(2-methoxypyridin-4-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000109_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (94 mg, 0.37 mmol) and 4-chloro-2-methoxy-pyridine (160 mg, 1.11 mmol) gave the title compound as an colourless oil after purification by silica FCC (50 mg, 36%). LCMS data: Calculated MH+ (361); Found 100% (MH+) m/z 361, Rt = 3.87 mins (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.97 (1 H, d, J=6.0 Hz), 6.38 (1 H, dd, J=5.9,
2.2 Hz), 5.95 (1 H, d, J=2.1 Hz), 4.82 - 4.91 (1 H, m), 4.32 (2 H, dd, J=9.5, 6.5 Hz), 4.01 (2
H, dd, J=9.5, 4.2 Hz), 3.90 (3 H, s), 3.35 - 3.47 (4 H, m), 2.82 (1 H, quin, J=7.9 Hz), 2.45 -
2.52 (2 H, m), 2.37 - 2.44 (2 H, m), 1.97 - 2.05 (2 H, m), 1.73 - 1.89 (4 H, m), 1.53 - 1.70 (2
H, m).
Example 57 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)pyridin-2-amine. Potency range A
Figure imgf000110_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (91 mg, 0.36 mmol) and 2-amino-4-chloropyridine (55 mg, 0.43 mmol) gave the title compound as an white solid (4 mg, 3%) after purification by silica FCC and recrystallisation (Heptane/EtOAc).
LCMS data: Calculated MH+ (346); Found 99% (MH+) m/z 346, Rt = 3.37 min (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 7.73 (1 H, d, J=6.0 Hz), 6.17 (1 H, dd, J=6.1,
2.3 Hz), 5.93 (1 H, d, J=2.1 Hz), 4.93 - 5.02 (1 H, m), 4.40 (2 H, dd, J=9.4, 6.6 Hz), 3.99 (2 H, dd, J=9.6, 4.0 Hz), 3.38 - 3.52 (4 H, m), 2.91 (1 H, m), 2.51 - 2.61 (2 H, m), 2.40 - 2.49 (2 H, m), 2.03 - 2.12 (2 H, m), 1.78 - 1.93 (4 H, m), 1.60 - 1.76 (2 H, m).
Example 58 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N,N-dimethylpyridin-2-amine. Potency range A
Figure imgf000110_0002
In a similar fashion (Route 20, GP I), 1 -[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (118 mg, 0.47 mmol) and 4-chloro-N,N-dimethylpyridin-2-amine (87 mg, 0.56 mmol) gave the title compound as a colourless oil (70 mg, 39%).
LCMS data: Calculated MH+ (374); Found 100% (MH+) m/z 374, Rt = 3.94 min (High pH method). NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.99 (1 H, d, J=5.6 Hz), 5.98 (1 H, dd, J=5.7, 1.9 Hz), 5.79 (1 H, d, J=I.8 Hz), 4.85 - 4.97 (1 H, m), 4.31 (2 H, dd, J=9.2, 6.8 Hz), 4.01 (2 H, dd, J=9.5, 4.0 Hz), 3.34 - 3.51 (4 H, m), 2.99 - 3.11 (6 H, s), 2.76 - 2.89 (1 H, m), 2.36 - 2.55 (4 H, m), 1.96 - 2.06 (2 H, m), 1.75 - 1.92 (4 H, m), 1.52 - 1.73 (2 H, m).
Example 59 - Preparation of l-cyclobutyl-4-({3-[(6-methylpyridazin-3-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000111_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (1.09 g, 4.3 mmol) and 3-chloro-6-methylpyridazine (611mg, 4.7 mmol) in THF at 50 0C gave the title compound as a pale pink oil after purification by silica FCC (975 mg, 66%).
LCMS data: Calculated MH+ (345); Found 100% (MH+) m/z 345, Rt = 3.51 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.23 - 7.30 (1 H, d, J=9.0 Hz), 6.94 (1 H, d, J=9.0 Hz), 5.42 - 5.55 (1 H, m), 4.42 (2 H, dd, J=9.6, 6.7 Hz), 4.05 (2 H, dd, J=9.7, 4.3 Hz),
3.35 - 3.51 (4 H, m), 2.77 - 2.89 (1 H, m), 2.61 (3 H, s), 2.35 - 2.54 (4 H, m), 1.96 - 2.08 (2 H, m), 1.72 - 1.92 (4 H, m), 1.52 - 1.72 (2 H, m).
Example 60 - Preparation of 2-[4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}oxy)-2-fluorophenyl]propan-2-ol. Potency range A
Figure imgf000111_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (88 mg, 0.35 mmol) and 2-(2,4-difluoro-phenyl)-propan-2-ol (66 mg, 0.38 mmol) gave the title compound as a colourless oil after purification by preparative HPLC as the TFA salt (24 mg, 13%).
LCMS data: Calculated MH+ (406); Found 99% (MH+) m/z 406, Rt = 4.17 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.60 (1 H, dd, J=8.5, 7.0 Hz), 6.63 - 6.75 (1
H, m), 6.47 (1 H, dd, J=10.7, 2.3 Hz), 4.95 - 5.09 (1 H, m), 4.46 (2 H, dd, J=9.0, 6.7 Hz), 4.04 (2 H, dd, J=9.4, 3.7 Hz), 3.47 (5 H, t, J=6.0 Hz), 3.08 - 3.27 (1 H, m), 2.54 - 2.99 (4 H, m), 2.11 - 2.26 (2 H, m), 1.85 - 2.07 (4 H, m), 1.66 - 1.82 (2 H, m), 1.60 (6 H, s).
Example 61 - Preparation of l-cyclobutyl-4-({3-[(3,5-dimethylpyrazin-2-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000112_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (333 mg, 1.31 mmol) and 2-chloro-3,5-dimethylpyrazine (207 mg, 1.44 mmol) gave the title compound as a brown oil after purification by FCC (297 mg, 63%). LCMS data: Calculated MH+ (360); Found 99% (MH+) m/z 360, Rt = 3.92 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.71 (1 H, s), 5.25 - 5.35 (1 H, m), 4.36 (2 H, dd, J=9.6, 6.9 Hz), 4.02 (2 H, dd, J=9.7, 4.5 Hz), 3.36 - 3.52 (4 H, m), 2.84 (1 H, m), 2.49 - 2.54 (2 H, m), 2.47 (3 H, s), 2.40 - 2.45 (5 H, m), 1.99 - 2.07 (2 H, m), 1.72 - 1.91 (4 H, m), 1.57 - 1.71 (2 H, m).
Example 62 - Preparation of l-cyclobutyl-4-({3-[(2-methoxypyrimidin-4-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000112_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (333 mg, 1.31 mmol) and 4-chloro-2-methoxypyrimidine (377 mg, 2.63 mmol) at 50 0C in
THF gave the title compound as light orange oil (309 mg, 65%).
LCMS data: Calculated MH+ (362); Found 97% (MH+) m/z 362, Rt = 3.71 min (High pH method). NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.24 (1 H, d, J=5.6 Hz), 6.42 (1 H, d, J=5.6
Hz), 5.34 - 5.44 (1 H, m), 4.36 (2 H, dd, J=9.6, 6.9 Hz), 4.03 (2 H, dd, J=9.6, 4.4 Hz), 3.96 (3
H, s), 3.35 - 3.51 (4 H, m), 2.83 (1 H, m), 2.46 - 2.56 (2 H, m), 2.35 - 2.46 (2 H, m), 1.97 -
2.08 (2 H, m), 1.74 - 1.93 (4 H, m), 1.50 - 1.72 (2 H, m).
Example 63 - Preparation of l-cyclobutyl-4-({3-[(6-methylpyrazin-2-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000113_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (120 mg, 0.47 mmol) and 2-chloro-6-methylpyrazine (61 μl, 0.52 mmol) gave the title compound as a yellow oil after purification by FCC (114 mg, 70%). LCMS data: Calculated MH+ (346); Found 99% (MH+) m/z 346, Rt = 3.81 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.01 (1 H, s), 7.99 (1 H, s), 5.27 - 5.34 (1 H, m), 4.32 (2 H, dd, J=9.7, 6.8 Hz), 3.98 (2 H, dd, J=9.8, 4.4 Hz), 3.35 - 3.47 (4 H, m), 2.74 - 2.85 (1 H, m), 2.43 - 2.52 (2 H, m), 2.32 - 2.42 (5 H, m), 1.93 - 2.03 (2 H, m), 1.71 - 1.87 (4 H, m), 1.50 - 1.68 (2 H, m).
Example 64 - Preparation of l-cyclobutyl-4-({3-[(3,6-dimethylpyrazin-2-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000113_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (120 mg, 0.47 mmol) and 3-chloro-2,5-dimethylpyrazine (62 μl, 0.52 mmol) gave the title compound as a colourless oil after purification by FCC (131 mg, 77%).
LCMS data: Calculated MH+ (360); Found 99% (MH+) m/z 360, Rt = 4.01 min (High pH method). NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.87 (1 H, s), 5.25 - 5.37 (1 H, m), 4.34 (2 H, dd, J=9.5, 6.7 Hz), 4.01 (2 H, dd, J=9.5, 4.7 Hz), 3.35 - 3.51 (4 H, m), 2.77 - 2.90 (1 H, m), 2.47 - 2.55 (2 H, m), 2.38 - 2.46 (5 H, m), 2.34 (3 H, s), 1.97 - 2.08 (2 H, m), 1.74 - 1.92 (4 H, m), 1.50 - 1.71 (2 H, m).
Example 65 - Preparation of l-cyclobutyl-4-({3-[(2-methylpyrimidin-4-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000113_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (354 mg, 1.40 mmol) and 4-chloro-2-methylpyrimidine (197 mg, 1.53 mmol) gave the title compound as a yellow oil after purification by FCC (270, 56%).
LCMS data: Calculated MH+ (346) Found 100% (MH+) m/z 346, Rt = 3.59 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.35 (1 H, d, J=5.8 Hz), 6.57 (1 H, d, J=5.8 Hz), 5.34 - 5.48 (1 H, m), 4.35 (2 H, dd, J=9.9, 6.9 Hz), 4.01 (2 H, dd, J=9.9, 4.4 Hz), 3.38 - 3.52 (4 H, m), 2.79 - 2.89 (1 H, m), 2.57 (3 H, s), 2.47 - 2.55 (2 H, m), 2.39 - 2.47 (2 H, m), 1.99 - 2.08 (2 H, m), 1.55 - 1.92 (6 H, m).
Example 66 - Preparation of l-cyclobutyl-4-({3-[(6-methoxypyrazin-2-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000114_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl] azetidin-3- ol (110 mg, 0.43 mmol) and 2-chloro-6-methoxypyrazine (70 mg, 0.47 mmol) gave the title compound as a colourless oil after purification by FCC (114 mg, 73%).
LCMS data: Calculated MH+ (362) Found 99% (MH+) m/z 362, Rt = 3.92 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.81 (1 H, s), 7.79 (1 H, s), 5.25 - 5.33 (1 H, m), 4.34 (2 H, dd, J=9.5, 6.8 Hz), 4.04 (2 H, dd, J=9.7, 4.5 Hz), 3.88 (3 H, s), 3.34 - 3.50 (4
H, m), 2.82 (1 H, m), 2.45 - 2.53 (2 H, m), 2.37 - 2.44 (2 H, m), 1.97 - 2.06 (2 H, m), 1.73 -
1.90 (4 H, m), 1.51 - 1.70 (2 H, m).
Example 67 - Preparation of l-({3-[(3-chloropyridin-2-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000114_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 3,4-dichloropyridine (35 mg, 0.24 mmol) gave the title compound as colourless oil after purification by FCC (32 mg, 45%). LCMS data: Calculated MH+ (365); Found 100% (MH+) m/z 365, Rt = 2.11 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.43 (1 H, s), 8.28 (1 H, d, J=5.5 Hz), 6.44 (1 H, d, J=5.5 Hz), 4.88 - 4.97 (1 H, m), 4.32 (2 H, dd, J=9.6, 6.6 Hz), 4.05 (2 H, dd, J=9.7, 4.2 Hz), 3.38 - 3.44 (2 H, m), 3.35 (2 H, m), 2.77 (1 H, m), 2.41 - 2.49 (2 H, m), 2.31 - 2.39 (2 H, m), 1.91 - 2.06 (2 H, m), 1.68 - 1.85 (4 H, m), 1.47 - 1.65 (2 H, m).
Example 68 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)quinoline. Potency range A
Figure imgf000115_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 4-chloroquinoline (42 mg, 0.26 mmol) gave the title compound as colourless oil after purification by FCC (35 mg, 47%).
LCMS data: Calculated MH+ (381); Found 93% (MH+) m/z 381, Rt = 1.96 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.73 (1 H, d, J=5.0 Hz), 8.24 (1 H, d, J=8.2
Hz), 8.06 (1 H, d, J=8.4 Hz), 7.69 - 7.78 (1 H, m), 7.55 (1 H, m), 6.42 (1 H, d, J=5.2 Hz), 5.09 - 5.19 (1 H, m), 4.48 (2 H, dd, J=9.5, 6.6 Hz), 4.20 (2 H, dd, J=9.5, 4.2 Hz), 3.39 - 3.55 (4 H, m), 2.85 (1 H, m), 2.49 - 2.59 (2 H, m), 2.39 - 2.48 (2 H, m), 1.99 - 2.11 (2 H, m), 1.76 - 1.94
(4 H, m), 1.55 - 1.73 (2 H, m).
Example 69 - Preparation of l-cyclobutyl-4-({3-[(2,6-dimethylpyridin-4-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000115_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 4-chloro-2,6-dimethylpyridine hydrochloride (42 mg, 0.24 mmol) gave the title compound as colourless oil after purification by FCC (30 mg, 42%). LCMS data: Calculated MH+ (359); Found 99% (MH+) m/z 359, Rt = 3.71 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 6.27 (2 H, s), 4.83 (1 H, m), 4.27 (2 H, dd, J=9.3, 6.6 Hz), 3.94 (2 H, dd, J=9.5, 4.1 Hz), 3.37 - 3.43 (2 H, m), 3.35 (2 H, m), 2.72 - 2.82 (1 H, m), 2.42 - 2.47 (2 H, m), 2.39 (6 H, s), 2.32 - 2.37 (2 H, m), 1.96 (2 H, m), 1.69 - 1.83 (4 H, m), 1.48 - 1.64 (2 H, m). Example 70 - Preparation of 8-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)imidazo[l,2-a]pyridine. Potency range A
Figure imgf000116_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 8-chloroimidazo[l,2-a]pyridine (36 mg, 0.24 mmol) gave the title compound as white solid after purification by preparative HPLC (16.7 mg, 23%). LCMS data: Calculated MH+ (370); Found 100% (MH+) m/z 370, Rt = 3.49 min (High pH method). NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.10 (1 H, d, J=6.9 Hz), 7.85 (1 H, d, J=Ll Hz), 7.54 (1 H, d, J=Ll Hz), 6.81 (1 H, t, J=7.2 Hz), 6.47 (1 H, d, J=7.6 Hz), 5.19 (1 H, m), 4.50 (2 H, dd, J=9.5, 6.6 Hz), 4.18 (2 H, dd, J=9.5, 4.0 Hz), 3.44 - 3.52 (4 H, m), 2.92 (1 H, m), 2.56 - 2.61 (2 H, m), 2.46 - 2.51 (2 H, m), 2.08 (2 H, m), 1.83 - 1.94 (4 H, m), 1.69 (2 H, m).
Example 71 - Preparation of 7-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)imidazo[l,2-a]pyridine. Potency range A
Figure imgf000116_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 7-chloroimidazo[l,2-a]pyridine (36 mg, 0.24 mmol) gave the title compound as colourless oil after purification by preparative HPLC (15 mg, 21%).
LCMS data: Calculated MH+ (370); Found 100% (MH+) m/z 370, Rt = 3.54 min (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.31 (1 H, d, J=7.5 Hz), 7.66 (1 H, d, J=I.2 Hz), 7.41 (1 H, d, J=I.2 Hz), 6.61 - 6.67 (2 H, m), 5.07 (1 H, m), 4.47 (2 H, dd, J=9.5, 6.5
Hz), 4.05 (2 H, dd, J=9.5, 4.0 Hz), 3.41 - 3.49 (4 H, m), 2.80 (1 H, m), 2.54 - 2.58 (2 H, m),
2.44 - 2.48 (2 H, m), 2.02 - 2.10 (2 H, m), 1.81 - 1.91 (4 H, m), 1.67 (2 H, m).
Example 72 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)pyridine-2-carboxamide. Potency range A
Figure imgf000117_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) was reacted with and 4-chloro-pyridine-2-carbonitrile (32 mg, 0.24 mmol). The hydro lysed product was recovered as colourless oil after purification by preparative HPLC as the TFA salt (40 mg, 54%).
LCMS data: Calculated MH+ (374); Found 97% (MH+) m/z 374, Rt = 2.04 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.51 (1 H, d, J=5.8 Hz), 7.59 - 7.65 (1 H, m), 7.10 - 7.15 (1 H, m), 5.20 - 5.26 (1 H, m), 4.55 - 4.64 (1 H, m), 4.42 - 4.49 (1 H, m), 4.13 - 4.20 (1 H, m), 4.01 - 4.07 (1 H, m), 3.88 - 3.97 (1 H, m), 3.68 - 3.77 (1 H, m), 3.39 - 3.60 (5 H, m), 2.92 - 3.07 (2 H, m), 2.30 - 2.39 (2 H, m), 2.17 - 2.28 (3 H, m), 2.05 - 2.17 (1 H, m), 1.74 - 1.92 (2 H, m).
Example 73 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-(cyclopropylmethyl)pyridine-2-carboxamide. Potency range A
Figure imgf000117_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 4-chloro-N-(cyclopropylmethyl)pyridine-2-carboxamide (84 mg, 0.40 mmol) gave the title compound as brown oil after purification by preparative HPLC as the TFA salt (25 mg, 23%). LCMS data: Calculated MH+ (428); Found 100% (MH+) m/z 428, Rt = 2.81 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.08 - 8.22 (2 H, m), 7.94 - 8.07 (1 H, m), 7.12 (1 H, dd, J=8.7, 2.7 Hz), 4.97 - 5.07 (1 H, m), 4.48 - 4.62 (1 H, m), 4.15 - 4.38 (2 H, m), 3.91 - 4.05 (2 H, m), 3.50 - 3.65 (3 H, m), 3.25 - 3.49 (5 H, m), 2.79 - 2.98 (1 H, m), 2.37 - 2.72 (4 H, m), 2.10 - 2.33 (3 H, m), 1.82 - 2.01 (1 H, m), 1.62 - 1.80 (1 H, m), 0.97 - 1.15 (1 H, m), 0.47 - 0.61 (2 H, m), 0.22 - 0.37 (2 H, m).
Example 74 - Preparation of l-cyclobutyl-4-[(3-{[6-(piperidin-l-ylcarbonyl)pyridin-3- yl]oxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000118_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 4-chloro-2-(piperidin-l-ylcarbonyl)pyridine (90 mg, 0.40 mmol) gave the title compound as colourless oil after purification by preparative HPLC (16 mg, 18%).
LCMS data: Calculated MH+ (442); Found 100% (MH+) m/z 442, Rt = 2.56 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.20 (1 H, d, J=2.7 Hz), 7.55 (1 H, d, J=8.5 Hz), 7.37 (1 H, dd, J=8.7, 2.8 Hz), 5.08 - 5.16 (1 H, m), 4.46 (2 H, dd, J=9.3, 6.5 Hz), 4.05 (2 H, dd, J=9.5, 3.8 Hz), 3.66 - 3.75 (2 H, m), 3.38 - 3.53 (6 H, m), 2.95 - 3.07 (1 H, m), 2.50 - 2.70 (4 H, m), 2.06 - 2.15 (2 H, m), 1.84 - 1.96 (4 H, m), 1.62 - 1.77 (6 H, m), 1.57 (2 H, m).
Example 75 - Preparation of 3-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylbenzamide. Potency range A
Figure imgf000118_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 3-fluoro-N-methyl-benzamide (46 mmol, 0.30 mmol) gave the title compound as colourless oil after purification by preparative HPLC as the TFA salt (4 mg, 3%). LCMS data: Calculated MH+ (387); Found 100% (MH+) m/z 387, Rt = 2.37 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 7.35 - 7.44 (2 H, m), 7.21 - 7.27 (1 H, m), 7.00 (1 H, m), 5.02 - 5.09 (1 H, m), 4.55 (1 H, m), 4.40 (1 H, m), 4.12 (1 H, m), 3.87 - 4.04 (2 H, m), 3.73 (1 H, quin, J=8.4 Hz), 3.38 - 3.62 (5 H, m), 3.00 (2 H, m), 2.91 (3 H, s), 2.35 (2 H, m), 2.23 (3 H, m), 2.05 - 2.15 (1 H, m), 1.74 - 1.95 (2 H, m).
Example 76 - Preparation of l-({3-[(5-chloropyridin-2-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000118_0003
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 2,3-dichloropyridine (38 mg, 0.26 mmol) gave the title compound as yellow oil after purification by FCC (28 mg, 39%).
LCMS data: Calculated MH+ (367); Found 97% (MH+) m/z 367, Rt = 2.78 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.00 (1 H, dd, J=4.9, 1.6 Hz), 7.66 (1 H, dd, J=7.7, 1.7 Hz), 6.88 (1 H, dd, J=7.7, 5.0 Hz), 5.37 (1 H, m), 4.38 (2 H, dd, J=9.7, 6.8 Hz), 4.09 (2 H, dd, J=9.9, 4.6 Hz), 3.40 - 3.51 (4 H, m), 2.85 (1 H, quin, J=7.8 Hz), 2.49 - 2.56 (2 H, m), 2.40 - 2.47 (2 H, m), 2.00 - 2.08 (2 H, m), 1.77 - 1.91 (4 H, m), 1.63 - 1.72 (2 H, m).
Example 77 - Preparation of l-({3-[(5-chloropyridin-2-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000119_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 2,5-dichloropyridine (38 mg, 0.26 mmol) gave the title compound as orange oil after purification by FCC (38 mg, 53%).
LCMS data: Calculated MH+ (367); Found 100% (MH+) m/z 367, Rt = 2.79 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.05 (1 H, d, J=2.4 Hz), 7.56 (1 H, dd, J=8.8, 2.8 Hz), 6.74 (1 H, d, J=8.8 Hz), 5.25 - 5.32 (1 H, m), 4.34 (2 H, dd, J=9.4, 6.7 Hz), 4.00 (2
H, dd, J=9.6, 4.5 Hz), 3.44 - 3.49 (2 H, m), 3.42 (2 H, m), 2.84 (1 H, quin, J=7.8 Hz), 2.49 -
2.55 (2 H, m), 2.40 - 2.45 (2 H, m), 1.99 - 2.08 (2 H, m), 1.77 - 1.90 (4 H, m), 1.62 - 1.72 (2
H, m).
Example 78 - Preparation of l-cyclobutyl-4-({3-[(3,5-dimethylpyrazin-2-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000119_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (333 mg, 1.31 mmol) and 2-chloro-3,5-dimethylpyrazine (207 mg, 1.44 mmol) gave the title compound as brown oil after purification by FCC (297 mg, 63%). LCMS data: Calculated MH+ (360); Found 97% (MH+) m/z 360, Rt = 3.93 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.71 (1 H, s), 5.25 - 5.32 (1 H, m), 4.36 (2 H, dd, J=9.8, 6.8 Hz), 4.02 (2 H, dd, J=9.8, 4.5 Hz), 3.45 - 3.50 (2 H, m), 3.43 (2 H, m), 2.84 (1
H, quin, J=7.9 Hz), 2.49 - 2.56 (2 H, m), 2.46 - 2.48 (3 H, s), 2.38 - 2.45 (5 H, m), 1.99 - 2.08
(2 H, m), 1.77 - 1.91 (4 H, m), 1.57 - 1.72 (2 H, m).
Example 79 - Preparation of l-({3-[(3-chloropyridin-4-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000120_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 3,4-dichloropyridine (35 mg, 0.24) gave the title compound as colourless oil after purification by FCC (32 mg, 45%).
LCMS data: Calculated MH+ (365); Found 100% (MH+) m/z 365, Rt = 2.11 min (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.43 (1 H, s), 8.28 (1 H, d, J=5.5 Hz), 6.44 (1
H, d, J=5.5 Hz), 4.88 - 4.97 (1 H, m), 4.32 (2 H, dd, J=9.6, 6.6 Hz), 4.05 (2 H, dd, J=9.7, 4.2
Hz), 3.38 - 3.44 (2 H, m), 3.35 (2 H, m), 2.77 (1 H, m), 2.41 - 2.49 (2 H, m), 2.31 - 2.39 (2 H, m), 1.91 - 2.06 (2 H, m), 1.68 - 1.85 (4 H, m), 1.47 - 1.65 (2 H, m).
Example 80 - Preparation of l-({3-[(5-chloropyridin-3-yl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000120_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.20 mmol) and 3,5-dichloropyridine (37 mg, 0.26 mmol) gave the title compound as brown oil after purification by FCC (36 mg, 52% yield). LCMS data: Calculated MH+ (365); Found 100% (MH+) m/z 365, Rt = 2.55 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.25 (1 H, d, J=2.0 Hz), 8.08 (1 H, d, J=2.4 Hz), 7.08 (1 H, t, J=2.2 Hz), 4.94 (1 H, m), 4.37 (2 H, dd, J=9.4, 6.5 Hz), 4.06 (2 H, dd J=9.7, 3.9 Hz), 3.35 - 3.56 (4 H, m), 2.89 (1 H, m), 2.39 - 2.58 (4 H, m), 2.01 - 2.11 (2 H, m), 1.82 1.92 (4 H, m), 1.69 (2 H, m).
Example 81 - Preparation of l-cyclobutyl-4-{[3-(pyridin-4-yloxy)azetidin-l-yl]carbonyl}- 1,4-diazepane. Potency range A
Figure imgf000121_0001
In a similar fashion (Route 20, GP I) 1 -[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (315 mg, 1.24 mmol) and 4-chloropyridine (240 mg, 1.61 mmol) gave the title compound as pale yellow oil after purification by FCC (200 mg, 44% yield). LCMS data: Calculated MH+ (330); Found 98% (MH+) m/z 330, Rt = 3.47 mins (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.39 (2 H, dd, J=4.9, 1.5 Hz), 6.93 (2 H, dd, J=4.9, 1.5 Hz), 5.09 - 5.16 (1 H, m), 4.47 (2 H, dd, J=9.6, 6.6 Hz), 4.04 (2 H, dd, J=9.8, 3.9 Hz), 3.42 - 3.51 (4 H, m), 2.88 - 2.98 (1 H, m), 2.53 - 2.61 (2 H, m), 2.45 - 2.54 (2 H, m), 2.05 - 2.13 (2 H, m), 1.82 - 1.94 (4 H, m), 1.62 - 1.76 (2 H, m).
Example 82 - Preparation of l-cyclobutyl-4-({3-[(5-methoxypyridin-3-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000121_0002
In a similar fashion (Route 20, GP I) 1- [(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (260 mg, 1.03 mmol) and 3-chloro-5-methoxypyridine (191 mg, 1.34 mmol) gave the title compound as dark yellow oil after purification by preparative HPLC (54 mg, 15% yield). LCMS data: Calculated MH+ (360); Found 96% (MH+) m/z 360, Rt = 3.68 min (High pH method). NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.00 (1 H, d, J=2.3 Hz), 7.76 (1 H, d, J=2.3 Hz), 6.62 (1 H, t, J=2.4 Hz), 4.94 (1 H, m), 4.29 - 4.41 (2 H, dd, J=9.5, 6.5 Hz), 4.05 (2 H, dd, j=9.4, 3.9 Hz), 3.85 (3 H, s), 3.56 (2 H, m), 3.42 (2 H, m), 2.93 - 3.05 (1 H, m), 2.44 - 2.84 (4 H, m), 1.93 - 2.15 (5 H, m), 1.54 - 1.80 (3 H, m). Example 83 - Preparation of 2-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-6-(cyclopropylcarbonyl)-5,6,7,8-tetrahydro-l,6-naphthyridine. Potency range A
Figure imgf000122_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (32 mg, 0.13 mmol) and 2-chloro-6-(cyclopropylcarbonyl)-5,6,7,8-tetrahydro-l,6- naphthyridine (60 mg, 0.25 mmol) gave the title compound as orange oil after FCC (7 mg, 11%). LCMS data: Calculated MH+ (454); Found 95% (MH+) m/z 454, Rt = 2.72 mins. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.42 - 7.58 (1 H, m), 6.63 - 6.75 (1 H, m), 5.23 - 5.40 (1 H, m), 4.55 - 4.69 (1 H, m), 4.38 (2 H, dd, J=9.4, 6.5 Hz), 3.92 - 4.10 (3 H, m), 3.79 - 3.91 (1 H, m), 3.38 - 3.51 (4 H, m), 2.72 - 2.98 (3 H, m), 2.60 - 2.70 (1 H, m), 2.39 - 2.61 (4 H, m), 1.97 - 2.14 (3 H, m), 1.76 - 1.93 (4 H, m), 1.58 - 1.74 (2 H, m), 0.76 - 0.97 (4 H, m).
Example 84 - Preparation of 2-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-6-(cyclopropylacetyl)-5,6,7,8-tetrahydro-l,6-naphthyridine. Potency range A
Figure imgf000122_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (28 mg, 0.11 mmol) and 2-chloro-6-(cyclopropylacetyl)-5,6,7,8-tetrahydro-l,6- naphthyridine (56 mg, 0.22 mmol) gave the title compound after preparative HPLC (29 mg,
%».
LCMS data: Calculated MH+ (468); Found (MH+) m/z 468. The product eluted in the solvent front. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 8.17 - 8.34 (1 H, m), 7.37 (1 H, d, J=8.8 Hz), 5.44 - 5.62 (1 H, m), 4.60 - 5.04 (4 H, m), 3.90 - 4.15 (3 H, m), 3.65 - 3.84 (3 H, m), 3.41 - 3.63 (5 H, m), 2.81 - 3.22 (4 H, m), 2.02 - 2.51 (8 H, m), 1.71 - 1.98 (2 H, m), 0.94 - 1.17 (1 H, m), 0.44 - 0.68 (2 H, m), 0.10 - 0.32 (2 H, m). Example 85 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylpyridine-3-carboxamide. Potency range A
Figure imgf000123_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- ol (25 mg, 0.10 mmol), 4-chloro-N-methylpyridine-3-carboxamide (25 mg, 0.15 mmol) with KO1Bu (13 mg, 0.12 mmol) gave the title compound after purification by FCC (23 mg, 59%). LCMS data: Calculated MH+ (388); Found 100% (MH+) m/z 388, Rt = 3.17 mins (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.76 (1 H, s), 8.48 (1 H, d, J=6.0 Hz), 6.90 (1 H, d, J=6.0 Hz), 5.16 - 5.26 (1 H, m), 4.48 (2 H, dd, J=9.7, 6.6 Hz), 4.13 (2 H, dd, J=9.7, 4.0 Hz), 3.40 - 3.51 (4 H, m), 2.96 (3 H, s), 2.91 (1 H, quin, J=7.9 Hz), 2.52 - 2.62 (2 H, m), 2.40 - 2.50 (2 H, m), 1.99 - 2.12 (2 H, m), 1.78 - 1.96 (4 H, m), 1.57 - 1.75 (2 H, m).
Example 85a - Preparation of ethyl 5-({l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl] azetidin-3-yl}oxy)pyridine-2-carboxylate.
Figure imgf000123_0002
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (415 mg, 1.64 mmol) and ethyl 3-chloropyridine-2-carboxylate (530 mg, 2.87 mmol) gave the title compound after purification by FCC (124 mg, 65%). LCMS data: Calculated MH+ (403); Found 98% (MH+) m/z 403, Rt = 0.9 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.30 (1 H, d, J=2.7 Hz), 8.12 (1 H, d, J=8.7 Hz), 7.11 (1 H, dd, J=8.7, 2.7 Hz), 4.94 - 5.06 (1 H, m), 4.41 - 4.51 (2 H, q, J=7.2 Hz), 4.38 (2 H, dd, J=9.5, 6.4 Hz), 4.07 (2 H, dd, J=9.6, 4.1 Hz), 3.37 - 3.51 (4 H, m), 2.84 (1 H, s), 2.48 - 2.58 (2 H, m), 2.38 - 2.48 (2 H, m), 1.98 - 2.11 (2 H, m), 1.75 - 1.92 (4 H, m), 1.59 - 1.74 (2 H, m), 1.44 (3 H, t, J=7.2 Hz).
Example 85b - Preparation of l-cyclobutyl-4-{[3-(3-methyl-4-nitrophenoxy)azetidin-l- yl] carbonyl}- 1 ,4-diazepane.
Figure imgf000124_0001
In a similar fashion (Route 20, GP I) l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (125 mg, 0.49 mmol) and 4-fluoro-2-methyl-l -nitrobenzene (115 mg, 0.74 mmol) gave the title compound as colourless oil after purification by FCC (124 mg, 65%). LCMS data: Calculated MH+ (389); Found (MH+) m/z 389, Rt = 1.39 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.04 - 8.11 (1 H, m), 6.60 - 6.69 (2 H, m), 4.91 - 5.01 (1 H, m), 4.37 (2 H, dd, J=9.5, 6.6 Hz), 4.04 (2 H, dd, J=9.5, 4.1 Hz), 3.39 - 3.50 (4 H, m), 2.79 - 2.91 (1 H, m), 2.63 (3 H, s), 2.47 - 2.56 (2 H, m), 2.37 - 2.47 (2 H, m), 1.98 - 2.10 (2 H, m), 1.76 - 1.94 (4 H, m), 1.54 - 1.74 (2 H, m).
Route 21
General
Figure imgf000124_0002
CuI, 100 0C
General Procedure J:
Example 86 - Preparation of l-cyclobutyl-4-{[3-(4-methoxyphenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000124_0003
To a stirred suspension of 4-cyclobutyl-[l,4]diazepan-l-yl)-(3-hydroxy-azetidin-l-yl)- methanone (50 mg, 0.197 mmol) in toluene (2 ml) was added 4-iodoanisole (69 mg, 0.296 mmol), Cs2CO3 (128 mg, 0.394 mmol), CuI (3.7 mg, 0.0197 mmol) and 1,10-phenanthroline (7.1 mg, 0.04 mmol). The resulting mixture was heated at 100 0C overnight, then cooled to RT and filtered through a plug of silica gel, eluting with EtOAc. The filtrate was concentrad in vacuo and the residue purified by FCC [silica, eluting with DCM/MeOH/NH3; 90:10:1) to provide the title compound as colourless oil (27 mg, 39%). LCMS data: Calculated MH+ (360); Found 98% (MH+) m/z 360, Rt = 2.71 min. NMR data: 1H NMR (360 MHz, MeOH) δ ppm 6.81 - 6.87 (2 H, m), 6.70 - 6.77 (2 H, m), 4.85 - 4.92 (1 H, m), 4.36 (2 H, dd, J=9.5, 6.4 Hz), 3.96 (2 H, dd, J=9.5, 4.1 Hz), 3.73 (3 H, s), 3.39 - 3.50 (4 H, m), 2.90 - 3.02 (1 H, m), 2.47 - 2.65 (4 H, m), 2.03 - 2.14 (2 H, m), 1.82 - 1.96 (4 H, m), 1.58 - 1.76 (2 H, m).
The following compounds were made as described in Route 21, General Procedure J above
Example 87 - Preparation of l-cyclobutyl-4-({3-[4-(lH-pyrazol-l-yl)phenoxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000125_0001
In a similar fashion (Route 21, GP J), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-(4-iodophenyl)-lH-pyrazole (69 mg, 0.26 mmol) gave the title compound as colourless oil after purification by preparative HPLC (41 mg, 41%). LCMS data: Calculated MH+ (396); Found 100% (MH+) m/z 396, Rt = 2.82 min. NMR data: 1H NMR (360 MHz, MeOH) δ ppm 8.10 (1 H, d, J=2.7 Hz), 7.69 (1 H, d, J=I.8 Hz), 7.61 - 7.67 (2 H, m), 6.90 - 6.97 (2 H, m), 6.50 (1 H, t, J=2.3 Hz), 5.00 - 5.08 (1 H, m), 4.46 (2 H, m), 3.85 - 4.16 (3 H, m), 3.64 - 3.76 (1 H, m), 3.38 - 3.61 (5 H, m), 2.88 - 3.07 (2 H, m), 2.05 - 2.38 (6 H, m), 1.72 - 1.92 (2 H, m).
Example 88 - Preparation of l-cyclobutyl-4-({3-[4-(trifluoromethoxy)phenoxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000125_0002
In a similar fashion (Route 21, GP J) except for replacing phenanthroline with 3,4,7,8- tetramethylphenanthroline, l-[(4-cyc Io butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.19 mmol) and l-iodo-4-(trifluoromethoxy)benzene (86 mg, 0.3 mmol) gave the title compound as colourless oil after purification by preparative HPLC (44 mg, 52%). LCMS data: Calculated MH+ (414); Found 100% (MH+) m/z 414, Rt = 3.15 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.14 - 7.29 (2 H, m), 6.81 - 6.97 (2 H, m), 4.98 - 5.09 (1 H, m), 4.28 - 4.62 (2 H, m), 3.81 - 4.20 (3 H, m), 3.63 - 3.82 (1 H, m), 3.34 - 3.62 (5 H, m), 2.82 - 3.15 (2 H, m), 1.99 - 2.45 (6 H, m), 1.65 - 1.99 (2 H, m). Example 89 - Preparation of l-cyclobutyl-4-({3-[4-(difluoromethoxy)phenoxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000126_0001
In a similar fashion (Route 21, GP J) except for replacing phenanthroline with 3,4,7,8- tetramethylphenanthroline, l-[(4-cyc Io butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.19 mmol) and l-(difluoromethoxy)-4-iodobenzene (81 mg, 0.3 mmol) gave the title compound as colourless oil after purification by preparative HPLC (47 mg, 57%). LCMS data: Calculated MH+ (396); Found 100% (MH+) m/z 396, Rt = 2.92 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.04 - 7.14 (2 H, m), 6.78 - 6.88 (2 H, m), 6.69 (1 H, t), 4.97 - 5.03 (1 H, m), 4.28 - 4.60 (2 H, m), 3.82 - 4.16 (3 H, m), 3.63 - 3.81 (1 H, m), 3.35 - 3.62 (5 H, m), 2.83 - 3.13 (2 H, m), 2.03 - 2.42 (6 H, m), 1.67 - 1.95 (2 H, m).
Example 90 - Preparation of l-{[3-(4-chloro-2-fluorophenoxy)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000126_0002
In a similar fashion (Route 21, GP J) except for replacing phenantroline with 3,4,7,8- tetramethylphenantroline, l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.19 mmol) and 4-chloro-2-fluoro-l-iodobenzene (77 mg, 0.3 mmol) gave the title compound as colourless oil after purification by preparative HPLC (60 mg, 61%). LCMS data: Calculated MH+ (382); Found 100% (MH+) m/z 382, Rt = 3.06 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.23 (1 H, dd, J=I 1.0, 2.4 Hz), 7.11 (1 H, dt, J=8.8, 1.9 Hz), 6.86 (1 H, t, J=8.8 Hz), 4.97 - 5.14 (1 H, m), 4.26 - 4.63 (2 H, m), 3.83 - 4.25 (3 H, m), 3.62 - 3.82 (1 H, m, J=8.3, 8.3, 8.3, 8.3 Hz), 3.52 (5 H, br. s.), 2.82 - 3.17 (2 H, m), 2.01 - 2.43 (6 H, m), 1.67 - 1.96 (2 H, m).
Example 91 - Preparation of l-cyclobutyl-4-{[3-(3-methoxyphenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000126_0003
In a similar fashion (Route 21, GP J), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-iodo-3-methoxybenzene (69 mg, 0.3 mmol) gave the title compound as colourless oil after purification by preparative HPLC (6 mg, 6%). LCMS data: Calculated MH+ (360); Found 100% (MH+) m/z 360, Rt = 2.76 min. NMR data: 1H NMR (360 MHz, MeOH) δ ppm 7.12 - 7.22 (1 H, m), 6.51 - 6.58 (1 H, m), 6.32 - 6.40 (2 H, m), 4.93 - 5.01 (1 H, m), 4.28 - 4.57 (2 H, m), 3.84 - 4.15 (3 H, m), 3.65 - 3.79 (4 H, m), 3.35 - 3.59 (5 H, m), 2.87 - 3.08 (2 H, m), 2.01 - 2.40 (6 H, m), 1.70 - 1.92 (2 H, m).
Example 92 - Preparation of l-cyclobutyl-4-{[3-(2-methoxyphenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000127_0001
In a similar fashion (Route 21, GP J), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (50 mg, 0.19 mmol) and l-iodo-2-methoxybenzene (69 mg, 0.3 mmol) gave the title compound as colourless oil after purification by preparative HPLC (24 mg, 26%). LCMS data: Calculated MH+ (360); Found 100% (MH+) m/z 360, Rt = 2.65 min. NMR data: 1H NMR (360 MHz, MeOH) δ ppm 6.93 - 7.03 (2 H, m), 6.82 - 6.91 (1 H, m), 6.72 (1 H, d, J=7.7 Hz), 4.93 - 5.01 (1 H, m), 4.27 - 4.54 (2 H, m), 4.08 - 4.20 (1 H, m), 3.79 - 4.07 (5 H, m), 3.73 (1 H, quin, J=8.3 Hz), 3.37 - 3.61 (5 H, m), 2.88 - 3.09 (2 H, m), 2.00 - 2.41 (6 H, m), 1.73 - 1.95 (2 H, m).
Example 93 - Preparation of 6-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-2-methylquinoline. Potency range A
Figure imgf000127_0002
In a similar fashion (Route 21, GP J) except for replacing phenantroline with 3,4,7,8- tetramethylphenantroline, l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (128 mg, 0.51 mmol) and 6-bromo-2-methylquinoline (224 mg, 1.01 mmol) gave the title compound as brown oil after purification by FCC (52 mg, 25%). LCMS data: Calculated MH+ (395); Found 100% (MH+) m/z 395, Rt = 4.02 min. NMR data: 1U NMR (500 MHz, CDCl3) δ ppm 7.88 - 7.98 (2 H, m), 7.28 - 7.33 (1 H, m), 7.26 (1 H, d, J=8.4 Hz), 6.78 (1 H, d, J=2.8 Hz), 4.98 - 5.05 (1 H, m), 4.42 (2 H, dd, J=9.3, 6.5 Hz), 4.11 (2 H, dd, J=9.4, 4.1 Hz), 3.37 - 3.56 (4 H, m), 2.86 (1 H, t, J=7.6 Hz), 2.72 (3 H, s), 2.50 - 2.60 (2 H, m), 2.32 - 2.49 (2 H, m), 1.99 - 2.10 (2 H, m), 1.77 - 1.93 (4 H, m), 1.55 - 1.74 (2 H, m).
Example 94 - Preparation of l-cyclobutyl-4-[(3-{[6-(trifluoromethyl)pyridin-3- yl]oxy}azetidin-l-yl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000128_0001
In a similar fashion (Route 21, GP J) except for replacing phenantroline with 3,4,7,8- tetramethylphenantroline, l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.20 mmol) and 5-bromo-2-trifluoromethylpyridine (59 mg, 0.26 mmol) gave the title compound as a brown oil after purification by preparative HPLC (15 mg, 14%). LCMS data: Calculated MH+ (399); Found 100% (MH+) m/z 399, Rt = 2.81 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.32 (1 H, d, J=2.7 Hz), 7.77 (1 H, d, J=8.7 Hz), 7.42 (1 H, dd, J=8.6, 2.6 Hz), 5.14 - 5.21 (1 H, m), 4.54 - 4.61 (1 H, m), 4.38 - 4.47 (1 H, m), 4.11 - 4.20 (1 H, m), 4.00 - 4.08 (1 H, m), 3.88 - 3.97 (1 H, m), 3.72 (1 H, quin, J=8.4 Hz), 3.39 - 3.61 (5 H, m), 3.00 (2 H, m, J=10.9 Hz), 2.30 - 2.40 (2 H, m), 2.18 - 2.30 (3 H, m), 2.05 - 2.18 (1 H, m), 1.73 - 1.93 (2 H, m).
Route 22
Figure imgf000128_0002
General Procedure L
Figure imgf000128_0003
Figure imgf000128_0004
General Procedure K:
Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl methanesulfonate.
Figure imgf000129_0001
To a stirred solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (100 mg, 0.395 mmol) in DCM (5 ml) at 0 0C was added TEA (120 mg, 1.2 mmol) and methansulphonyl chloride (110 mg, 0.94 mmol). The mixture was stirred for 2 h at RT, then diluted with DCM (15 ml) and washed with saturated NaHCOs (10 ml). The organic layer was separated, dried (Na2SO4), filtered and concentrated providing the title compound as pale yellow solid (130 mg, 92%).
LCMS data: Calculated MH+ (332); Found 100% (MH+) m/z 332, Rt = 0.74 min. NMR data: 1H NMR (360 MHz, chloroform-J) δ ppm 5.18 - 5.26 (1 H, m), 4.29 (2 H, dd, J=10.9, 6.8 Hz), 4.12 (2 H, dd, J=10.9, 4.5 Hz), 3.35 - 3.47 (4 H, m), 3.07 (3 H, s), 2.83 (1 H, quin, J=7.8 Hz), 2.47 - 2.54 (2 H, m), 2.36 - 2.45 (2 H, m), 1.98 - 2.09 (2 H, m), 1.74 - 1.91 (4 H, m), 1.55 - 1.73 (2 H, m).
General Procedure L:
Example 95 - Preparation of l-cyclobutyl-4-({3-[(4-fluorobenzyl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000129_0002
To a stirred solution of (4-fluorophenyl)methanol (27 mg, 0.2 mmol) in DMSO (1.5 mL) was added NaH (8.5 mg, 0.2 mmol, 60% purity) at RT. The mixture was stirred for 1 h and a solution o f 1 1 - [(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -yl methanesulfonate (33 mg, 0.1 mmol) in DMSO (0.5 mL) was added. The resulting mixture was stirred at 100 0C overnight, cooled to RT and diluted with EtOAc. The crude mixture and washed with water/brine; 1/1 solution, dried (Na2SO4), filtered and concentrated at reduced pressure. Purification by preparative HPLC provided the title compound as colourless oil (8 mg, 18%). LCMS data: Calculated MH+ (362); Found 100% (MH+) m/z 362, Rt = 2.79 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.29 - 7.44 (2 H, m), 7.00 - 7.15 (2 H, m), 4.47 (2 H, s), 4.32 - 4.43 (1 H, m), 4.02 - 4.31 (2 H, m), 3.63 - 4.01 (4 H, m), 3.34 - 3.62 (5 H, m), 2.86 - 3.09 (2 H, m), 1.96 - 2.43 (6 H, m), 1.68 - 1.96 (2 H, m).
The following compounds were made as described in Route 22, General Procedure L above
Example 96 - Preparation of l-cyclobutyl-4-[(3-methoxyazetidin-l-yl)carbonyl]-l,4- diazepane. Potency range A
Figure imgf000130_0001
In a similar fashion (Route 22, GP L), l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl methanesulfonate (33 mg, 0.1 mmol) and sodium methoxide (11 mg, 0.2 mmol) gave the title compound as colourless oil after purification by preparative HPLC (8 mg, 20%). LCMS data: Calculated MH+ (268); Found 100% (MH+) m/z 268, Rt = 3.43 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 4.04 - 4.35 (2 H, m), 3.67 - 3.99 (4 H, m), 3.34 - 3.67 (6 H, m), 3.29 (3 H, br. s.), 2.85 - 3.12 (2 H, m), 2.00 - 2.44 (6 H, m), 1.70 - 1.96 (2 H, m).
Route 23
General Procedure M
Figure imgf000130_0002
General Procedure M:
Example 97 - Preparation of l-({3-[(4-chlorobenzyl)oxy]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000130_0003
To a stirred solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (40 mg, 0.158 mmol) in THF (3mL) was added NaH (13 mg, 0.316 mmol, 60% in mineral oil). The suspension was stirred at RT for 1 h before l-(bromomethyl)-4-chlorobenzene (65 mg, 0.316 mmol) was added in one portion. The resulting mixture was heated at 80 0C for 1 h, cooled to RT and concentrated at reduced pressure. The crude residue was dissolved in MeOH and filtered through a short pad of silica before purification by preparative HPLC to provide the title compound (31mg, 40%) as colourless oil.
LCMS data: Calculated MH+ (378); Found 100% (MH+) m/z 378, Rt = 2.66 min. 1H NMR (250 MHz, MeOD) δ ppm 7.35 (4 H, s), 4.47 (2 H, s), 4.33 - 4.43 (1 H, m), 4.19 - 4.32 (1 H, m), 4.03 - 4.18 (1 H, m), 3.77 - 4.02 (3 H, m), 3.62 - 3.77 (1 H, m), 3.37 - 3.60 (5 H, m), 2.81 - 3.09 (2 H, m), 2.02 - 2.44 (6 H, m), 1.65 - 1.96 (2 H, m).
The following compounds were made as described in Route 23, General Procedure M above.
Example 98 - Preparation of 4-[({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)methyl]benzonitrile. Potency range A
Figure imgf000131_0001
In a similar fashion (Route 23, GP M), l-[(4-cyclo butyl- 1,4-diazepan-l- yl)carbonyl]azetidin-3-ol (40 mg, 0.158 mmol) and 4-(bromomethyl)benzonitrile (62 mg, 0.158 mmol) gave the title compound as colourless oil after purification by preparative HPLC (17 mg, 22%).
LCMS data: Calculated MH+ (369); Found 99% (MH+) m/z 369, Rt = 2.66 min. 1H NMR (250 MHz, MeOD) δ ppm 7.72 (2 H, d), 7.54 (2 H, d, J=8.5 Hz), 4.58 (2 H, s), 4.36 - 4.48 (1 H, m), 4.06 - 4.35 (2 H, m), 3.80 - 4.06 (3 H, m), 3.62 - 3.80 (1 H, m), 3.35 - 3.62 (5 H, m), 2.83 - 3.12 (2 H, m), 2.03 - 2.43 (6 H, m), 1.69 - 1.96 (2 H, m).
Example 99 - Preparation of l-cyclobutyl-4-{[3-(prop-2-yn-l-yloxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000131_0002
In a similar fashion (Route 23, GP M), l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3-ol (52 mg, 0.20 mmol) and propargyl bromide (60 μl of a 80% wt solution in toluene, 0.23 mmol) gave the title compound as yellow oil after purification by preparative HPLC (10 mg,
17%).
LCMS data: Calculated MH+ (292); Found 100% (MH+) m/z 292, Rt = 3.67 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 4.37 - 4.52 (1 H, m), 4.11 - 4.25 (4 H, m),
3.90 (2 H, dd, J=9.3, 4.3 Hz), 3.36 - 3.50 (4 H, m), 2.81 - 2.99 (2 H, m), 2.40 - 2.61 (4 H, m),
1.98 - 2.15 (2 H, m), 1.76 - 1.96 (4 H, m), 1.55 - 1.76 (2 H, m).
Route 24
A
Figure imgf000132_0001
Preparation of bis(l-methylethyl) 3,3-dimethoxycyclobutane-l,l-dicarboxylate
Figure imgf000132_0002
To a stirred suspension of NaH (11.7 g, 293 mmol, 60% purity) in DMF (100 ml) was added diisopropylmalonic ester dropwise, keeping the temperature below 40 0C. The resulting mixture was stirred for 1 h at RT and then l,3-dibromo-2,2-dimethoxypropane (34.8 g, 133 mmol) was added in one portion. The resulting mixture was heated at 140 0C for 24 h and then cooled to RT. Saturated NH4Cl aqueous (400 ml) was added and the mixture extracted with hexane (2 x 190 ml). The combined organic phases were washed with H2O (2 x 250 ml) saturated NaHCO3 (2 x 250 ml), H2O (2 x 250 ml) and brine (250 ml). The organic phase was dried (Na2SO4), filtered and concentrated at reduced pressure to provide an orange oil. Purification by in vacuo distillation to remove excess of l,3-dibromo-2,2-dimethoxypropane (b.p. 60-62 0C, 0.1 mniHg) and diisopropylmalonic ester (b.p 78-80 0C, 0.1 mmHg) provided the title compound (20 g, 52%) as orange oil in the distillation flask. MS data: Calculated MH+ (289); Found 100% (MH+) m/z 289.
NMR data: 1H NMR (360 MHz, CHLOROFORM- d) δ ppm 5.07 (2 H, spt, J=6.3 Hz), 3.16 (6 H, s), 2.70 (4 H, s), 1.24 (12 H, d, J=6.4 Hz).
Preparation of 3,3-dihydroxycyclobutanecarboxylic acid
Figure imgf000133_0001
To a stirred solution of 20% HCl (7 ml) was added bis(l-methylethyl) 3,3- dimethoxycyclo butane- 1,1-dicarboxylate (2.5 g, 8.7 mmol) at RT. The resulting mixture was heated at 100 0C overnight and then cooled to RT and extracted with diethyl ether (3 x 20 ml).
The organic phases were combined, dried (Na2SO4), filtered and concentrated at reduced pressure. The resulting light brown oil was slurried in DCM (2 ml) and the resulting solid collected by filtration, washed with pentane and dried at reduced pressure to yield a pale brown solid (530 mg, 47%).
LCMS data: Calculated MH+ (133); compound below 150 amu detection limit.
NMR data: 1H NMR (250 MHz, CHLOROFORM-^) δ ppm 3.07 - 3.43 (5 H, m).
General Procedure N: Example 100 - Preparation of 3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutanone. Potency range A
Figure imgf000133_0002
To a stirred solution of 3,3-dihydroxycyclobutanecarboxylic acid (80 mg, 0.61 mmol) in 4:1 DCM/DMF (2.5 ml) was added CDI (103 mg, 0.64 mmol) at RT. The mixture was stirred for 1.5 h at RT and 1 -eye Io butyl- 1 ,4-diazepane (98 mg, 0.64 mmol) was added. The resulting solution was stirred at RT for 3 h, diluted with DCM (20 ml) and washed with 1 : 1 H2θ/brine (20 ml). The organic layer was dried (Na2SO4), filtered and concentrated at reduced pressure. Purification by silica gel FCC (eluting with DCM/MeOH/NH3 90:10:1) provided the title compound as colourless oil (84 mg, 56%). LCMS data: Calculated MH+ (251); Found 100% (MH+) m/z 251 , Rt = 1.31 min. NMR data: 1H NMR (250 MHz, CHLOROFORM- d) δ ppm 3.63 - 3.74 (2 H, m), 3.45 - 3.62 (4 H, m), 3.27 - 3.43 (1 H, m), 3.09 - 3.26 (2 H, m), 2.78 - 2.95 (1 H, m), 2.37 - 2.58 (4 H, m), 1.97 - 2.13 (2 H, m), 1.53 - 1.97 (6 H, m).
General Procedure O:
Example 101 - Preparation of c/s-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutanol. Potency range B
Figure imgf000134_0001
To a stirred solution of 3-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]cyclobutanone (50 mg, 0.2 mmol) in MeOH (2.5 ml) at 0 0C was added NaBH4 (3.7 mg, 0.1 mmol). After 10 mins the reaction mixture was warmed to RT and stirred for a further Ih. The solvent was evaporated in vacuuo and the crude solid was partitioned between DCM and 0.5 M NaOH.
The organic phase was separated, dried (Na2SO4), filtered and concentrated at reduced pressure. The resulting yellow oil was purified by silica gel FCC (eluant DCM.MeOH/NH3 90: 10: 1) to provide the title compound as off white solid (35 mg, 70%).
LCMS data: Calculated MH+ (253); Found 100% (MH+) m/z 253, Rt = 3.10 min.
NMR data: 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 4.06 - 4.24 (1 H, m), 3.00 - 3.66
(5 H, m), 2.66 - 2.91 (2 H, m), 2.34 - 2.62 (6 H, m), 2.15 - 2.32 (2 H, m), 1.94 - 2.10 (2 H, m),
1.50 - 1.92 (6 H, m).
The following compounds were made as described in Route 20, General Procedure I above.
Example 102 - Preparation of 6-({c/s-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutyl}oxy)-N-methylpyridine-3-carboxamide. Potency range A
Figure imgf000134_0002
In a similar fashion (Route 20, GP I), cώ-3-[(4-cyclo butyl- 1,4-diazepan-l - yl)carbonyl]cyclobutanol (40 mg, 0.16 mmol) and 6-chloro-N-methylpyridine-3-carboxamide (35 mg, 0.21 mmol) gave the title compound as colourless oil after purification by silica FCC (12 mg, 20%). LCMS data: Calculated MH+ (387); Found 100% (MH+) m/z 387, Rt = 2.26 min. NMR data: 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 8.54 (1 H, d, J=2.4 Hz), 7.98 (1 H, dd, J=8.7, 2.4 Hz), 6.71 (1 H, d, J=8.7 Hz), 6.29 - 6.46 (1 H, m), 5.07 - 5.24 (1 H, m), 3.54 - 3.68 (2 H, m), 3.39 - 3.53 (2 H, m), 2.99 (3 H, d, J=4.9 Hz), 2.79 - 2.95 (2 H, m), 2.61 - 2.79 (2 H, m), 2.35 - 2.54 (6 H, m), 1.50 - 2.10 (9 H, m).
Example 103 - Preparation of 4-({c/s-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutyl}oxy)benzonitrile. Potency range A
Figure imgf000135_0001
In a similar fashion (Route 20, GP I), cώ-3-[(4-cyclo butyl- 1,4-diazepan-l- yl)carbonyl]cyclobutanol (30 mg, 0.12 mmol) and 4-fluorobenzonitrile (17 mg, 0.14 mmol) gave the title compound as white solid after purification by silica FCC (8 mg, 20%).
LCMS data: Calculated MH+ (354); Found 94% (MH+) m/z 354, Rt = 2.83 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.56 (2 H, d, J=8.8 Hz), 6.85 (2 H, d, J=8.8
Hz), 4.65 (1 H, m), 3.57 - 3.70 (2 H, m), 3.42 - 3.54 (2 H, m), 2.77 - 3.00 (2 H, m), 2.64 - 2.76 (2 H, m), 2.44 - 2.62 (4 H, m), 2.34 - 2.44 (2 H, m), 1.99 - 2.09 (2 H, m), 1.74 - 1.94 (4 H, m),
1.54 - 1.74 (2 H, m).
Example 104 - Preparation of l-cyclobutyl-4-[(c/s-3-{[5-(trifluoromethyl)pyridin-2- yl]oxy}cyclobutyl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000135_0002
In a similar fashion (Route 20, GP I), cώ-3-[(4-cyclo butyl- 1,4-diazepan-l- yl)carbonyl]cyclobutanol (30 mg, 0.12 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (26 mg, 0.14 mmol) gave the title compound as colourless oil after purification by silica FCC (15 mg, 31%). LCMS data: Calculated MH+ (398); Found 97% (MH+) m/z 398, Rt = 3.04 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.39 (1 H, s), 7.75 (1 H, dd, J=8.7, 2.1 Hz), 6.78 (1 H, d, J=8.8 Hz), 5.14 - 5.24 (1 H, m), 3.58 - 3.68 (2 H, m), 3.45 - 3.52 (2 H, m), 2.79 - 2.98 (2 H, m), 2.67 - 2.78 (2 H, m), 2.45 - 2.58 (4 H, m), 2.36 - 2.44 (2 H, m), 1.99 - 2.10 (2 H, m), 1.74 - 1.92 (4 H, m), 1.55 - 1.73 (2 H, m). Route 25 Q
Figure imgf000136_0001
Figure imgf000136_0002
General Procedure P:
Preparation of c/s-3-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]cyclobutyl 4- methylbenzenesulfonate.
Figure imgf000136_0003
To a stirred solution of cώ-3-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]cyclobutanol (50 mg,
0.19 mmol) in DCM (2 ml) at RT was added triethylamine (77 mg, 0.7 mmol) and toluene-4- sulfonyl chloride (108 mg, 0.57 mmol). The mixture was stirred at RT for 1 h and then at 35
0C for 2 h. After cooling to RT and dilution with DCM the mixture was washed with 1:1
H2θ/saturated NaHCOs. The organic layer was dried (Na2SO4), filtered and concentrated at reduced pressure. Purification by silica FCC (eluting with DCM/MeOH/ NH3 90:10:1) provided the title compound as colourless oil (73 mg, 91%).
LCMS data: Calculated MH+ (407); Found 100% (MH+) m/z 407, Rt = 1.36 min.
NMR data: 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 7.76 (2 H, d, J=8.4 Hz), 7.32 (2
H, d, J=7.9 Hz), 4.77 (1 H, m, J=7.6, 7.6, 7.6, 7.6, 1.6 Hz), 3.50 - 3.60 (2 H, m), 3.30 - 3.41 (2
H, m), 2.62 - 2.88 (2 H, m), 2.29 - 2.52 (11 H, m), 1.92 - 2.07 (2 H, m), 1.49 - 1.87 (6 H, m).
General Procedure O: Example 104a - Preparation of *røns-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutyl acetate.
Figure imgf000137_0001
To a stirred solution cώ-3-[(4-cyc Io butyl- l,4-diazepan-l-yl)carbonyl]cyclo butyl 4- methylbenzenesulfonate (73 mg, 0.18 mmol) in DMF (3 ml) at RT was added potassium acetate (108 mg, 1.1 mmol). The mixture was heated at 110 0C overnight and then cooled to RT and diluted with DCM. The resulting mixture was washed with 1 :1 H2O/brine and the organic phase dried (Na2SO4), filtered and concentrated at reduced pressure to yield the title compound (50 mg, 94%), which was used without further purification. LCMS data: Calculated MH+ (295); Found 100% (MH+) m/z 295, Rt = 0.9 min.
NMR data: 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 4.95 - 5.08 (1 H, m), 3.50 - 3.61 (2 H, m), 3.18 - 3.37 (3 H, m), 2.58 - 2.85 (3 H, m), 2.12 - 2.46 (6 H, m), 1.89 - 2.04 (5 H, m), 1.45 - 1.87 (6 H, m).
General Procedure R:
Example 105 - Preparation of *røns-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutanol. Potency range A
Figure imgf000137_0002
To a stirred solution trαns-3-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]cyclo butyl acetate (50 mg, 0.17 mmol) in 5:1 THF/H2O (93 ml) at RT was added LiOKH2O (8.5 mg, 0.2 mmol). The mixture was stirred at RT overnight, diluted with H2O and extracted with DCM. The organic layer was then dried (Na2SO4), filtered and concentrated at reduced pressure to yield the title compound as pale yellow oil (40 mg, 93%). LCMS data: Calculated MH+ (253); Found 100% (MH+) m/z 253, Rt = 3.07 min.
NMR data: 1H NMR (250 MHz, CHLOROFORM-J) δ ppm 4.45 - 4.59 (1 H, m), 3.57 - 3.68 (2 H, m), 3.36 - 3.45 (2 H, m), 3.18 - 3.32 (1 H, m), 2.77 - 2.93 (1 H, m), 2.54 - 2.69 (2 H, m), 2.34 - 2.52 (4 H, m), 1.96 - 2.24 (4 H, m), 1.55 - 1.93 (7 H, m).
The following compounds were made as described in Route 20, General Procedure I above. Example 106 - Preparation of 4-({*røns-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutyl}oxy)benzonitrile. Potency range A
Figure imgf000138_0001
In a similar fashion (Route 20, GP I), trans-3-[(4-cyck> butyl- 1,4-diazepan-l- yl)carbonyl]cyclobutanol (33 mg, 0.13 mmol) and 4-fluorobenzonitrile (19 mg, 0.16 mmol) gave the title compound as yellow oil after purification by silica FCC (13 mg, 28%). LCMS data: Calculated MH+ (354); Found 94% (MH+) m/z 354, Rt = 2.83 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.56 (2 H, d, J=8.6 Hz), 6.84 (2 H, d, J=8.6 Hz), 4.83 - 4.93 (1 H, m), 3.59 - 3.70 (2 H, m), 3.34 - 3.50 (3 H, m), 2.82 (3 H, m), 2.49 (2 H, m), 2.34 - 2.45 (4 H, m), 2.03 (2 H, m), 1.74 - 1.93 (4 H, m), 1.55 - 1.71 (2 H, m).
Example 107 - Preparation of l-cyclobutyl-4-[(^rans-3-{[5-(trifluoromethyl)pyridin-2- yl]oxy}cyclobutyl)carbonyl]-l,4-diazepane. Potency range A
Figure imgf000138_0002
In a similar fashion (Route 20, GP I), trans -3 -[(4-cycto butyl- 1,4-diazepan-l- yl)carbonyl]cyclobutanol (33 mg, 0.13 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (29 mg, 0.16 mmol) gave the title compound as colourless oil after purification by silica FCC (12mg, 24%). LCMS data: Calculated MH+ (398); Found 94% (MH+) m/z 398, Rt = 3.08 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.41 (1 H, s), 7.76 (1 H, dd, J=8.6, 2.0 Hz), 6.79 (1 H, d, J=8.8 Hz), 5.35 (1 H, m), 3.59 - 3.71 (2 H, m), 3.32 - 3.46 (3 H, m), 2.79 - 2.91 (3 H, m), 2.46 - 2.54 (2 H, m), 2.32 - 2.46 (4 H, m), 1.98 - 2.08 (2 H, m), 1.74 - 1.94 (4 H, m), 1.54 - 1.72 (2 H, m).
Route 26
Figure imgf000138_0003
Example 108 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- one. Potency range A
Figure imgf000139_0001
To a stirred solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (27 mg, 0.11 mmol) in dichloromethane (2 ml) was added Dess Martin periodinane (80 mg, 0.19 mmol) at room temperature. The mixture was stirred for 3 hours and then concentrated and purified by FCC (eluting with DCM/MeOH/NH3 gradient 95:5:1 to 90:10:1) to provide the title compound as colourless oil (17 mg, 63%).
LCMS data: Calculated MH+ (252); Found 86% (MH+) m/z 252, Rt = 3.26 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 3.53 - 3.61 (2 H, m), 3.41 - 3.52 (2 H, m), 2.83 - 3.02 (1 H, m), 2.62 - 2.73 (2 H, m), 2.48 - 2.60 (2 H, m), 1.86 - 2.15 (8 H, m), 1.51 - 1.81 (2 H, m).
Route 27
Figure imgf000139_0002
Preparation of l-[(3-azidoazetidin-l-yl)carbonyl]-4-cyclobutyl-l,4-diazepane
Figure imgf000139_0003
l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-yl methanesulfonate (200 mg, 0.61 mmol) was dissolved in DMSO (4 ml) and sodium azide (157 mg, 2.41 mmol) was added. The reaction was heated at 80 0C for 48 hours and then diluted with DCM (30 ml) and washed with water (10 ml), dried (MgSO4), filtered and concentrated at reduced pressure giving a yellow solid (140 mg, 83%), which was used directly in the next step.
LCMS data: Calculated MH+ (279); Found 100% (MH+) m/z 279, Rt = 0.65 min. NMR data: 1H NMR (250 MHz, MeOD) δ ppm 4.19 - 4.40 (3 H, m), 3.88 (2 H, dd, J=8.9, 3.7 Hz), 3.36 - 3.49 (4 H, m), 2.91 (1 H, m), 2.51 - 2.60 (2 H, m), 2.41 - 2.51 (2 H, m), 2.06 (2 H, m), 1.76 - 2.00 (4 H, m), 1.56 - 1.76 (2 H, m).
Example 109 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- amine. Potency range A
Figure imgf000140_0001
l-[(3-azidoazetidin-l-yl)carbonyl]-4-cyclobutyl-l,4-diazepane (140 mg, 0.50 mmol), was dissolved in THF (5 ml) and water (0.28 ml, 5 mmol) was added. PPI13 was then added as a solid and the reaction was stirred for 16 hours giving a clear solution. The reaction was concentrated in vacuo and purified by FCC (DCM/MeOH/MH3 gradient, 95:5: 1 to 70:30:1) to provide the title compound as pale yellow solid (51 mg, 40%).
LCMS data: Calculated MH+ (253); Found 99% (MH+) m/z 253, Rt = 2.94 min (High pH method). NMR data: 1H NMR (500 MHz, MeOD) δ ppm 4.11 - 4.21 (2 H, m), 3.66 - 3.75 (3 H, m),
3.38 - 3.48 (4 H, m), 2.88 - 2.98 (1 H, m), 2.53 - 2.60 (2 H, m), 2.42 - 2.52 (2 H, m), 2.02 -
2.12 (2 H, m), 1.81 - 1.93 (4 H, m), 1.61 - 1.76 (2 H, m).
Route 28
Figure imgf000140_0002
MeCN Example 110 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}amino)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000141_0001
To a solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-amine (22 mg, 87 μmol) in degassed toluene (2 ml) was added 5-bromo-N-methylpyridine-2-carboxamide (19 mg, 87 μmol), racemic BINAP (8 mg, 13 μmol), 1BuOK (12 mg, 0.10 mmol), followed by Pd2(dba)3 (8 mg, 9 μmol). The reaction was heated at 100 0C for 16 hours, concentrated and purified by FCC (DCM/MeOH/NH3 gradient, 98:2:1 to 95:5:1) giving the title compound as colourless oil (26 mg, 78%). LCMS data: Calculated MH+ (387); Found 96% (MH+) m/z 387, Rt = 2.22 min (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 7.94 (1 H, d, J=2.4 Hz), 7.84 (1 H, d, J=8.6 Hz), 6.92 (1 H, dd, J=8.6, 2.6 Hz), 4.34 - 4.41 (2 H, m), 4.25 - 4.33 (1 H, m), 3.84 (2 H, dd, J=8.3, 5.0 Hz), 3.40 - 3.49 (4 H, m), 2.86 - 2.97 (4 H, m), 2.52 - 2.60 (2 H, m), 2.44 - 2.52 (2 H, m), 2.03 - 2.11 (2 H, m), 1.79 - 1.91 (4H, m), 1.59 - 1.75 (2 H, m).
Example 111 - Preparation of 5-[{l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}(methyl)amino]-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000141_0002
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} amino)-N-methylpyridine-2- carboxamide (34 mg, 92 μmol) was dissolved in 1 :1 MeCN/water (3 ml) and formaldehyde (50 μl of a 37% wt. soln, 1.8 mmol) followed by NaBH3CN (34 mg, 0.56 mmol) were added. After 10 minutes, acetic acid (40 μl, 0.72 mmol) was added and the reaction stirred at room temperature for 16 hours. The reaction mixture was concentrated at reduced pressure and purified by FCC (DCM/MeOH/NH3 gradient, 98:2: 1 to 90: 10: 1) giving the title compound as colourless oil (7 mg, 19%).
LCMS data: Calculated MH+ (401); Found 96% (MH+) m/z 401, Rt = 2.38 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.04 (1 H, d, J=8.6 Hz), 7.97 (1 H, d, J=2.9 Hz), 7.74 (1 H, br. s.), 7.02 (1 H, dd, J=8.8, 2.9 Hz), 4.45 - 4.55 (1 H, m), 4.25 (2 H, t, J=8.2 Hz), 4.03 (2 H, dd, J=8.8, 5.9 Hz), 3.39 - 3.52 (4 H, m), 3.03 - 3.08 (3 H, m), 3.01 (3 H, d, J=5.1 Hz), 2.78 - 2.92 (1 H, m), 2.49 - 2.60 (2 H, m), 2.36 - 2.48 (2 H, m), 2.00 - 2.09 (2 H, m), 1.54 - 1.96 (6 H, m).
Route 29
Figure imgf000142_0001
Example 112 - Preparation of 4-[({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}amino)methyl]benzonitrile. Potency range A
Figure imgf000142_0002
To a solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-amine (20 mg, 80 μmol) in dichloroethane (2 ml) was added 4-(bromomethyl)benzonitrile (17 mg, 87 μmol) and DIPEA (15 μl, 87 μmol). The reaction was heated at 100 0C for 16 hours, concentrated at reduced pressure and purified by FCC (DCM/MeOH/NH3 with gradient, 98:2:1 to 90:10:1) to provide the title compound as colourless oil (10 mg, 33%).
LCMS data: Calculated MH+ (368); Found 96% (MH+) m/z 368, Rt = 3.93 min (High pH method).
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 7.71 (2 H, d, J=8.4 Hz), 7.55 (2 H, d, J=8.4
Hz), 4.02 - 4.15 (2 H, m), 3.80 (2 H, s), 3.72 (2 H, dd, J=8.2, 5.5 Hz), 3.53 - 3.67 (1 H, m), 3.35 - 3.51 (4 H, m), 2.98 (1 H, s), 2.57 (4 H, dt, J=19.0, 5.1 Hz), 2.01 - 2.18 (2 H, m), 1.79 - 2.01 (4 H, m), 1.57 - 1.79 (2 H, m).
Route 30
Figure imgf000143_0001
Preparation of tert-butyl 4-[(3-hydroxyazetidin-l-yl)carbonyl]-l,4-diazepane-l- carboxylate
Figure imgf000143_0002
In a similar fashion (Route 20, GP H), [l^Jdiazepane-l-carboxylic acid tert-butyi ester (877 mg, 4.4 mmol) gave the title compound as yellow oil (1.10 g, 84%).
LCMS data: Calculated MH+ (300); Found 86% MH+ m/z (300), Rt = 0.97 min.
NMR data: 1H NMR (250 MHz, MeOD) δ ppm 4.39 - 4.56 (1 H, m), 4.09 - 4.26 (2 H, m), 3.80 (2 H, m), 3.31 - 3.58 (8 H, m), 1.81 (2 H, m), 1.46 (9 H, s).
Preparation of tert-butyl 4-[(3-hydroxyazetidin-l-yl)carbonyl]-l,4-diazepane-l- carboxylate
Figure imgf000143_0003
In a similar fashion (Route 20, GP I), tert-butyl 4-[(3-hydroxyazetidin-l-yl)carbonyl]-l,4- diazepane-1-carboxylate (1.22 g, 4.10 mmol) and 5-chloro-N-methylpyridine-2-carboxamide (835 mg, 4.91 mmol) gave the title compound as yellow solid after purification by FCC (1.0 g, 56%). LCMS data: Calculated MH+ (434); Found 100% (MH+) m/z 434, Rt = 1.37 min. NMR data: 1H NMR (400 MHz, MeOD) δ ppm 8.23 (1 H, d, J=2.7 Hz), 8.03 (1 H, d, J=8.7 Hz), 7.34 (1 H, d, J=8.5 Hz), 5.13 (1 H, d, J=2.9 Hz), 4.46 (2 H, dd, J=9.2, 6.6 Hz), 4.01 - 4.08 (2 H, m), 3.35 - 3.57 (8 H, m), 2.94 (3 H, s), 1.81 (2 H, br. s.), 1.45 (9 H, d, J=7.0 Hz).
Preparation of 5-{[l-(l,4-diazepan-l-ylcarbonyl)azetidin-3-yl]oxy}-N-methylpyridine-2- carboxamide
Figure imgf000144_0001
To a stirred solution of tert-butyl 4-[(3-hydroxyazetidin-l-yl)carbonyl]-l,4-diazepane-l- carboxylate (651 mg, 1.5 mmol) in DCM (6 ml) was added TFA (1 ml) at 0 0C. The mixture was allowed to warm to RT and was stirred at this temperature over night. The reaction mixture was concentrated in vacuo. The residue was taken up in DCM, AMBERSEP resin (500 mg) was added and the mixture was shaken over night. The mixture was filtered and the filtrate concentrated in vacuo to afford title compound as light brown oil (262 mg, 52%). 1H NMR data: (250MHz, CDCl3) δ ppm 8.24 (1 H, d, J=2.7 Hz), 8.04 (1 H, d, J=8.7 Hz), 7.28 - 7.41 (1 H, m), 5.13 (1 H, tt, J=6.4, 4.0 Hz), 4.40 - 4.55 (2 H, m), 3.99 - 4.13 (2 H, m), 3.42 - 3.52 (4 H, m), 2.79 - 3.03 (7 H, m), 1.79 - 1.93 (2 H, m).
The following compounds were made as described in Route 1, General Procedure A above.
Example 113 - Preparation of 5-({l-[(4-methyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)-N-methylpyridine-2-carboxamide. Potency range C
Figure imgf000144_0002
In a similar fashion (Route 1, GP A; except that MeCN was used as solvent), 5-{[l-(l,4- diazepan-l-ylcarbonyl)azetidin-3-yl]oxy}-N-methylpyridine-2-carboxamide (25 mg, 0.075 mmol) and formaldehyde (6.1 μl of a 37% aq solution, 0.075 mmol) gave the title compound as colourless oil (5.3 mg, 20%) after purification by preparative HPLC.
LCMS data: Calculated MH+ (348); Found 99% (MH+) m/z 348, Rt = 2.19 min.
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.24 (1 H, d, J=2.7 Hz), 8.04 (1 H, d, J=8.7 Hz), 7.34 (1 H, dd, J=8.7, 2.8 Hz), 5.12 - 5.18 (1 H, m), 4.53 - 4.60 (1 H, m), 4.39 - 4.46 (1 H, m), 4.11 - 4.18 (1 H, m), 3.97 - 4.06 (1 H, m), 3.84 - 3.94 (1 H, m), 3.41 - 3.63 (6 H, m), 3.17 - 3.29 (2 H, m), 2.94 (7 H, d, J=5.2 Hz), 1.98 - 2.30 (1 H, m).
Example 114 - Preparation of 5-({l-[(4-(l-methylethyl)-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000145_0001
In a similar fashion (Route 1, GP A; except that MeCN was used as solvent), 5-{[l-(l,4- diazepan-l-ylcarbonyl)azetidin-3-yl]oxy}-N-methylpyridine-2-carboxamide (25 mg, 0.075 mmol) and acetone (5.5 μl, 0.075 mmol) gave the title compound as colourless oil (4 mg, 14%) after purification by preparative HPLC.
LCMS data: Calculated MH+ (376); Found 100% (MH+) m/z 376, Rt = 2.31 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.24 (1 H, d, J=2.7 Hz), 8.04 (1 H, d, J=8.7 Hz), 7.34 (1 H, dd, J=8.7, 2.8 Hz), 5.12 - 5.19 (1 H, m), 4.58 (1 H, dd, J=9.2, 6.5 Hz), 4.43 (1 H, dd, J=9.3, 6.6 Hz), 4.16 (1 H, dd, J=9.5, 3.7 Hz), 4.03 (1 H, dd, J=9.5, 3.7 Hz), 3.88 - 3.96 (1 H, m), 3.62 - 3.70 (1 H, m), 3.56 - 3.62 (1 H, m), 3.38 - 3.56 (4 H, m), 3.15 - 3.29 (2 H, m), 2.93 - 2.96 (3 H, s), 2.19 - 2.28 (1 H, m), 2.05 - 2.17 (1 H, m), 1.35 (6 H, s).
Example 115 - Preparation of 5-({l-[(4-cyclopentyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}oxy)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000145_0002
In a similar fashion (Route 1, GP A; except TEA (46 μl, 0.33 mmol) was used as base), 5-{[l-
(1 ,4-diazepan- 1 -ylcarbonyl)azetidin-3-yl]oxy} -N-methylpyridine-2-carboxamide (50 mg, 0.11 mmol) and cyclopentanone (9.7 μl, 0.11 mmol) gave the title compound (2 mg, 5%) as colourless oil after purification by preparative HPLC. LCMS data: Calculated MH+ (402); Found 98% (MH+) m/z 402, Rt = 2.48 min.
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.14 (1 H, d, J=2.6 Hz), 7.94 (1 H, d, J=8.8 Hz), 7.24 (1 H, dd, J=8.6, 2.8 Hz), 5.01 - 5.08 (1 H, m), 4.34 - 4.44 (2 H, m), 3.98 (2 H, dd, J=9.6, 3.2 Hz), 3.49 - 3.64 (2 H, m), 3.36 - 3.45 (4 H, m), 2.82 - 2.87 (3 H, m), 1.96 - 2.06 (4 H, m), 1.65 - 1.77 (2 H, m), 1.52 - 1.63 (4 H, m), 1.14 - 1.24 (3 H, m). Route 31
Figure imgf000146_0001
Preparation of 6-fluoro-3,4-dihydroisoquinolin-l(2H)-one
Figure imgf000146_0002
To a stirred solution of 5-fluoro-2,3-dihydro-lH-inden-l-one (433 mg, 2.9 mmol) in dichloromethane (2.5 ml) and methanesulfonic acid (2.5 ml) was added sodium azide (378 mg, 5.8 mmol) portionwise at room temperature. Gas evolution was seen immediately and after 3 hours, complete conversion was observed by TLC. The reaction mixture was added dropwise to a rapidly stirred 5M NaOH solution (8 ml) in ice maintaining the internal temperature below 15 0C. On complete addition, the aqueous phase (pH 14) was extracted with dichloromethane (3 x 25 ml). The organics were combined and washed with water (2 x 25 ml), dried (MgSO4), filtered and concentrated in vacuo. NMR showed a 7:3 mixture of regio isomers that were separated by FCC (using a gradient of eluents 1 :1 Hexane/EtOAc to EtOAc) providing the title compound as white solid (267 mg, 58%). LCMS data: Calculated MH+ (166); Found 100% [MH+] m/z (166), Rt = 1.27 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.09 (1 H, dd, J=8.6, 5.9 Hz), 7.04 (1 H, ddd, J=8.6, 5.9, 2.6 Hz), 6.92 (1 H, dd, J=8.9, 2.5 Hz), 6.20 (1 H, br. s.), 3.59 (2 H, td, J=6.6, 2.8 Hz), 3.01 (2 H, t, J=6.5 Hz).
Route 32
Figure imgf000146_0003
Preparation of 6-fluoro-2-methyl-3,4-dihydroisoquinolin-l(2H)-one
Figure imgf000146_0004
To a stirred solution of 6-fluoro-3,4-dihydroisoquinolin-l(2H)-one (102 mg, 0.62 mmol) in THF (5 ml) was added NaH (49 mg of a 60% dispersion in mineral oil, 1.23 mmol) giving a thick white precipitate. After 30 mintutes, methyl iodide (76 μl, 1.23 mmol) was added and the reaction was heated at 50 0C for 1 hour. Complete conversion was observed by TLC and the reaction was concentrated, diluted with dichloromethane (30 ml), washed with saturated NaHCO3 (15 ml), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by FCC (using a gradient of eluents 1 :1 Hexane/EtOAc to EtOAc) to provide the title compound as colourless oil (106 mg, 96%).
LCMS data: Calculated MH+ (180); Found 100% [MH+] m/z (180), Rt = 1.61 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 8.09 (1 H, dd, J=8.6, 5.9 Hz), 7.00 (1 H, ddd, .7=8.6, 5.9, 2.4 Hz), 6.86 (1 H, dd, .7=8.8, 2.4 Hz), 3.57 (2 H, t, J=6.7 Hz), 3.00 (2 H, t, J=6.7 Hz).
The following compounds were made as described in Route 20, General Procedure I above.
Example 116 - Preparation of 6-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}oxy)-3,4-dihydroisoquinolin-l(2H)-one. Potency range A
Figure imgf000147_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (38 mg, 0.15 mmol) and 6-fluoro-3,4-dihydroisoquinolin-l(2H)-one (30 mg, 0.18 mmol) gave the title compound as white solid after purification by FCC (44 mg, 73%).
LCMS data: Calculated MH+ (399); Found 100% (MH+) m/z 399, Rt = 2.46 min.
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.00 (1 H, d, J=8.6 Hz), 6.67 (1 H, dd, .7=8.6,
2.0 Hz), 6.56 (1 H, s), 6.38 (1 H, br. s.), 4.88 - 4.97 (1 H, m), 4.35 (2 H, dd, .7=9.0, 7.0 Hz), 4.03 (2 H, dd, .7=9.4, 4.1 Hz), 3.50 - 3.60 (2 H, m), 3.35 - 3.49 (4 H, m), 2.95 (2 H, t, J=6.5
Hz), 2.83 (1 H, quin), 2.47 - 2.55 (2 H, m), 2.38 - 2.45 (2 H, m), 2.03 (2 H, q, .7=8.1 Hz), 1.75
- 1.90 (4 H, m), 1.54 - 1.72 (2 H, m).
Example 117 - Preparation of 6-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}oxy)-2-methyl-3,4-dihydroisoquinolin-l(2H)-one. Potency range A
Figure imgf000148_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (32 mg, 0.13 mmol) and 6-fluoro-2-methyl-3,4-dihydroisoquinolin-l(2H)-one (25 mg, 0.14 mmol) gave the title compound as white solid after purification by FCC (18 mg, 34%). LCMS data: Calculated MH+ (413); Found 100% (MH+) m/z 413, Rt = 2.58 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.01 (1 H, d, J=8.4 Hz), 6.65 (1 H, dd, J=8.5, 2.3 Hz), 6.51 (1 H, d, J=I.8 Hz), 4.88 - 4.95 (1 H, m), 4.34 (2 H, dd, J=9.3, 6.7 Hz), 4.03 (2 H, dd, J=9.4, 4.1 Hz), 3.54 (2 H, t, J=6.7 Hz), 3.44 - 3.50 (2 H, m), 3.41 (2 H, t, J=6.1 Hz), 3.13 (3 H, s), 2.96 (2 H, t, J=6.6 Hz), 2.79 - 2.89 (1 H, m), 2.48 - 2.56 (2 H, m), 2.38 - 2.47 (2 H, m), 1.99 - 2.07 (2 H, m), 1.77 - 1.92 (4 H, m), 1.55 - 1.72 (2 H, m).
Route 33
Figure imgf000148_0002
Example 118 - Preparation of 2-[5-({l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan-2-ol. Potency range A
Figure imgf000148_0003
MeMgBr (0.96 ml of a 3M solution in diethyl ether, 2.88 mmol) was added dropwise to a solution of ethyl 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridine- 2-carboxylate (386 mg, 0.96 mmol) in diethyl ether (20 ml) at 0 0C. The reaction was warmed to room temperature and after 1 hour was quenched and washed with water (2 x 20 ml), dried (MgSO4) and concentrated under reduced pressure. The crude material was purified by preparative HPLC to give the title compound (179 mg, 37%) as colourless oil and l-[5- ( ( 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]ethanone (2.5 mg, 1%) as colourless oil.
LCMS data: Calculated MH+ (389); Found 100% (MH+) m/z 389, Rt = 1.73 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.03 (1 H, d, J=2.6 Hz), 7.32 (1 H, d, J=8.6 Hz), 7.11 (1 H, dd, J=8.6, 2.8 Hz), 4.86 - 5.01 (1 H, m), 4.36 (2 H, dd, J=9.3, 6.7 Hz), 4.05 (2 H, dd, J=9.4, 4.1 Hz), 3.35 - 3.54 (4 H, m), 2.80 - 2.95 (1 H, m), 2.35 - 2.62 (4 H, m), 2.00 - 2.10 (2 H, m), 1.89 (4 H, d, J=15.0 Hz), 1.57 - 1.75 (2 H, m), 1.53 (6 H, s).
Example 119 - Preparation of l-[5-({l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]ethanone. Potency range A
Figure imgf000149_0001
The title compound (2.5 mg, 1%) was formed in the reaction illustrated in Route 33. LCMS data: Calculated MH+ (373); Found 95% (MH+) m/z 373, Rt = 2.36 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.21 (1 H, d, J=2.6 Hz), 8.05 (1 H, d, J=8.7 Hz), 7.11 (1 H, dd, J=8.7, 2.9 Hz), 4.97 - 5.07 (1 H, m), 4.39 (2 H, dd, J=9.4, 6.6 Hz), 4.08 (2 H, dd, J=9.5, 4.0 Hz), 3.36 - 3.52 (4 H, m), 2.79 - 2.91 (1 H, m), 2.69 (3 H, s), 2.48 - 2.55 (2 H, m), 2.38 - 2.47 (2 H, m), 2.04 (2 H, d, J=8.1 Hz), 1.75 - 1.95 (4 H, m), 1.61 - 1.73 (2 H, m).
Route 34
1. NaH, DMSO, 60°C
Figure imgf000149_0002
Example 120 - Preparation of l-cyclobutyl-4-({3-[(5-methoxypyrimidin-2- yl)oxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000149_0003
To a stirred solution of l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (50 mg, 0.197 mmol) in DMSO (2 ml) was added NaH (16 mg of a 60% dispersion in mineral oil, 0.40 mmol) at room temperature in one portion. The suspension was stirred for 2 hours at room temperature then 2-chloro-5-fluoro-pyrimidine (26 mg, 0.20 mmol) was added in one portion. The mixture was heated at 60 0C in a sealed tube for 16 hours. After cooling to room temperature the solution was treated with MeOH (8 μl, 0.20 mmol) and NaH (16 mg, 0.40 mmol, 60 in mineral oil) and heated at 60 0C in a sealed tube for 16 hours. After cooling to room temperature the reaction was diluted with dichloromethane (30 ml) and washed twice with saturated NaHCO3 (15ml), dried (Na2SO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 98:2:1 to 90:10:1) to provide the title compound as colourless oil (20 mg, 28%). LCMS data: Calculated MH+ (362); Found 100% (MH+) m/z 362, Rt = 2.17 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.09 (2 H, s), 4.85 - 4.91 (1 H, m), 4.32 (2 H, dd, J=9.5, 6.5 Hz), 4.05 (2 H, dd, J=9.6, 4.1 Hz), 3.97 (3 H, s), 3.44 - 3.49 (2 H, m), 3.42 (2 H, m), 2.80 - 2.89 (1 H, m), 2.48 - 2.55 (2 H, m), 2.40 - 2.46 (2 H, m), 1.99 - 2.09 (2 H, m), 1.87 (4 H, m), 1.56 - 1.73 (2 H, m).
Route 35
Figure imgf000150_0001
Example 121 - Preparation of l-cyclobutyl-4-({3-[(6-methylpyridin-3-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000150_0002
3-Hydroxy-6-methylpyridine (24 mg, 0.22 mmol) and K2CO3 (33 mg, 0.24 mmol) were stirred in DMF (1 ml) for 30 minutes and 1 -[(4-cyc Io butyl- 1,4-diazepan-l- yl)carbonyl]azetidin-3-yl methanesulfonate (66 mg, 0.20) was added. The reaction was stirred at 90 0C for 3 days and then diluted with dichloromethane (30 ml) and washed with saturated NaHCO3 (3 x 15 ml), dried (MgSO4), filtered and concentrated at reduced pressure.
The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 98:2:1 to 90:10:1) to give the title product as off- white solid (24 mg, 35%). LCMS data: Calculated MH+ (345); Found 99% (MH+) m/z 345, Rt = 3.68 mins (High pH method).
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.01 (1 H, s), 7.20 - 7.26 (2 H, m), 4.99 - 5.06
(1 H, m), 4.41 (2 H, dd, J=9.2, 6.5 Hz), 4.00 (2 H, dd, J=9.4, 4.0 Hz), 3.40 - 3.49 (4 H, m),
2.90 (1 H, quin, J=8.0 Hz), 2.53 - 2.58 (2 H, m), 2.43 - 2.49 (5 H, m), 2.03 - 2.11 (2 H, m),
1.80 - 1.92 (4 H, m), 1.60 - 1.74 (2 H, m).
Route 36
General Procedure H
Figure imgf000151_0001
Preparation of methyl azetidine-3-carboxylate hydrochloride
HCl. HN^Λ
O
A stirred suspension of azetidine-3-carboxylic acid (2 g, 19.8 mmol) in MeOH (8 ml) was cooled to 5 0C in an ice-water bath. Thionyl chloride (4.3 ml, 59 mmol) was added dropwise at such a rate as to maintain reaction temperature below 30 0C. A further portion of MeOH (8 ml) was added carefully and the mixture heated at 650C overnight. Evaporation of the solvent and co-evaporation with MeOH (2 x 20 ml) at reduced pressure provided the title compound as viscous brown oil that crystallized on standing (3.17 g, 100%). The material was used without purification.
LCMS data: Calculated MH+ (116); Found 100% (MH+) m/z 116, Rt = 0.18 min.
NMR data: 1H NMR (250 MHz, DMSO) δ ppm 9.60-8.90 (2H, br m), 4.05 (4H, br s), 3.65
(3H, s) Preparation of 4-nitrophenyl-4-cyclobutyl-l,4-diazepane-l-carboxylate
Figure imgf000152_0001
To a stirred solution of 1-cyclo butyl- 1 ,4-diazepane (4.81 g, 31 mmol) and DIPEA (5.4 ml, 34 mmol) in DCM (85 ml) at 5 0C was added dropwise a solution of 4-nitrophenyl chloroformate (6.29 g, 31 mmol) in DCM (40 ml). An ice-water bath was used to maintain the reaction temperature below 100C during addition. When addition was complete, the reaction was allowed to warm to RT overnight with stirring. The reaction mixture was quenched by the careful addition of water (20 ml). The organic fraction was washed with water (2 x 30 ml), dried (Na2SO4), filtered and evaporated at reduced pressure. Purification by FCC on silica provided the title compound as yellow oil (3.79 g, 39%).
LCMS data: Calculated MH+ (320); Found 100% (MH+) m/z 320, Rt = 0.85 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.27 (2H, d, J = 9 Hz), 7.32 (2H, d, J=9 Hz), 3.73 (2H, t, J=5.4 Hz), 3.68-3.63 (2H, m), 2.99-2.89 (IH, m), 2.63-2.56 (2H, m), 2.56-2.49 (2H, m), 2.14-2.04 (2H, m), 2.00-1.60 (6H, m).
Example 122 - Preparation of methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate. Potency range A
Figure imgf000152_0002
To a stirred solution of 4-nitrophenyl 4-cyclo butyl- 1,4-diazepane-l-carboxylate (2.4 g, 7.5 mmol) in isopropyl alcohol (6 ml) and methanol (3 ml) was added DIPEA (3.80 ml, 24 mmol) followed by methyl azetidine-3-carboxylate hydrochloride (1.70 g, 11 mmol) portion wise over 2 minutes. The resulting suspension was heated at 850C for 72 h. The mixture was allowed to cool and the solvent was removed in vacuo. The residue was dissolved in DCM (100 ml) and washed with IM sodium carbonate solution (3 x 30 ml), dried (Na2SO4), filtered and evaporated at reduced pressure. Purification by FCC on silica provided the title compound as pale yellow oil (0.95 g, 43 %).
LCMS data: Calculated MH+ (296); Found 100% (MH+) m/z 296, Rt = 3.53 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.17-4.10 (5H, m), 3.76 (3H, s), 3.50-3.36 (5H, m), 2.90-2.79 (IH, m), 2.57-2.38 (4H, m), 2.09-2.00 (2H, m), 1.96-1.78 (4H, m), 1.77- 1.57 (3H, m), 1.31-1.24 (2H, m). General Procedure S:
Example 123 - Preparation of N-(4-chlorophenyl)-l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxamide. Potency range A
Figure imgf000153_0001
To a solution of methyl methyl 1 - [(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidine-3 - carboxylate (40 mg, 0.14 mmol) in THF (0.3 ml) and MeOH (0.3 ml) was added 2M LiOH solution (0.09 ml, 0.18 mmol). The reaction mixture was stirred overnight at room temperature. The solvent was removed in vacuo and the residue co-evaporated with toluene (2 x 10 ml) to dryness. The residue was suspended in DMF (2 ml) and HBTU (67 mg, 0.18 mmol) and HOBt (26 mg, 0.19 mmol) added. The resulting solution was stirred for 1 hr, 4- chloroaniline (26 mg, 0.20 mmol) was added in one portion and the reaction mixture stirred at RT for 64 h. Solvent was evaporated in vacuo and the residue dissolved in MeOH (1 ml), loaded onto an SCX column and eluted with 2M NH3 in MeOH. The basic fractions were combined and concentrated in vacuo and the residue purified by FCC on silica to afford the title compound as white solid (12 mg, 23 %).
LCMS data: Calculated MH+ (391); Found 100% (MH+) m/z 391, Rt = 2.85 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 7.79 (IH, br s, NH), 7.44 (2H, d, J=8.8 Hz), 7.24-7.20 (2H, m), 4.17-4.04 (4H, m), 3.41-3.27 (5H, m), 2.81-2.71 (IH, m), 2.49-2.31 (4H, m), 2.01-1.91 (2H, m), 1.85-1.47 (6H, m).
The following compounds were made as described in Route 36, General Procedure S above.
Example 124 - Preparation of l-cyclobutyl-4-{[3-(piperidin-l-ylcarbonyl)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000153_0002
In a similar fashion (Route 21, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (20 mg, 0.07 mmol) and piperidine (6.3 mg, 0.07 mmol) gave the title compound (1.8 mg, 8 %, free base) as colourless oil after purification by FCC. LCMS data: Calculated MH+ (349); Found 100% (MH+) m/z 349, Rt = 2.48 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.24-4.20 (IH, m), 4.17-4.08 (3H, m), 3.77 (IH, m), 3.60-3.56 (IH, m), 3.49-3.36 (5H, m), 3.24-3.20 (IH, m), 2.90-2.81 (IH, m), 2.56- 2.40 (4H, m), 2.09-2.01 (2H, m), 1.93-1.78 (4H, m), 1.75-1.51 (9H, m).
Example 125 - Preparation of l-cyclobutyl-4-{[3-(morpholin-4-ylcarbonyl)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000154_0001
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (50 mg, 0.18 mmol) and morpholine (22.1 mg, 0.25 mmol) gave the title compound as white solid (7.4 mg, 12 %) after purification by FCC on silica.
LCMS data: Calculated MH+ (351); Found 100% (MH+) m/z 351, Rt = 3.27 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.02 - 4.27 (4 H, m), 3.55 - 3.79 (8 H, m), 3.36 - 3.52 (3 H, m), 3.22 - 3.33 (2 H, m), 2.98 - 3.14 (1 H, m), 2.00 - 2.97 (10 H, m), 1.74 - 1.89 (1 H, m), 1.58 - 1.72 (I H, m).
Example 126 - Preparation of l-{[3-(azetidin-l-ylcarbonyl)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000154_0002
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (40 mg, 0.14 mmol) and azetidine (35 mg, 0.61 mmol) gave the title compound as colourless oil after purification by FCC (18 mg, 40 %). LCMS data: Calculated MH+ (321); Found 100% (MH+) m/z 321, Rt = 3.20 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.10 - 4.27 (2 H, m), 3.91 - 4.10 (6 H, m), 3.81 - 3.91 (1 H, m), 3.17 - 3.54 (7 H, m), 2.73 - 2.84 (1 H, m), 2.51 - 2.62 (1 H, m), 2.32 - 2.50 (3 H, m), 2.27 (2 H, m), 2.02 - 2.22 (3 H, m), 1.77 - 1.88 (1 H, m), 1.57 - 1.71 (1 H, m).
Example 127 - Preparation of l-cyclobutyl-4-{[3-(pyrrolidin-l-ylcarbonyl)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000155_0001
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (40 mg, 0.14 mmol) and pyrrolidine (43 mg, 0.61 mmol) gave the title compound as colourless oil after purification by FCC (18.8 mg, 41%). LCMS data: Calculated MH+ (335); Found 100% (MH+) m/z 335, Rt = 3.40 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.36 (1 H, m), 4.29 (1 H, m), 4.04 - 4.16 (2 H, m), 3.89 - 4.00 (1 H, m), 3.26 - 3.62 (11 H, m), 2.81 - 2.94 (1 H, m), 2.60 - 2.72 (1 H, m), 2.39 - 2.57 (3 H, m), 2.08 - 2.30 (3 H, m), 1.83 - 2.06 (5 H, m), 1.64 - 1.80 (1 H, m).
Example 128 - Preparation of l-{[3-(azepan-l-ylcarbonyl)azetidin-l-yl]carbonyl}-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000155_0002
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (40 mg, 0.14 mmol) and azepane (60 mg, 0.61 mmol) gave the title compound as colourless oil after purification by FCC (16 mg, 31%). LCMS data: Calculated MH+ (363); Found 100% (MH+) m/z 363, Rt = 3.84 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.30 - 4.39 (1 H, m), 4.22 - 4.30 (1 H, m), 4.08 - 4.15 (1 H, m), 4.00 - 4.08 (1 H, m), 3.90 - 3.99 (1 H, ), 3.38 - 3.61 (8 H, m), 3.24 - 3.38 (3 H, m), 2.80 - 2.92 (1 H, m), 2.58 - 2.67 (1 H, m), 2.41 - 2.57 (3 H, m), 2.10 - 2.29 (3 H, m), 1.83 - 1.96 (1 H, m), .64 - 1.79 (5 H, m), 1.58 (4 H, m).
Example 129 - Preparation of l-cyclobutyl-4-({3-[(4-fluoropiperidin-l- yl)carbonyl]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000155_0003
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (40 mg, 0.14 mmol) and 4-fluoropiperidine (85 mg, 0.61 mmol) gave the title compound as colourless oil after purification by FCC (13 mg, 25%). LCMS data: Calculated MH+ (367); Found 100% (MH+) m/z 367, Rt = 3.50 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.89 - 4.99 (1 H, m), 4.22 - 4.39 (2 H, m), 4.01 - 4.16 (2 H, m), 3.87 - 4.01 (2 H, m), 3.39 - 3.63 (8 H, m), 3.29 - 3.39 (1 H, m), 3.17 - 3.29 (1 H, m), 2.85 (1 H, m), 2.57 - 2.69 (1 H, m), 2.38 - 2.57 (3 H, m), 2.10 - 2.30 (3 H, m), 1.65 - 1.97 (6 H, m).
Example 130 - Preparation of l-cyclobutyl-4-({3-[(4,4-difluoropiperidin-l- yl)carbonyl]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000156_0001
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (40 mg, 0.14 mmol) and 4,4-difluoropiperidine hydrochloride (96 mg, 0.61 mmol) gave the title compound as colourless oil after purification by FCC (10 mg, 19%).
LCMS data: Calculated MH+ (385); Found 100% (MH+) m/z 385, Rt = 3.72 min.
NMR data: 1H NMR (500 MHz, CDCl3) ppm 4.18 - 4.36 (2 H, m), 3.99 - 4.13 (2 H, m), 3.85 - 3.99 (1 H, m), 3.70 - 3.84 (2 H, m), 3.35 - 3.63 (8 H, m), 3.24 - 3.34 (1 H, m), 2.70 - 2.88 (1
H, m), 2.44 - 2.66 (4 H, m), 2.07 - 2.26 (3 H, m), 1.84 - 2.06 (4 H, m), 1.61 - 1.84 (2 H, m).
Example 131 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]-N- cyclohexylazetidine-3-carboxamide. Potency range A
Figure imgf000156_0002
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (40 mg, 0.14 mmol) and cyclohexylamine (60 mg, 0.61 mmol) gave the title compound as colourless oil after purification by FCC (12 mg, 24%). LCMS data: Calculated MH+ (363); Found 100% (MH+) m/z 363, Rt = 3.80 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 5.50 (1 H, d, J=8.1 Hz), 4.21 - 4.32 (2 H, m), 4.00 - 4.10 (2 H, m), 3.89 - 3.99 (1 H, m), 3.74 - 3.84 (1 H, m), 3.29 - 3.60 (6 H, m), 3.14 - 3.24 (1 H, m), 2.82 - 2.93 (1 H, m), 2.58 - 2.70 (1 H, m), 2.40 - 2.57 (3 H, m), 2.09 - 2.31 (3 H, m), 1.86 - 1.98 (3 H, m), 1.68 - 1.79 (3 H, m), 1.61 - 1.68 (1 H, m), 1.32 - 1.43 (2 H, m), 1.08 - 1.24 (3 H, m). Example 132 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]-N-(6- methylpyridin-3-yl)azetidine-3-carboxamide. Potency range A
Figure imgf000157_0001
In a similar fashion (Route 36, GP S), methyl l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidine-3-carboxylate (102 mg, 0.35 mmol) and 3-amino-6-methylpyridine (83 mg, 0.77 mmol) gave the title compound after purification by FCC (51 mg, 39%). LCMS data: Calculated MH+ (371); Found 99% (MH+) m/z 371, Rt = 3.37 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.62 (1 H, d, J=2.1 Hz), 8.02 (1 H, dd, J=8.4, 2.6 Hz), 7.28 (1 H, d, J=8.5 Hz), 4.89 - 5.00 (1 H, m), 4.14 - 4.27 (4 H, m), 3.39 - 3.64 (4 H, m), 2.79 - 3.02 (1 H, m), 2.40 - 2.64 (7 H, m), 2.01 - 2.18 (2 H, m), 1.80 - 1.98 (4 H, m), 1.58 - 1.78 (2 H, m).
Route 37
Figure imgf000157_0002
Example 133 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]-N- methylazetidine-3-carboxamide. Potency range B
Figure imgf000157_0003
A solution of methyl 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidine-3-carboxylate
(6.5 mg, 0.02 mmol) in methylamine (2M in MeOH, 1 ml) was heated to 650C for 2.5h. After cooling to room temperature the solvent was removed in vacuo and the residue purified by FCC on silica to afford the title compound as colourless oil (4 mg, 61 %). LCMS data: Calculated MH+ (295); Found 100% (MH+) m/z 295, Rt = 3.11 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 5.56 (IH, br s), 4.07-4.00 (4H, m), 3.40-3.30 (4H, m), 3.16-3.08 (IH, m), 2.78 (3H, d, J=4.8), 2.77-2.72 (IH, m), 2.46-2.41 (2H, m), 2.37- 2.33 (2H, m), 2.00-1.92 (2H, m), 1.82-1.49 (6H, m). Route 38
Figure imgf000158_0001
Example 134 - Preparation of {l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}methanol. Potency range A
Figure imgf000158_0002
To a stirred solution of {l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3-yl} methanol
(72 mg, 0.02 mmol) in ethanol (1 ml) was added sodium borohydride (18 mg, 0.05 mmol) portion wise over 3 minutes. The mixture was stirred overnight at room temperature.
Evaporation at reduced pressure and purification by FCC on silica provided the title compound (18.1 mg, 28 %) as colourless oil.
LCMS data: Calculated MH+ (268); Found 100% (MH+) m/z 268, Rt = 3.10 min.
NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 4.08-3.95 (2H, m), 3.82-3.67 (4H, m), 3.50-
3.31 (4H, m), 2.91-2.62 (2H, m), 2.55-2.34 (4H, m), 2.32-1.50 (9H, m).
The following compounds were made as described in Route 20, General Procedure I above.
Example 135 - Preparation of l-({3-[(4-chlorophenoxy)methyl]azetidin-l-yl}carbonyl)-4- cyclobutyl-l,4-diazepane. Potency range A
Figure imgf000158_0003
In a similar fashion (Route 20, GP I), {l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}methanol (20 mg, 0.07 mmol) and 4-fluoro-l-chlorobenzene (19 mg, 0.15 mmol) gave the title compound as colourless oil after purification by preparative HPLC (11.6 mg, 32 %). LCMS data: Calculated MH+ (378); Found 100% (MH+) m/z 378, Rt = 3.05 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.29-7.23 (2 H, m), 6.86-6.79 (2 H, m), 4.30 (IH, t, J=8.5), 4.11- 3.93 (5 H, m), 3.80 (1 H, dd, J=8.4, 5.5), 3.63-3.32 (6H, m), 3.11-3.01 (IH, m), 2.97-2.87 (IH, m), 2.72 - 2.61 (IH, m), 2.57 - 2.41 (3H, m), 1.91 (IH, q, J=10.2), 1.79-1.67 (IH, m).
Example 136 - Preparation of 6-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3-yl}methoxy)-3,4-dihydroisoquinolin-l(2H)-one. Potency range A
Figure imgf000159_0001
In a similar fashion (Route 20, GP I), {l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin- 3-yl}methanol (39 mg, 0.15 mmol) and 6-fluoro-3,4-dihydroisoquinolin-l(2H)-one (31 mg, 0.19 mmol) gave the title compound as colourless oil after purification by preparative HPLC (26.2 mg, 34 %). LCMS data: Calculated MH+ (413); Found 100% (MH+) m/z 413, Rt = 3.74 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.07 (1 H, s), 8.01 (1 H, d, J=8.6 Hz), 6.88 (IH, dd, J=8.7 and 2.5 Hz), 6.76 (1 H, d, J=2.2 Hz), 4.30 (IH, t, j=8.5), 4.18 (2H, d, J=6.4 Hz), 4.12-3.92 (3H, m), 3.77 (IH, dd, J=8.4 and 5.5 Hz), 3.66-3.49 (8H, m), 3.44 (2H, dd, j=7.9 and 5.6 Hz), 3.39-3.29 (IH, m), 3.17-3.04 (IH, m), 3.00 (2H, t, j=6.8), 2.93-2.81 (IH, m), 2.68-2.45 (4H, m), 2.28-2.12 (3H, m), 1.96-1.87 (IH, m), 1.79-1.67 (IH, m).
Example 137 - Preparation of 6-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3-yl}methoxy)-2-methyl-3,4-dihydroisoquinolin-l(2H)-one. Potency range A
Figure imgf000159_0002
In a similar fashion (Route 20, GP I), {l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin- 3-yl}methanol (39 mg, 0.15 mmol) and 6-fluoro-2-methyl-3,4-dihydroisoquinolin-l(2H)-one (34 mg, 0.19 mmol) gave the title compound as colourless oil after purification by preparative HPLC (15.3 mg, 19 %). LCMS data: Calculated MH+ (427); Found 100% (MH+) m/z 427, Rt = 4.02 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.03 (1 H, d, J=8.6), 6.85 (IH, dd, J=8.7 and 2.3 Hz), 6.70 (1 H, d, J=2.0 Hz), 4.35-4.26 (IH, m), 4.15 (2H, d, J=6.4 Hz), 4.11-3.94 (3H, m), 3.84-3.73 (IH, m), 3.64-3.48 (5H, m), 3.48-3.41 (2H, m), 3.39-3.29 (IH, m), 3.19 (3H, s), 3.12-3.08 (IH, m), 3.00 (2H, t, J=6.7), 2.96-2.85 (IH, m), 2.73-2.46 (4H, m), 2.30-2.11 (3H, m), 1.96-1.88 (IH, m), 1.79-1.70 (IH, m).
Example 138 - Preparation 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}methoxy)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000160_0001
In a similar fashion (Route 20, GP I), {l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3 -yl} methanol (39 mg, 0.15 mmol) and 5-chloro-N-methylpyridine-2-carboxamide (37 mg, 0.22 mmol) gave the title compound as colourless oil after purification by preparative HPLC (11.2 mg, 15 %). LCMS data: Calculated MH+ (402); Found 100% (MH+) m/z 402, Rt = 3.75 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.24 (IH, d, J=2.8 Hz), 8.19 (1 H, d, J=8.6), 8.10-8.05 (IH, br m), 7.36-7.31 (IH, m), 4.39-4.32 (IH, m), 4.23 (2H, d, J=6.4), 4.16-4.05 (3H, m), 4.03-3.95 (IH, m), 3.88-3.80 (IH, m), 3.64-3.34 (6H, m), 3.18-3.10 (IH, m), 3.07 (3H, d, J=5.1), 3.00-2.89 (IH, m), 2.73-2.63 (IH, m), 2.60-2.42 (3H, m), 2.33-2.15 (3H, m), 1.98-1.88 (IH, m), 1.81-1.70 (IH, m).
Route 39
Figure imgf000160_0002
DMF Example 139 - Preparation of N-{l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}-6-methylpyridine-3-carboxamide. Potency range A
Figure imgf000161_0001
To a stirred solution of 6-methylnicotinic acid (5.5 mg, 40 μmol) in 1 :1 DCM:DMF (1 ml) was added HOBt (12 mg, 87 μmol) followed by HBTU (30 mg, 80 μmol) at room temperature. After 15 minutes l-[(4-cyclo butyl- l,4-diazepan-l-yl)carbonyl]azetidin-3 -amine (10 mg, 40 μmol) was added and the reaction was stirred for 16 hours. The reaction was concentrated at reduced pressure and purified directly via preparative HPLC to give the title compound (5 mg, 34%). LCMS data: Calculated MH+ (372); Found 99% (MH+) m/z 372, Rt = 1.68 min.
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.88 (1 H, d, J=2.2 Hz), 8.15 (1 H, dd, J=8.2, 2.2 Hz), 7.41 (1 H, d, J=8.2 Hz), 4.70 - 4.80 (1 H, m), 4.29 - 4.38 (2 H, m), 4.00 (2 H, dd, J=8.7, 5.8 Hz), 3.39 - 3.50 (4 H, m), 2.91 (1 H, quin, J=8.0 Hz), 2.59 (3 H, s), 2.53 - 2.58 (2 H, m), 2.43 - 2.50 (2 H, m), 2.01 - 2.13 (2 H, m), 1.80 - 1.93 (4 H, m), 1.60 - 1.75 (2 H, m).
Route 40
General Procedure T
Figure imgf000161_0002
General Procedure T:
Example 140 - Preparation of 4-chloro-N-{l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}benzamide. Potency range A
Figure imgf000161_0003
To a solution of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-amine (46 mg, 0.18 mmol) in dichloroethane (3 ml) was added 4-chlorobenzoyl chloride (20 μl, 0.18 mmol) and DIPEA (38 μl, 0.22 mmol). The reaction was stirred at room temperature for 3 hours and then diluted with dichloromethane (30 ml) and washed twice with saturated NaHCO3 (15ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NHs with gradient, 98:2:1 to 90:10:1) to provide the title compound as white solid (26 mg, 37%).
LCMS data: Calculated MH+ (391); Found 100% (MH+) m/z 391, Rt = 2.77 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.89 (1 H, d, J=6.6 Hz), 7.84 (2 H, d, J=8.6
Hz), 7.38 (2 H, d, J=8.6 Hz), 4.78 - 4.88 (1 H, m), 4.27 (2H, dd, J=8.4, 6.1 Hz), 3.97 (2 H, dd,
J=8.4, 6.1 Hz), 3.30 - 3.40 (4 H, m), 2.73 - 2.82 (1 H, m), 2.37 (4 H, m), 1.95 - 2.05 (2 H, m),
1.71 - 1.84 (4 H, m), 1.54 - 1.70 (2 H, m).
The following compounds were made as described in Route 40, General Procedure T above.
Example 141 - Preparation of N-{l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}cyclohexanecarboxamide. Potency range A
Figure imgf000162_0001
In a similar fashion (Route 40, GP T), l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-amine (46 mg, 0.18 mmol) and cyclohexanecarbonyl chloride (25 μl, 0.18 mmol) gave the title compound as white solid after purification by silica FCC (40 mg, 62%). LCMS data: Calculated MH+ (363); Found 99% (MH+) m/z 363, Rt = 2.59 min. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 6.61 (1 H, d, J=7.0 Hz), 4.54 - 4.64 (1 H, m), 4.19 (2 H, dd, J=8.5, 6.0 Hz), 3.75 (2 H, dd, J=8.5, 6.0 Hz), 3.30 - 3.44 (4 H, m), 2.80 (1 H, quin, J=7.8 Hz), 2.42 - 2.50 (2 H, m), 2.34 - 2.42 (2 H, m), 2.09 (1 H, m), 2.00 (2 H, m), 1.69 - 1.87 (8 H, m), 1.52 - 1.69 (3 H, m), 1.34 - 1.47 (2 H, m), 1.12 - 1.29 (3 H, m).
Route 41
General
Figure imgf000162_0002
General Procedure U:
Example 142 - Preparation of 4-chloro-N-{l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}-N-methylbenzamide. Potency range A
Figure imgf000163_0001
To a solution of 4-chloro-N-{l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- yl}benzamide (15 mg, 38 μmol) in THF (2 ml) was added NaH (3 mg of a 60% dispersion in mineral oil, 76 μmol). The reaction was stirred at room temperature for 30 minutes and then MeI (2.6 μmol, 46 μmol) was added. The reaction was heated in a sealed tube at 50 0C for 3 hours and then concentrated at reduced pressure, diluted with dichloromethane (30 ml), washed twice with saturated NaHCO3 (15ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 95:5:1 to 90:10:1) to provide the title compound as colourless oil (10 mg, 66%). LCMS data: Calculated MH+ (405); Found 91 % (MH+) m/z 405, Rt = 2.69 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.12 - 7.47 (4 H, m), 4.44 - 5.14 (1 H, m), 3.93 - 4.34 (4 H, m), 3.33 - 3.53 (4 H, m), 3.09 (3 H, m), 2.83 (1 H, m), 2.47 - 2.58 (2 H, m), 2.32 - 2.47 (2 H, m), 1.97 - 2.09 (2 H, m), 1.73 - 1.93 (4 H, m), 1.54 - 1.72 (2 H, m).
The following compounds were made as described in Route 41, General Procedure U above.
Example 143 - Preparation of N-{l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}-N,6-dimethylpyridine-3-carboxamide. Potency range A
Figure imgf000163_0002
In a similar fashion (Route 41, GP U), N- {l-[(4-cyclobutyl- 1,4-diazepan-l - yl)carbonyl]azetidin-3-yl}-6-methylpyridine-3-carboxamide (49 mg, 0.13 mmol) gave the title compound after purification by silica FCC (8 mg, 16%).
LCMS data: Calculated MH+ (386); Found 94% (MH+) m/z 386, Rt = 3.39 min.
NMR data - a 1 :1 mixture of rotamers was observed: 1H NMR (500 MHz, MeOD) δ ppm 8.33 - 8.62 (1 H, m), 7.65 - 7.91 (1 H, m), 7.40 (1 H, d, J=8.1 Hz), 4.92 - 5.13 (0.5 H, m),
4.55 - 4.78 (0.5 H, m), 4.05 - 4.38 (4 H, m), 3.44 (4 H, m), 2.98 - 3.28 (3 H, m), 2.90 (1 H, quin, J=8.0 Hz), 2.59 (3 H, s), 2.51 - 2.58 (2 H, m), 2.39 - 2.50 (2 H, m), 2.00 - 2.13 (2 H, m),
1.80 - 1.97 (4 H, m), 1.54 - 1.78 (2 H, m). Example 144 - Preparation of N-{l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}-N-methylcyclohexanecarboxamide. Potency range A
Figure imgf000164_0001
In a similar fashion (Route 41, GP U), N- {l-[(4-cyclo butyl- 1,4-diazepan-l- yl)carbonyl]azetidin-3-yl}cyclohexanecarboxamide (14 mg, 38 μmol) gave the title compound after purification by silica FCC as colourless oil (9 mg, 64%). LCMS data: Calculated MH+ (377); Found 97% (MH+) m/z 377, Rt = 2.67 min. NMR data - a 7:3 mixture of rotamers was observed: 1H NMR (500 MHz, CDCl3) δ ppm 5.02 - 5.16 (0.7 H, m), 4.83 (0.3 H, m), 4.09 - 4.28 (2 H, m), 3.96 - 4.09 (0.6 H, m), 3.80 - 3.96 (1.4 H, m), 3.29 - 3.57 (4 H, m), 3.08 (2.1 H, s), 3.03 (0.9 H, s), 2.78 - 2.92 (1 H, m), 2.33 - 2.59 (5 H, m), 2.04 (2 H, m), 1.56 - 1.94 (11 H, m), 1.39 - 1.56 (2 H, m), 1.14 - 1.38 (3 H, m).
Example 145 - Preparation of l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]-N-methyl-N-
(6-methylpyridin-3-yl)azetidine-3-carboxamide. Potency range A
Figure imgf000164_0002
In a similar fashion (Route 41, GP U) l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]-N-(6- methylpyridin-3-yl)azetidine-3-carboxamide (51 mg, 0.14 mmol) gave the title compound (1.3 mg, 3%) after purification by silica FCC.
LCMS data: Calculated MH+ (386); Found 93% (MH+) m/z 386, Rt = 3.51 min. NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.31 - 8.38 (1 H, m), 7.62 - 7.71 (1 H, m), 7.38 - 7.47 (1 H, m), 4.05 - 4.14 (2 H, m), 3.69 - 3.80 (2 H, m), 3.25 - 3.48 (8 H, m), 2.83 - 2.94 (1 H, m), 2.49 - 2.62 (5 H, m), 2.40 - 2.49 (2 H, m), 2.01 - 2.13 (2 H, m), 1.77 - 1.92 (4 H, m), 1.56 - 1.74 (2 H, m).
Example 146 - Preparation of N-(4-chlorophenyl)-l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]-N-methylazetidine-3-carboxamide. Potency range A
Figure imgf000164_0003
In a similar fashion (Route 41, GP U) l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]-N-(6- methylpyridin-3-yl)azetidine-3-carboxamide (51 mg, 0.14 mmol) gave the title compound (2.3 mg, 3%) after purification by silica FCC.
LCMS data: Calculated MH+ (405); Found 100% (MH+) m/z 405, Rt = 2.96 min. NMR data: - a 6:4 mixture of rotamers was observed : 1H NMR (500 MHz, MeOD) δ ppm 7.54 - 7.63 (0.6 H, d, J=8.5 Hz), 7.47 - 7.53 (0.4 H, d, J=8.5 Hz), 7.30 - 7.37 (0.6 H, d, J=8.5 Hz), 7.22 - 7.30 (0.4 H, d, J=8.5 Hz), 4.00 - 4.39 (2 H, m), 3.64 - 3.98 (2 H, m), 3.21 - 3.63 (12 H, m), 2.85 - 3.13 (1 H, m), 2.31 - 2.41 (2 H, m), 1.99 - 2.29 (4 H, m), 1.73 - 1.93 (2 H, m).
Example 147 - Preparation of 4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3-yl}oxy)-N-methylpyridine-2-carboxamide. Potency range A
Figure imgf000165_0001
In a similar fashion (Route 41, GP U), 4-({l-[(4-cyclo butyl- 1,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)pyridine-2-carboxamide (15 mg, 40 μmol) in DMF (2 ml) gave the title compound (10 mg, 50%) as colourless oil after purification by preparative HPLC
(TFA salt).
LCMS data: Calculated MH+ (388); Found 100% (MH+) m/z 388, Rt = 2.23 min
NMR data: 1H NMR (500 MHz, MeOD) δ ppm 8.49 (1 H, d, J=4.7 Hz), 7.52 - 7.57 (1 H, m), 7.03 - 7.08 (1 H, m), 5.18 - 5.24 (1 H, m), 4.58 - 4.65 (1 H, m), 4.43 - 4.49 (1 H, m), 4.14 -
4.21 (1 H, m), 4.01 - 4.07 (1 H, m), 3.91 - 3.98 (1 H, m), 3.70 - 3.79 (1 H, m), 3.41 - 3.61 (5
H, m), 2.98 (5 H, m), 2.33 - 2.42 (2 H, m), 2.05 - 2.31 (4 H, m), 1.76 - 1.94 (2 H, m).
Example 148 - Preparation of l-cyclobutyl-4-{[3-(methoxymethyl)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000165_0002
In a similar fashion (Route 41, GP U), {l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}methanol (20 mg, 74 μmol) in DMSO (2 ml) gave the title compound after purification by FCC (6 mg, 30%). LCMS data: Calculated MH+ (282); Found 90% (MH+) m/z 282, Rt = 3.60 min NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 4.04 (2 H, t, J=8.3 Hz), 3.70 (2 H, dd, J=8.2, 5.6 Hz), 3.53 (2 H, d, J=7.0 Hz), 3.43 - 3.47 (2 H, m), 3.35 - 3.41 (5 H, m), 2.73 - 2.88 (2 H, m), 2.47 - 2.55 (2 H, m), 2.38 - 2.46 (2 H, m), 1.98 - 2.08 (2 H, m), 1.77 - 1.93 (4 H, m), 1.56 - 1.75 (2 H, m).
Route 42
General Procedure V
Figure imgf000166_0001
Figure imgf000166_0002
General Procedure V:
Example 149 - Preparation of l-cyclobutyl-4-({3-[4-(l-methyl-lH-pyrazol-4- yl)phenoxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000166_0003
l-Methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (21 mg, 101 μmol), tricyclohexylphosphine (3.1 mg, 11 μmol) and Pd2(dba)3 (4.2 mg, 5 μmol) were dissolved in dioxane (0.25 ml) under a nitrogen atmosphere. Solid l-cyclobutyl-4-{[3-(4- iodophenoxy)azetidin-l-yl]carbonyl}-l,4-diazepane (42 mg, 92 μmol) was added followed by K3PO4 (122 μl of a 1.27 M aqueous solution, 156 μmol). The reaction was stirred at room temperature for 30 minutes and then at 110 0C for 16 hours. The reaction was diluted with dichloromethane (30 ml), filtered through celite, washed twice with saturated NaHCO3 (15 ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 98:2:1 to 90:10:1) and then recrystallised (Heptane/EtOAc) to give the title product as white solid (16 mg, 42%). LCMS data: Calculated MH+ (410); Found 99% (MH+) m/z 410, Rt = 2.63 min. NMR data: 1H NMR (250 MHz, CDCl3) δ ppm 7.69 (1 H, s), 7.53 (1 H, s), 7.38 (2 H, d, J=8.7 Hz), 6.75 (2 H, d, J=8.7 Hz), 4.82 - 4.99 (1 H, m), 4.34 (2 H, dd, J=9.3, 6.5 Hz), 4.05 (2 H, dd, J=9.4, 4.1 Hz), 3.94 (3 H, s), 3.35 - 3.53 (4 H, m), 2.73 - 2.93 (1 H, m), 2.34 - 2.59 (4 H, m), 1.95 - 2.14 (2 H, m), 1.47 - 1.95 (6 H, m). The following compounds were made as described in Route 42, General Procedure V above.
Example 150 - Preparation of l-cyclobutyl-4-({3-[4-(l,3,5-trimethyl-lH-pyrazol-4- yl)phenoxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000167_0001
In a similar fashion (Route 42, GP V), l-cyclobutyl-4-{[3-(4-iodophenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane (42 mg, 92 μmol) and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole (24 mg, 101 μmol) gave the title compound (15 mg, 37%) as yellow oil after purification by silica FCC. LCMS data: Calculated MH+ (438); Found 98% (MH+) m/z 438, Rt = 2.70 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.15 (2 H, d, J=8.7 Hz), 6.79 (2 H, d, J=8.7 Hz), 4.88 - 4.95 (1 H, m), 4.35 (2 H, dd, J=9.3, 6.7 Hz), 4.07 (2 H, dd, J=9.5, 4.3 Hz), 3.77 (3 H, s), 3.39 - 3.52 (4 H, m), 2.78 - 2.90 (1 H, m), 2.48 - 2.57 (2 H, m), 2.38 - 2.47 (2 H, m), 2.22 (6 H, d, J=3.1 Hz), 1.98 - 2.08 (2 H, m), 1.74 - 1.92 (4 H, m), 1.54 - 1.73 (2 H, m).
Route 43
General Procedure W
Figure imgf000167_0002
KF / Kryptofix-222
Figure imgf000167_0003
2. NaH, DMSO
General Procedure W: Example 151 - Preparation of l-cyclobutyl-4-({3-[(3-fluoro-2-methylpyridin-4- yl)oxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000167_0004
KF (73 mg, 1.25 mmol) was dried under vacuum for 2 hours and then stirred with Rryptofix-
222 (282 mg, 0.75 mmol) and 4-chloro-3-fluoro-2-methylpyridine (40 mg, 0.28 mmol) in DMSO (3 ml) at 120 0C for 16 hours in a sealed tube. After cooling to room temperature, NaH (100 mg of a 60% dispersion in mineral oil, 2.5 mmol) and 1 -[(4-cyc Io butyl- 1,4- diazepan-l-yl)carbonyl]azetidin-3-ol (63 mg, 0.25 mmol) were added and stirred for a further 8 hours. The reaction was diluted with EtOAc (30 ml) and washed with saturated NaHCOs (3 x 15 ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 98:2:1 to 90:10:1) to give the title compound (32 mg, 35%) as yellow oil.
LCMS data: Calculated MH+ (363); Found 99% (MH+) m/z 363, Rt = 3.76 mins (High pH method).
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.07 (1 H, d, J=5.5 Hz), 6.37 - 6.47 (1 H, m), 4.88 - 4.98 (1 H, m), 4.32 (2 H, dd, J=9.7, 6.6 Hz), 4.05 (2 H, dd, J=9.7, 4.0 Hz), 3.32 - 3.46 (4 H, m), 2.75 - 2.85 (1 H, m), 2.41 - 2.49 (5 H, m), 2.33 - 2.41 (2 H, m), 1.92 - 2.05 (2 H, m), 1.70 - 1.89 (4 H, m), 1.58 (2 H, m).
The following compounds were made as described in Route 43, General Procedure W above.
Example 152 - Preparation of l-cyclobutyl-4-{[3-(naphthalen-2-yloxy)azetidin-l- yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000168_0001
In a similar fashion (Route 43, GP W), l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-ol (30 mg, 0.12 mmol) and 2-chloronapthalene (39 mg, 0.24 μmol) gave the title compound after purification by preparative HPLC (7 mg, 10%).
LCMS data: Calculated MH+ (380); Found 79% (MH+) m/z 380, Rt = 3.17 min.
Approximately 95% purity by NMR was observed.
NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 7.79 (2 H, d, J=8.8 Hz), 7.71 (1 H, d, J=8.3 Hz), 7.44 - 7.50 (1 H, m), 7.35 - 7.41 (1 H, m), 7.12 (1 H, dd, J=9.0, 2.6 Hz), 6.83 (1 H, d,
J=2.4 Hz), 5.01 - 5.11 (1 H, m), 4.59 (1 H, dd, J=9.1, 6.9 Hz), 4.29 - 4.40 (1 H, m), 4.25 (1 H, dd, J=9.4, 3.9 Hz), 3.93 - 4.06 (2 H, m), 3.40 - 3.64 (5 H, m), 3.28 - 3.39 (1 H, m), 2.84 - 2.95
(1 H, m), 2.41 - 2.71 (4 H, m), 2.10 - 2.29 (3 H, m), 1.84 - 1.96 (1 H, m), 1.64 - 1.79 (1 H, m).
Route 44
Figure imgf000169_0001
DMSO
Example 153 - Preparation of l-cyclobutyl-4-{[3-({[6-(trifluoromethyl)pyridin-3- yl]oxy}methyl)azetidin-l-yl]carbonyl}-l,4-diazepane. Potency range A
Figure imgf000169_0002
To a solution of {l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}methanol (20 mg, 74 μmol) in DMSO (1 ml) was added NaH (6 mg of a 60% dispersion in mineral oil, 0.15 mmol). After 30 minutes CsF (12 mg, 74 μmol) and 5-bromo-2-trifluoromethylpyridine (34 mg, 0.15 mmol) were added and the mixture was heated at 85 0C for 2 hours. The reaction was cooled to room temperature, diluted with dichloromethane (20 ml), washed with water (20 ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by preparative HPLC to give the title compound (14 mg, 45%). LCMS data: Calculated MH+ (413); Found 86% (MH+) m/z 413, Rt = 2.87 mins. 95% purity by NMR was observed. NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.42 (1 H, d, J=2.6 Hz), 7.66 (1 H, d, J=8.6 Hz), 7.33 (1 H, dd, J=8.7, 2.5 Hz), 4.32 (1 H, m), 4.23 (2 H, d, J=6.4 Hz), 4.07 - 4.14 (1 H, m), 4.00 - 4.06 (1 H, m), 3.91 - 4.00 (1 H, m), 3.79 (1 H, dd, J=8.4, 5.5 Hz), 3.48 - 3.63 (3 H, m), 3.30 - 3.48 (3 H, m), 3.06 - 3.18 (1 H, m), 2.84 - 2.96 (1 H, m), 2.59 - 2.70 (1 H, m), 2.41 - 2.59 (3 H, m), 2.11 - 2.31 (3 H, m), 1.85 - 1.97 (1 H, m), 1.67 - 1.82 (1 H, m).
Route 45
Figure imgf000169_0003
Example 154 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-
3-yl}oxy)-lH-indole. Potency range A
Figure imgf000170_0001
To a stirred solution of l-cyclobutyl-4-{[3-(3-methyl-4-nitrophenoxy)azetidin-l- yl]carbonyl}-l,4-diazepane (40 mg, 0.16 mmol) in DMF (2 ml) was added DMF.DMA (100 μl, 0.75 mmol) and pyrrolidine (100 μl, 0.75 mmol) at 130 0C in one portion. The suspension was stirred for 2h at 130 0C then cooled to room temperature and concentrated at reduced pressure. The residue was dissolved in 1:1 THF/MeOH (4 ml) and Raney Nickel (0.7 ml, 50% w/v in H2O) and hydrazine (0.7 ml, IM solution in THF) were added. The reaction was stirred at room temperature for 3 hours then filtered over celite and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 98:2:1 to
95:5:1) to give the title compound (43mg, 37%) as light brown oil.
LCMS data: Calculated MH+ (369); Found 98% (MH+) m/z 369, Rt = 4.12 min.
NMR data: 1H NMR (250 MHz, CDCl3) δ 8.48 (1 H, br. s.), 7.16 - 7.28 (1 H, m), 7.12 (1 H, m), 6.64 - 6.83 (2 H, m), 6.38 (1 H, m), 4.84 (1 H, m), 4.27 (2 H, dd, J=9.7, 6.4 Hz), 4.00 (2
H, dd, J=9.8, 4.3 Hz), 3.27 - 3.47 (4 H, m), 2.66 - 2.84 (1 H, m), 2.27 - 2.52 (4 H, m), 1.86 -
2.07 (2 H, m), 1.44 - 1.86 (6 H, m).
Example 155 - Preparation of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-yl}oxy)-l-methyl-lH-indole. Potency range A
Figure imgf000170_0002
To a stirred solution of 5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)- lH-indole (30 mg, 81 μmol) in DMF (2 ml) was added NaH (4 mg of a 60% dispersion in mineral oil, 97 μmol) at room temperature in one portion. The suspension was stirred for 30 min at room temperature under a nitrogen atmosphere then cooled to 0 0C and MeI (6 μl, 97 μmol) was added. The reaction was allowed to warm to room temperature and stirred for 16 hours then diluted with dichloromethane (30 ml) and washed twice with saturated NaHCO3 (15ml), dried (MgSO4), filtered and concentrated at reduced pressure. The residue was purified by FCC (DCM/MeOH/NH3 with gradient, 98:2: 1 to 90:10: 1) to provide the title compound (23 mg, 74%) as light brown oil.
LCMS data: Calculated MH+ (383); Found 99% (MH+) m/z 383, Rt = 2.89 min. NMR data: 1H NMR (500 MHz, CDCl3) 7.15 (1 H, d, J=8.7 Hz), 6.93 - 6.98 (1 H, d, J=3.1 Hz m), 6.71 - 6.79 (2 H, m), 6.31 (1 H, d, J=3.1 Hz), 4.81 - 4.90 (1 H, m), 4.27 (2 H, dd, J=9.2, 6.6 Hz), 4.00 (2 H, dd, J=9.3, 4.3 Hz), 3.69 (3 H, s), 3.37 - 3.43 (2 H, m), 3.35 (2 H, m), 2.77 (1 H, m), 2.41 - 2.49 (2 H, m), 2.32 - 2.39 (2 H, m), 1.96 (2 H, m), 1.70 - 1.83 (4 H, m), 1.48 - 1.64 (2 H, m).
Route 46
Figure imgf000171_0001
Preparation of methyl 2-(5-bromopyridin-2-yl)-2-methylpropanoate
Figure imgf000171_0002
Diisopropylamine (0.45 ml, 3.17 mmol) was dissolved in THF (10 ml) under a nitrogen atmosphere and cooled to -10 0C. n-BuLi (2.64 ml, 3.17 mmol, 1.2M solution in THF) was added dropwise over 5 minutes. The reaction mixture was stirred at -1O0C for 30 minutes, after which time the reaction mixture was cooled to -780C. Methyl isobutyrate (0.36 ml, 3.17 mmol) was added dropwise over 5 minutes. Stirring was continued at -780C for 45 minutes. 2,5-Dibromopyridine (0.5 g, 2.11 mmol) in THF (10 ml) was added and the mixture allowed to warm to room temperature and stirred for 2 hours. The reaction was quenched by addition of saturated aqueous ammonium chloride solution, extracted into DCM (3 x 20 ml), the combined organics dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by FCC on silica gel [19:1 heptane/EtOAc as eluent] to provide the title compound as colourless oil (195 mg, 36%). LCMS data: Calculated MH+ (258/260); Found 97% m/z (258/260), Rt = 1.92 min. NMR data: 1H NMR (500 MHz, Chloroform-^) δ ppm 8.60 (1 H, s), 7.77 (1 H, dd, J=5 10Hz), 7.21 (1 H, d, J=IOHz), 3.68 (3 H, s), 1.60 (6 H, s). Example 155a - Preparation of methyl 2-[5-({l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl] azetidin-3-yl} oxy)pyridin-2-yl] -2-methylpropanoate
Figure imgf000172_0001
In a similar fashion (Route 21, GP J), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (383 mg, 1.51 mmol), methyl 2-(5-bromopyridin-2-yl)-2-methylpropanoate
(195 mg, 0.755 mmol), CuI (7.2 mg, 0.038 mmol), 1,10-phenanthroline (13.6 mg, 0.0755 mmol) and Cs2CO3 (0.49 g, 1.51 mmol) gave the title compound as yellow oil (62% LCMS UV purity) after purification by preparative HPLC (110 mg), which was taken onto the next step without further purification. LCMS data: Calculated MH+ (431 ); Found 62% (MH+) m/z 431 , Rt = 1.22 min.
Example 156 - Preparation of 2-[5-({l-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]-2-methylpropan-l-ol. Potency range A
Figure imgf000172_0002
To a 0 0C solution of LiAlH4 (0.56 ml, 0.562 mmol, IM in THF) in THF (1 ml) under a nitrogen atmosphere was added methyl 2-[5-({l-[(4-cyclo butyl- 1,4-diazepan-l - yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]-2-methylpropanoate (110 mg, 62% UV purity) in THF (1 ml). TLC analysis of the reaction mixture after 30 minutes indicated complete consumption of starting material. Water (1 ml), 2M NaOH (1 ml), and water (1 ml) were cautiously added to the reaction mixture. The mixture was diluted with EtOAc (20 ml), dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by FCC on silica gel [eluting with 5% methanolic ammonia (7N) in DCM] to provide the title compound as colourless oil (34.5 mg). LCMS data: Calculated MH+ (403); Found 97% m/z (403), Rt = 2.14 min. NMR data: 1H NMR (500 MHz, Chloroform-J) δ ppm 8.04 (1 H, d, J=5 Hz), 7.28 (1 H, d, J=IOHz), 7.10 (1 H, dd, J=5 10Hz), 4.92-4.97 (1 H, m), 4.73 (1 H, br s), 4.37 (2 H, dd, J=5 10 Hz), 4.07 (2 H, dd, J=5 10 Hz), 3.74 (2 H, s), 3.42-3.51 (4 H, m), 2.84-2.90 (1 H, m), 2.44- 2.50 (4 H, m), 2.04-2.09 (2H, m), 1.81-1.92 (4 H, m), 1.62-1.73 (2 H, m) 1.33 (6 H, s). The following compounds were made as described in Route 20, General Procedure I above.
Example 157 - Preparation of 2-[5-({l-[(4-ethyl-l,4-diazepan-l-yl)carbonyl]azetidin-3- yl}oxy)pyridin-2-yl]propan-2-ol. Potency range A
Figure imgf000173_0001
In a similar fashion (Route 20, GP I), l-[(4-ethyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-ol (90 mg, 0.40 mmol) and 2-(5-fluoropyridin-2-yl)propan-2-ol (95 mg, 0.44 mmol) were used to give the title compound. Crude material (53 mg) after workup gave the title compound as colourless oil (35.6 mg) after purification by preparative HPLC. LCMS data: Calculated MH+ (363); Found 100% (MH+) m/z 363, Rt = 3.48 min.
NMR data: 1H NMR (500 MHz, CDCl3) δ 8.04 (1 H, d, J=2.7 Hz), 7.32 (1 H, d, J=8.7 Hz), 7.08 - 7.14 (1 H, m), 4.91 - 4.98 (1 H, m), 4.62 (1 H, br. s.), 4.36 (2 H, dd, J=9.5, 6.6 Hz), 4.06 (2 H, dd, J=9.5, 4.1 Hz), 3.46 - 3.52 (2 H, m), 3.42 (2 H, m), 2.68 - 2.75 (2 H, m), 2.60 - 2.67 (2 H, m), 2.56 (2 H, q), 1.86 - 1.96 (2 H, m), 1.53 (6 H, s), 1.07 (3 H, t, J=7.1 Hz).
Example 158 - Preparation of 2-{5-[(l-{[4-(l-methylethyl)-l,4-diazepan-l- yl]carbonyl}azetidin-3-yl)oxy]pyridin-2-yl}propan-2-ol. Potency range A
Figure imgf000173_0002
In a similar fashion (Route 20, GP I), l-{[4-(l-methylethyl)-l,4-diazepan-l- yl]carbonyl}azetidin-3-ol (100 mg, 0.41 mmol) and 2-(5-fluoropyridin-2-yl)propan-2-ol (90 mg, 0.41 mmol) were used to give the title compound. Crude material (50 mg) after workup gave the title compound as colourless oil (17.7 mg) after purification by preparative HPLC. LCMS data: Calculated MH+ (377); Found 100% (MH+) m/z 377, Rt = 3.86 min. NMR data: 1H NMR (500 MHz, CDCl3) δ 8.04 (1 H, d, J=2.6 Hz), 7.32 (1 H, d, J=8.7 Hz), 7.12 (1 H, d, J=2.7 Hz), 4.89 - 5.00 (1 H, m), 4.63 (1 H, s), 4.32 - 4.42 (2 H, m), 4.06 (2 H, dd, J=9.4, 4.0 Hz), 3.37 - 3.50 (4 H, m), 2.85 - 2.99 (1 H, m), 2.54 - 2.76 (4 H, m), 1.77 - 1.92 (2 H, m), 1.53 (6 H, s), 1.01 (6 H, d, J=6.4 Hz). Example 159 - Preparation of 2-[5-({l-[(4-cyclopentyl-l,4-diazepan-l- yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan-2-ol. Potency range C
Figure imgf000174_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclopentyl-l,4-diazepan-l-yl)carbonyl]azetidin- 3-ol (100 mg, 0.41 mmol) and 2-(5-fluoropyridin-2-yl)propan-2-ol (90 mg, 0.41 mmol) were used to give the title compound. Crude material (38 mg) after workup gave the title compound as colourless oil (19.3 mg) after purification by preparative HPLC. LCMS data: Calculated MH+ (403); Found 99% (MH+) m/z 403, Rt = 4.08 min. NMR data: 1H NMR (500 MHz, CDCl3) δ 8.04 (1 H, d, J=2.7 Hz), 7.32 (1 H, d, J=8.7 Hz), 7.09 - 7.14 (1 H, m), 4.91 - 4.98 (1 H, m), 4.63 (1 H, s), 4.31 - 4.42 (2 H, m), 4.02 - 4.11 (2 H, m), 3.46 - 3.54 (2 H, m), 3.43 (2 H, t), 2.63 - 2.79 (5 H, m), 1.77 - 1.95 (4 H, m), 1.63 - 1.72 (2 H, m), 1.58 (2 H, br. s.), 1.53 (6 H, s), 1.33 - 1.45 (2 H, m).
Example 160 - Preparation of l-cyclobutyl-4-({3-[(5-fluoropyrimidin-2-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000174_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (1.49 g, 5.9 mmol) and 2-chloro-5-fluoropyrimidine (856 mg, 6.48 mmol) gave the title compound as orange solid after purification by FCC (1.10 g, 54%).
LCMS data: Calculated MH+ (350); Found 100% (MH+) m/z 350, Rt = 2.23 min. 1H NMR (500 MHz, MeOD) δ ppm 8.54 (2 H, s), 5.27 - 5.39 (1 H, m), 4.42 (2 H, dd, J=9.8, 6.7 Hz), 4.04 (2 H, dd, J=9.8, 4.2 Hz), 3.38 - 3.53 (4 H, m), 2.86 - 2.99 (1 H, m), 2.39 - 2.63 (4 H, m), 2.02 - 2.15 (2 H, m), 1.79 - 1.96 (4 H, m), 1.61 - 1.75 (2 H, m).
Example 161 - Preparation of l-cyclobutyl-4-({3-[(5-methoxypyridin-2-yl)oxy]azetidin- l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000174_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (100 mg, 0.40 mmol) and 2-bromo-5-methoxypyridine (82 mg, 0.43 mmol) gave the title compound as pale yellow oil after purification by FCC (17 mg, 12%). LCMS data: Calculated MH+ (361); Found 83% (MH+) m/z 361, Rt = 2.54 min. 1H NMR (250 MHz, CDCl3) δ ppm 7.73 (1 H, d, J=2.6 Hz), 7.22 (1 H, dd, J=8.9, 3.1 Hz), 6.70 (1 H, d, J=9.0 Hz), 5.17 - 5.34 (1 H, m), 4.23 - 4.43 (2 H, m), 3.98 (2 H, m), 3.80 (3 H, s), 3.33 - 3.51 (4 H, m), 2.73 - 2.93 (1 H, m), 2.34 - 2.59 (4 H, m), 1.94 - 2.12 (2 H, m), 1.70 - 1.94 (4 H, m), 1.52 - 1.70 (2 H, m).
Example 162 - Preparation of l-cyclobutyl-4-({3-[(5-ethylpyrimidin-2-yl)oxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range C
Figure imgf000175_0001
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (70 mg, 0.28 mmol) and 2-chloro-5-ethylpyrimidine (43 mg, 0.30 mmol) gave the title compound as colourless oil after purification by FCC (54 mg, 55%).
LCMS data: Calculated MH+ (360); Found 96% (MH+) m/z 360, Rt = 3.40 min. 1H NMR (500 MHz, MeOD) δ 8.58 (1 H, d, J=3.2 Hz), 8.06 (1 H, d, J=3.1 Hz), 5.05 (1 H, m), 4.29 (1 H, dd, J=13.7, 2.9 Hz), 4.04 (1 H, dd, J=13.9, 8.9 Hz), 3.93 (1 H, dd, J=12.4, 9.0 Hz), 3.57 (1 H, dd, J=12.4, 5.6 Hz), 3.44 - 3.52 (4 H, m), 2.96 (1 H, m), 2.44 - 2.60 (6 H, m), 2.04 - 2.16 (2 H, m), 1.81 - 1.94 (4 H, m), 1.62 - 1.77 (2 H, m), 1.23 (3 H, t, J=7.6 Hz).
Example 163 - Preparation of l-cyclobutyl-4-({3-[4-(methylsulfonyl)phenoxy]azetidin-l- yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000175_0002
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (100 mg, 0.40 mmol) and 4-fluorophenyl methyl sulfone (78 mg, 0.43 mmol) gave the title compound as colourless oil after purification by preparative HLPC (16 mg, 10%). LCMS data: Calculated MH+ (408); Found 100% (MH+) m/z 408, Rt = 3.94 min. 1H NMR (500 MHz, MeOD) δ 8.12 (2 H, d, J=8.9 Hz), 7.27 (2 H, d, J=8.8 Hz), 5.27 - 5.39 (1 H, m), 4.68 (2 H, dd, J=9.3, 6.6 Hz), 4.25 (2 H, dd, J=9.5, 3.8 Hz), 3.63 - 3.78 (4 H, m), 3.24 - 3.35 (4 H, m), 2.72 - 3.04 (4 H, m), 2.29 - 2.41 (2 H, m), 2.07 - 2.22 (4 H, m), 1.82 - 2.03 (2 H, m).
Route 47
Figure imgf000176_0001
Preparation of 5-(chloromethyl)-2-methylpyridine
Figure imgf000176_0002
To a stirred solution of (6-methyl-3-pyridinyl)methanol (166 mg, 1.35 mmol) in dichloromethane (10 ml) was added thionyl chloride (108 μl, 1.48 mmol) giving a colourless solution. After 30 minutes the mixture was concentrated giving a brown solid (240 mg, quant, yield) that was used directly in the next step without purification. 1H NMR (500 MHz, CDCl3) δ 8.79 (1 H, br. s.), 8.55 (1 H, dd, J=8.3, 1.6 Hz), 7.93 (1 H, d, J=8.4 Hz), 4.89 (2 H, s), 2.77 (3 H, s).
Example 164 - Preparation of l-cyclobutyl-4-({3-[(6-methylpyridin-3- yl)methoxy]azetidin-l-yl}carbonyl)-l,4-diazepane. Potency range A
Figure imgf000176_0003
In a similar fashion (Route 20, GP I), l-[(4-cyclo butyl- 1,4-diazepan-l -yl)carbonyl]azetidin-3- ol (317 mg, 1.35 mmol) and 5-(chloromethyl)-2-methylpyridine (240 mg, 1.35 mmol) gave the title compound as colourless oil after purification by FCC (22 mg, 5%). LCMS data: Calculated MH+ (359); Found 99% (MH+) m/z 359, Rt = 3.79 min. 1H NMR (500 MHz, CDCl3) δ 8.44 (1 H, d, J=1.4 Hz), 7.58 (1 H, dd, J=7.9, 2.0 Hz), 7.16 (1 H, d, J=7.9 Hz), 4.44 (2 H, s), 4.27 - 4.36 (1 H, m), 4.03 - 4.16 (2 H, m), 3.83 - 3.96 (2 H, m), 3.32 - 3.48 (4 H, m), 2.75 - 2.89 (1 H, m), 2.56 (3 H, s), 2.36 - 2.52 (4 H, m), 1.97 - 2.09 (2 H, m), 1.75 - 1.89 (4 H, m), 1.55 - 1.75 (2 H, m). Route 48
1. secBuLi (1.2eq), diethyl ether, ,OH -780C, 30 mins,
FA f/YN Br - 2. Acetone (2eq.), r RT
Preparation of 2-(5-fluoropyridin-2-yl)propan-2-ol
Figure imgf000177_0001
To a stirred solution of 2-bromo-5-fluoropyridine (1.0 g, 5.7 mmol) in diethyl ether (20 ml) under a nitrogen atmosphere at -78 0C was added sesBuLi (4.87 ml of a 1.4 M solution in heptanes, 6.8 mmol). The resulting dark orange solution was stirred for 30 minutes at -78 0C and acetone (0.84 ml, 11.4 mmol) was then added dropwise. After a further 1 hour the reaction temperature was raised to room temperature giving a clear yellow solution. This was quenched with water (2 ml), diluted with EtOAc (30 ml) and washed with water (2 x 20 ml), dried (MgSO4), filtered and concentrated. The residue was purified via silica FCC (using a gradient of eluents; 9:1 to 4:6 hexane/diethyl ether) to give the title product as colourless oil (395 mg, 45%). LCMS data: Calculated MH+ (156); Found 78% (MH+) m/z 156, Rt = 0.91 min. 1H NMR (500 MHz, CDCl3) δ 8.37 (1 H, d, J=2.0 Hz), 7.36 - 7.48 (2 H, m), 4.48 (1 H, br. s.), 1.55 (6 H, s).
The following compound was made as described in Route 20, General Procedure I above.
Example 165 - Preparation of 2-[5-({c/s-3-[(4-cyclobutyl-l,4-diazepan-l- yl)carbonyl]cyclobutyl}oxy)pyridin-2-yl]propan-2-ol. Potency range A
Figure imgf000177_0002
In a similar fashion (Route 20, GP I), cώ-3-[(4-cyclo butyl- 1,4-diazepan-l- yl)carbonyl]cyclobutanol (50 mg, 0.20 mmol) and 2-(5-fluoropyridin-2-yl)propan-2-ol (31 mg, 0.20 mmol) gave the title compound as colourless oil after purification by silica FCC (4 mg, 5%). LCMS data: Calculated MH+ (388); Found 100% (MH+) m/z 388, Rt = 1.87 min. 1U NMR (500 MHz, MeOD) δ 8.07 (1 H, d, J=2.8 Hz), 7.57 (1 H, d, J=8.8 Hz), 7.29 (IH, dd, J=8.8, 2.8 Hz), 4.68 - 4.76 (1 H, m), 3.54 - 3.63 (4 H, m), 3.09 - 3.18 (1 H, m), 2.88 - 2.97 (1 H, m), 2.71 - 2.78 (2 H, m), 2.51 - 2.59 (2 H, m), 2.44 - 2.49 (2 H, m), 2.32 - 2.39 (2 H, m), 2.04 - 2.12 (2 H, m), 1.81 - 1.93 (4 H, m), 1.63 - 1.72 (2 H, m), 1.51 (6 H, s).
Route 49
Figure imgf000178_0001
NEt3
Figure imgf000178_0002
/ DMF
Figure imgf000178_0003
Preparation of 1-benzyl 4-ethyl 5-oxoazepane-l,4-dicarboxylate
Figure imgf000178_0004
To a suspension of benzyl 4-oxo-l-piperazinecarboxylate (11.7 g, 50.3 mmol) in diethyl ether (100 ml) at -78 0C was added ethyl diazoacetate (6.84 ml, 65.3 mmol) followed by BF3OEt2 (6.30 ml, 50.3 mmol). After 1 hour the reaction was raised to room temperature giving a clear yellow solution. A saturated aqueous solution Of K2CO3 was added dropwise until no further gas evolution was observed. The organic layer was separated and washed with saturated aqueous K2CO3 (2 x 50 ml), dried (MgSO4), filtered and concentrated giving the title product as yellow oil (16.5 g, quant, yield). The product was used without further purification. LCMS data: Calculated MH+ (320); Found 85% (MH+) m/z 320, Rt = 1.92 min. 1H NMR (500 MHz, CDCl3) δ 7.27 - 7.40 (5 H, m), 5.05 - 5.19 (2 H, m), 4.13 - 4.30 (2 H, m), 3.84 - 3.98 (1 H, m), 3.67 - 3.84 (2 H, m), 3.34 - 3.57 (2 H, m), 2.62 - 2.93 (2 H, m), 1.98 - 2.14 (2 H, m), 1.18 - 1.34 (3 H, m).
Preparation of 1-benzyl 4-ethyl-5-hydroxyazepane-l,4-dicarboxylate
Figure imgf000179_0001
NaBH4 (1.96 g, 51.7 mmol) was added portionwise to a stirred solution of 1-benzyl 4-ethyl 5- oxoazepane-l,4-dicarboxylate (16.5 g, 51.7 mmol) in EtOH (150 ml) at 0 0C. After 10 minutes the reaction was raised to room temperature and stirred for a further 30 minutes. The reaction was quenched by dropwise addition of a saturated solution of aqueous potassium sodium tartrate (10 ml). The resulting solids were separated and the filtrate concentrated. The resulting residue was diluted with dichloromethane (150 ml) and washed with saturated aqueous potassium sodium tartrate (50 ml), water (2 x 50 ml), dried (MgSO4), filtered and concentrated at reduced pressure. NMR analysis of the crude material showed a 3:1 mixture of diastereoisomers. The residue was purified by silica FCC (using a gradient of eluents; 4:1 to 1 :1 Hexane/EtOAc) to give the major syn diastereoisomer of the title product as colourless oil (5.3 g, 32%).
LCMS data: Calculated MH+ (322); Found 97% (MH+) m/z 322, Rt = 1.83 min. 1H NMR (500 MHz, MeOD) δ 7.27 - 7.40 (5 H, m), 5.05 - 5.19 (2 H, m), 4.13 - 4.30 (2 H, m), 3.84 - 3.98 (1 H, m), 3.67 - 3.84 (2 H, m), 3.34 - 3.57 (2 H, m), 2.62 - 2.93 (2 H, m), 1.98 - 2.14 (2 H, m), 1.18 - 1.34 (3 H, m).
Preparation of 1-benzyl 4-ethyl 2,3,6,7-tetrahydro-lH-azepine-l,4-dicarboxylate
Figure imgf000179_0002
To a stirred solution 1-benzyl 4-ethyl-5-hydroxyazepane-l,4-dicarboxylate (4.4 g, 13.7 mmol) in THF (100 ml) was added MsCl (2.58 ml, 33.6 mmol) and TEA (5.69 ml, 40.5 mmol) in three portions over 16 hours. The mixture was then concentrated, diluted with dichloromethane (100 ml), washed with saturated aqueous NaHCO3 (2 x 50 ml), dried (MgSO4), filtered and reconcentrated. The residue was dissolved in THF (100 ml) and DBU (3.1 ml, 20.6 mmol) was added and the resulting mixture was heated at 80 0C for 1 hour. The reaction was then concentrated, diluted with dichloromethane (100 ml), washed with saturated aqueous NaHCO3 (3 x 30 ml), dried (MgSO4), filtered and reconcentrated. The residue was purified via silica FCC (using a gradient of eluents; 9:1 to 7:3 Hexane/EtOAc) to give the title product as colourless oil (2.1 g, 51%).
LCMS data: Calculated MH+ (304); Found 82% (M+Na+) m/z 326, Rt = 2.14 min. 1H NMR (500 MHz, MeOD) δ 7.24 - 7.43 (5 H, m), 7.12 (1 H, br. s.), 5.14 (2 H, s), 4.16 (2 H, q, J=7.0 Hz), 3.49 - 3.66 (4 H, m), 2.63 - 2.75 (2 H, m), 2.40 - 2.57 (2 H, m), 1.27 (3 H, t, J=7.0 Hz).
Preparation of 1-benzyl 4-ethyl azepane-l,4-dicarboxylate
Figure imgf000180_0001
A solution of 1-benzyl 4-ethyl 2,3,6,7-tetrahydro-lH-azepine-l,4-dicarboxylate (890 mg, 2.93 mmol) and 5% Pd/C (90 mg) in THF (70 ml) were stirred under a hydrogen atmosphere for 12 hours. The mixture was then filtered over celite and concentrated giving colourless oil. This was dissolved in dichloromethane (10 ml), cooled to 0 0C and DIPEA (1.02 ml, 5.86 mmol) followed by benzyl chloroformate (0.45 ml, 3.22 mmol) were added. On complete addition the reaction was raised to room temperature and stirred for a further 1 hour. The mixture was then diluted with dichloromethane (40 ml) and washed with water (2 x 20 ml), dried (MgSO4), filtered and concentrated. The residue was purified by silica FCC (using a gradient of eluents; 99:1 to 90:10 dichloromethane/MeOH) to give the title product as colourless oil (521 mg, 59%).
LCMS data: Calculated MH+ (306); Found 86% (M+Na+) m/z 328, Rt = 2.09 min. 1H NMR (500 MHz, MeOD) δ 7.28 - 7.42 (5 H, m), 5.07 - 5.20 (2 H, m), 4.02 - 4.17 (2 H, m), 3.59 - 3.68 (1 H, m), 3.47 - 3.57 (1 H, m), 3.34 - 3.47 (2 H, m), 2.42 - 2.54 (1 H, m), 1.76 - 2.10 (4 H, m), 1.57 - 1.73 (2 H, m), 1.23 (3 H, d, J=7.1 Hz).
l-[(benzyloxy)carbonyl]azepane-4-carboxylic acid
Figure imgf000180_0002
cbz-Vj
To a stirred solution of 1-benzyl 4-ethyl azepane-l,4-dicarboxylate (500 mg, 1.64 mmol) in
THF (3 ml) was added LiOH (96 mmol, 2.30 mmol) dissolved in water (3 ml). After 16 hours the mixture was concentrated, diluted with dichloromethane (30 ml), washed with IM aq. HCl (15 ml), water (15 ml), dried (MgSO4), filtered and concentrated giving the title product as colourless oil (372 mg, 82%) that was used without and further purification. LCMS data: Calculated MH+ (278); Found 86% (M+Na+) m/z 300, Rt = 1.77 min 1H NMR (500 MHz, MeOD) δ 7.25 - 7.43 (5 H, m), 5.06 - 5.18 (2 H, m), 3.49 - 3.68 (2 H, m), 3.35 - 3.48 (2 H, m), 2.38 - 2.51 (1 H, m), 1.74 - 2.12 (4 H, m), 1.55 - 1.72 (2 H, m).
Preparation of benzyl 4-[(3-hydroxyazetidin-l-yl)carbonyl]azepane-l-carboxylate
Figure imgf000181_0001
To a stirred solution of l-[(benzyloxy)carbonyl]azepane-4-carboxylic acid (317 mg, 1.14 mmol) in DMF (5 ml) was added HOBt (154 mg, 1.14 mmol) followed by EDCI (218 mg, 1.14 mmol). After 5 minutes, a solution of 3-hydroxyazetidine hydrochloride (138 mg, 1.26 mmol) and DIPEA (0.44 ml, 2.51 mmol) in DMF (1 ml) was added and the resulting solution was stirred for 12 hours at room temperature. The mixture was diluted with EtOAc (30 ml) and washed with saturated aqueous NaHCO3 (3 x 15 ml), dried (MgSO4), filtered and concentrated. The residue was purified by silica FCC (using a gradient of eluents; 99:1 to 92:8 DCM/MeOH) to give the title product as colourless oil (265 mg, 70%). LCMS data: Calculated MH+ (333); Found 100% (M+Na+) m/z 355, Rt = 1.56 min 1H NMR (500 MHz, MeOD) δ 7.26 - 7.42 (5 H, m), 5.05 - 5.22 (2 H, m), 4.48 - 4.60 (1 H, m), 4.23 - 4.41 (1 H, m), 4.09 - 4.20 (1 H, m), 3.84 - 3.98 (1 H, m), 3.54 - 3.76 (3 H, m), 3.33 - 3.48 (2 H, m), 2.33 (1 H, m), 1.69 - 1.99 (4 H, m), 1.46 - 1.69 (2 H, m).
Preparation of benzyl 4-({3-[(6-methylpyridin-3-yl)oxy]azetidin-l-yl}carbonyl)azepane-
1-carboxylate
Figure imgf000181_0002
0.29 mmol) and 4-chloro-2-methylpyridine (52 μl, 0.46 mmol) in DMSO (2 ml) was added NaH (37 mg of a 60% dispersion in mineral oil, 0.93 mmol). The mixture was stirred at room temperature for 12 hours, 50 0C for 3 hours and a further 12 hours at room temperature. The reaction was then diluted with EtOAc (20 ml) and washed with water (3 x 10 ml), dried (MgSO4), filtered and concentrated. The residue was purified by silica FCC (using a gradient of eluents; 99:1 :1 to 95:5:1 DCM/MeOH/2M NH3 in MeOH) to give the title product as colourless oil (35 mg, 29%).
LCMS data: Calculated MH+ (424); Found 96% (MH+) m/z 424, Rt = 1.44 min 1H NMR (500 MHz, MeOD) δ 8.21 - 8.29 (1 H, m), 7.16 - 7.42 (5 H, m), 6.69 - 6.82 (2 H, m), 5.04 - 5.21 (3 H, m), 4.51 - 4.68 (1 H, m), 4.32 - 4.44 (1 H, m), 4.05 - 4.23 (1 H, m), 3.86 - 3.99 (1 H, m), 3.53 - 3.71 (2 H, m), 3.33 - 3.50 (2 H, m), 2.49 (3 H, s), 2.30 - 2.41 (1 H, m), 1.69 - 2.00 (4 H, m), 1.48 - 1.69 (2 H, m).
Example 166 - Preparation of l-cyclobutyl-4-({3-[(6-methylpyridin-3-yl)oxy]azetidin-l- yl}carbonyl)azepane. Potency range A
Figure imgf000182_0001
A mixture of benzyl 4-({3-[(6-methylpyridin-3-yl)oxy]azetidin-l-yl}carbonyl)azepane-l- carboxylate (37 mg, 87 μmol), cyclobutanone (13 μl, 0.18 mmol) and 5% Pd/C (5 mg) in EtOH (4 ml) were stirred under a hydrogen atmosphere for 12 hours. The reaction was then filtered over celite and concentrated. The residue was dissolved in EtOAc (30 ml) and washed with water (3 x 15 ml), dried (MgSO4), filtered and concentrated. The residue was purified by silica FCC (using a gradient of eluents; 98:2:1 to 90:10:1 DCM/MeOH/2M NH3 in MeOH) to give the title product as colourless oil (12 mg, 40%). LCMS data: Calculated MH+ (344); Found 87% (MH+) m/z 344, Rt = 4.20 min. 1H NMR (500 MHz, MeOD) δ 8.24 (1 H, d, J=5.8 Hz), 6.70 - 6.84 (2 H, m), 5.10 - 5.19 (1 H, m), 4.62 - 4.75 (1 H, m), 4.36 - 4.45 (1 H, m), 4.19 - 4.28 (1 H, m), 3.90 - 3.99 (1 H, m), 2.95 - 3.07 (1 H, m), 2.58 - 2.78 (3 H, m), 2.42 - 2.58 (5 H, m), 2.02 - 2.13 (2 H, m), 1.79 - 1.96 (6 H, m), 1.60 - 1.79 (4 H, m).

Claims

Patent claims
1. A compound of formula (I)
Figure imgf000183_0001
or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein
R1 is Ci_5 alkyl; C2-5 alkenyl; C2-5 alkynyl; or T0, wherein Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; CN; and T0;
T0 is C3_5 cycloalkyl; or 4 to 5 membered saturated heterocyclyl, wherein T0 is optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; Ci .5 alkyl; C2-5 alkenyl; C2-5 alkynyl; OH; O-C1.5 alkyl; O-C2-5 alkenyl; O-C2-5 alkynyl; and CN, wherein Ci-5 alkyl; C2-5 alkenyl; C2-5 alkynyl; O-Ci_5 alkyl; O-C2-5 alkenyl; and O-C2-5 alkynyl are optionally substituted with one or more halogen, which are the same or different;
n is 1 or 2;
X1 is N; or CH;
X2 is O; S; N-CN; N-OH; or N-0d_4 alkyl;
X3 is N; CH; or CF;
X4 is H; F; or (CH2)niX5(CH2)n2R2;
R0 is F; m is 0, 1, 2, 3, or 4;
R is H; or F;
Optionally, R, X4 are joined to form oxo (=0);
nl; n2 are independently selected from the group consisting of 0; 1; and 2;
X5 is C(O); C(O)O; OC(O); O; C(0)N(Rla); N(Rla)C(0); S(O)2N(Rla); N(Rla)S(O)2; S(O)N(Rla); N(Rla)S(O); S(O)2; S(O); N(Rla)S(0)2N(Rlb); S; N(Rla);
N(Rla)C(0)N(Rlb); N(Rla)C(0)0; or 0C(0)N(Rla);
Rla, Rlb are independently selected from the group consisting of H; Ci_4 alkyl; C2_4 alkenyl; and C2_4 alkynyl, wherein Ci_4 alkyl; C2_4 alkenyl; and C2_4 alkynyl are optionally substituted with one or more halogen, which are the same or different;
R2 is H; T; Ci_6 alkyl; C2_6 alkenyl; or C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more R3, which are the same or different;
R3 is halogen; CN; C(O)R4; C(O)OR4; OR4; C(O)N(R4R4a); S(O)2N(R4R4a);
S(O)N(R4R4a); S(O)2R4; S(O)R4; N(R4)S(O)2N(R4aR4b); SR4; N(R4R4a); NO2;
OC(O)R4; N(R4)C(O)R4a; N(R4)SO2R4a; N(R4)S(O)R4a; N(R4)C(O)N(R4aR4b);
N(R4)C(O)OR4a; OC(O)N(R4R4a); or T;
R4, R4a, R4b are independently selected from the group consisting of H; T; Ci_6 alkyl;
C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more R5, which are the same or different;
R5 is halogen; CN; C(O)R6; C(O)OR6; OR6; C(O)N(R6R6a); S(O)2N(R6R6a);
S(O)N(R6R6a); S(O)2R6; S(O)R6; N(R6)S(O)2N(R6aR6b); SR6; N(R6R6a); NO2; OC(O)R6; N(R6)C(O)R6a; N(R6)SO2R6a; N(R6)S(O)R6a; N(R6)C(O)N(R6aR6b); N(R6)C(O)OR6a; OC(O)N(R6R6a); or T; R6, R6a, R6b are independently selected from the group consisting of H; T; Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
T is phenyl; naphthyl; azulenyl; indenyl; indanyl; C3-7 cycloalkyl; 3 to 7 membered heterocyclyl; or 7 to 11 membered heterobicyclyl, wherein T is optionally substituted with one or more R7, which are the same or different;
R7 is halogen; CN; C(O)OR8; OR8; C(O)R8; C(O)N(R8R8a); S(O)2N(R8R8a); S(O)N(R8R8a); S(O)2R8; S(O)R8; N(R8)S(O)2N(R8aR8b); SR8; N(R8R8a); NO2;
OC(O)R8; N(R8)C(O)R8a; N(R8)S(O)2R8a; N(R8)S(O)R8a; N(R8)C(O)OR8a;
N(R8)C(O)N(R8aR8b); OC(O)N(R8R8a); oxo (=0), where the ring is at least partially saturated; T1; Ci_6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R9, which are the same or different;
R8, R8a, R8b are independently selected from the group consisting of H; T1; Ci_6 alkyl;
C2-6 alkenyl; and C2-6 alkynyl, wherein Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R10, which are the same or different;
R9, R10 are independently selected from the group consisting of halogen; CN;
C(O)R11; C(O)OR11; OR11; C(O)N(R11R1 la); S(O)2N(R11R1 la); S(O)N(R11R1 la);
S(O)2R11; S(O)R11; N(R1 ^S(O)2N(R1 laRl lb); SR11; N(RπRl la); NO2; OC(O)R11;
N(R1 ^C(O)R11*; N(R1 ^SO2R11*; N(R1 ^S(O)R11*; N(R1 ^C(O)N(R1 laRl lb); N(R1 ^C(O)OR11*; OC(O)N(R11R1 la); and T1;
R11, Rl la, Rl lb are independently selected from the group consisting of H; T1; Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein Ci_6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
T1 is phenyl; C3_7 cycloalkyl; or 3 to 7 membered heterocyclyl, wherein T1 is optionally substituted with one or more R12, which are the same or different; R12 is halogen; CN; C(O)OR13; OR13; C(O)R13; C(O)N(R13R13a); S(O)2N(R13R13a); S(O)N(R13R13a); S(O)2R13; S(O)R13; N(R13)S(O)2N(R13aR13b); SR13; N(R13R13a); NO2; OC(O)R13; N(R13)C(O)R13a; N(R13)S(O)2R13a; N(R13)S(O)R13a; N(R13)C(O)OR13a; N(R13)C(O)N(R13aR13b); OC(O)N(R13R13a); oxo (=0), where the ring is at least partially saturated; Ci_6 alkyl; C2_6 alkenyl; or C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
R13, R13a, R13b are independently selected from the group consisting of H; Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl, wherein Ci_6 alkyl; C2_6 alkenyl; and C2_6 alkynyl are optionally substituted with one or more halogen, which are the same or different,
provided that the following compound salts are excluded:
1 -Propyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyljpiperazine fumarate
[1 :1];
1 -Methyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyljpiperazine oxalate
[1 :1.5];
1 -Methyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyljpiperazine fumarate [1 :1];
1 - [3 -(4-Bromophenoxy)- 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1]; l-[3-(3-Bromophenoxy)-l-azetidinylcarbonyl]-4-methylpiperazine fumarate [1 :1];
1 - [3 -(4-Fluorophenoxy)- 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1];
1 - [3 -(3 ,4-Dichlorophenoxy)- 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1]; 1 - [3 - [(4-Chlorophenyl)thio] - 1 -azetidinylcarbonyl] -4-methylpiperazine fumarate [1 :1];
Hexahydro- 1 -methyl-4- [3 - [3 -(trifluoromethyl)phenoxy] - 1 -azetidinylcarbonyl] - IH-
1 ,4-diazepine fumarate [1:1].
2. A compound of claim 1, wherein R1 is Ci_5 alkyl; C2_5 alkenyl; C2_5 alkynyl; C3-5 cycloalkyl; CH2-Cy clopropyl; CHF-cyclopropyl; CF2-Cy clopropyl; CH2-Cy clo butyl;
CHF-cyclobutyl; CF2-cyclobutyl; or 4 to 5 membered saturated heterocyclyl, wherein Ci_5 alkyl; C2_5 alkenyl; C2_5 alkynyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; and CN, and wherein C3-5 cycloalkyl; CH2-cyclopropyl; CHF-cyclopropyl; CF2-cyclopropyl; CH2-cyclobutyl; CHF- cyclobutyl; CF2-cyclobutyl; and 4 to 5 membered saturated heterocyclyl are optionally substituted with one or more substituents, which are the same or different and selected from the group consisting of halogen; OH; OCH3; OCH2F; OCHF2; OCF3; CN; CH3; CH2F; CHF2; and CF3.
3. A compound of claim 1 or 2, wherein n is 2.
4. A compound of any of claims 1 to 3, wherein X1 is N.
5. A compound of any of claims 1 to 4, wherein X2 is O;
6. A compound of any of claims 1 to 5, wherein at least one of X1, X3 is N.
7. A compound of any of claims 1 to 6, wherein m is 0.
8. A compound of any of claims 1 to 7, wherein nl; n2 are independently selected from the group consisting of 0; and 1.
9. A compound of any of claims 1 to 8, wherein X5 is C(O); O; C(0)N(Rla); N(Rla)C(0); S(O)2N(Rla); N(Rla)S(O)2; N(Rla); or N(Rla)C(0)N(Rlb).
10. A compound of any of claims 1 to 9, wherein R2 is H; or T.
11. A compound of claim 1 selected from the group consisting of
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-ol;
1 -[(4-cyclobutylpiperazin- 1 -yl)carbonyl]azetidin-3 -ol;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylpyridine-3-carboxamide; 5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridine-2- carboxamide.;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylpyridine-2-carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N- dimethylpyridine-2-carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N- diethylpyridine-2-carboxamide;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylbenzamide;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N- dimethylbenzamide;
1 -cyclobutyl-4-( {3-[4-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4- [(3 - { [5 -(trifluoromethyl)pyridin-2-yl]oxy } azetidin- 1 -yl)carbonyl] -1,4- diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)benzonitrile;
1 -cyclobutyl-4- { [3-(4-fluorophenoxy)azetidin- 1 -yl]carbonyl} - 1 ,4-diazepane;
1 - { [3-(4-chlorophenoxy)azetidin- 1 -yl]carbonyl} -4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3 -phenoxyazetidin- 1 -yl)carbonyl]- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3 - [4-( 1 H-pyrazo 1- 1 -ylmethyl)phenoxy] azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane; 1 -cyclobutyl-4-[(3- { [5-( 1 H-pyrazol- 1 -ylmethyl)pyridin-2-yl]oxy } azetidin- 1 - yl)carbonyl]- 1 ,4-diazepane;
1 -[4-( { l-[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3- yl}oxy)phenyl]pyrrolidin-2-one;
1 -cyclobutyl-4-( {3-[4-(piperidin- 1 -ylmethyl)phenoxy] azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4- [(3 - {4- [(4-methylpiperazin- 1 -yl)methyl]phenoxy } azetidin- 1 - yl)carbonyl]- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3- {4-[(4,4-difluoropiperidin- 1 -yl)methyl]phenoxy} azetidin- 1 - yl)carbonyl]- 1 ,4-diazepane;
1 -( {3-[(5-bromopyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(3 ,4-dichlorophenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -( {3-[(6-bromopyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 - { [3-(4-chloro-2-methylphenoxy)azetidin- 1 -yljcarbonyl} -4-cyc Io butyl- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[4-(lH-imidazol- 1 -yl)phenoxy] azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[(2-methylpyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[3-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[2-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane; 3-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)benzonitrile;
2-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)benzonitrile;
1 - { [3-(3-chlorophenoxy)azetidin- 1 -yljcarbonyl} -4-cyclo butyl- 1 ,4-diazepane;
1 - { [3-(2-chlorophenoxy)azetidin- 1 -yljcarbonyl} -4-cyclo butyl- 1 ,4-diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,3- dimethylbenzamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- (cyclopropylmethyl)pyridine-2-carboxamide;
1 -cyclobutyl-4- [(3 - { [5 -(trifluoromethyl)pyridin-3 -yl]oxy } azetidin- 1 -yl)carbonyl] - 1 ,4- diazepane;
5 -( { 1 - [(4-cyclo butylpiperazin- 1 -yl)carbonyl] azetidin-3 -yl} oxy)-N-methylpyridine-2- carboxamide;
1 -cyclobutyl-4- [(3 -phenoxyazetidin- 1 -yl)carbonyl]piperazine;
1 -cyclobutyl-4-( {3-[4-(trifluoromethyl)phenoxy]azetidin- 1 -yl} carbonyl)piperazine;
4-( { 1 -[(4-cyclo butylpiperazin- 1 -yl)carbonyl] azetidin-3 -yl}oxy)benzonitrile;
1 -cyclobutyl-4- { [3 -(4-fluorophenoxy)azetidin- 1 -yl] carbonyl} piperazine;
6-cyclobutyl-2-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)- 5,6,7,8-tetrahydro-l,6-naphthyridine;
4-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-3-fluoro-N- methylbenzamide; 1 -cyclobutyl-4- { [3-(4-iodophenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(5-fluoropyridin-3-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -( {3-[(6-chloropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-2-fluoro-N- methylbenzamide;
1 -( {3-[(4-chloropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(3-fluoropyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -( {3-[(4-chloro-2-methylpyridin-3-yl)oxy]azetidin- 1 -yl}carbonyl)-4-cyc Io butyl- 1 ,4- diazepane;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)imidazo[l ,5- a]pyridine;
1 -cyclobutyl-4-( {3-[(2-methoxypyrimidin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
2-[4-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2- yl]propan-2-ol;
1 -cyclobutyl-4-( {3-[(2-ethylpyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4- [(3 -{ [2-( 1 -methylethyl)pyridin-4-yl]oxy } azetidin- 1 -yl)carbonyl] - 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[(2-methoxypyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-amine; 4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N,N- dimethylpyridin-2-amine;
1 -cyclobutyl-4-( {3-[(6-methylpyridazin-3-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,A- diazepane;
2-[4-( { l-[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-2- fluorophenyl]propan-2-ol;
1 -cyclobutyl-4-( {3-[(3,5-dimethylpyrazin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(2-methoxypyrimidin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(6-methylpyrazin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(3,6-dimethylpyrazin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(2-methylpyrimidin-4-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(6-methoxypyrazin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -( {3-[(3-chloropyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)quinoline;
1 -cyclobutyl-4-( {3-[(2,6-dimethylpyridin-4-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane; 8-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)imidazo[l ,2- a]pyridine;
7-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)imidazo[l ,2- a]pyridine;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridine-2- carboxamide;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N-
(cyclopropylmethyl)pyridine-2-carboxamide;
1 -cyclobutyl-4-[(3- {[6-(piperidin- 1 -ylcarbonyl)pyridin-3-yl]oxy} azetidin- 1 - yl)carbonyl]- 1 ,4-diazepane;
3-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylbenzamide;
1 -( {3-[(5-chloropyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -( {3-[(5-chloropyridin-2-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(3,5-dimethylpyrazin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -( {3-[(3-chloropyridin-4-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -( {3-[(5-chloropyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(pyridin-4-yloxy)azetidin- 1 -yl] carbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(5-methoxypyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane; 2-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-6- (cyclopropylcarbony^-S^J^-tetrahydro-l^-naphthyridine;
2-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-6- (cyclopropylacetyl)-5,6,7,8-tetrahydro-l,6-naphthyridine;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylpyridine-3 -carboxamide;
1 -cyclobutyl-4- {[3-(4-methoxyphenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[4-( 1 H-pyrazol- 1 -yl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[4-(trifluoromethoxy)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[4-(difluoromethoxy)phenoxy] azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane;
1 - { [3-(4-chloro-2-fluorophenoxy)azetidin- 1 -yljcarbonyl} -4-cyclobutyl- 1 ,4-diazepane;
1 -cyclobutyl-4- {[3 -(3 -methoxyphenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(2-methoxyphenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
6-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-2- methylquinoline;
1 -cyclobutyl-4- [(3 - {[6-(trifluoromethyl)pyridin-3-yl]oxy} azetidin- 1 -yl)carbonylj- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[(4-fluorobenzyl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane; 1 -cyclobutyl-4-[(3-methoxyazetidin- 1 -yl)carbonyl]- 1 ,4-diazepane;
1 -( {3-[(4-chlorobenzyl)oxy]azetidin- 1 -yl} carbonyl)-4-cyclo butyl- 1 ,4-diazepane;
4-[( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3- yl} oxy)methyl]benzonitrile;
1 -cyclobutyl-4- { [3-(prop-2-yn- 1 -yloxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
3 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutanone;
cώ-3- [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutanol;
6-( {cis-3- [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)-N- methylpyridine-3 -carboxamide;
4-( {cis-3- [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)benzonitrile;
l-cyclobutyl-4-[(cώ-3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}cyclobutyl)carbonyl]- 1,4-diazepane;
trans-3 - [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] cyclobutano 1;
4-( {trans-3-[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)benzonitrile;
l-cyclobutyl-4-[(trα/?5-3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}cyclobutyl)carbonyl]- 1 ,4-diazepane;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-one;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3 -amine;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} amino)-N- methylpyridine-2-carboxamide; 5-[ { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} (methyl)amino]-N- methylpyridine-2-carboxamide;
4-[( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 - yl}amino)methyl]benzonitrile;
5 -( { 1 - [(4-methyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -yl} oxy)-N-methylpyridine-2- carboxamide;
5-( { 1 -[(4-(l-methylethyl)- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -yl}oxy)-N- methylpyridine-2-carboxamide;
5-( { 1 -[(4-cyclopentyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylpyridine-2-carboxamide;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} oxy)-3 ,A- dihydroisoquino lin- 1 (2H)-one;
6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} oxy)-2-methyl-3 ,A- dihydroisoquino lin- 1 (2H)-one;
2- [5 -({ 1 - [(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3 -yl} oxy)pyridin-2- yl]propan-2-ol;
1 -[5-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-2- yljethanone;
1 -cyclobutyl-4-( {3-[(5-methoxypyrimidin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(6-methylpyridin-3-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4-diazepane;
methyl 1 - [(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidine-3 -carboxylate; N-(4-chlorophenyl)- 1 -[(4-cyc Io butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidine-3- carboxamide;
1 -cyclobutyl-4- { [3-(piperidin- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(morpholin-4-ylcarbonyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 - { [3-(azetidin- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} -4-cyclobutyl- 1 ,4-diazepane;
1 -cyclobutyl-4- { [3-(pyrrolidin- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 - { [3-(azepan- 1 -ylcarbonyl)azetidin- 1 -yljcarbonyl} -4-cyclobutyl- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3-[(4-fluoropiperidin- 1 -yl)carbonyl]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4-( {3-[(4,4-difluoropiperidin- 1 -yl)carbonyl]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-cyclohexylazetidine-3-carboxamide;
1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-(6-methylpyridin-3-yl)azetidine-3- carboxamide;
1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-methylazetidine-3-carboxamide;
{ 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methanol;
1 -( {3-[(4-chlorophenoxy)methyl]azetidin- 1 -yl}carbonyl)-4-cyc Io butyl- 1 ,4-diazepane;
6-( { 1 -[(4-cyclobutyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methoxy)-3,4- dihydroisoquino lin- 1 (2H)-one; 6-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methoxy)-2-methyl- 3,4-dihydroisoquinolin-l(2H)-one;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}methoxy)-N- methylpyridine-2-carboxamide;
N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -6-methylpyridine-3- carboxamide;
4-chloro-N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}benzamide;
N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3- yl} cyclohexanecarboxamide;
4-chloro-N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -N- methylbenzamide;
N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -N,6-dimethylpyridine- 3-carboxamide;
N- { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl} -N- methylcyclohexanecarboxamide;
1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-methyl-N-(6-methylpyridin-3- yl)azetidine-3-carboxamide;
N-(4-chlorophenyl)- 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]-N-methylazetidine- 3-carboxamide;
4-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)-N- methylpyridine-2-carboxamide;
1 -cyclobutyl-4- { [3 -(methoxymethyl)azetidin- 1 -yl] carbonyl} - 1 ,4-diazepane; 1 -cyclobutyl-4-( {3 - [4-( 1 -methyl- 1 H-pyrazol-4-yl)phenoxy] azetidin- 1 -yl} carbonyl)- 1 ,4-diazepane;
1 -cyclobutyl-4-( {3 - [4-( 1 ,3 ,5 -trimethyl- 1 H-pyrazol-4-yl)phenoxy] azetidin- 1 - yl}carbonyl)-l,4-diazepane;
1 -cyclobutyl-4-( {3-[(3-fluoro-2-methylpyridin-4-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,4- diazepane;
1 -cyclobutyl-4- {[3-(naphthalen-2-yloxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane;
1 -cyclobutyl-4- { [3 -( { [6-(trifluoromethyl)pyridin-3 -yl]oxy }methyl)azetidin- 1 - yl]carbonyl} - 1 ,4-diazepane;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)- lH-indole;
5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)- 1 -methyl- IH- indole;
2-[5-({l-[(4-cyclobutyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]-2- methylpropan- 1 -ol;
2-[5-({l-[(4-ethyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2-yl]propan- 2-ol;
2-{5-[(l-{[4-(l -methylethyl)- 1 ,4-diazepan- 1 -yl] carbonyl} azetidin-3 -yl)oxy]pyridin-2- yl}propan-2-ol;
2-[5-({l-[(4-cyclopentyl-l,4-diazepan-l-yl)carbonyl]azetidin-3-yl}oxy)pyridin-2- yl]propan-2-ol;
1 -cyclobutyl-4-( {3-[(5-fluoropyrimidin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,4- diazepane; 1 -cyclobutyl-4-( {3-[(5-methoxypyridin-2-yl)oxy]azetidin- 1 -yl}carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(5-ethylpyrimidin-2-yl)oxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[4-(methylsulfonyl)phenoxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
1 -cyclobutyl-4-( {3-[(6-methylpyridin-3-yl)methoxy]azetidin- 1 -yl} carbonyl)- 1 ,A- diazepane;
2-[5-( {cώ-3-[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]cyclobutyl}oxy)pyridin-2- yl]propan-2-ol;
1 -cyclobutyl-4-( {3-[(6-methylpyridin-3-yl)oxy]azetidin- 1 -yl} carbonyl)azepane;
1 -[(4-ethyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-ol;
1 - { [4-( 1 -methylethyl)- 1 ,4-diazepan- 1 -yljcarbonyl} azetidin-3-ol;
1 -[(4-cyclopentyl- 1 ,4-diazepan- 1 -yl)carbonyl] azetidin-3-ol;
ethyl 5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridine-2- carboxylate;
1 -cyclobutyl-4- {[3-(3-methyl-4-nitrophenoxy)azetidin- 1 -yljcarbonyl} - 1 ,4-diazepane; trans-3 - [(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl] eye Io butyl acetate; and
methyl 2-[5-( { 1 -[(4-cyclo butyl- 1 ,4-diazepan- 1 -yl)carbonyl]azetidin-3-yl}oxy)pyridin-
2-yl]-2-methylpropanoate.
12. A pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 11 together with a pharmaceutically acceptable carrier, optionally in combination with one or more other bioactive compounds or pharmaceutical compositions.
13. A compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 11 for use as a medicament.
14. A compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 11 for use in a method of treating or preventing diseases and disorders associated with the H3 receptor.
15. A compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 11 for use in a method of treating or preventing neurological disorders; disorders affecting energy homeostasis as well as complications associated therewith; Pain; cardiovascular disorders; gastrointestinal disorders; vestibular dysfunction; nasal congestion; allergic rhinitis; or asthma.
16. Use of a compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 11 for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with the H3 receptor.
17. Use of a compound or a pharmaceutically acceptable salt thereof of any of claims 1 to 11 for the manufacture of a medicament for the treatment or prophylaxis of neurological disorders; disorders affecting energy homeostasis as well as complications associated therewith; Pain; cardiovascular disorders; gastrointestinal disorders; vestibular dysfunction; nasal congestion; allergic rhinitis; or asthma.
18. A method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of diseases and disorders associated with the H3 receptor, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound of any of claims 1 to 11 or a pharmaceutically acceptable salt thereof.
19. A method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions selected from the group consisting of neurological disorders; disorders affecting energy homeostasis as well as complications associated therewith; Pain; cardiovascular disorders; gastrointestinal disorders; vestibular dysfunction; nasal congestion; allergic rhinitis; and asthma, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound of any of claims 1 to 11 or a pharmaceutically acceptable salt thereof.
20. A method for the preparation of a compound of any of claims 1 to 11, wherein in formula (I) X1 and X3 are N; X2 is O; nl and n2 are 0 in the definition of X4 and R2 is an aromatic cycle T, comprising the steps of
(a) reacting the amino group of a compound of formula (II) with a suitable chloroformate
Figure imgf000202_0001
wherein n and R1 have the meaning as indicated in claim 1 ;
(b) reacting the resulting carbamate compound from step (a) with a compound of formula (III)
Figure imgf000202_0002
wherein X4 is OH and R has the meaning as indicated in claim 1; and
(c) reacting the resulting compound with a compound of formula Cl-T or F-T to yield a compound of formula (I), wherein X1 and X3 are N; X2 is O; nl and n2 are 0 in the definition of X4 and R2 is an aromatic cycle T.
21. A method for the preparation of a compound of any of claims 1 to 11, wherein in formula (I) X1 is N and X3 is CH; X2 is O; m is 0; R is H, comprising the steps of
(a) reacting a malonate ester with a strong base and reacting the resulting di- anion with a l,3-dihalo-2,2-dialkoxypropane to form a compound of formula (Id)
Figure imgf000203_0001
(b) treating the compound of formula (Id) with strong acid at elevated temperature to form a compound represented by formula (Ie)
Figure imgf000203_0002
(c) reacting a compound of formula (Ie) with amide coupling reagents and treating the resulting intermediate with a compound of formula (II);
Figure imgf000203_0003
(d) reducing the ketone group of step (c) product with a reducing agent to give a predominantly (>95:5) cis alcohol of formula (If), wherein X5 is O and R1 and n have the meaning as indicated in claim 1
Figure imgf000204_0001
optionally comprising the further steps
(e) converting the alcohol to a suitable leaving group by reaction with the appropriate sulfonyl chloride in the presence of base;
(f) reacting the resulting sulfonate ester with an acetate salt such as potassium acetate at high temperature;
(g) hydrolysis of the acetate group with base to give a predominantly (>9.5:1) trans alcohol of formula (Ig)
Figure imgf000204_0002
optionally comprising the further step of
(h) deprotonating the alcohol with a strong base and reacting the resulting alkoxide with a suitable alkyl halide, benzyl halide, activated alcohol or (hetero)aromatic halide at room temperature or elevated temperature to yield a compound of formula (I), wherein X4 is 0(CH2)D2R2.
22. A method for the preparation of a compound of any of claims 1 to 11, wherein in formula (I) X1 and X3 are N and X2 is O, comprising the steps of (a) reacting the amino group of compound of formula (Ha) with a suitable chloroformate
Figure imgf000205_0001
wherein n has the meaning as indicated in claim 1 and R1 is R1 as indicated claim 1 or as suitable N-atom protecting group to yield a compound of formula (I), optionally after removal of the protecting group and reacting the liberated amino group with a compound of formula R1=O, wherein the oxo group is attached to a carbon atom of R1, followed by reduction of the resulting imine; and
(b) reacting the resulting carbamate compound from step (a) with a compound of formula (Ilia)
Figure imgf000205_0002
wherein X4 is H; OH; or C(O)2(alkyl), R has the meaning as indicated claim 1 , to yield a compound of formula (I) when X4 is defined as in claim 1.
23. A method for the preparation of a compound of any of claims 1 to 11, wherein in formula (I) X5 C(O), comprising the steps of
(a) reacting a compound represented by formula (VI) with base or acid;
Figure imgf000205_0003
(b) reacting the resulting carboxylic acid compound from step (a) with with amide coupling reagents and reacting the resulting activated ester with either a primary or secondary amine compound, as defined for R2, to yield a compound of formula (I), wherein X4 is X5(CH2)n2R2.
24. A method for the preparation of a compound of any of claims 1 to 11, comprising the further step where compounds of formula (I) represented by formula (XI), wherein the meanings are as indicated in claim 1, are further modified as follows:
Figure imgf000206_0001
• reacting the ester group with a Grignard reagent, optionally in the presence of lithium chloride, at a temperature usually between -780C and 15O0C, to yield a compound of formula (I).
PCT/EP2009/055418 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine h3 receptor antagonists WO2009135842A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/991,225 US8691804B2 (en) 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine H3 receptor antagonists
EP09742060.8A EP2300422B1 (en) 2008-05-08 2009-05-05 Azetidines as histamine h3 receptor antagonists
CN200980117615.XA CN102015636B (en) 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine H3 receptor antagonists
BRPI0913057A BRPI0913057A2 (en) 2008-05-08 2009-05-05 azetidines and cyclobutanes as h3 histamine receptor antagonists
JP2011507892A JP5780954B2 (en) 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine H3 receptor antagonists
CA2721303A CA2721303C (en) 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine h3 receptor antagonists
IL208613A IL208613A (en) 2008-05-08 2010-10-11 Azetidine derivatives, methods of their preparation, compositions comprising them and uses thereof
HK11110177.1A HK1155749A1 (en) 2008-05-08 2011-09-27 Azetidines and cyclobutanes as histamine h3 receptor antagonists h3

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08155915.5 2008-05-08
EP08155915 2008-05-08
US13946108P 2008-12-19 2008-12-19
US61/139,461 2008-12-19

Publications (1)

Publication Number Publication Date
WO2009135842A1 true WO2009135842A1 (en) 2009-11-12

Family

ID=39720542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/055418 WO2009135842A1 (en) 2008-05-08 2009-05-05 Azetidines and cyclobutanes as histamine h3 receptor antagonists

Country Status (10)

Country Link
US (1) US8691804B2 (en)
EP (1) EP2300422B1 (en)
JP (1) JP5780954B2 (en)
CN (1) CN102015636B (en)
BR (1) BRPI0913057A2 (en)
CA (1) CA2721303C (en)
HK (1) HK1155749A1 (en)
IL (1) IL208613A (en)
TW (1) TWI454468B (en)
WO (1) WO2009135842A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006621A1 (en) * 2009-07-11 2011-01-20 Bayer Schering Pharma Aktiengesellschaft Radiolabelling method using cycloalkyl groups
WO2012004588A3 (en) * 2010-07-06 2012-08-09 Astrazeneca Ab Therapeutic agents 976
WO2012114348A1 (en) 2011-02-23 2012-08-30 Suven Life Sciences Limited Novel compounds as histamine h3 receptor ligands
CN103168027A (en) * 2010-02-18 2013-06-19 阿斯利康(瑞典)有限公司 Processes for making cyclopropyl amide derivatives and intermediates associated therewith
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2014030170A1 (en) 2012-08-23 2014-02-27 Suven Life Sciences Limited Acrylamide compounds as histamine h3 receptor ligands
US8685958B2 (en) 2011-07-15 2014-04-01 Astrazeneca Ab Therapeutic agents
US8912176B2 (en) 2009-02-02 2014-12-16 Evotec Ag Azetidines as histamine H3 receptor antagonists
US8993577B2 (en) 2009-02-20 2015-03-31 Astrazeneca Ab Cyclopropyl amide derivatives
CN104603104A (en) * 2012-09-05 2015-05-06 浙江海正药业股份有限公司 Crystal forms of azetidinone compounds and preparing methods thereof
US9029381B2 (en) 2007-08-22 2015-05-12 Astrazeneca Ab Cyclopropyl amide derivatives
WO2021195403A1 (en) 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112279809A (en) * 2020-09-23 2021-01-29 山东省海洋化工科学研究院 Preparation method of 2-cyano-4-fluoropyridine
CN115073276A (en) * 2022-07-15 2022-09-20 济南大学 Preparation and control method of posaconazole main ring impurity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007049123A1 (en) * 2005-10-27 2007-05-03 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007136324A1 (en) 2006-05-18 2007-11-29 Albireo Ab 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA861210B (en) 1985-02-28 1987-10-28 Robins Co Inc A H 3-aryloxyazetidinecarboxamides as anticonvulsants and antiepileptics
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
DE10150310A1 (en) 2001-10-11 2003-04-24 Bayer Ag New piperazinyl cyclohexanecarboxamide derivatives useful as adenosine uptake inhibitors for treating ischemic peripheral and cardiovascular diseases
SI1802307T1 (en) 2004-10-15 2008-08-31 Glaxo Group Ltd Pyrrolidine derivatives as histamine receptors ligands
EP1965862A2 (en) 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
AU2007204426A1 (en) 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators
UA103468C2 (en) 2007-11-20 2013-10-25 Янссен Фармацевтика Н.В. Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007049123A1 (en) * 2005-10-27 2007-05-03 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007136324A1 (en) 2006-05-18 2007-11-29 Albireo Ab 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 1971, XP002498942 *
DATABASE CHEMCATS Chemical abstract service, Ohio, US; 13 February 2008 (2008-02-13), XP002498940 *
DATABASE CHEMCATS Chemical abstract service, Ohio, US; 20 November 2007 (2007-11-20), XP002498938 *
ZIRVI ET AL., JOURNAL OF THE CHEMICAL SOCIETY, SECTION B, 1971, pages 1603 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029381B2 (en) 2007-08-22 2015-05-12 Astrazeneca Ab Cyclopropyl amide derivatives
US8912176B2 (en) 2009-02-02 2014-12-16 Evotec Ag Azetidines as histamine H3 receptor antagonists
US8993577B2 (en) 2009-02-20 2015-03-31 Astrazeneca Ab Cyclopropyl amide derivatives
WO2011006621A1 (en) * 2009-07-11 2011-01-20 Bayer Schering Pharma Aktiengesellschaft Radiolabelling method using cycloalkyl groups
CN103168027B (en) * 2010-02-18 2015-08-26 阿斯利康(瑞典)有限公司 Prepare the method for cyclopropyl amide derivatives and relevant intermediate thereof
CN103168027A (en) * 2010-02-18 2013-06-19 阿斯利康(瑞典)有限公司 Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US9012452B2 (en) 2010-02-18 2015-04-21 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US8546375B2 (en) 2010-07-06 2013-10-01 Astrazeneca Ab (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds
CN103209979B (en) * 2010-07-06 2016-02-10 阿斯利康(瑞典)有限公司 Therapeutical agent 976
AU2011275547B2 (en) * 2010-07-06 2015-10-29 Astrazeneca Ab Therapeutic agents 976
WO2012004588A3 (en) * 2010-07-06 2012-08-09 Astrazeneca Ab Therapeutic agents 976
CN103209979A (en) * 2010-07-06 2013-07-17 阿斯利康(瑞典)有限公司 Therapeutic agents 976
US9079888B2 (en) 2011-02-23 2015-07-14 Suven Life Sciences Limited Compounds as histamine H3 receptor ligands
WO2012114348A1 (en) 2011-02-23 2012-08-30 Suven Life Sciences Limited Novel compounds as histamine h3 receptor ligands
US8685958B2 (en) 2011-07-15 2014-04-01 Astrazeneca Ab Therapeutic agents
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2014030170A1 (en) 2012-08-23 2014-02-27 Suven Life Sciences Limited Acrylamide compounds as histamine h3 receptor ligands
CN104603104A (en) * 2012-09-05 2015-05-06 浙江海正药业股份有限公司 Crystal forms of azetidinone compounds and preparing methods thereof
CN104603104B (en) * 2012-09-05 2016-12-07 浙江海正药业股份有限公司 Crystal formation of azetidine ketonic compound and preparation method thereof
WO2021195403A1 (en) 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators

Also Published As

Publication number Publication date
HK1155749A1 (en) 2012-05-25
IL208613A (en) 2015-07-30
US8691804B2 (en) 2014-04-08
BRPI0913057A2 (en) 2015-10-13
TW201006820A (en) 2010-02-16
JP2011519891A (en) 2011-07-14
CN102015636B (en) 2014-08-13
IL208613A0 (en) 2010-12-30
CA2721303A1 (en) 2009-11-12
EP2300422A1 (en) 2011-03-30
EP2300422B1 (en) 2014-11-05
CA2721303C (en) 2016-06-28
JP5780954B2 (en) 2015-09-16
CN102015636A (en) 2011-04-13
TWI454468B (en) 2014-10-01
US20110105459A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
EP2300422B1 (en) Azetidines as histamine h3 receptor antagonists
JP7033141B2 (en) Condensation bicyclic inhibitor of menin-MLL interaction
KR102049534B1 (en) NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
CA3033239A1 (en) Spiro bicyclic inhibitors of menin-mll interaction
IL263082A (en) Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
KR20180103683A (en) CCR2 modulator
JP2021518340A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitor
WO2021081375A1 (en) Inhibitors of raf kinases
TW201623304A (en) Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
WO2010026113A1 (en) Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2011083316A1 (en) Benzazepine derivatives for the treatment of central nervous system disorders
TW201030000A (en) (Dihydro) naphthyridinone derivatives as histamine H3 receptor antagonists
EP2391617B1 (en) Azetidines as histamine h3 receptor antagonists
KR20240021758A (en) Novel pyrazolo[1,5-a]pyrimidine derivatives as sigma ligands
JP6370294B2 (en) Cyclic aminomethylpyrimidine derivatives
CN115843296B (en) CDK9 inhibitors and uses thereof
EP4211118A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
JP2023545065A (en) autotaxin inhibitor compounds
CN117957225A (en) Compounds for targeting degradation of IRAK4 proteins
WO2010133544A1 (en) Piperazine and aminopyrrolidine compounds as histamine h3 receptor antagonists
EA045404B1 (en) CONDENSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
KR20190132703A (en) NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980117615.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09742060

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2721303

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011507892

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 7193/CHENP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009742060

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12991225

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0913057

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101108